Participation of p53 protein in the cellular response to I

Citation Report

51, 6304-11

#	Article	IF	CITATIONS
1	Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53 Genes and Development, 1992, 6, 1886-1898.	2.7	220
2	Wild-type p53 is a cell cycle checkpoint determinant following irradiation Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 7491-7495.	3.3	1,707
3	Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding Molecular and Cellular Biology, 1992, 12, 5581-5592.	1.1	346
4	Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet, The, 1992, 340, 259-263.	6.3	201
5	Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 1992, 70, 923-935.	13.5	1,345
6	Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 1992, 70, 937-948.	13.5	1,116
7	ras-Induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell, 1992, 70, 153-161.	13.5	137
8	Regulation of the specific DNA binding function of p53. Cell, 1992, 71, 875-886.	13.5	975
9	Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell, 1992, 71, 543-546.	13.5	778
10	A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 1992, 71, 587-597.	13.5	3,006
11	Apoptosis and the regulation of cell numbers in normal and neoplastic tissues: an overview. Cancer and Metastasis Reviews, 1992, 11, 95-103.	2.7	555
12	Apoptosis induced by anticancer drugs. Cancer and Metastasis Reviews, 1992, 11, 121-139.	2.7	820
13	The involvement of oncogenes and tumor suppressor genes in the control of apoptosis. Cancer and Metastasis Reviews, 1992, 11, 141-148.	2.7	94
14	p53, guardian of the genome. Nature, 1992, 358, 15-16.	13.7	4,739
15	Checkpoint policing by p53. Nature, 1992, 359, 486-487.	13.7	13
16	Creative blocks: cell-cycle checkpoints and feedback controls. Nature, 1992, 359, 599-601.	13.7	712
17	Aberrant expression of p53 tumour-suppressor protein in non-melanoma skin cancer. British Journal of Dermatology, 1992, 127, 463-469.	1.4	97
18	p53 expression in Reed-Sternberg cells of Hodgkin's disease. British Journal of Cancer, 1992, 66, 649-652.	2.9	32

#	ARTICLE	IF	CITATIONS
19	SV40 T antigen induced chromosomal changes reflect a process that is both clastogenic and aneuploidogenic and is ongoing throughout neoplastic progression of human fibroblasts. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1992, 284, 265-273.	0.4	55
20	Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer, 1993, 72, 1272-1280.	2.0	83
21	Screening for TP53 mutations in osteosarcomas using constant denaturant gel electrophoresis (CDGE). Human Mutation, 1993, 2, 274-285.	1.1	42
22	Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cellsin vitro. International Journal of Cancer, 1993, 53, 863-871.	2.3	58
23	Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. International Journal of Cancer, 1993, 55, 678-684.	2.3	183
24	Oncogene mutations as intermediate markers. Journal of Cellular Biochemistry, 1993, 53, 184-187.	1.2	4
25	Direct growth stimulation of normal human epithelial cells by mutantp53. Molecular Carcinogenesis, 1993, 7, 83-88.	1.3	29
26	No point mutation of ha-ras orp53 genes expressed in preneoplastic-to-neoplastic progression as modeled in mouse JB6 cell variants. Molecular Carcinogenesis, 1993, 8, 49-57.	1.3	42
27	Inhibition of Polyamine Synthesis Suppresses Growth and $\hat{I}^3$ -Ray-Induced Sublethal and Potentially Lethal Damage Recovery in Human Tumor Cells in Culture. Radiation Oncology Investigations, 1993, 1, 41-49.	1.3	2
28	Stress response genes induced in mammalian cells by ionizing radiation. Radiation Oncology Investigations, 1993, 1, 81-93.	1.3	18
29	Expression of P53 protein in normal, dysplastic, and malignant gastric mucosa: An immunohistochemical study. Journal of Pathology, 1993, 170, 279-283.	2.1	78
30	Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiationin vitro. Cytotechnology, 1993, 12, 265-288.	0.7	28
31	The biology of radioresistance: similarities, differences and interactions with drug resistance. Cytotechnology, 1993, 12, 325-345.	0.7	18
32	The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Research and Treatment, 1993, 27, 95-102.	1.1	45
33	Cell-signaling targets for antitumour drug development. Cancer Chemotherapy and Pharmacology, 1993, 32, 1-19.	1.1	49
34	A death in the life of p53. Nature, 1993, 362, 786-787.	13.7	351
35	p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 1993, 362, 847-849.	13.7	2,829
36	Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature, 1993, 363, 281-283.	13.7	334

#	Article	IF	CITATIONS
37	No room at the p53 inn. Nature, 1993, 365, 17-18.	13.7	110
38	Cell checkpoint and radiosensitivity. Nature, 1993, 365, 22-22.	13.7	25
39	Inhibition of DNA replication factor RPA by p53. Nature, 1993, 365, 79-82.	13.7	373
40	p53 protein overexpression identifies a group of central primitive neuroectodermal tumours with poor prognosis. British Journal of Cancer, 1993, 68, 801-807.	2.9	38
41	Experimental models of human carcinogenesis. Nature Genetics, 1993, 5, 207-208.	9.4	8
42	Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before weaning. Nature Genetics, 1993, 5, 217-224.	9.4	309
43	p53 protein expression in non-neoplastic lesions and benign and malignant neoplasms of soft tissue. Histopathology, 1993, 22, 45-50.	1.6	92
44	p53 immunoreactivity in cutaneous PUVA tumors is similar to that in other non-melanoma skin neoplasms. Journal of Cutaneous Pathology, 1993, 20, 435-441.	0.7	12
45	The tumore suppressor p53. Biochimica Et Biophysica Acta: Reviews on Cancer, 1993, 1155, 181-205.	3.3	176
46	Trans-plication factors?. Current Biology, 1993, 3, 709-712.	1.8	10
47	The origin of chromosome rearrangements at early stages of AMPD2 gene amplification in Chinese hamster cells. Current Biology, 1993, 3, 255-264.	1.8	80
48	Towards the cellular functions of tumour suppressors. Trends in Cell Biology, 1993, 3, 31-35.	3.6	24
49	Genetic instability on chromosome 16 in a human B lymphoblastoid cell line. Somatic Cell and Molecular Genetics, 1993, 19, 515-527.	0.7	30
50	Chromosomal approaches to hematopoietic oncogenesis. Stem Cells, 1993, 11, 9-19.	1.4	3
51	A closer look at the cell cycle. Virchows Archiv A, Pathological Anatomy and Histopathology, 1993, 422, 341-343.	1.4	3
52	p53-mediated cell death: relationship to cell cycle control Molecular and Cellular Biology, 1993, 13, 1415-1423.	1.1	348
53	Point mutations of the P53 gene, human hepatocellular carcinoma and aflatoxins. Journal of Hepatology, 1993, 19, 312-315.	1.8	33
54	Evidence of post-translational regulation of P-glycoprotein associated with the expression of a distinctive multiple drug-resistant phenotype in Chinese hamster ovary cells. European Journal of Cancer, 1993, 29, 2243-2248.	1.3	29

#	Article	IF	Citations
55	A Correlative Study of p53 Protein Alteration and p53 Gene Mutation in Glioblastoma Multiforme. Brain Pathology, 1993, 3, 229-235.	2.1	110
56	Replication of Damaged DNA and the Molecular Mechanism of Ultraviolet Light Mutagenesis. Critical Reviews in Biochemistry and Molecular Biology, 1993, 28, 465-513.	2.3	112
57	Toxicological and Pathological Applications of Proliferating Cell Nuclear Antigen (PCNA), A Novel Endogenous Marker for Cell Proliferation. Critical Reviews in Toxicology, 1993, 23, 77-109.	1.9	166
58	Molecular biology and gastric carcinoma Gut, 1993, 34, 145-147.	6.1	55
59	Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 3221-3225.	3.3	130
60	Tumor suppressor genes. Neuron, 1993, 11, 191-196.	3.8	56
61	Tumor-suppressor p53 and the cell cycle. Current Opinion in Genetics and Development, 1993, 3, 50-54.	1.5	115
62	Doing the right thing: feedback control and p53. Current Opinion in Cell Biology, 1993, 5, 214-218.	2.6	25
63	Expression of p53 protein in benign and malignant epidermal pathologic conditions. Journal of the American Academy of Dermatology, 1993, 29, 741-748.	0.6	38
64	Tumor suppressor genes in urologic tumors. Urology, 1993, 42, 461-466.	0.5	8
65	p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 1993, 74, 957-967.	13.5	2,848
66	p53 protein expression in mammary ductal carcinoma in situ: Relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Human Pathology, 1993, 24, 463-468.	1.1	147
67	Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis?. Human Pathology, 1993, 24, 469-476.	1.1	216
68	Induction of cellular p53 activity by DNA-damaging agents and growth arrest Molecular and Cellular Biology, 1993, 13, 4242-4250.	1.1	438
69	Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 3988-3992.	3.3	490
70	Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Research, 1993, 21, 3167-3174.	6.5	202
71	The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. Nucleic Acids Research, 1993, 21, 345-350.	6.5	120
72	Structure of the rat p53 tumor suppressor gene. Nucleic Acids Research, 1993, 21, 713-717.	6.5	82

#	Article	IF	Citations
73	Sister chromatid fusion initiates amplification of the dihydrofolate reductase gene in Chinese hamster cells Genes and Development, 1993, 7, 605-620.	2.7	186
74	Apoptosis (the 1992 Frank Rose Memorial Lecture). British Journal of Cancer, 1993, 67, 205-208.	2.9	437
75	Mutations of the p53 Gene in B-cell Lymphoma. Leukemia and Lymphoma, 1993, 11, 21-25.	0.6	20
76	Regulation and Mechanisms of Mammalian Gene Amplification. Advances in Cancer Research, 1993, 61, 87-113.	1.9	136
77	Immunohistochemical analysis of p53 expression in anal squamous neoplasia Journal of Clinical Pathology, 1993, 46, 507-512.	1.0	31
78	Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis Genes and Development, 1993, 7, 535-545.	2.7	647
79	Mapping of the p53 and mdm-2 interaction domains Molecular and Cellular Biology, 1993, 13, 4107-4114.	1.1	645
81	Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B Genes and Development, 1993, 7, 546-554.	2.7	833
82	Barrett's esophagus: Cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology, 1993, 105, 119-129.	0.6	178
83	Oncogenic Basis of Radiation Resistance. Advances in Cancer Research, 1993, 61, 195-233.	1.9	37
84	The Treatment of Anaplastic Oligodendrogliomas and Mixed Gliomas. Neurosurgery, 1993, 32, 365-371.	0.6	97
85	Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin Molecular and Cellular Biology, 1993, 13, 1456-1463.	1.1	131
86	Isolation of x-ray-inducible transcripts from radioresistant human melanoma cells Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 7200-7204.	3.3	123
87	Mutation of p53 in primary biopsy material and cell lines from Hodgkin disease Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 2817-2821.	3.3	46
88	p53 mutations increase resistance to ionizing radiation Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 5742-5746.	3.3	516
89	Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 8910-8914.	3.3	190
90	The ionizing radiation-induced replication protein A phosphorylation response differs between ataxia telangiectasia and normal human cells Molecular and Cellular Biology, 1993, 13, 7222-7231.	1.1	191
91	Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53 Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 5954-5958.	3.3	95

#	Article	IF	CITATIONS
92	Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperativity with c-myc suppression Molecular and Cellular Biology, 1993, 13, 7942-7952.	1.1	77
93	Antioncogenes and human cancer. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 10914-10921.	3.3	726
94	Lethality induced by a single site-specific double-strand break in a dispensable yeast plasmid Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 5613-5617.	3.3	239
95	RAD9-dependent G1 arrest defines a second checkpoint for damaged DNA in the cell cycle of Saccharomyces cerevisiae Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 7985-7989.	3 <b>.</b> 3	194
96	Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9075-9079.	3.3	178
97	Modulation of cell proliferation and gene expression by a p53-estrogen receptor hybrid protein Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9252-9256.	3.3	28
98	p53: A target for new anticancer drugs or a target for old drugs?. Annals of Oncology, 1993, 4, 623-629.	0.6	4
99	Cell cycle controls: potential targets for chemical carcinogens?. Environmental Health Perspectives, 1993, 101, 9-14.	2.8	26
100	Predisposing Genes in Breast and Ovarian Cancer: An Overview. Tumori, 1993, 79, 291-296.	0.6	6
101	Control of G1 arrest after DNA damage Environmental Health Perspectives, 1993, 101, 55-58.	2.8	40
102	Induction of internucleosomal DNA fragmentation by carcinogenic chromate: relationship to DNA damage, genotoxicity, and inhibition of macromolecular synthesis Environmental Health Perspectives, 1994, 102, 159-167.	2.8	60
103	The genetics of human cancer: implications for ecotoxicology Environmental Health Perspectives, 1994, 102, 75-80.	2.8	8
104	Potential molecular mechanisms of oxidant-induced carcinogenesis Environmental Health Perspectives, 1994, 102, 155-157.	2.8	39
105	Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins Genes and Development, 1994, 8, 666-677.	2.7	337
106	Role of kit-ligand in proliferation and suppression of apoptosis in mast cells: basis for radiosensitivity of white spotting and steel mutant mice Journal of Experimental Medicine, 1994, 179, 1777-1787.	4.2	157
107	Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status Molecular and Cellular Biology, 1994, 14, 6264-6277.	1.1	587
108	Apoptosis in erythroid progenitors deprived of erythropoietin occurs during the G1 and S phases of the cell cycle without growth arrest or stabilization of wild-type p53 Molecular and Cellular Biology, 1994, 14, 4183-4192.	1.1	74
109	Rescue of T cell-specific V(D)J recombination in SCID mice by DNA-damaging agents. Science, 1994, 266, 450-455.	6.0	106

#	Article	IF	CITATIONS
110	Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Research, 1994, 22, 1012-1017.	6.5	52
111	Tumor Suppressor and Immediate Early Transcription Factor Genes in Non-small Cell Lung Cancer. Chest, 1994, 106, 372S-376S.	0.4	6
112	Radiosensitivity in Ataxia-telangiectasia: Anomalies in Radiation-induced Cell Cycle Delay. International Journal of Radiation Biology, 1994, 65, 175-184.	1.0	176
113	Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential Genes and Development, 1994, 8, 1739-1749.	2.7	281
114	Molecular Determinants of Radiosensitivity in Mammalian Cells. International Journal of Radiation Biology, 1994, 65, 49-55.	1.0	37
115	CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest Genes and Development, 1994, 8, 453-464.	2.7	293
116	Loss of cell cycle controls in apoptotic lymphoblasts of the bursa of Fabricius Molecular Biology of the Cell, 1994, 5, 763-772.	0.9	13
117	DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways Molecular and Cellular Biology, 1994, 14, 1815-1823.	1.1	803
118	DNA Damage Levels Determine Cyclobutyl Pyrimidine Dimer Repair Mechanisms in Alfalfa Seedlings Plant Cell, 1994, 6, 1635-1641.	3.1	69
119	Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts Genes and Development, 1994, 8, 1627-1639.	2.7	282
120	Loss of p53 protein during radiation transformation of primary human mammary epithelial cells Molecular and Cellular Biology, 1994, 14, 2468-2478.	1.1	81
121	Induction versus progression of brain tumor development: differential functions for the pRB- and p53-targeting domains of simian virus 40 T antigen Molecular and Cellular Biology, 1994, 14, 2686-2698.	1.1	104
122	Molecular Pathogenesis of Cancer of the Cervix and Its Causation by Specific Human Papillomavirus Types. Current Topics in Microbiology and Immunology, 1994, 186, 131-156.	0.7	312
123	The novel primary response gene MyD $118$ and the proto-oncogenes myb, myc, and bcl-2 modulate transforming growth factor beta 1-induced apoptosis of myeloid leukemia cells Molecular and Cellular Biology, 1994, 14, 2352-2360.	1.1	178
124	Absence of p53 Gene Mutations in Cutaneous Melanoma. Journal of Investigative Dermatology, 1994, 102, 819-821.	0.3	99
125	Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence Gut, 1994, 35, 764-768.	6.1	50
126	Determinants of Cellular Sensitivity to Topoisomerase-Targeting Antitumor Drugs. Advances in Pharmacology, 1994, 29B, 127-143.	1.2	16
127	Cellular Radiosensitivity in Ataxia-telangiectasia. International Journal of Radiation Biology, 1994, 66, S87-S96.	1.0	60

#	Article	IF	Citations
128	Alterations in Oncogene Expression and Radiosensitivity in the Most Frequently Used SV40-transformed Human Skin Fibroblasts. International Journal of Radiation Biology, 1994, 65, 665-673.	1.0	15
129	Defect in Radiation Signal Transduction in Ataxia-telangiectasia. International Journal of Radiation Biology, 1994, 66, S151-S156.	1.0	24
130	Ionizing Radiation-induced Cell Death. International Journal of Radiation Biology, 1994, 66, 329-341.	1.0	110
131	Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells Genes and Development, 1994, 8, 2227-2240.	2.7	124
132	Metastasis-Associated <i>mts1 </i> Gene Expression Correlates with Increased p53 Detection in the B16 Murine Melanoma. DNA and Cell Biology, 1994, 13, 343-351.	0.9	42
133	Genetics of primary brain tumors: a review. Journal of Neuro-Oncology, 1994, 18, 69-81.	1.4	77
134	Significance of P53 in human thyroid tumors. World Journal of Surgery, 1994, 18, 535-540.	0.8	20
135	P53 accumulation in precursor lesions and early stages of bladder cancer. World Journal of Urology, 1994, 12, 79-83.	1.2	50
136	Molecular prognostic factors in bladder cancer. World Journal of Urology, 1994, 12, 84-8.	1.2	24
137	Immunohistochemical detection of p53 protein in cutaneous lesions from transplant recipients harbouring human papillomavirus DNA. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1994, 424, 623-30.	1.4	3
138	Expression of p53 protein in laryngeal squamous cell carcinoma and dysplasia: possible correlation with human papillomavirus infection and clinicopathological findings. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1994, 425, 481-9.	1.4	47
139	Tumor suppressor genes in molecular medicine. The Clinical Investigator, 1994, 72, 619-30.	0.6	11
140	Radiation response of human cervical carcinoma cells transfected with sense and antisensep53 retroviral constructs. Radiation Oncology Investigations, 1994, 2, 212-218.	1.3	2
141	On the expression of the p53 protein in human cancer. Molecular Biology Reports, 1994, 19, 23-29.	1.0	44
142	Tumor suppressor genes and their roles in breast cancer. Breast Cancer Research and Treatment, 1994, 32, 19-38.	1.1	44
143	The p53 tumor suppressor gene in breast cancer. Breast Cancer Research and Treatment, 1994, 32, 39-47.	1.1	137
144	Immunohistochemical detection of p53 protein in cutaneous lesions from transplant recipients harbouring human papillomavirus DNA. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1994, 424, 623-630.	1.4	8
145	Absence of MDM-2 gene amplification in experimentally induced tumors regardless of p53 status. Molecular Carcinogenesis, 1994, 9, 40-45.	1.3	13

#	ARTICLE	IF	CITATIONS
146	Mutation and altered expression ofp53 genes in experimental rat bladder tumor cells. Molecular Carcinogenesis, 1994, 9, 95-104.	1.3	11
147	Recovery from ultraviolet-induced growth arrest of primary rat hepatocytes byp53 antisense oligonucleotide treatment. Molecular Carcinogenesis, 1994, 9, 167-174.	1.3	17
148	Mutations and expression of thep53 gene in rat bladder carcinomas and cell lines. Molecular Carcinogenesis, 1994, 9, 236-244.	1.3	12
149	FrequentP53 mutation in mouse tumors induced by repeated $\hat{l}^2$ -irradiation. Molecular Carcinogenesis, 1994, 11, 236-242.	1.3	22
150	p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer, 1994, 73, 181-186.	2.0	64
151	Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer, 1994, 73, 406-415.	2.0	58
152	p53 expression in pseudoepitheliomatous hyperplasia, keratoacanthoma, and squamous cell carcinoma of skin. Cancer, 1994, 73, 2317-2323.	2.0	60
153	Identification of a distinctive p-glycoprotein-mediated resistance phenotype in human ovarian carcinoma cells after their in vitro exposure to fractionated x-irradiation. Cancer, 1994, 73, 2990-2999.	2.0	20
154	The emerging picture of p53. International Journal of Biochemistry & Cell Biology, 1994, 26, 145-154.	0.8	38
155	UV-responsive element (TGACAACA) from rat fibroblasts to human melanomas. Environmental and Molecular Mutagenesis, 1994, 23, 157-163.	0.9	20
156	Chromosome aberrations induced in vitro: Mechanisms, delayed expression, and intriguing questions. Environmental and Molecular Mutagenesis, 1994, 23, 44-53.	0.9	49
157	Oligonucleotides in the treatment of leukemia. Hematological Oncology, 1994, 12, 9-14.	0.8	26
158	The regulation ofp53 function: Steiner award lecture. International Journal of Cancer, 1994, 57, 623-627.	2.3	147
159	Increased UV-induced SCEs but normal repair of DNA damage inp53-deficient mouse cells. International Journal of Cancer, 1994, 58, 254-257.	2.3	56
160	Cell cycle control and cancer chemotherapy. Journal of Cellular Biochemistry, 1994, 54, 440-452.	1.2	75
161	p53 Expression in the carcinogenesis in the oral mucosa. Journal of Cellular Biochemistry, 1994, 56, 444-448.	1.2	23
162	Growth factors as survival factors: Regulation of apoptosis. BioEssays, 1994, 16, 133-138.	1.2	168
163	Roadblocks and detours during DNA replication: Mechanisms of mutagenesis in mammalian cells. BioEssays, 1994, 16, 557-564.	1.2	35

#	ARTICLE	IF	Citations
164	Fludarabine improves the therapeutic ratio of radiotherapy in mouse tumors after single-dose irradiation. International Journal of Radiation Oncology Biology Physics, 1994, 30, 363-371.	0.4	24
165	Cell cycle control and cancer. Science, 1994, 266, 1821-1828.	6.0	2,234
166	Radiation-induced Genomic Instability. International Journal of Radiation Biology, 1994, 66, 603-609.	1.0	84
167	Modulation of the spontaneous G2 phase blockage in Fanconi anemia cells by caffeine: differences from cells arrested by X-irradiation. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994, 308, 149-157.	0.4	24
168	The induction of chromosomal damage and cell killing in mouse spermatogonial stem cells following combined treatments with hydroxyurea, 3-aminobenzamide and X-rays. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994, 311, 217-224.	0.4	7
169	Gene-targeting and the p53 tumor-suppressor gene. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994, 307, 557-572.	0.4	14
170	DNA damage, oncogenesis and the p53 tumour-suppressor gene. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1994, 307, 573-581.	0.4	55
171	Regrowth resistance in leukemia and lymphoma: The need for a new system to classify treatment failure and for new approaches to treatment. Leukemia Research, 1994, 18, 149-160.	0.4	32
172	Altered p53 expression and epidermal cell proliferation is seen in vulval lichen sclerosus. Journal of Cutaneous Pathology, 1994, 21, 316-323.	0.7	52
173	Lymphocyte Apoptosis - Mechanisms and Implications in Disease. Immunological Reviews, 1994, 142, 141-156.	2.8	32
174	Analysis of the UV-Induced Melanogenesis and Growth Arrest of Human Melanocytes. Pigment Cell & Melanoma Research, 1994, 7, 326-332.	4.0	50
175	Cooperative tumorigenic effects of germline mutations in Rb and p53. Nature Genetics, 1994, 7, 480-484.	9.4	379
176	Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genetics, 1994, 8, 171-176.	9.4	313
177	p53 protein in low-grade astrocytomas: a study with long-term follow-up. British Journal of Cancer, 1994, 69, 586-591.	2.9	38
178	Overexpression of p53 and long-term survival in colon carcinoma. British Journal of Cancer, 1994, 70, 293-296.	2.9	74
179	The p53 status of cultured human premalignant oral keratinocytes. British Journal of Cancer, 1994, 70, 591-595.	2.9	30
180	Accumulation of p53 is associated with tumour progression in cutaneous lesions of renal allograft recipients. British Journal of Cancer, 1994, 70, 662-667.	2.9	20
181	Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. British Journal of Cancer, 1994, 69, 26-31.	2.9	139

#	Article	IF	Citations
182	TP53 allele loss, mutations and expression in malignant melanoma. British Journal of Cancer, 1994, 69, 253-259.	2.9	65
183	The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. British Journal of Cancer, 1994, 69, 409-416.	2.9	403
184	RECENT ADVANCES IN THE MOLECULAR GENETICS OF UROGENITAL TUMORS. International Journal of Urology, 1994, 1, 1-16.	0.5	16
185	The clinical relevance of the p53 tumour suppressor gene. Cytopathology, 1994, 5, 133-145.	0.4	29
186	Diagnostic associations of p53 immunostaining in fine needle aspiration cytology of the breast. Cytopathology, 1994, 5, 146-153.	0.4	20
187	The Immunocytochemical Detection of P53 Protein In Cytological Specimens: Technical Considerations. Cytopathology, 1994, 5, 76-81.	0.4	25
188	Suppression of GI Arrest and Enhancement of G2 Arrest by Inhibitors of Poly(ADP-ribose) Polymerase: Possible Involvement of Poly(ADP-ribosyl)ation in Cell Cycle Arrest Following $\hat{I}^3$ -Irradiation. Japanese Journal of Cancer Research, 1994, 85, 1094-1098.	1.7	28
189	Tumor spectrum analysis in p53-mutant mice. Current Biology, 1994, 4, 1-7.	1.8	1,903
190	Allosteric activation of latent p53 tetramers. Current Biology, 1994, 4, 865-875.	1.8	304
191	Cip1 inhibits DNA replication but not PCNA-dependent nucleotide excision—repair. Current Biology, 1994, 4, 1062-1068.	1.8	150
192	Expression of p53 mRNA is proliferation-dependent in the human fibroblast cell line WI-38. Cell Proliferation, 1994, 27, 465-473.	2.4	0
193	Immunohistological expression of p53 in primary pTl transitional cell bladder cancer in relation to tumour progression. British Journal of Urology, 1994, 73, 526-532.	0.1	70
194	Differential effect of p53 on the promoters of mouse DNA polymerase beta gene and proliferating-cell-nuclear-antigen gene. FEBS Journal, 1994, 221, 227-237.	0.2	36
195	DNA content and expression of PCNA and p53 in Hodgkin's disease and Hodgkin'sâ€like Bâ€ceil lymphoma. Apmis, 1994, 102, 865-873.	0.9	5
196	Evidence for a second tumor suppressor gene on 17p linked to high S-phase index in primary human breast carcinomas. Cancer Genetics and Cytogenetics, 1994, 76, 106-111.	1.0	18
197	Modern chemotherapy for gynaecological cancer. Part 1: models, mechanisms and methods. Current Obstetrics & Gynaecology, 1994, 4, 14-22.	0.2	0
198	Apoptosis, senescence, immortalization and cancer. Pharmacological Research, 1994, 30, 301-315.	3.1	7
199	The role of the p53 protein in the apoptotic response. Philosophical Transactions of the Royal Society B: Biological Sciences, 1994, 345, 277-280.	1.8	57

#	Article	IF	CITATIONS
200	Insights from transgenic mice regarding the role of bcl -2 in normal and neoplastic lymphoid cells. Philosophical Transactions of the Royal Society B: Biological Sciences, 1994, 345, 289-295.	1.8	35
201	Life, death and genomic change in perturbed cell cycles. Philosophical Transactions of the Royal Society B: Biological Sciences, 1994, 345, 311-317.	1.8	28
202	Mechanisms of Action of the p53 Tumor Suppressor and Prospects for Cancer Gene Therapy by Reconstitution of p53 Function. Annals of the New York Academy of Sciences, 1994, 716, 265-282.	1.8	20
203	Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer. New England Journal of Medicine, 1994, 331, 1259-1264.	13.9	756
204	Oncogenes and cell death. Current Opinion in Genetics and Development, 1994, 4, 120-129.	1.5	251
205	Tumor suppressor genes. Current Opinion in Genetics and Development, 1994, 4, 135-141.	1.5	207
206	Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells. Cancer Chemotherapy and Pharmacology, 1994, 34, S14-S18.	1.1	23
207	DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts Genes and Development, 1994, 8, 2540-2551.	2.7	1,061
208	p53 expression in nitric oxide-induced apoptosis. FEBS Letters, 1994, 355, 23-26.	1.3	367
209	The molecular biology of esophageal and gastric cancer and their precursors: Oncogenes, tumor suppressor genes, and growth factors. Human Pathology, 1994, 25, 968-981.	1.1	108
210	p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Human Pathology, 1994, 25, 1346-1351.	1.1	58
211	A theory that may explain the Hayflick limit — a means to delete one copy of a repeating sequence during each cell cycle in certain human cells such as fibroblasts. Mechanisms of Ageing and Development, 1994, 75, 205-213.	2.2	6
212	p53 Protein expression in squamous cell carcinomas from sun-exposed and non-sun-exposed sites. Journal of the American Academy of Dermatology, 1994, 31, 417-422.	0.6	15
213	Apoptosis and Programmed Cell Death in Health and Disease. Advances in Clinical Chemistry, 1994, 31, 177-246.	1.8	113
214	Cancer genetics. Current Opinion in Genetics and Development, 1994, 4, 109-119.	1.5	12
215	Maintenance of identical p53 mutations throughout progression of squamous cell carcinomas of the tongue. European Journal of Cancer Part B, Oral Oncology, 1994, 30, 335-337.	0.9	18
216	Molecular interactions between G-actin, DNase I and the beta-thymosins in apoptosis: a hypothesis. Medical Hypotheses, 1994, 43, 125-131.	0.8	24
217	Cellular accumulation of p53 protein: an independent prognostic factor in stage II breast cancer. European Journal of Cancer, 1994, 30, 175-180.	1.3	63

#	Article	IF	CITATIONS
218	Genetics of growth arrest and cell death: Key determinants of tissue homeostasis. European Journal of Cancer, 1994, 30, 2001-2012.	1.3	18
219	New approaches in cancer pharmacology: Drug design and development (part 2). European Journal of Cancer, 1994, 30, 1148-1160.	1.3	8
220	p53 proteins accumulated by heat stress associate with heat shock proteins HSP72/HSC73 in human glioblastoma cell lines. Cancer Letters, 1994, 87, 39-46.	3.2	98
221	Apoptosis and a re-investigation of the biologic basis for cancer therapy. Radiotherapy and Oncology, 1994, 33, 3-10.	0.3	47
222	Nuclear accumulation of p53 in response to treatment with DNA-damaging agents. Toxicology Letters, 1994, 72, 43-52.	0.4	24
223	The molecular basis for cell cycle delays following ionizing radiation: a review. Radiotherapy and Oncology, 1994, 31, 1-13.	0.3	275
224	Radiation-induced G <sub>2</sub> Delay and Spontaneous Chromosome Aberrations in Ataxia-telangiectasia Homozygotes and Heterozygotes. International Journal of Radiation Biology, 1994, 66, S157-S163.	1.0	44
225	P53 Status, DNA Double-strand Break Repair Proficiency, and Radiation Response of Mouse Lymphoid and Myeloid Cell Lines. International Journal of Radiation Biology, 1994, 66, 557-560.	1.0	33
226	Intragenomic Heterogeneity of DNA Damage Formation and Repair: A Review of Cellular Responses to Covalent Drug DNA Interaction. Critical Reviews in Toxicology, 1994, 24, 281-322.	1.9	17
227	Mediation of c-Myc-induced apoptosis by p53. Science, 1994, 265, 2091-2093.	6.0	718
228	p53: a glimpse at the puppet behind the shadow play. Science, 1994, 265, 334-335.	6.0	153
229	Chapter 23 Analysis of Intracellular Proteins. Methods in Cell Biology, 1994, 41, 351-376.	0.5	29
230	Mutations in the p53 gene: An early marker of neoplastic progression in ulcerative colitis. Gastroenterology, 1994, 107, 369-378.	0.6	391
231	Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma. Gastroenterology, 1994, 106, 1645-1651.	0.6	74
232	p53: Tumor suppression through control of the cell cycle. Gastroenterology, 1994, 106, 1708-1711.	0.6	26
234	The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. British Journal of Cancer, 1994, 70, 335-341.	2.9	142
235	p53 mutations have no additional prognostic value over stage in bladder cancer. British Journal of Cancer, 1994, 70, 496-500.	2.9	45
236	Cisplatin resistance in mouse fibrosarcoma cells after low-dose irradiation in vitro and in vivo. British Journal of Cancer, 1994, 70, 579-584.	2.9	15

#	Article	IF	CITATIONS
237	Accumulation of the p53 Tumor-Suppressor Gene Product in Oral Leukoplakia. Otolaryngology - Head and Neck Surgery, 1994, 111, 758-763.	1.1	22
238	Radiation effects on DNA synthesis in a defined chromosomal replicon Molecular and Cellular Biology, 1994, 14, 1901-1908.	1.1	80
239	p53 induction is associated with neuronal damage in the central nervous system Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 7525-7529.	3.3	245
240	Inducible growth arrest: new mechanistic insights Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 1985-1986.	3.3	18
241	Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 2026-2030.	3.3	272
242	The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 5124-5128.	3.3	200
243	Involvement of the Ku autoantigen in the cellular response to DNA double-strand breaks Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 7623-7627.	3.3	199
244	Prognostic Implications of p53 Overexpression in Supratentorial Astrocytic Tumors. Neurosurgery, 1994, 35, 831-838.	0.6	62
245	Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7 Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 4382-4386.	3.3	233
246	Activation of the pp90rsk and mitogen-activated serine/threonine protein kinases by ionizing radiation Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 5416-5420.	3.3	47
247	Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 2684-2688.	3.3	271
248	Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells Molecular and Cellular Biology, 1994, 14, 1698-1708.	1.1	74
249	Molecular biology and the radiation oncologist. Journal of Medical Imaging and Radiation Oncology, 1994, 38, 215-220.	0.6	0
250	p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 413-417.	3.3	271
251	Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 4130-4134.	3.3	570
252	p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 5320-5324.	3.3	320
253	p53 and E2F-1 cooperate to mediate apoptosis Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 3602-3606.	3.3	776
254	Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors Molecular and Cellular Biology, 1994, 14, 7805-7815.	1.1	105

#	Article	IF	CITATIONS
255	A UV-Responsive G <sub>2</sub> Checkpoint in Rodent Cells. Molecular and Cellular Biology, 1995, 15, 3722-3730.	1.1	77
256	Platelet-derived growth factor induces apoptosis in growth-arrested murine fibroblasts Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 9500-9504.	3.3	66
257	Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 8876-8880.	3.3	325
258	Expression of the wild-type p53 antioncogene induces guanine nucleotide-dependent stem cell division kinetics Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 136-140.	3.3	66
259	Oxidative DNA damage and senescence of human diploid fibroblast cells Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 4337-4341.	3.3	639
260	p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 8493-8497.	3.3	788
261	The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 9455-9459.	3.3	182
262	Regulation of p53-Mediated Apoptosis and Cell Cycle Arrest by Steel Factor. Molecular and Cellular Biology, 1995, 15, 6953-6960.	1.1	61
263	The p53-mediated G <sub>1</sub> checkpoint is retained in tumorigenic rat embryo fibroblast clones transformed by the human papillomavirus type 16 E7 gene and EJ- <i>ras</i> . Molecular and Cellular Biology, 1995, 15, 1446-1454.	1.1	29
264	Cyclin E Restores p53 Activity in Contact-Inhibited Cells. Molecular and Cellular Biology, 1995, 15, 3926-3933.	1.1	30
265	Cytokines Inhibit p53-Mediated Apoptosis but Not p53-Mediated G <sub>1</sub> Arrest. Molecular and Cellular Biology, 1995, 15, 6045-6054.	1.1	83
266	Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. British Journal of Cancer, 1995, 71, 215-218.	2.9	39
267	Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53. Annals of Oncology, 1995, 6, 589-593.	0.6	19
268	Gene Therapy for Brain Tumors. Brain Pathology, 1995, 5, 345-381.	2.1	93
269	Molecular Genetics of Exocrine Pancreatic Neoplasms. Surgical Clinics of North America, 1995, 75, 857-869.	0.5	58
270	p53: DNA damage, DNA repair, and apoptosis. Reviews of Physiology, Biochemistry and Pharmacology, 1995, 127, 65-95.	0.9	44
271	Mutation and Cancer: A Personal Odyssey. Advances in Cancer Research, 1995, 67, 1-23.	1.9	29
272	Tumor Necrosis Factor-α Induces p53-dependent Apoptosis in Rat Glioma Cells. Neurosurgery, 1995, 37, 758-763.	0.6	38

#	Article	IF	CITATIONS
273	Tumor Suppressor p53 Mutations and Breast Cancer: A Critical Analysis. Advances in Cancer Research, 1995, 66, 71-141.	1.9	79
274	V(D)J Recombination and Double-Strand Break Repair. Advances in Immunology, 1995, 58, 29-85.	1.1	55
275	Expression of p53 in urothelial cell cultures from tumour-bearing and tumour-free patients. British Journal of Cancer, 1995, 71, 25-29.	2.9	12
276	The p53 tumor suppressor gene. Advances in Genome Biology, 1995, 3, 55-141.	0.3	2
277	Genetic aspects of tumor suppressor genes. Advances in Genome Biology, 1995, 3, 143-162.	0.3	0
278	A possible screening test for inherited p53-related defects based on the apoptotic response of peripheral blood lymphocytes to DNA damage. British Journal of Cancer, 1995, 72, 654-662.	2.9	37
279	p53 as a prognostic factor in stage I breast cancer. British Journal of Cancer, 1995, 72, 715-719.	2.9	25
280	A dominant-negative mutant of human poly(ADP-ribose) polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 4753-4757.	3.3	203
281	Increased activity of p53 in senescing fibroblasts Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 8348-8352.	3.3	285
282	Gas1-Induced Growth Suppression Requires a Transactivation-Independent p53 Function. Molecular and Cellular Biology, 1995, 15, 7152-7160.	1.1	93
283	Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression. Molecular and Cellular Biology, 1995, 15, 3032-3040.	1.1	692
284	Is TFIIH an activator of the p53-mediated G1/S checkpoint?. Trends in Genetics, 1995, 11, 165-166.	2.9	9
285	Regrowth resistance in cancer: why has it been largely ignored?. Cell Proliferation, 1995, 28, 347-356.	2.4	13
286	Differential effects of nitrogen mustard <i>in vivo</i> on the cancer and host cells in MCaâ€11 tumours. Cell Proliferation, 1995, 28, 403-414.	2.4	2
287	Elevated levels of wild-type p53 induced by radiolabeling of cells leads to apoptosis or sustained growth arrest. Current Biology, 1995, 5, 423-431.	1.8	67
288	The role of p53 in regulating genomic stability when DNA and RNA synthesis are inhibited. Trends in Biochemical Sciences, 1995, 20, 431-434.	3.7	65
289	Transgenic mouse models for tumourâ€suppressor genes. Journal of Internal Medicine, 1995, 238, 233-238.	2.7	16
290	p53 Immunostaining distinguishes malignant from benign lesions of the gallâ€bladder. Pathology International, 1995, 45, 58-65.	0.6	60

#	Article	IF	CITATIONS
291	Phosphorylation Studies on Rat p53 Using the Baculovirus Expression System. Manipulation of the Phosphorylation State with Okadaic Acid and Influence on DNA Binding. FEBS Journal, 1995, 228, 625-639.	0.2	39
292	Accumulation of wildâ€ŧype p53 in meningiomas. Neuropathology and Applied Neurobiology, 1995, 21, 136-142.	1.8	36
293	Molecular genetics and chromosomal alterations in prostate cancer. Cancer, 1995, 75, 2004-2012.	2.0	31
294	Expression and mutation analysis of the p53 gene in uterine papillary serous carcinoma. Cancer, 1995, 75, 2700-2705.	2.0	57
295	Prognostic implication of the p53 protein and Ki-67 antigen immunohistochemistry in malignant fibrous histiocytoma. Cancer, 1995, 76, 618-625.	2.0	41
296	Molecular basis of endometrial cancer. Cancer, 1995, 76, 2034-2040.	2.0	89
297	Does telomere shortening drive selection forp53 mutation in human cancer?. Molecular Carcinogenesis, 1995, 12, 119-123.	1.3	41
298	Thep53 andmdm-2 genes in human testicular germ-cell tumors. Molecular Carcinogenesis, 1995, 12, 124-131.	1.3	90
299	Overexpression of MDM-2 mRNA and mutation of thep53 tumor suppressor gene in bladder carcinoma cell lines. Molecular Carcinogenesis, 1995, 13, 173-181.	1.3	35
300	Use of wild-typep53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Molecular Carcinogenesis, 1995, 14, 275-285.	1.3	91
301	Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage. BioEssays, 1995, 17, 501-508.	1.2	292
302	Stopped for repairs. BioEssays, 1995, 17, 545-548.	1.2	70
303	Life and death by P53. BioEssays, 1995, 17, 923-930.	1.2	110
304	Transfected mutantp53 gene increases X-ray-induced cell killing and mutation in human fibroblasts immortalized with 4-nitroquinoline 1-oxide but does not induce neoplastic transformation of the cells. International Journal of Cancer, 1995, 61, 76-79.	2.3	26
305	Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-typep53 andWAF1/CIP1 genes. International Journal of Cancer, 1995, 61, 397-401.	2.3	36
306	Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line. International Journal of Cancer, 1995, 62, 170-175.	2.3	21
307	The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. International Journal of Cancer, 1995, 64, 37-46.	2.3	86
308	p53 protein accumulation and the presence of human papillomavirus dna in bronchiolo-alveolar carcinoma correlate with poor prognosis. International Journal of Cancer, 1995, 64, 424-429.	2.3	34

#	Article	IF	CITATIONS
309	Thep53 gene and its role in human brain tumors. Glia, 1995, 15, 308-327.	2.5	172
310	Regulation of c-fos expression in senescing Werner syndrome fibroblasts differs from that observed in senescing fibroblasts from normal donors. Journal of Cellular Physiology, 1995, 162, 277-283.	2.0	75
311	Nucleolar p120 is expressed as a delayed early response gene and is inducible by DNA-damaging agents. Journal of Cellular Physiology, 1995, 164, 634-643.	2.0	6
312	Molecular aspects of chemical carcinogenesis: The roles of oncogenes and tumour suppressor genes. Toxicology, 1995, 96, 173-194.	2.0	88
313	Expression of cell cycle regulatory proteins (p53, pRB) in the human female genital tract. Journal of Assisted Reproduction and Genetics, 1995, 12, 123-131.	1.2	14
314	Analysis of the p53 gene mutations in acute myelogenous leukemia: The p53 gene mutations associated with a deletion of chromosome 17. Annals of Hematology, 1995, 71, 83-87.	0.8	11
315	Effects of ionizing radiation on cell cycle progression. Radiation and Environmental Biophysics, 1995, 34, 79-83.	0.6	133
316	Murine models of neoplasia: functional analysis of the tumour suppressor genesRb-1 andp53. Cancer and Metastasis Reviews, 1995, 14, 125-148.	2.7	17
317	Apoptosis, cancer and the p53 tumour suppressor gene. Cancer and Metastasis Reviews, 1995, 14, 149-161.	2.7	154
318	P53, cell cycle control and apoptosis: Implications for cancer. Cancer and Metastasis Reviews, 1995, 14, 3-15.	2.7	433
319	Cell cycle regulation in response to DNA damage in mammalian cells: A historical perspective. Cancer and Metastasis Reviews, 1995, 14, 17-29.	2.7	102
320	Cell cycle checkpoints and DNA repair preserve the stability of the human genome. Cancer and Metastasis Reviews, 1995, 14, 31-41.	2.7	66
321	A role for genomic instability in cellular radioresistance?. Cancer and Metastasis Reviews, 1995, 14, 49-58.	2.7	50
322	Genetic instability as a consequence of inappropriate entry into and Progression through S-phase. Cancer and Metastasis Reviews, 1995, 14, 59-73.	2.7	82
323	Molecular mechanisms of virus-induced carcinogenesis: the interaction of viral factors with cellular tumor suppressor proteins. Journal of Molecular Medicine, 1995, 73, 529-38.	1.7	35
324	Correlation of p53 protein expression with apoptotic incidence in colorectal neoplasia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1995, 427, 27-32.	1.4	37
325	Role of tumor suppressor genes in determining radiation-induced G1 arrest and transformation in human cells. Radiation Oncology Investigations, 1995, 3, 268-271.	1.3	0
326	Mini review:Molecular mechanisms of immortalization of human mammary epithelial cells. Radiation Oncology Investigations, 1995, 3, 430-434.	1.3	0

#	Article	IF	Citations
327	Molecular mechanisms of drug resistance in tumours. Journal of Pathology, 1995, 175, 7-12.	2.1	76
328	Demonstration of DNA damage/repair in individual cells usingin situ end labelling: Association of p53 with sites of DNA damage. Journal of Pathology, 1995, 176, 19-26.	2.1	70
329	Expression ofbcl-2 oncoprotein in renal cell tumours. Journal of Pathology, 1995, 177, 247-252.	2.1	45
330	p53 immunoreactivity is uncommon in primary cutaneous lymphoma. British Journal of Dermatology, 1995, 132, 353-358.	1.4	29
331	Nuclear Accumulation of p53 in Normal Human Fibroblasts Is Induced by Various Cellular Stresses which Evoke the Heat Shock Response, Independently of the Cell Cycle. Japanese Journal of Cancer Research, 1995, 86, 415-418.	1.7	58
332	Inhibition of p53 Protein Phosphorylation by 9-Hydroxyellipticine: A Possible Anticancer Mechanism. Japanese Journal of Cancer Research, 1995, 86, 819-827.	1.7	62
333	Tumor Suppressor Genes: Prospects for Cancer Therapies. Nature Biotechnology, 1995, 13, 127-131.	9.4	3
334	A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53–deficient mice. Nature Genetics, 1995, 9, 305-311.	9.4	224
335	A subset of p53-deficient embryos exhibit exencephaly. Nature Genetics, 1995, 10, 175-180.	9.4	544
336	A teratologic suppressor role for p53 in benzo(a)pyrene–treated transgenic p53-deficient mice. Nature Genetics, 1995, 10, 181-187.	9.4	234
337	Molecular foundations of cancer: New targets for intervention. Nature Medicine, 1995, 1, 309-320.	15.2	100
338	Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature, 1995, 378, 206-208.	13.7	1,169
339	Family history of cancer, body weight, and p53 nuclear overexpression in Duke's C colorectal cancer. British Journal of Cancer, 1995, 71, 888-893.	2.9	15
340	Abnormal pattern of post- $\hat{l}^3$ -ray DNA replication in radioresistant fibroblast strains from affected members of a cancer-prone family with Li-Fraumeni syndrome. British Journal of Cancer, 1995, 71, 1221-1230.	2.9	22
341	p53 status of head and neck cancer: relation to biological characteristics and outcome of radiotherapy. British Journal of Cancer, 1995, 71, 1248-1252.	2.9	61
342	Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. British Journal of Cancer, 1995, 72, 849-856.	2.9	121
343	Induction of p53 protein by gamma radiation in lymphocyte lines from breast cancer and ataxia telangiectasia patients. British Journal of Cancer, 1995, 72, 1096-1101.	2.9	16
344	Differences in resistance to 5-fluorouracil as a function of cell cycle delay and not apoptosis. British Journal of Cancer, 1995, 72, 1389-1396.	2.9	31

#	ARTICLE	IF	CITATIONS
345	Expression of p53 protein in oral squamous cell carcinomas and adjacent non-tumorous mucosa of the floor of the mouth: an archival immunohistochemical study using wet autoclave pretreatment for antigen retrieval. Journal of Oral Pathology and Medicine, 1995, 24, 337-342.	1.4	29
346	Proto-oncogenes and oncogenes in epidermal neoplasia. Experimental Dermatology, 1995, 4, 65-73.	1.4	2
347	The specificity of p53 mutation spectra in sunlight induced human cancers. Journal of Photochemistry and Photobiology B: Biology, 1995, 28, 115-124.	1.7	137
348	Transforming growth factor alpha expression as a potential survival prognosticator in patients with esophageal adenocarcinoma receiving high-dose radiation and chemotherapy. International Journal of Radiation Oncology Biology Physics, 1995, 31, 567-569.	0.4	10
349	Astro research fellowship: Apoptosis as a predictor of tumor response to radiation in Stage IB cervical carcinoma. International Journal of Radiation Oncology Biology Physics, 1995, 32, 1487-1493.	0.4	101
350	V(D)J recombination and the cell cycle. Trends in Immunology, 1995, 16, 279-289.	7.5	89
351	Mitotic and post mitotic consequences of genomic instability induced by oncogenic Ha-Ras. Somatic Cell and Molecular Genetics, 1995, 21, 241-253.	0.7	41
352	c-Myc and apoptosis. Biochimica Et Biophysica Acta: Reviews on Cancer, 1995, 1242, 11-28.	3.3	127
353	Stage-specific DNA synthesis of rat spermatogenesis as an indicator of genotoxic effects of vinblastine, mitomycin C and ionizing radiation on rat spermatogonia and spermatocytes. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1995, 331, 181-190.	0.4	19
354	p53 gene mutations with chromosome 17 abnormalities in chronic myelogenous leukemia blast crisis patients persist in long term cell lines but may be acquired in acute myeloid leukemia cells in vitro. Cancer Genetics and Cytogenetics, 1995, 82, 35-40.	1.0	9
355	The relative radiosensitivity of TK6 and WI-L2-NS lymphoblastoid cells derived from a common source is primarily determined by their p53 mutational status. Mutation Research-Fundamental and Molecular Mechanisms of Mutagenesis, 1995, 346, 85-92.	1.2	55
356	Progress against cancer. Journal of Cancer Research and Clinical Oncology, 1995, 121, 633-647.	1.2	8
357	Lack of a correlation between p53 protein expression and radiation response in human tumor primary cultures. Stem Cells, 1995, 13, 77-85.	1.4	19
358	Higher Level of P-glycoprotein Expression in Human Breast Cancer Cells after Radiation Therapy. Breast Cancer, 1995, 2, 99-103.	1.3	4
359	Suppression of the Yeast Mutation rft1-1 by Human p53. Journal of Biological Chemistry, 1995, 270, 22556-22564.	1.6	14
360	Alternatively Spliced Forms in the Carboxy-Terminal Domain of the p53 Protein Regulate Its Ability to Promote Annealing of Complementary Single Strands of Nucleic Acids. Molecular and Cellular Biology, 1995, 15, 497-504.	1.1	115
361	Cervical cancer: is herpes simplex virus type II a cofactor?. Clinical Microbiology Reviews, 1995, 8, 549-556.	5.7	39
362	Apoptosis and inflammation. Mediators of Inflammation, 1995, 4, 5-15.	1.4	122

#	Article	IF	CITATIONS
363	A p53-dependent mouse spindle checkpoint. Science, 1995, 267, 1353-1356.	6.0	683
364	To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo?. Human and Experimental Toxicology, 1995, 14, 222-225.	1.1	26
365	p53 Is Phosphorylated in Vitro and in Vivo by an Ultraviolet Radiation-induced Protein Kinase Characteristic of the c-Jun Kinase, JNK1. Journal of Biological Chemistry, 1995, 270, 5511-5518.	1.6	215
366	Accumulation of mutant p53 and hsp72 by heat treatment, and their association in a human glioblastoma cell line. International Journal of Hyperthermia, 1995, 11, 663-671.	1.1	16
367	Growth factor modulation of p53-mediated growth arrest versus apoptosis Genes and Development, 1995, 9, 600-611.	2.7	331
368	Inhibition of Nucleotide Excision Repair by the Cyclin-dependent Kinase Inhibitor p21. Journal of Biological Chemistry, 1995, 270, 22008-22016.	1.6	134
369	Cell Cycle Arrest Induced by an Inhibitor of Glucosylceramide Synthase. Journal of Biological Chemistry, 1995, 270, 2859-2867.	1.6	152
370	Radiation Injury and Radiation Carcinogenesis with Special Reference to Combination Effects with Chemical Agents., 1995,, 473-508.		0
371	Inhibitors of mammalian G1 cyclin-dependent kinases Genes and Development, 1995, 9, 1149-1163.	2.7	2,940
372	p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Research, 1995, 23, 362-369.	6.5	163
373	Two Distinct Signaling Pathways Activate the Latent DNA Binding Function of p53 in a Casein Kinase II-independent Manner. Journal of Biological Chemistry, 1995, 270, 18165-18174.	1.6	96
374	Immortalization of Keratinocytes by Human Papillomaviruses. Infectious Agents and Pathogenesis, 1995, , 91-109.	0.1	1
375	Short Communication. Biological Chemistry Hoppe-Seyler, 1995, 376, 627-636.	1.4	30
376	Regulation of p53-Dependent Apoptosis by E1A and E1B. Current Topics in Microbiology and Immunology, 1995, , 33-58.	0.7	24
377	p53, Rb and bcl-2 expression during the cell cycle: a study in phytohaemagglutinin stimulated lymphocytes and microwave irradiated lymphoid tissue sections Journal of Clinical Pathology, 1995, 48, 151-159.	1.0	20
378	p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. British Journal of Cancer, 1995, 72, 952-957.	2.9	48
379	Identification of a Novel p53 Promoter Element Involved in Genotoxic Stress-Inducible p53 Gene Expression. Molecular and Cellular Biology, 1995, 15, 4489-4496.	1.1	100
380	Up-Regulation of p21WAF1/CIP1 in Psoriasis and After the Application of Irritants and Tape Stripping. Journal of Investigative Dermatology, 1995, 105, 274-279.	0.3	33

#	Article	IF	Citations
381	The P53 Tumor Suppressor Protein. , 1995, , 407-418.		2
382	Effects of Tumor Necrosis Factor-α on Antimitogenicity and Cell Cycle-related Proteins in MCF-7 Cells. Journal of Biological Chemistry, 1995, 270, 18367-18373.	1.6	64
383	Potential Role of WAF1/Cip1/p21 as a Mediator of TGF- $\hat{l}^2$ Cytoinhibitory Effect. Journal of Biological Chemistry, 1995, 270, 4971-4974.	1.6	211
384	Essential role for p53-mediated transcription in E1A-induced apoptosis Genes and Development, 1995, 9, 2184-2192.	2.7	214
385	p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 1342-1346.	3.3	51
386	Wild Type p53 Stimulates Expression from the Human Multidrug Resistance Promoter in a p53-negative Cell Line. Journal of Biological Chemistry, 1995, 270, 1894-1898.	1.6	57
387	[8] Analysis of cell cycle checkpoint status in mammalian cells. Methods in Enzymology, 1995, 254, 125-133.	0.4	12
388	Apoptosis Overview Emphasizing the Role of Oxidative Stress, DNA Damage and Signal-Transduction Pathways. Leukemia and Lymphoma, 1995, 19, 43-93.	0.6	161
389	Cellular aging in vitro. Reviews in Clinical Gerontology, 1995, 5, 369-381.	0.5	5
390	UV Irradiation and Heat Shock Mediate JNK Activation via Alternate Pathways. Journal of Biological Chemistry, 1995, 270, 26071-26077.	1.6	199
391	p53: A Cell Cycle Regulator Activated by DNA Damage. Advances in Cancer Research, 1995, 66, 143-180.	1.9	107
392	p53-dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin Journal of Cell Biology, 1995, 128, 1185-1196.	2.3	162
393	p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F Genes and Development, 1995, 9, 1740-1752.	2.7	236
394	Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability Genes and Development, 1995, 9, 882-895.	2.7	246
395	p53-dependent growth arrest of REF52 cells containing newly amplified DNA Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 3224-3228.	3.3	38
396	Regulation of the Sequence-specific DNA Binding Function of p53 by Protein Kinase C and Protein Phosphatases. Journal of Biological Chemistry, 1995, 270, 5405-5411.	1.6	186
397	Different regulation of p53 stability in UV-irradiated normal and DNA repair deficient human cells. Mutation Research DNA Repair, 1995, 336, 169-180.	3.8	18
398	Preferential repair of the transcribed DNA strand in the dihydrofolate reductase gene throughout the cell cycle in UV-irradiated human cells. Mutation Research DNA Repair, 1995, 336, 181-192.	3.8	40

#	Article	IF	Citations
399	Genomic instability and cancer. Mutation Research DNA Repair, 1995, 337, 1-7.	3.8	82
400	Apoptosis and the cell cycle. Current Opinion in Cell Biology, 1995, 7, 825-834.	2.6	316
401	Apoptosis in the embryo and tumorigenesis. European Journal of Cancer, 1995, 31, 116-123.	1.3	30
402	differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: Implication in drug and radioresistance. European Journal of Cancer Part B, Oral Oncology, 1995, 31, 384-391.	0.9	63
403	Role of poly(ADP-ribose) polymerase in cell-cycle checkpoint mechanisms following $\hat{I}^3$ -irradiation. Biochimie, 1995, 77, 462-465.	1.3	63
404	Apoptosis and nuclear levels of p53 protein and proliferating cell nuclear antigen in human hepatoma cells cultured with tumor promoters. Cancer Letters, 1995, 91, 11-17.	3.2	13
405	Binding between wild-type p53 and hsp72 accumulated after UV and $\hat{l}^3$ -ray irradiation. Cancer Letters, 1995, 92, 127-133.	3.2	64
406	Passage of X-ray-induced immortal, non-transformed phenotype by DNA-mediated transfection. Cancer Letters, 1995, 97, 39-47.	3.2	2
407	Transgenic models and cancer treatment. Cancer Treatment Reviews, 1995, 21, 565-576.	3.4	1
408	Cloning and characterization of two processed p53 pseudogenes from the rat genome. Gene, 1995, 156, 183-189.	1.0	11
409	A splice donor site mutation results in the insertion of five extra amino acids into P53 from SEWA mouse sarcoma cells. Gene, 1995, 162, 231-234.	1.0	2
410	p53 Expression and DNA ploidy of cartilage lesions. Human Pathology, 1995, 26, 620-624.	1.1	67
411	p53 Mediated tumor cell response to chemotherapeutic dna damage: A preliminary study in matched pairs of breast cancer biopsies. Human Pathology, 1995, 26, 1293-1301.	1.1	35
412	Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell, 1995, 82, 675-684.	13.5	2,022
413	Small peptides activate the latent sequence-specific DNA binding function of p53. Cell, 1995, 83, 237-245.	13.5	477
414	The retinoblastoma protein and cell cycle control. Cell, 1995, 81, 323-330.	13.5	4,548
415	Induction of p53 and apoptosis byl 12-PGJ2in human hepatocarcinoma SK-HEP-1 cells. FEBS Letters, 1995, 368, 348-352.	1.3	34
416	The Spectrum of Mutations at the p53 Locus. Annals of the New York Academy of Sciences, 1995, 768, 111-128.	1.8	91

#	Article	IF	Citations
417	Yeast Checkpoint Genes in DNA Damage Processing: Implications for Repair and Arrest. Science, 1995, 270, 1488-1491.	6.0	386
418	p53 mutations, O6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors. Cancer, 1995, 75, 1339-1342.	2.0	41
419	The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. Radiotherapy and Oncology, 1995, 36, 218-224.	0.3	28
420	Biopathologic Features of Hodgkin's Disease. Leukemia and Lymphoma, 1995, 16, 385-396.	0.6	8
421	Radiation-induced Apoptotic Cell Death in Human Gastric Epithelial Tumour Cells; Correlation Between Mitotic Death and Apoptosis. International Journal of Radiation Biology, 1995, 67, 677-685.	1.0	54
422	The Prognostic Value of P53 in Superficially Infiltrating Transitional Cell Carcinoma. Scandinavian Journal of Urology and Nephrology, 1995, 29, 491-495.	1.4	29
423	p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell, 1995, 81, 1013-1020.	13.5	394
424	Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man. Toxicology Letters, 1995, 82-83, 425-430.	0.4	25
425	Irregular variations in radiation sensitivity when the linear energy transfer is increased. Radiotherapy and Oncology, 1995, 36, 133-142.	0.3	24
426	Radiation induced G1-block and p53 status in six human cell lines. Radiotherapy and Oncology, 1995, 37, 20-28.	0.3	47
427	NEW APPROACHES TO ADJUVANT THERAPY FOR PATIENTS WITH ADVERSE HISTOPATHOLOGIC FINDINGS FOLLOWING RADICAL PROSTATECTOMY. Urologic Clinics of North America, 1996, 23, 685-696.	0.8	4
428	Expression of p34cdc2 Protein Kinase and p53 in Supraglottic Carcinomas. Auris Nasus Larynx, 1996, 23, 105-110.	0.5	2
429	lonizing radiation-induced phosphorylation of RPA p34 is deficient in ataxia telangiectasia and reduced in aged normal fibroblasts. Radiotherapy and Oncology, 1996, 39, 43-52.	0.3	38
430	The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiotherapy and Oncology, 1996, 40, 197-223.	0.3	185
431	The role of thymidylate synthase in cellular regulation. Advances in Enzyme Regulation, 1996, 36, 143-163.	2.9	46
432	p53 accumulation in the organs of low-dose X-ray-irradiated mice. Cancer Letters, 1996, 104, 79-84.	3.2	27
433	Heat-shock enhanced reactivation of a UV-damaged reporter gene in human cells involves the transcription coupled DNA repair pathway. Mutation Research DNA Repair, 1996, 363, 125-135.	3.8	23
434	The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. Trends in Molecular Medicine, 1996, 2, 32-37.	2.6	51

#	Article	IF	Citations
435	Predominant p53 mutations in enzootic bovine leukemic cell lines. Veterinary Immunology and Immunopathology, 1996, 52, 53-63.	0.5	19
436	Influence of both salvage and DNA damage response pathways on resistance to chemotherapeutic antimetabolites. Biochemical Pharmacology, 1996, 52, 425-431.	2.0	11
437	Non-histone protein 1 (NHP1) is a member of the Ku protein family which is upregulated in differentiating mouse myoblasts and human promyelocytes. FEBS Letters, 1996, 382, 313-318.	1.3	8
438	The role of DNA repair in the prevention of cancer. Molecular Aspects of Medicine, 1996, 17, 235-383.	2.7	6
439	Nitric oxide donors induce apoptosis in glomerular mesangial cells, epithelial cells and endothelial cells. European Journal of Pharmacology, 1996, 317, 137-149.	1.7	89
440	Immunohistochemical Expression of p53 Protein, Mitotic Index and Nuclear Morphometry in Primary Malignant Melanoma of the Skin. Pathology Research and Practice, 1996, 192, 825-833.	1.0	20
441	p53 and PCNA Coexpression of 81 Pleural and Peritoneal Effusion Specimens: An Immunohistochemical Study. Pathology Research and Practice, 1996, 192, 834-839.	1.0	3
442	p21ras in Carcinogenesis. Pathology Research and Practice, 1996, 192, 658-668.	1.0	12
443	The Role of p53 in Cell Cycle Regulation. Pathology Research and Practice, 1996, 192, 669-675.	1.0	104
444	Role of induced genetic instability in the mutagenic effects of chemicals and radiation. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1996, 367, 11-23.	1.2	59
445	p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. European Journal of Surgical Oncology, 1996, 22, 182-185.	0.5	33
446	The flow cytometric analysis of total p53 protein content and proliferation indices in colorectal cancer, in relation to clinical outcome. European Journal of Surgical Oncology, 1996, 22, 508-515.	0.5	6
447	p53: puzzle and paradigm Genes and Development, 1996, 10, 1054-1072.	2.7	2,145
448	Abnormal Centrosome Amplification in the Absence of p53. Science, 1996, 271, 1744-1747.	6.0	773
449	Increased Radiosensitivity is Associated with p53 Mutations in Cell Lines Derived from Oral Cavity Carcinoma. Acta Oto-Laryngologica, 1996, 116, 341-344.	0.3	30
450	Increased Cisplatin Sensitivity of Human Fibroblasts from a Subject with Inherent Glutathione Deficiency. Acta Oncológica, 1996, 35, 683-690.	0.8	10
451	Regulation of transcription factor activity during cellular aging. Biochemistry and Cell Biology, 1996, 74, 523-534.	0.9	33
452	The stress response to ionizing radiation involoves c-Abl-dependent phosphorylation of SHPTP1  Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 6898-6901.	3.3	85

#	Article	IF	CITATIONS
453	DNA strand breaks in human nasal respiratory epithelium are induced upon exposure to urban pollution Environmental Health Perspectives, 1996, 104, 160-168.	2.8	47
454	Immunohistochemical study of oral leukoplakia. Correlation of epithelial dysplasia with Ley antigen and P53 protein Nihon Koku Geka Gakkai Zasshi, 1996, 42, 264-269.	0.0	0
455	Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 4827-4832.	3.3	339
456	DNA damage and p53-mediated cell cycle arrest: A reevaluation. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 15209-15214.	3.3	179
457	Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53 Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 2442-2447.	3.3	413
458	A human homolog of the Schizosaccharomyces pombe rad9+ checkpoint control gene. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 13890-13895.	3.3	116
459	Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 15335-15340.	3.3	401
460	Cytoplasmic Sequestration of Wild-Type p53 Protein Impairs the G <sub>1</sub> Checkpoint after DNA Damage. Molecular and Cellular Biology, 1996, 16, 1126-1137.	1.1	265
461	Inhibition of p53-Mediated Growth Arrest by Overexpression of Cyclin-Dependent Kinases. Molecular and Cellular Biology, 1996, 16, 4445-4455.	1.1	34
462	Immunohistochemical Detection of p53 Tumor Suppressor Protein in Porokeratosis. Journal of Dermatology, 1996, 23, 365-368.	0.6	16
463	A Mutation in Mouse <i>rad51</i> Results in an Early Embryonic Lethal That Is Suppressed by a Mutation in <i>p53</i> Molecular and Cellular Biology, 1996, 16, 7133-7143.	1.1	665
464	The Role of the p53 Tumor Suppressor Gene in the Tumorigenesis of Inverting Papilloma of the Nose and Paranasal Sinuses. American Journal of Rhinology & Allergy, 1996, 10, 97-100.	2.3	4
465	Reducing the radiation-induced G2 delay causes HeLa cells to undergo apoptosis instead of mitotic death. International Journal of Radiation Biology, 1996, 69, 575-584.	1.0	68
466	Induction of inositol 1,4,5 trisphosphate receptor genes by ionizing radiation. International Journal of Radiation Biology, 1996, 69, 539-546.	1.0	14
467	Spontaneous p53 mutation in murine mesothelial cells:increased sensitivity to dna damage induced by asbestos and ionizing radiation. Toxicology and Applied Pharmacology, 1996, 141, 264-271.	1.3	17
468	Signals from the Stressed Endoplasmic Reticulum Induce C/EBP-Homologous Protein (CHOP/GADD153). Molecular and Cellular Biology, 1996, 16, 4273-4280.	1.1	635
469	A Mutant p53 That Discriminates between p53-Responsive Genes Cannot Induce Apoptosis. Molecular and Cellular Biology, 1996, 16, 4961-4971.	1.1	285
470	p53 Plays a Regulatory Role in Differentiation and Apoptosis of Central Nervous System-Associated Cells. Molecular and Cellular Biology, 1996, 16, 5178-5185.	1.1	194

#	Article	IF	CITATIONS
471	Ascorbic Acid 2-OALPHAGlucoside, a Stable Form of Ascorbic Acid, Rescues Human Keratinocyte Cell Line, SCC, from Cytotoxicity of Ultraviolet Light B Biological and Pharmaceutical Bulletin, 1996, 19, 984-987.	0.6	24
472	Early p53 alterations in mouse skin carcinogenesis by UVB radiation: immunohistochemical detection of mutant p53 protein in clusters of preneoplastic epidermal cells Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 274-278.	3.3	205
473	Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53 Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 895-899.	3.3	120
474	17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7081-7084.	3.3	321
475	EGR-1 Induction Is Required for Maximal Radiosensitivity in A375-C6 Melanoma Cells. Journal of Biological Chemistry, 1996, 271, 29231-29237.	1.6	61
476	p53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma. British Journal of Cancer, 1996, 74, 1157-1160.	2.9	11
477	Apoptosis induction resulting from proteasome inhibition. Biochemical Journal, 1996, 317, 385-388.	1.7	225
478	Mammalian cells resistant to tumor suppressor genes Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 8390-8394.	3.3	9
479	Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 10309-10314.	3.3	165
480	The DNA damage response in DNA-dependent protein kinase-deficient SCID mouse cells: Replication protein A hyperphosphorylation and p53 induction. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 13825-13830.	3.3	93
481	p53 gene alterations and protein accumulation in colorectal cancer. Journal of Clinical Pathology, 1996, 49, M85-M90.	2.1	7
482	Cancer Cell Cycles. Science, 1996, 274, 1672-1677.	6.0	4,932
483	Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors. Diseases of the Colon and Rectum, 1996, 39, 1269-1274.	0.7	15
484	Cyclin D1 induced apoptosis maintains the integrity of the G1/S checkpoint following ionizing radiation irradiation. Somatic Cell and Molecular Genetics, 1996, 22, 135-144.	0.7	36
486	Midgut carcinoids and solid carcinomas of the intestine: Differences in endocrine markers and p53 mutations. Endocrine Pathology, 1996, 7, 273-279.	5.2	14
487	Increased tubulin acetylation accompanies reversion to stable ploidy in vincristine-resistant CCRF-CEM cells. Cancer Genetics and Cytogenetics, 1996, 87, 117-122.	1.0	14
488	The role of dna damage in cellular aging: Is it time for a reassessment?. Experimental Gerontology, 1996, 31, 61-68.	1.2	10
489	Chromosome changes caused by alterations of p53 expression. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1996, 354, 129-138.	0.4	50

#	Article	IF	CITATIONS
490	A mutation in the p53 tumor suppressor gene of AHH-1 tk+â^ human lymphoblastoid cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1996, 356, 129-134.	0.4	17
491	p53 and translational control. Biochimica Et Biophysica Acta: Reviews on Cancer, 1996, 1242, 181-184.	3.3	29
492	p53 in growth control and neoplasia. Biochimica Et Biophysica Acta: Reviews on Cancer, 1996, 1287, 77-102.	3.3	268
493	Pterygia and limbal epithelial cells: Relationship and molecular mechanisms. Progress in Retinal and Eye Research, 1996, 15, 297-329.	7.3	13
494	Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. Journal of Cancer Research and Clinical Oncology, 1996, 122, 489-494.	1.2	33
495	Lack ofp53 mutations and loss of heterozygosity in non-cultured human melanocytic lesions. Journal of Cancer Research and Clinical Oncology, 1996, 122, 541-548.	1.2	60
496	Lessons from thep53 mutant mouse. Journal of Cancer Research and Clinical Oncology, 1996, 122, 319-327.	1.2	33
497	Proliferative (mib1, mdm2) versus anti-proliferative (p53) markers in head and neck cancer. An Immunohistochemical study. Pathology and Oncology Research, 1996, 2, 37-42.	0.9	5
498	Regulation of the cell cycle following DNA damage in normal and Ataxia telangiectasia cells. Experientia, 1996, 52, 316-328.	1.2	14
499	Role of protein kinase activity in apoptosis. Experientia, 1996, 52, 979-994.	1.2	60
500	The p53 tumour suppressor gene: a mediator of a G1 growth arrest and of apoptosis. Experientia, 1996, 52, 1001-1007.	1.2	70
501	P53, apoptosis, and breast cancer. Journal of Mammary Gland Biology and Neoplasia, 1996, 1, 163-175.	1.0	35
502	Photoreversion of ultraviolet induced apoptosis in Rat Kangaroo cells. Apoptosis: an International Journal on Programmed Cell Death, 1996, 1, 153-160.	2.2	6
503	Outcome of 31 intracranial haemangiopericytomas: Poor predictive value of cell proliferation indices. Acta Neurochirurgica, 1996, 138, 1399-1408.	0.9	71
504	Nuclear image analysis of immunohistochemically stained cells in breast carcinomas. Histochemistry and Cell Biology, 1996, 105, 479-485.	0.8	13
505	Cell-cycle arrests and p53 accumulation induced by geldanamycin in human ovarian tumour cells. Cancer Chemotherapy and Pharmacology, 1996, 37, 423-428.	1.1	27
506	cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemotherapy and Pharmacology, 1996, 37, 463-471.	1.1	84
507	Dependence of fluorodeoxyuridine-induced cytotoxicity and megabase DNA fragment formation on S phase progression in HT29 cells. Cancer Chemotherapy and Pharmacology, 1996, 37, 486-490.	1.1	7

#	Article	IF	Citations
508	Cell cycle-dependent expression of the mouseRad51 gene in proliferating cells. Molecular Genetics and Genomics, 1996, 251, 1-12.	2.4	78
509	Apoptosis: Molecular Regulation of Cell Death. FEBS Journal, 1996, 236, 1-26.	0.2	563
510	Expression and mutational analysis of P53 in stage IB and IIA cervical cancers. American Journal of Obstetrics and Gynecology, 1996, 175, 1266-1271.	0.7	18
511	Cell Cycle Kinetics Following UVA Irradiation in Comparison to UVB and UVC Irradiation. Photochemistry and Photobiology, 1996, 63, 492-497.	1.3	52
512	Teratogen-induced eye defects mediated by p53-dependent apoptosis. Current Biology, 1996, 6, 60-69.	1.8	70
513	Radiation-mediated gene expression in the pathogenesis of the clinical radiation response. Seminars in Radiation Oncology, 1996, 6, 250-267.	1.0	33
514	Molecular biology of the cell cycle: Potential for therapeutic applications in radiation oncology. Seminars in Radiation Oncology, 1996, 6, 284-294.	1.0	20
515	Repair of DNA damage produced by ionizing radiation: A minireview. Seminars in Radiation Oncology, 1996, 6, 295-305.	1.0	46
516	Tumor hypoxia and heterogeneity: Challenges and opportunities for the future. Seminars in Radiation Oncology, 1996, 6, 59-70.	1.0	88
517	Arsenic-induced neural tube defects in mice: Alterations in cell cycle gene expression. Reproductive Toxicology, 1996, 10, 447-454.	1.3	72
518	p53 protein expression in pancreatic tumors and its relationship to clinicopathological factors and prognosis., 1996, 62, 279-283.		4
519	Regulation of cellular proliferation effects on alteration of normal signaling pathways. Medical and Pediatric Oncology, 1996, 27, 20-24.	1.0	1
520	POSITIVE CORRELATION BETWEEN APOPTOTIC AND PROLIFERATIVE INDICES IN GASTROINTESTINAL LYMPHOMAS OF MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT). Journal of Pathology, 1996, 178, 379-384.	2.1	42
521	REVIEW ARTICLE. p53: GUARDIAN OF CELLULAR SENESCENCE. , 1996, 180, 118-121.		55
522	Molecular genetic analysis of clear cell adenocarcinomas of the vagina and cervix associated and unassociated with diethylstilbestrol exposure in utero. , 1996, 77, 507-513.		89
523	A research shortcut from a common cold virus to human cancer. , 1996, 78, 558-565.		5
524	Radioresistance and p53 status of T2 laryngeal carcinoma: Analysis by immunohistochemistry and denaturing gradient gel electrophoresis., 1996, 78, 991-997.		20
525	Ataxia telangiectasia and signal transduction. Radiation Oncology Investigations, 1996, 4, 101-107.	1.3	O

#	Article	IF	CITATIONS
526	Ionizing radiation and the cell cycle: A review. Radiation Oncology Investigations, 1996, 4, 147-158.	1.3	2
527	Prognostic significance of clinical factors and p53 expression in patients with glottic carcinoma treated with radiation therapy. Cancer, 1996, 78, 1693-1700.	2.0	43
528	Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: A review. , 1996, 69, 225-235.		244
529	Association ofp53 gene mutation with decreased chemosensitivity in human malignant gliomas. , 1996, 69, 236-240.		66
530	Cisplatin-induced apoptosis andp53 gene status in a cisplatin-resistant human ovarian carcinoma cell line., 1996, 68, 67-74.		46
531	Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines withp21/WAF1/CIP1 and/orp53 gene alterations. , 1996, 68, 501-505.		46
532	Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: Repression of E6/E7-oncogene expression and induction of apoptosis., 1996, 68, 506-513.		97
533	ADP-ribosylation of p53 tumor suppressor protein: Mutant but not wild-type p53 is modified., 1996, 62, 90-101.		69
534	MCL-1, a member of the BCL-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation., 1996, 166, 523-536.		156
535	Programmed cell death during mammary tissue involution induced by weaning, litter removal, and milk stasis., 1996, 168, 559-569.		131
536	Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells. Molecular Carcinogenesis, 1996, 16, 20-31.	1.3	124
537	p53 transactivation through various p53-responsive elements. , 1996, 16, 101-108.		13
538	The role of thymidylate synthase as an RNA binding protein. BioEssays, 1996, 18, 191-198.	1.2	115
539	Signalling to p53: where does it all start?. BioEssays, 1996, 18, 617-619.	1.2	31
540	P53 overexpression in head and neck carcinoma and radiotherapy results. International Journal of Radiation Oncology Biology Physics, 1996, 34, 323-332.	0.4	50
542	p53-Dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma. International Journal of Radiation Oncology Biology Physics, 1996, 36, 95-103.	0.4	100
543	p53 Expression in four human medulloblastoma-derived cell lines. Child's Nervous System, 1996, 12, 76-80.	0.6	4
544	The expression of retinoblastoma protein in epidermis is induced by ultraviolet B exposure. British Journal of Dermatology, 1996, 135, 406-411.	1.4	3

#	Article	IF	CITATIONS
545	Coexpression of p21Waf1/Cip1 and p53 in sun-exposed normal epidermis, but not in neoplastic epidermis. British Journal of Dermatology, 1996, 135, 717-720.	1.4	6
546	Programmed cell death and radioresistance. Cancer and Metastasis Reviews, 1996, 15, 119-131.	2.7	69
547	Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones. Clinical and Experimental Metastasis, 1996, 14, 95-106.	1.7	25
548	Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas. Journal of Neuro-Oncology, 1996, 27, 117-26.	1.4	30
549	Apoptosis in human gastric mucosa, chronic gastritis, dysplasia and carcinoma: analysis by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labelling. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1996, 428-428, 229-35.	1.4	58
550	Overexpression of p53 protein in squamous cell carcinoma of buccal mucosa and tongue in Taiwan: an immunohistochemical and clinicopathological study. Journal of Oral Pathology and Medicine, 1996, 25, 55-59.	1.4	36
551	Mdm-2 is not induced by p53 in human keratinocytes in vivo. Journal of Cutaneous Pathology, 1996, 23, 25-29.	0.7	6
552	Early Alterations of Apoptosis and Cell Proliferation in Azoxymethane-initiated Rat Colonic Epithelium. Japanese Journal of Cancer Research, 1996, 87, 575-582.	1.7	38
553	Identification of BTG2, an antiproliferative p53–dependent component of the DNA damage cellular response pathway. Nature Genetics, 1996, 14, 482-486.	9.4	384
554	Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Medicine, 1996, 2, 72-79.	15.2	626
555	A functionally inactive p53 protein interatocarcinoma cells is activated by either DNA damage or cellular differentiation. Nature Medicine, 1996, 2, 804-810.	15.2	205
556	Structure–based rescue of common tumor–derived p53 mutants. Nature Medicine, 1996, 2, 1143-1146.	15.2	96
557	Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature, 1996, 382, 816-818.	13.7	329
558	Relationship between p53 status and radiosensitivity in human tumour cell lines. British Journal of Cancer, 1996, 73, 581-588.	2.9	63
559	Comparative alterations in p53 expression and apoptosis in the irradiated rat small and large intestine. British Journal of Cancer, 1996, 74, 406-412.	2.9	24
560	No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines. British Journal of Cancer, 1996, 74, 698-703.	2.9	14
561	3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. British Journal of Cancer, 1996, 74, 1030-1036.	2.9	108
562	Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbation. British Journal of Cancer, 1996, 74, 1359-1368.	2.9	21

#	Article	IF	CITATIONS
563	Preferential radiosensitization of G1 checkpointâ€"Deficient cells by methylxanthines. International Journal of Radiation Oncology Biology Physics, 1996, 36, 1099-1106.	0.4	44
564	Involvement ofp53in DNA Strand Break-induced Apoptosis in Postmitotic CNS Neurons. European Journal of Neuroscience, 1996, 8, 1812-1821.	1.2	126
565	Defect in Multiple Cell Cycle Checkpoints in Ataxia-Telangiectasia Postirradiation. Journal of Biological Chemistry, 1996, 271, 20486-20493.	1.6	121
566	p53 Tumor Suppressor Protein Overexpression in Osteogenic Tumors of Dogs. Veterinary Pathology, 1996, 33, 213-221.	0.8	56
567	Mutations in the p53 and SCID genes cooperate in tumorigenesis Genes and Development, 1996, 10, 2055-2066.	2.7	153
568	Distinct roles of yeast MEC and RAD checkpoint genes in transcriptional induction after DNA damage and implications for function Molecular Biology of the Cell, 1996, 7, 703-718.	0.9	85
569	p53 tumour suppressor gene expression in pancreatic neuroendocrine tumour cells Gut, 1996, 38, 403-409.	6.1	35
570	The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein Genes and Development, 1996, 10, 461-477.	2.7	318
571	Cyclin G1 and Cyclin G2 Comprise a New Family of Cyclins with Contrasting Tissue-specific and Cell Cycle-regulated Expression. Journal of Biological Chemistry, 1996, 271, 6050-6061.	1.6	142
572	p53 Gene and Cell Cycling in Uveal Melanoma. American Journal of Ophthalmology, 1996, 121, 561-567.	1.7	35
573	Cyclin-dependent Kinases Are Inactivated by a Combination of p21 and Thr-14/Tyr-15 Phosphorylation after UV-induced DNA Damage. Journal of Biological Chemistry, 1996, 271, 13283-13291.	1.6	140
574	Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. Nucleic Acids Research, 1996, 24, 1119-1126.	6.5	71
575	Heterologous expression of the human cyclin-dependent kinase inhibitor p21Cip1 in the fission yeast, Schizosaccharomyces pombe reveals a role for PCNA in the chk1+ cell cycle checkpoint pathway Molecular Biology of the Cell, 1996, 7, 651-662.	0.9	31
576	p53 and Breast Cancer. International Journal of Surgical Pathology, 1996, 4, 93-110.	0.4	5
577	Inhibition of initiation of simian virus 40 DNA replication during acute response of cells irradiated by ultraviolet light. Nucleic Acids Research, 1996, 24, 3149-3157.	6.5	3
578	Dual roles of ATM in the cellular response to radiation and in cell growth control Genes and Development, 1996, 10, 2401-2410.	2.7	364
579	Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys Genes and Development, 1996, 10, 836-850.	2.7	115
580	Role of the Stress-activated/c-Jun NH2-terminal Protein Kinase Pathway in the Cellular Response to Adriamycin and Other Chemotherapeutic Drugs. Journal of Biological Chemistry, 1996, 271, 30950-30955.	1.6	186

#	Article	IF	CITATIONS
581	<i>&gt;anti</i> -Benzo[a]pyrene-7,8-diol-9,10-epoxide Treatment Increases Levels of the Proteins p53 and p21 <sup>WAF1</sup> in the Human Mammary Carcinoma Cell Line MCF-7. Polycyclic Aromatic Compounds, 1996, 10, 299-306.	1.4	18
582	p53-dependent Induction of WAF1 by Heat Treatment in Human Glioblastoma Cells. Journal of Biological Chemistry, 1996, 271, 14510-14513.	1.6	85
583	Interference with p53 protein inhibits hematopoietic and muscle differentiation Journal of Cell Biology, 1996, 134, 193-204.	2.3	118
584	Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus Journal of Clinical Pathology, 1996, 49, 456-459.	1.0	24
585	Differential Taxol-dependent arrest of transformed and nontransformed cells in the G1 phase of the cell cycle, and specific-related mortality of transformed cells Journal of Cell Biology, 1996, 135, 689-700.	2.3	93
586	A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage Genes and Development, 1996, 10, 934-947.	2.7	472
587	Sensitivity of C3H10T1/2 cells to radiation-induced killing and neoplastic transformation as a function of cell cycle. International Journal of Radiation Biology, 1996, 69, 57-66.	1.0	11
588	The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region. Nucleic Acids Research, 1996, 24, 3560-3567.	6.5	61
589	Continuous Infusion of Antisense Phosphorothioate Therapeutics., 1996, 1, 201-212.		1
590	Induction of multiple PCR-SSCPE mobility shifts in exons in cultures of normal human urothelium exposed to low-dose gamma radiation. International Journal of Radiation Biology, 1997, 72, 21-31.	1.0	12
591	lonizing radiation induces apoptosis and elevates cyclin A1-Cdk2 activity before but not after the midblastula transition in Xenopus Molecular Biology of the Cell, 1997, 8, 1195-1206.	0.9	104
592	DNA damage induces phosphorylation of the amino terminus of p53. Genes and Development, 1997, 11, 3471-3481.	2.7	718
593	Segmental genomic replacement by Cre-mediated recombination: genotoxic stress activation of the p53 promoter in single-copy transformants. Nucleic Acids Research, 1997, 25, 2828-2834.	6.5	83
594	Immunoexpression of c-erbB-2 and p53 in benign and malignant salivary neoplasms with myoepithelial differentiation Journal of Clinical Pathology, 1997, 50, 661-663.	1.0	37
595	Mechanisms of Apoptosis. Advances in Molecular and Cell Biology, 1997, 20, 183-229.	0.1	3
596	P53 Activates Fanconi Anemia Group C Gene Expression. Human Molecular Genetics, 1997, 6, 277-283.	1.4	23
597	p53-mediated DNA renaturation can mimic strand exchange. Nucleic Acids Research, 1997, 25, 4004-4012.	6.5	10
598	Proteolytic Cleavage of the mdm2 Oncoprotein during Apoptosis. Journal of Biological Chemistry, 1997, 272, 22966-22973.	1.6	112

#	Article	IF	CITATIONS
599	The role of inhibitory phosphorylation of CDC2 following DNA replication block and radiation-induced damage in human cells Molecular Biology of the Cell, 1997, 8, 1013-1023.	0.9	85
600	Apoptosis, Neurotrophic Factors and Neurodegeneration. Reviews in the Neurosciences, 1997, 8, 223-65.	1.4	40
601	Mammalian GADD34, an Apoptosis- and DNA Damage-inducible Gene. Journal of Biological Chemistry, 1997, 272, 13731-13737.	1.6	151
602	Molecular Aspects of UVB-Induced Immunosuppression. Archives of Toxicology Supplement, 1997, 19, 97-109.	0.7	16
603	Expression of Wild-type p53 Is Required for Efficient Global Genomic Nucleotide Excision Repair in UV-irradiated Human Fibroblasts. Journal of Biological Chemistry, 1997, 272, 28073-28080.	1.6	318
604	Prognostic Markers in Chondrosarcoma: Evaluation of Cell Proliferation and of Regulators of the Cell Cycle. Sarcoma, 1997, 1, 79-87.	0.7	15
606	Ubiquitination of p53 and p21 Is Differentially Affected by Ionizing and UV Radiation. Molecular and Cellular Biology, 1997, 17, 355-363.	1.1	312
607	The Significance and Potential Molecular Mechanisms of Gastrointestinal Barrier Homeostasis. Scandinavian Journal of Gastroenterology, 1997, 32, 1073-1082.	0.6	10
608	lonizing Radiation-inducible Apoptosis in the Absence of p53 Linked to Transcription Factor EGR-1. Journal of Biological Chemistry, 1997, 272, 33056-33061.	1.6	77
609	Cyclin G2 Is Up-regulated during Growth Inhibition and B Cell Antigen Receptor-mediated Cell Cycle Arrest. Journal of Biological Chemistry, 1997, 272, 12650-12661.	1.6	109
610	Early Growth Response-1-dependent Apoptosis Is Mediated by p53. Journal of Biological Chemistry, 1997, 272, 20131-20138.	1.6	154
611	Transferrin–Liposome-Mediated p53 Sensitization of Squamous Cell Carcinoma of the Head and Neck to Radiation <i>In Vitro</i> . Human Gene Therapy, 1997, 8, 467-475.	1.4	94
612	Chemotherapy-Induced Apoptosis. Advances in Pharmacology, 1997, 41, 461-499.	1.2	126
613	The Molecular Epidemiology of Lung Cancer. Critical Reviews in Toxicology, 1997, 27, 319-365.	1.9	82
614	Identification of a Novel Transcriptional Regulatory Element Common to the p53 and Interferon Regulatory Factor 1 Genes. Journal of Biological Chemistry, 1997, 272, 29801-29809.	1.6	12
615	The Murine C′-Terminally Alternatively Spliced Form of p53 Induces Attenuated Apoptosis in Myeloid Cells. Molecular and Cellular Biology, 1997, 17, 713-722.	1.1	23
616	Cytoplasmic p53 Polypeptide Is Associated with Ribosomes. Molecular and Cellular Biology, 1997, 17, 3146-3154.	1.1	58
617	Inhibition of DNA Topoisomerase Ilα Gene Expression by the p53 Tumor Suppressor. Molecular and Cellular Biology, 1997, 17, 389-397.	1.1	147

#	Article	IF	CITATIONS
618	Proteolytic Cleavage of Human p53 by Calpain: a Potential Regulator of Protein Stability. Molecular and Cellular Biology, 1997, 17, 460-468.	1.1	298
619	Nijmegen breakage syndrome cells fail to induce the p53-mediated DNA damage response following exposure to ionizing radiation. Molecular and Cellular Biology, 1997, 17, 5016-5022.	1.1	111
620	Synergy between the Mos/Mitogen-Activated Protein Kinase Pathway and Loss of p53 Function in Transformation and Chromosome Instability. Molecular and Cellular Biology, 1997, 17, 506-518.	1.1	122
621	Inactivation of the Cyclin-Dependent Kinase Cdc28 Abrogates Cell Cycle Arrest Induced by DNA Damage and Disassembly of Mitotic Spindles in <i>Saccharomyces cerevisiae</i> Biology, 1997, 17, 2723-2734.	1.1	50
622	p53 Transactivation and Protein Accumulation Are Independently Regulated by UV Light in Different Phases of the Cell Cycle. Molecular and Cellular Biology, 1997, 17, 3074-3080.	1.1	31
623	<i>neu/ERBB2</i> Cooperates with <i>p53-172H</i> during Mammary Tumorigenesis in Transgenic Mice. Molecular and Cellular Biology, 1997, 17, 3155-3163.	1.1	97
624	The Pattern of P53 and p21WAF1/CIP1 Immunoreactivity in Non-Hodgkin's Lymphomas Predicts P53 Gene Status. Diagnostic Molecular Pathology, 1997, 6, 222-228.	2.1	15
625	The CDK <sub>7</sub> -cycH-p36 Complex of Transcription Factor IIH Phosphorylates p53, Enhancing Its Sequence-Specific DNA Binding Activity In Vitro. Molecular and Cellular Biology, 1997, 17, 5923-5934.	1.1	144
626	Transformed Cells Require Continuous Activity Of RNA Polymerase II To Resist Oncogene-Induced Apoptosis. Molecular and Cellular Biology, 1997, 17, 7306-7316.	1.1	83
627	Illegitimate Recombination Leading to Allelic Loss and Unbalanced Translocation in p53-Mutated Human Lymphoblastoid Cells. Molecular and Cellular Biology, 1997, 17, 4774-4781.	1.1	54
628	Activation of CPP32 and Mch3α in wild-type p53-induced apoptosis. Biochemical Journal, 1997, 322, 19-23.	1.7	23
629	Role of p53 in Apoptosis. Advances in Pharmacology, 1997, 41, 429-460.	1.2	58
630	Foulds' Dangerous Idea Revisited: The Multistep Development of Tumors 40 Years Later. Advances in Cancer Research, 1997, 72, 1-23.	1.9	37
631	Abnormal G1 Arrest in the Cell Lines from LEC Strain Rats after X-Irradiation Journal of Veterinary Medical Science, 1997, 59, 769-773.	0.3	8
632	Mitotic Activity and Nuclear DNA Damage of Large Cells in Hodgkin's Disease: Comparison with the Expression of p53 and bcl-2 Proteins and the Presence of Epstein-Barr Virus. Leukemia and Lymphoma, 1997, 25, 153-161.	0.6	6
633	Inhibition of growth and induction of differentiation of metastatic melanoma cells in vitro by genistein: chemosensitivity is regulated by cellular p53. British Journal of Cancer, 1997, 75, 1559-1566.	2.9	65
634	Apoptosis and 1-methyl-2-nitroimidazole toxicity in CHO cells. British Journal of Cancer, 1997, 76, 180-188.	2.9	11
635	Reduced expression of the ICE-related protease CPP32 is associated with radiation-induced cisplatin resistance in HeLa cells. British Journal of Cancer, 1997, 76, 1322-1327.	2.9	13

#	Article	IF	CITATIONS
636	Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation. British Journal of Cancer, 1997, 75, 528-536.	2.9	33
637	A p53-independent damage-sensing mechanism that functions as a checkpoint at the G1/S transition in Chinese hamster ovary cells. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 526-531.	3.3	51
638	Perspective: The Chemotherapeutic Relevance of Apoptosis and a Proposed Biochemical Cascade for Chemotherapeutically Induced Apoptosis. Cancer Investigation, 1997, 15, 372-381.	0.6	24
639	Foundations in Cancer Research p53 and ATM: Cell Cycle, Cell Death, and Cancer. Advances in Cancer Research, 1997, 71, 1-25.	1.9	267
640	p53 Mutations, Methylation and Genomic Instability in the Progression of Chronic Myeloid Leukaemia. Leukemia and Lymphoma, 1997, 26, 211-226.	0.6	32
641	Granule cell apoptosis and protein expression in hippocampal dentate gyrus after forebrain ischemia in the rat. Journal of the Neurological Sciences, 1997, 150, 93-102.	0.3	53
642	ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO Journal, 1997, 16, 6018-6033.	3.5	343
643	Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO Journal, 1997, 16, 1381-1390.	3.5	152
644	Evaluation of cross-reacting anti-human antibodies in the euthymic hairless guinea pig model (HGP) suggests that the HGP may be a model for the study of proliferative skin disease. Journal of Dermatological Science, 1997, 14, 240-250.	1.0	9
645	Immunohistochemical studies of basement membrane proteins and proliferation and apoptosis markers in sulfur mustard induced cutaneous lesions in weanling pigs. Journal of Dermatological Science, 1997, 15, 173-182.	1.0	40
646	Relationship between radiation response and p53 status in human bladder cancer cells. International Journal of Radiation Biology, 1997, 72, 11-20.	1.0	52
647	Somatic Frameshift Mutations in the BAXGene in Colon Cancers of the Microsatellite Mutator Phenotype. Science, 1997, 275, 967-969.	6.0	1,265
648	Oligomerization Is Not Essential for Growth Suppression by p53 in p53-Deficient Osteosarcoma Saos-2 Cells. Biochemical and Biophysical Research Communications, 1997, 232, 54-60.	1.0	18
649	Abrogation of G1 Arrest after DNA Damage Is Associated with Constitutive Overexpression ofMdm2, Cdk4,andIrf1mRNAs in the BALB/c 3T3 A31 Variant 1-1 Clone. Biochemical and Biophysical Research Communications, 1997, 233, 216-220.	1.0	1
650	Temporal Position of G1Arrest in Normal Human Fibroblasts after Exposure to $\hat{I}^3$ -Rays. Experimental Cell Research, 1997, 232, 161-166.	1.2	7
651	Hypoxia-Induced Apoptosis in Human Cells with Normal p53 Status and Function, without Any Alteration in the Nuclear Protein Level. Experimental Cell Research, 1997, 232, 361-370.	1.2	35
652	Early Ultraviolet B-Induced G1 Arrest and Suppression of the Malignant Phenotype by Wild-Type p53 in Human Squamous Cell Carcinoma Cells. Experimental Cell Research, 1997, 233, 135-144.	1.2	28
653	Effect of the Insulin-like Growth Factor I Receptor on Ionizing Radiation-Induced Cell Death in Mouse Embryo Fibroblasts. Experimental Cell Research, 1997, 235, 287-294.	1.2	41

#	Article	IF	CITATIONS
654	Involvement of p53 and WAF1/CIP1 in $\hat{I}^3$ -Irradiation-Induced Apoptosis of Retinoblastoma Cells. Experimental Cell Research, 1997, 236, 51-56.	1.2	29
655	The mammalian metabolite, 2-methoxyestradiol, affects p53 levels and apoptosis induction in transformed cells but not in normal cells. Journal of Steroid Biochemistry and Molecular Biology, 1997, 62, 253-267.	1.2	93
656	Apoptosis in oral erythema multiforme. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 1997, 83, 272-280.	1.6	21
657	Effects of gamma-linolenic acid and arachidonic acid on cell cycle progression and apoptosis induction in normal and transformed cells. Prostaglandins Leukotrienes and Essential Fatty Acids, 1997, 56, 271-280.	1.0	38
658	Hypofractionated radiation induces a decrease in cell proliferation but no histological damage to organotypic multicellular spheroids of human glioblastomas. European Journal of Cancer, 1997, 33, 645-651.	1.3	24
659	Investigation of oesophageal adenocarcinoma for viral genomic sequences. European Journal of Surgical Oncology, 1997, 23, 24-29.	0.5	12
660	Preferential incision of interstrand crosslinks induced by 8-methoxypsoralen plus UVA in yeast during the cell cycle. Mutation Research DNA Repair, 1997, 384, 23-32.	3.8	13
661	A role for p53 in DNA end rejoining by human cell extracts. Mutation Research DNA Repair, 1997, 385, 21-29.	3.8	38
664	Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF. Cell, 1997, 91, 649-659.	13.5	1,519
665	Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain. Cell, 1997, 90, 595-606.	13.5	2,376
666	Cell cycle specificity of Fas-mediated apoptosis in WIL-2 cells. FEBS Letters, 1997, 412, 91-93.	1.3	14
667	p53 gene mutations and HPV infection in primary head and neck squamous cell carcinomas do not correlate with overall survival: a long term follow-up study. Journal of Oral Pathology and Medicine, 1997, 26, 315-321.	1.4	55
668	Expression of Bax, Bcl-2, Waf-1, and PCNA gene products in an immortalized human endothelial cell line undergoing p53-mediated apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 1997, 2, 442-454.	2.2	7
669	Apoptosis in liver disease. Journal of Hepatology, 1997, 27, 405-412.	1.8	98
670	The in vitro micronucleus test: a multi-endpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage, chromosome loss and non-disjunction. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 1997, 392, 19-30.	0.9	263
671	G1 accumulation caused by iron deprivation with deferoxamine does not accompany change of pRB status in ML-1 cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1997, 1357, 297-305.	1.9	16
672	Induction of thioredoxin in human lymphocytes with low-dose ionizing radiation. Biochimica Et Biophysica Acta - Molecular Cell Research, 1997, 1359, 65-70.	1.9	26
673	Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma. Journal of the American Academy of Dermatology, 1997, 37, 430-437.	0.6	69

#	Article	IF	CITATIONS
674	Mammalian Rad51 protein: A RecA homologue with pleitropic functions. Biochimie, 1997, 79, 587-592.	1.3	29
675	Induction of cyclin-dependent kinase inhibitor, p21WAF1, by treatment with cancer cell line with mutant p53 gene. Cancer Letters, 1997, 112, 181-189.	3.2	20
676	Effect of passage number on cellular response to DNA-damaging agents: cell survival and gene expression. Cancer Letters, 1997, 113, 77-86.	3.2	78
677	Cyclin-dependent protein kinase 5 activity increases in rat brain following ischemia. Neurochemistry International, 1997, 31, 617-623.	1.9	35
678	Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treatment Reviews, 1997, 23, 35-61.	3.4	717
679	lonizing Radiation and Teniposide Increase p21 <sup>waf1/cip1</sup> and Promote Rb Dephosphorylation but Fail to Suppress E2F Activity in MCF-7 Breast Tumor Cells. Molecular Pharmacology, 1997, 52, 373-379.	1.0	13
680	p53, Cip1, and Gadd153 expression following treatment of A549 cells with natural and man-made vitreous fibers Environmental Health Perspectives, 1997, 105, 1143-1145.	2.8	20
681	The Fanconi Anemia Polypeptide, FAC, Binds to the Cyclin-Dependent Kinase, cdc2. Blood, 1997, 90, 1047-1054.	0.6	96
682	A proline-rich motif in p53 is required for transactivation- independent growth arrest as induced by Gas1. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 4675-4680.	3.3	88
683	Differential Regulation of the p21/WAF-1 and mdm2 Genes after High-Dose UV Irradiation: p53-Dependent and p53-Independent Regulation of the mdm2 Gene. Molecular Medicine, 1997, 3, 441-451.	1.9	150
684	Transcription Abnormalities Potentiate Apoptosis of Normal Human Fibroblasts. Molecular Medicine, 1997, 3, 852-863.	1.9	55
685	p53 and WAF1 Are Induced and Rb Protein Is Hypophosphorylated during Cell Growth Inhibition by the Thymidylate Synthase Inhibitor ZD1694 (Tomudex). Molecular Pharmacology, 1997, 51, 630-636.	1.0	13
686	DNA damage-inducible genes as biomarkers for exposures to environmental agents Environmental Health Perspectives, 1997, 105, 913-918.	2.8	18
687	Conformation-dependent phosphorylation of p53. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 1686-1691.	3.3	119
688	p53 Is Not Required for Regulation of Apoptosis or Radioprotection by Interleukin-3. Blood, 1997, 89, 2717-2722.	0.6	25
689	Measurement of Spontaneous and Therapeutic Agent-Induced Apoptosis With BCL-2 Protein Expression in Acute Myeloid Leukemia. Blood, 1997, 89, 243-255.	0.6	97
690	Apoptosis of Late-Stage Erythroblasts in Megaloblastic Anemia: Association With DNA Damage and Macrocyte Production. Blood, 1997, 89, 4617-4623.	0.6	86
691	Folate Deficiency Delays the Onset But Increases the Incidence of Leukemia in Friend Virus-Infected Mice. Blood, 1997, 90, 4054-4061.	0.6	9

#	Article	IF	Citations
692	Thrombopoietin Upregulates the Promoter Conformation of p53 in a Proliferation-Independent Manner Coincident With a Decreased Expression of Bax: Potential Mechanisms for Survival Enhancing Effects. Blood, 1997, 90, 4394-4402.	0.6	26
693	Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma. Journal of the American Academy of Dermatology, 1997, 37, 430-437.	0.6	41
694	Specific chromosomal imbalances in human papillomavirus-transfected cells during progression toward immortality. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 3854-3859.	3.3	85
695	PCNA and p53 in Urinary Bladder Cancer: Correlation with Histological Findings and Prognosis. International Journal of Urology, 1997, 4, 172-177.	0.5	19
696	Enhancement of Tumor Radio-response by Irinotecan in Human Lung Tumor Xenografts. Japanese Journal of Cancer Research, 1997, 88, 218-223.	1.7	73
697	Expressions of Cell Cycle Regulators in Human Colorectal Cancer Cell Lines. Japanese Journal of Cancer Research, 1997, 88, 855-860.	1.7	42
698	Wild-Type p53 Gene Transfer: A Novel Therapeutic Strategy for Neointimal Hyperplasia after Arterial Injury. Annals of the New York Academy of Sciences, 1997, 811, 395-400.	1.8	10
699	Central giant cell granulomas of the jaws: phenotype and proliferation-associated markers. Journal of Oral Pathology and Medicine, 1997, 26, 159-163.	1.4	92
700	Expression and mutations of p53 in salivary gland tumours. Journal of Oral Pathology and Medicine, 1997, 26, 217-223.	1.4	65
701	Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. Apmis, 1997, 105, 121-130.	0.9	27
702	Epidermal Proliferation but Not the Quantity of DNA Photodamage Is Correlated with UV-Induced Mouse Skin Carcinogenesis. Journal of Investigative Dermatology, 1997, 109, 340-347.	0.3	67
703	Potential molecular targets for manipulating the radiation response. International Journal of Radiation Oncology Biology Physics, 1997, 37, 639-653.	0.4	110
704	Coinfection of HPV-11 and HPV-16 in a Case of Laryngeal Squamous Papillomas With Severe Dysplasia. Laryngoscope, 1997, 107, 942-947.	1.1	25
705	Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. Nature Genetics, 1997, 17, 453-456.	9.4	185
706	Cell-cycle arrest versus cell death in cancer therapy. Nature Medicine, 1997, 3, 1034-1036.	15.2	351
707	Mdm2 promotes the rapid degradation of p53. Nature, 1997, 387, 296-299.	13.7	4,033
708	Spatial association of apoptosis-related gene expression and cellular death in clinical neuroblastoma. British Journal of Cancer, 1997, 75, 1185-1194.	2.9	40
709	Li-Fraumeni syndrome – a molecular and clinical review. British Journal of Cancer, 1997, 76, 1-14.	2.9	324

#	Article	IF	CITATIONS
710	DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. British Journal of Cancer, 1997, 76, 474-479.	2.9	60
711	Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer, 1997, 76, 480-485.	2.9	36
712	Cell Cycle Effects and Concomitant p53 Expression in Hairless Murine Skin after Longwave UVA (365) Tj ETQq0 (730-735.	0 0 rgBT /0 1.3	Overlock 10 1 30
713	Involvement of p53 in cell differentiation and development. Biochimica Et Biophysica Acta: Reviews on Cancer, 1997, 1333, F1-F27.	3.3	96
714	The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 1997, 1333, F151-F178.	3.3	85
715	Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. Current Biology, 1997, 7, 71-80.	1.8	179
716	MDM2-arbiter of p53's destruction. Trends in Biochemical Sciences, 1997, 22, 372-374.	3.7	126
717	Menadione Induces Both Necrosis and Apoptosis in Rat Pancreatic Acinar AR4-2J Cells. Free Radical Biology and Medicine, 1997, 23, 844-850.	1.3	77
718	Solution conformation of an essential region of the p53 transactivation domain. Folding & Design, 1997, 2, 331-342.	4.5	38
719	The in Vitro Phosphorylation of P53 by Calcium-Dependent Protein Kinase C. Characterization of a Protein-Kinase-C-Binding Site on p53. FEBS Journal, 1997, 245, 684-692.	0.2	34
720	p53 protein overexpression and Kâ€rascodon 12 mutation in pancreatic ductal carcinoma: Correlation with histologic factors. Pathology International, 1997, 47, 531-539.	0.6	13
721	The tumor suppressor p53 modifies mutational processes in a human lymphoblastoid cell line. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997, 373, 87-97.	0.4	28
722	Challenge to the simple paradigm that `carcinogens' are `mutagens' and to the in vitro and in vivo assays used to test the paradigm. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997, 373, 245-249.	0.4	42
723	Cytotoxic and mutagenic responses to X-rays and chemical mutagens in normal and p53-mutated human lymphoblastoid cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997, 374, 89-98.	0.4	61
724	The mouse lymphoma L5178Y Tk+/ $\hat{a}^{-}$ cell line is heterozygous for a codon 170 mutation in the p53 tumor suppressor gene. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997, 373, 157-165.	0.4	87
725	Spontaneous mutation frequencies and spectra in p53 (+/+) and p53 ( $\hat{a}$ '/ $\hat{a}$ ') mice: A test of the `guardian of the genome' hypothesis in the Big Blue $\hat{A}$ ® transgenic mouse mutation detection system. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1997, 379, 13-20.	0.4	39
726	Apoptosis and protein expression after focal cerebral ischemia in rat. Brain Research, 1997, 765, 301-312.	1.1	155
727	Methamphetamine-induced serotonin neurotoxicity is attenuated in p53-knockout mice. Brain Research, 1997, 768, 345-348.	1.1	23

#	Article	IF	CITATIONS
728	Apoptosis in HL-60 cells induced by 3-chloro-4-(dichloromethyl)-5-hydroxy-2[5H]-furanone (MX). Chemico-Biological Interactions, 1997, 106, 89-107.	1.7	21
729	Colorectal carcinogenesis: From chromosomal evolution pathways to molecular pathogenesis. Cancer Genetics and Cytogenetics, 1997, 93, 63-73.	1.0	22
730	Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients. Cancer Genetics and Cytogenetics, 1997, 98, 50-55.	1.0	40
731	Multiple centrosomal microtubule organising centres and increased microtubule stability are early features of VP-16-induced apoptosis in CCRF-CEM cells. Leukemia Research, 1997, 21, 491-499.	0.4	29
732	Participation of the human p53 $3\hat{a} \in ^2$ UTR in translational repression and activation following $\hat{I}^3$ -irradiation. EMBO Journal, 1997, 16, 4117-4125.	3.5	107
733	Regulation of ES cell differentiation by functional and conformational modulation of p53. EMBO Journal, 1997, 16, 6217-6229.	3.5	148
734	Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kappa B activation. EMBO Journal, 1997, 16, 7382-7392.	3.5	102
735	Transgenic mice with p53-responsive lacZ: p53activity varies dramatically during normal development and determines radiation and drug sensitivity invivo. EMBO Journal, 1997, 16, 1391-1400.	3.5	251
736	Serum withdrawal and etoposide induce apoptosis in human lung carcinoma cell line A549 via distinct pathways. Apoptosis: an International Journal on Programmed Cell Death, 1997, 2, 199-206.	2.2	22
737	Therapy for oral squamous cell carcinoma by tegafur and streptococcal agent OK-432 in combination with radiotherapy: Association of the therapeutic effect with differentiation and apoptosis in the cancer cells. Apoptosis: an International Journal on Programmed Cell Death, 1997, 2, 227-238.	2.2	37
738	Adriamycin (ADM) induced apoptosis in Transitional Cell Cancer (TCC) cell lines accompanied by p21 WAF1/CIP1 induction. Apoptosis: an International Journal on Programmed Cell Death, 1997, 2, 207-213.	2.2	10
739	5-Fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: role of the p53 gene. Apoptosis: an International Journal on Programmed Cell Death, 1997, 2, 221-226.	2.2	43
740	Radiation-induced apoptosis and its relationship to loss of clonogenic survival. Apoptosis: an International Journal on Programmed Cell Death, 1997, 2, 265-282.	2.2	39
741	The p53 Status of Chinese Hamster V79 Cells Frequently Used for Studies on DNA Damage and DNA Repair. Nucleic Acids Research, 1997, 25, 992-994.	6.5	108
742	The Old and the New in p53 Functional Regulation. Biochemical and Molecular Medicine, 1997, 62, 3-10.	1.5	9
743	Chemoprevention of gastrointestinal cancer. , 1997, 16, 405-419.		13
744	Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma. Digestive Diseases and Sciences, 1997, 42, 2453-2462.	1.1	56
745	Predictive value of p53, Bcl2 and bax in the radiotherapy of head and neck cancer. Pathology and Oncology Research, 1997, 3, 204-210.	0.9	22

#	Article	IF	CITATIONS
746	Apoptosis of L1210 leukemia cells induced by 3-deazaadenosine analogs: Differential expression of c-myc, NF-kappa B and molecular events. Journal of Biomedical Science, 1997, 4, 83-90.	2.6	12
747	Apoptosis in astrocytic neoplasms. Acta Neurochirurgica, 1997, 139, 845-850.	0.9	23
748	Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiation. International Journal of Radiation Oncology Biology Physics, 1997, 37, 145-154.	0.4	68
749	Regulation of p53 in response to ionizing radiation in ataxia telangiectasia fibroblasts. International Journal of Radiation Oncology Biology Physics, 1997, 37, 417-422.	0.4	13
750	Cell renewal, cell differentiation and programmed cell death (apoptosis) in pilomatrixoma. British Journal of Dermatology, 1997, 137, 714-720.	1.4	14
751	Flow cytometric analysis of p53 oncoprotein expression in cutaneous melanoma. British Journal of Surgery, 1997, 84, 803-807.	0.1	3
752	Epithelial apoptosis. BioEssays, 1997, 19, 711-720.	1.2	55
<b>7</b> 53	p53 protein immunoexpression in esophageal squamous cell carcinoma and adjacent epithelium. , 1997, 65, 3-9.		12
754	Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas., 1997, 181, 140-145.		55
755	Apoptosis induced by $\hat{l}^3$ -irradiation, but not CD4 ligation, of peripheral T lymphocytesin vivo is p53-dependent. , 1997, 181, 166-171.		13
756	OVEREXPRESSION OF $\rm p53$ IN NORMAL ORAL MUCOSA OF ORAL CANCER PATIENTS DOES NOT NECESSARILY PREDICT FURTHER MALIGNANT DISEASE. , 1997, 182, 180-184.		34
757	Correlations between p21 expression and clincopathological finding, p53 gene and protein alteration, and survival in patients with endometrial carcinoma. , 1997, 183, 318-324.		55
758	Patterns of p53 and Ki-67 protein expression in epithelial dysplasia from the floor of the mouth. Journal of Pathology, 1997, 183, 418-423.	2.1	55
759	Expression of p21 and mutant p53 gene products in residual prostatic tumor cells after radical radiotherapy., 1997, 32, 99-105.		9
760	Mdm-2: "big brother―of p53. , 1997, 64, 343-352.		149
761	The effect of differentTP53 mutations on the chromosomal stability of a human colonic adenoma derived cell line with endogenous wild type TP53 activity, before and after DNA damage., 1997, 20, 44-52.		10
762	Identification of additional complementation groups that regulate genomic instability. Genes Chromosomes and Cancer, 1997, 20, 103-112.	1.5	6
763	Upregulation of endogenousp53 and induction of in vivo apoptosis in B-lineage lymphomas of E $\hat{l}\frac{1}{4}$ -myc transgenic mice by deregulated c-myc transgene. , 1997, 18, 66-77.		13

#	ARTICLE	IF	Citations
764	Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function. Molecular Carcinogenesis, 1997, 18, 221-231.	1.3	13
765	Genetic alterations and oxidative metabolism in sporadic colorectal tumors from a Spanish community., 1997, 18, 232-243.		81
766	Prolonged p53 protein accumulation in trichothiodystrophy fibroblasts dependent on unrepaired pyrimidine dimers on the transcribed strands of cellular genes. Molecular Carcinogenesis, 1997, 20, 340-347.	1.3	59
767	Effect of p53 overexpression on radiation sensitivity of human colon cancer cells. Radiation Oncology Investigations, 1997, 5, 43-49.	1.3	16
768	p53-independent tumorigenic progression of human prostate cells. Radiation Oncology Investigations, 1997, 5, 269-274.	1.3	2
769	A comparison of p53 and p16 expression in human tumor cells treated with hyperthermia or ionizing radiation., 1997, 72, 307-312.		21
770	Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer., 1997, 74, 407-415.		62
771	Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis., 1997, 74, 502-507.		126
772	Treatment of the P815 murine mastocytoma with cisplatin or etoposide up-regulates cell-surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody-mediated cytotoxicity and to lysis by anti-CD3-activated killer-T cells., 1997, 73, 416-423.		19
773	Modulation of p53 expression in cultured colonic adenoma cell lines by the naturally occurring lumenal factors butyrate and deoxycholate., 1997, 73, 702-706.		22
774	A novel cytostatic process enhances the productivity of Chinese hamster ovary cells., 1997, 55, 927-939.		123
775	Two-dimensional gel analysis of apoptosis-specific p53 isoforms induced by 2-methoxyestradiol in human lung cancer cells. Apoptosis: an International Journal on Programmed Cell Death, 1998, 3, 421-430.	2.2	4
776	Crocidolite asbestos causes an induction of p53 and apoptosis in cultured A-549 lung carcinoma cells. Apoptosis: an International Journal on Programmed Cell Death, 1998, 3, 203-212.	2.2	16
777	Molecular Events and Mechanisms of Apoptosis. Sepsis, 1998, 2, 9-19.	0.5	24
778	The role of transforming growth factor beta in glioma progression. , 1998, 36, 123-140.		80
779	Biochemical and molecular mechanisms regulating apoptosis. , 1998, 178, 9-25.		46
780	Single-strand breaks, cell cycle arrest and apoptosis in HL-60 and LLCPK1 cells exposed to 1,2-dibromo-3-chloropropane. Cell Biology and Toxicology, 1998, 14, 267-282.	2.4	5
781	p53 and bcl-2 protein expression in non-small-cell lung carcinoma. Diagnostic Cytopathology, 1998, 19, 255-259.	0.5	12

#	Article	IF	CITATIONS
782	Expression and regulation of genes associated with cell death during murine preimplantation embryo development. Molecular Reproduction and Development, 1998, 51, 243-253.	1.0	244
783	Inhibition of ICE-like Proteases Inhibits Apoptosis and Increases Virus Production during Adenovirus Infection. Virology, 1998, 244, 108-118.	1.1	46
784	Levels of p53 in Epstein–Barr Virus-Infected Cells Determine Cell Fate: Apoptosis, Cell Cycle Arrest at the G1/S Boundary without Apoptosis, Cell Cycle Arrest at the G2/M Boundary without Apoptosis, or Unrestricted Proliferation. Virology, 1998, 251, 217-226.	1.1	19
785	DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature, 1998, 394, 700-704.	13.7	296
786	Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature, 1998, 395, 713-716.	13.7	397
787	Different Responses Other than the Formation of DNA-adducts between the Livers of Carcinogen-resistant Rats (DRH) and Carcinogen-sensitive Rats (Donryu) to 3′-Methyl-4-dimethylaminoazobenzene Administration. Japanese Journal of Cancer Research, 1998, 89, 806-813.	1.7	16
788	Ki-67 and p53 in T2 laryngeal cancer. Laryngoscope, 1998, 108, 1548-1552.	1.1	48
789	Identification of a Unique Form of p53 in Human Cord Blood Associated with the Development of Maternal Autoantibodies. American Journal of Reproductive Immunology, 1998, 39, 368-375.	1.2	3
790	Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1 /Fas) Mediated apoptosis. Nature Medicine, 1998, 4, 588-593.	15.2	285
791	ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nature Genetics, 1998, 19, 175-178.	9.4	437
792	Late G1 accumulation after 2 Gy of $\hat{l}^3$ -irradiation is related to endogenous Raf-1 protein expression and intrinsic radiosensitivity in human cells. British Journal of Cancer, 1998, 77, 1220-1228.	2.9	4
793	Anti-proliferative activity and mechanism of action of titanocene dichloride. British Journal of Cancer, 1998, 77, 2088-2097.	2.9	131
794	Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. British Journal of Cancer, 1998, 78, 745-751.	2.9	54
795	Mutation of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents. British Journal of Cancer, 1998, 77, 547-551.	2.9	25
796	Chromosomal Fragile Sites and DNA Amplification in Drug-resistant Cells. Biochemical Pharmacology, 1998, 56, 7-13.	2.0	20
797	The E6 and E7 genes of human papilloma virus-type 16 protect primary astrocyte cultures from injury. Brain Research, 1998, 795, 10-16.	1.1	19
798	Alteration of p53 protein in C3H/10T1/2 cells morphologically transformed by $\hat{l}^3$ -rays in stationary phase. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1998, 397, 345-352.	0.4	0
799	Fewer chromosome aberrations and earlier apoptosis induced by DNA synthesis inhibitors, a topoisomerase II inhibitor or alkylating agents in human cells with normal compared with mutant p53. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1998, 401, 39-53.	0.4	33

#	Article	IF	CITATIONS
800	Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation?. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1998, 400, 15-24.	0.4	190
801	Transgenic systems in studies on genotoxicity of alkylating agents: critical lesions, thresholds and defense mechanisms. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1998, 405, 179-191.	0.4	40
802	A study on p53 protein and anti-p53 antibodies in the sera of patients with oesophageal cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1998, 422, 271-277.	0.4	22
803	Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents. Leukemia Research, 1998, 22, 221-239.	0.4	36
804	Secondary leukemias induced by topoisomerase-targeted drugs. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1998, 1400, 233-255.	2.4	353
805	High-throughput gene expression analysis using SAGE. Drug Discovery Today, 1998, 3, 152-159.	3.2	38
806	Multisite Phosphorylation and the Integration of Stress Signals at p53. Cellular Signalling, 1998, 10, 159-166.	1.7	185
807	Tumor Resistance To Antimetabolites. General Pharmacology, 1998, 30, 623-626.	0.7	31
808	ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Current Biology, 1998, 8, 145-155.	1.8	423
809	Control of mouse hepatocyte proliferation and ploidy by p53 and p53ser246 mutationin vivo. Hepatology, 1998, 27, 73-80.	3.6	34
810	Loss of butyrate-induced apoptosis in human hepatoma cell lines HCC-M and HCC-T having substantial Bcl-2 expression. Hepatology, 1998, 27, 1233-1240.	3.6	35
811	p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer, 1998, 83, 7-18.	2.0	128
812	Ki-67 detected by MIB-1 predicts distant metastasis and tumor mortality in primary, high grade extremity soft tissue sarcoma., 1998, 83, 490-497.		90
813	Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with barrett's esophagus., 1998, 83, 641-651.		48
814	Induction of apoptosis in human keratinocytes containing mutated p53 alleles and its inhibition by both the E6 and E7 oncoproteins., 1998, 75, 96-104.		45
815	Inactivation of p53 in normal human cells increases G2/M arrest and sensitivity to DNA-damaging agents. , 1998, 75, 432-438.		35
816	p53 and Bcl-2 expression in pneumoconiosis-related pre-cancerous lesions and lung cancers: Frequent and preferential p53 expression in pneumoconiotic bronchiolar dysplasias., 1998, 75, 504-511.		16
817	Sunlight and carcinogenesis: Expression of p53 and pyrimidine dimers in human skin following UVA I, UVA I + II and solar simulating radiations., 1998, 76, 201-206.		83

#	Article	IF	CITATIONS
818	Therapeutic efficacy and apoptosis and necrosis kinetics of doxorubicin compared with cisplatin, combined with whole-body hyperthermia in a rat mammary adenocarcinoma., 1998, 76, 499-505.		18
819	Sublethal damage repair capacity in carcinoma cell lines with p53 mutations. , 1998, 20, 298-303.		15
820	Genomic instability associated with myotonic dystrophy does not involve p53 expression and activity., 1998, 16, 117-122.		3
821	Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs., 1998, 68, 19-24.		18
822	p53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma., 1998, 184, 360-368.		159
823	p53-dependent X-ray-induced modulation of cytokine mRNA levelsin vivo. , 1998, 186, 24-30.		10
824	Cell cycle dependent aneuploidy induction by x-rays in vitro in human lymphocytes., 1998, 40, 344-353.		6
825	Apoptosis during bone-like tissue development in vitro. Journal of Cellular Biochemistry, 1998, 68, 31-49.	1.2	146
826	Comparison ofbax,waf1, and IMP dehydrogenase regulation in response to wild-type p53 expression under normal growth conditions. , 1998, 177, 364-376.		18
827	Apoptotic response of spermatogenic cells to the germ cell mutagens etoposide, adriamycin, and diepoxybutane., 1998, 31, 133-148.		67
828	Growth arrest of immortalized human keratinocytes and suppression of telomerase activity byp21WAF1 gene expression. Molecular Carcinogenesis, 1998, 21, 26-36.	1.3	33
829	Relaxed cell-cycle arrests and propagation of unrepaired chromosomal damage in cancer cell lines with wild-typep53. Molecular Carcinogenesis, 1998, 23, 1-12.	1.3	23
830	DNA adduct levels associated with p53 induction and delay of MCF-7 cells in S phase after exposure to benzo[g]chrysene dihydrodiol epoxide enantiomers. Molecular Carcinogenesis, 1998, 23, 115-120.	1.3	20
831	S-phase arrest in mouse keratinocytes exposed to multiple doses of ultraviolet B/A radiation. Molecular Carcinogenesis, 1998, 23, 159-167.	1.3	19
832	Analysis of the p53 gene alterations in mouse embryo fibroblast cell line Balb 3T12 and its derivative 312. Journal of Biosciences, 1998, 23, 119-123.	0.5	0
833	p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma. Annals of Surgical Oncology, 1998, 5, 203-208.	0.7	42
834	Alteration ofbcl-2 andbax expression in embolized meningiomas. Brain Tumor Pathology, 1998, 15, 13-17.	1.1	7
835	Differential photosensitivity in wild-type and mutant p53 human colon carcinoma cell lines. Journal of Photochemistry and Photobiology B: Biology, 1998, 42, 104-107.	1.7	37

#	Article	IF	CITATIONS
836	Flow cytometric quantification of UY-induced cell death in a human squamous cell carcinoma-derived cell line: dose and kinetic studies. Journal of Photochemistry and Photobiology B: Biology, 1998, 44, 97-106.	1.7	44
837	A p53-dependent G1 checkpoint function is not required for induction of apoptosis by acute choline deficiency in immortalized rat hepatocytes in culture. Journal of Nutritional Biochemistry, 1998, 9, 476-481.	1.9	14
838	The Challenge of p53: Linking Biochemistry, Biology, and Patient Management. Stem Cells, 1998, 16, 248-260.	1.4	14
839	Induction of Squamous Cell Carcinoma in p53-Deficient Mice after Ultraviolet Irradiation. Journal of Investigative Dermatology, 1998, 110, 72-75.	0.3	86
840	Regulatory Effects of Heat on Normal Human Melanocyte Growth and Melanogenesis: Comparative Study with UVB. Journal of Investigative Dermatology, 1998, 110, 972-977.	0.3	31
841	Differential Regulation of P53 and Bcl-2 Expression by Ultraviolet A and B. Journal of Investigative Dermatology, 1998, 111, 380-384.	0.3	46
842	p53 Immunopositivity and Gene Mutation in a Group of Women at High Risk for Breast Cancer. Breast Journal, 1998, 4, 396-404.	0.4	2
843	Apoptosis in thyroid neoplasms: relationship with p53 and bclâ€2 expression. Histopathology, 1998, 32, 35-42.	1.6	35
844	Prognostic relevance of apoptotic cell death in nonâ∈Hodgkin's lymphomas: a multivariate survival analysis including Ki67 and p53 oncoprotein expression. Histopathology, 1998, 33, 240-247.	1.6	18
845	In vitro effects of growth hormone (GH) and insulin-like growth factor I and II (IGF-I and -II) on chromosome fragility and p53 protein expression in human lymphocytes. European Journal of Clinical Investigation, 1998, 28, 41-47.	1.7	33
846	Antimony trichloride induces DNA damage and apoptosis in mammalian cells. Toxicology, 1998, 129, 113-123.	2.0	41
847	The Prognostic Significance of P53 Expression for Survival and Local Control in Rectal Carcinoma Treated with Surgery and Postoperative Radiotherapy. International Journal of Radiation Oncology Biology Physics, 1998, 41, 29-35.	0.4	29
848	Absence of ATM truncations in patients with severe acute radiation reactions. International Journal of Radiation Oncology Biology Physics, 1998, 41, 1021-1027.	0.4	36
849	p53 suppresses cytokine induced, Stat5 mediated activation of transcription. Molecular and Cellular Endocrinology, 1998, 143, 143-154.	1.6	24
850	Increased susceptibility of the c-Myc overexpressing cell line, SNU-16, to TNF-alpha. Cancer Letters, 1998, 125, 17-23.	3.2	15
851	Altered expression of mitochondrial 16S ribosomal RNA in p53-deficient mouse embryos revealed by differential display. Biochimica Et Biophysica Acta - Molecular Cell Research, 1998, 1403, 254-264.	1.9	39
852	2,3,7,8-Tetrachlorodibenzo-p-dioxin suppresses apoptosis and leads to hyperphosphorylation of p53 in rat hepatocytes. Environmental Toxicology and Pharmacology, 1998, 6, 239-247.	2.0	16
853	Overexpression of p53 protein in interstitial lung diseases. Respiratory Medicine, 1998, 92, 184-190.	1.3	10

#	Article	IF	CITATIONS
854	Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. European Journal of Cancer, 1998, 34, 845-850.	1.3	34
855	Cellular and molecular determinants of cisplatin resistance. European Journal of Cancer, 1998, 34, 1535-1542.	1.3	339
856	Apoptotic neuronal death following cerebral ischaemia. Journal of Clinical Neuroscience, 1998, 5, 125-145.	0.8	10
857	Involvement of Brca2 in DNA Repair. Molecular Cell, 1998, 1, 347-357.	4.5	568
858	The C-terminal domain of p53 catalyzes DNA-renaturation and strand exchange toward annealing between intact ssDNAs and toward eliminating damaged ssDNA from duplex formation through preferential recognition of damaged DNA by a duocarmycin. Mutation Research DNA Repair, 1998, 409, 147-162.	3.8	4
859	Anticorps sériques anti-p53: Un nouveau marqueur tumoral?. Immuno-Analyse Et Biologie Specialisee, 1998, 13, 127-135.	0.0	1
860	Altered expression of the p53-regulated proteins, p21Waf1/Cip1, MDM2, and bax in ultraviolet-irradiated human skin. Human Pathology, 1998, 29, 559-564.	1.1	18
861	Leiomyosarcoma in soft tissue: Examination of p53 status and cell proliferating factors in different locations. Human Pathology, 1998, 29, 74-81.	1.1	41
862	Disruption of actin microfilaments by cytochalasin D leads to activation of p53. FEBS Letters, 1998, 430, 353-357.	1.3	75
863	MEDICAL ONCOLOGY IN THE MANAGEMENT OF HEAD AND NECK CANCERS. Otolaryngologic Clinics of North America, 1998, 31, 881-905.	0.5	2
864	RISK ASSESSMENT FOR METASTATIC TESTIS CANCER. Urologic Clinics of North America, 1998, 25, 389-395.	0.8	9
865	Stimulation of p53-mediated Transcriptional Activation by the p53-binding Proteins, 53BP1 and 53BP2. Journal of Biological Chemistry, 1998, 273, 26061-26068.	1.6	174
866	Tumor surveillance via the ARF–p53 pathway. Genes and Development, 1998, 12, 2984-2991.	2.7	641
867	The radioprotective effect of BBI is associated with the activation of DNA repair-relevant genes. International Journal of Radiation Biology, 1998, 74, 225-230.	1.0	27
868	Apoptosis: a novel therapeutic tool?. Expert Opinion on Investigational Drugs, 1998, 7, 889-904.	1.9	4
869	Like p53, the Proliferation-Associated Protein p120 Accumulates in Human Cancer Cells Following Exposure to Anticancer Drugs. Biochemical and Biophysical Research Communications, 1998, 244, 368-373.	1.0	9
870	ZK1, a Novel Krýppel-Type Zinc Finger Gene, Is Induced Following Exposure to Ionizing Radiation and Enhances Apoptotic Cell Death on Hematopoietic Cells. Biochemical and Biophysical Research Communications, 1998, 249, 595-600.	1.0	13
871	Prolongation of the p53 Response to DNA Strand Breaks in Cells Depleted of PARP by Antisense RNA Expression. Biochemical and Biophysical Research Communications, 1998, 253, 864-868.	1.0	20

#	Article	IF	CITATIONS
872	Oncoprotein v-Myb and Retinoic Acid Receptor $\hat{l}_{\pm}$ Are Mutual Antagonists. Blood Cells, Molecules, and Diseases, 1998, 24, 239-250.	0.6	7
873	Apoptosis Was Promoted at a Nonpermissive Temperature in DNA Replication-Defective Temperature-Sensitive Mutants of Mouse FM3A Cells. Experimental Cell Research, 1998, 238, 317-323.	1.2	3
874	Contribution of Protein Kinase C to p53-dependent WAF1 Induction Pathway after Heat Treatment in Human Glioblastoma Cell Lines. Experimental Cell Research, 1998, 238, 399-406.	1.2	34
875	Regulation of the Cell Cycle at the G2/M Boundary in Metastatic Melanoma Cells by 12-O-Tetradecanoyl Phorbol-13-acetate (TPA) by Blocking p34cdc2Kinase Activity. Experimental Cell Research, 1998, 242, 381-390.	1.2	35
876	Dissociation of Telomere Dynamics from Telomerase Activity in Human Thyroid Cancer Cells. Experimental Cell Research, 1998, 240, 333-339.	1.2	28
877	Inactivation of p53 in a Human Ovarian Cancer Cell Line Increases the Sensitivity to Paclitaxel by Inducing G2/M Arrest and Apoptosis. Experimental Cell Research, 1998, 241, 96-101.	1.2	81
878	The Accumulation of Cyclin-Dependent Kinase Inhibitor p27kip1ls a Primary Response to Staurosporine and Independent of G1 Cell Cycle Arrest. Experimental Cell Research, 1998, 243, 222-231.	1.2	20
879	Inhibitors of Transcription, Proteasome Inhibitors, and DNA-Damaging Drugs Differentially Affect Feedback of p53 Degradation. Experimental Cell Research, 1998, 244, 54-60.	1.2	50
880	cDNA Cloning and Gene Mapping of Human Homologs forSchizosaccharomyces pombe rad17, rad1,andhus1and Cloning of Homologs from Mouse,Caenorhabditis elegans,andDrosophila melanogaster. Genomics, 1998, 54, 424-436.	1.3	47
881	RAD1,a Human Structural Homolog of the Schizosaccharomyces pombe RAD1Cell Cycle Checkpoint Gene. Genomics, 1998, 54, 344-347.	1.3	23
882	p53-Regulated Apoptosis Is Differentiation Dependent in Ultraviolet B-Irradiated Mouse Keratinocytes. American Journal of Pathology, 1998, 153, 579-585.	1.9	95
883	Radiation-Induced p53 and p21WAF–1/CIP1 Expression in the Murine Intestinal Epithelium. American Journal of Pathology, 1998, 153, 899-909.	1.9	101
884	p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology, 1998, 51, 346-351.	0.5	72
885	Adaptive Response to DNA-Damaging Agents. Biochemical Pharmacology, 1998, 55, 941-951.	2.0	102
886	Evidence for Distinct Kinase-Mediated Pathways in gadd Gene Responses. Biochemical Pharmacology, 1998, 55, 853-861.	2.0	21
887	Decreased Drug Accumulation and Increased Tolerance to DNA Damage in Tumor Cells with a Low Level of Cisplatin Resistance. Biochemical Pharmacology, 1998, 55, 1247-1254.	2.0	55
888	Effects of Perturbations of Pools of Deoxyribonucleoside Triphosphates on Expression of Ribonucleotide Reductase, a $G1/S$ Transition State Enzyme, in p53-Mutated Cells. Biochemical Pharmacology, 1998, 55, 1353-1360.	2.0	16
889	Radiotherapy for oesophagus carcinoma: the impact of p53 on treatment outcome. Radiotherapy and Oncology, 1998, 46, 179-184.	0.3	19

#	Article	IF	CITATIONS
890	Nodal CT density and total tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer. Radiotherapy and Oncology, 1998, 47, 175-183.	0.3	83
891	Mechanisms of p53-induced apoptosis: in search of genes which are regulated during p53-mediated cell death. Toxicology Letters, 1998, 102-103, 491-496.	0.4	29
892	p53 binds and represses the HBV enhancer: an adjacent enhancer element can reverse the transcription effect of p53. EMBO Journal, 1998, 17, 544-553.	3.5	92
893	Requirement for p53 and p21 to Sustain G2 Arrest After DNA Damage. , 1998, 282, 1497-1501.		2,520
894	Co-Localization of Hypoxia and Apoptosis in Irradiated and Untreated HCT116 Human Colon Carcinoma Xenografts. Advances in Experimental Medicine and Biology, 1998, 454, 611-618.	0.8	4
895	HRAD1 and MRAD1 encode mammalian homologues of the fission yeast rad1(+) cell cycle checkpoint control gene. Nucleic Acids Research, 1998, 26, 3971-3976.	6.5	37
896	The p53 Tumor Suppressor Inhibits Transcription of the TATA-less Mouse DP1 Promoter. Journal of Biological Chemistry, 1998, 273, 10972-10978.	1.6	26
897	Transfer of Wild-Type p53 Gene Effectively Inhibits Vascular Smooth Muscle Cell Proliferation In Vitro and In Vivo. Circulation Research, 1998, 82, 147-156.	2.0	136
898	p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs. Journal of Experimental Medicine, 1998, 188, 2033-2045.	4.2	788
899	A Human Homologue of the Schizosaccharomyces pombe rad1+ Checkpoint Gene Encodes an Exonuclease. Journal of Biological Chemistry, 1998, 273, 18332-18339.	1.6	92
900	Characterization of ATM Expression, Localization, and Associated DNA-dependent Protein Kinase Activity. Molecular Biology of the Cell, 1998, 9, 2361-2374.	0.9	166
901	p21waf1/cip1mda-6Expression in Non-small-cell Lung Cancer: Relationship to Survival. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 213-217.	1.4	45
902	Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function. Journal of Neurosurgery, 1998, 88, 535-540.	0.9	55
903	Exposure to Hyperoxia Induces p53 Expression in Mouse Lung Epithelium. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 43-50.	1.4	645
904	Lipotrope deficiency inhibits cell growth and induces programmed cell death in human breast cancer cell line MCFâ€₹. Nutrition and Cancer, 1998, 32, 13-19.	0.9	6
905	Evidence of the involvement of p53 in gamma -radiation-induced DNA repair in human lymphoblasts. International Journal of Radiation Biology, 1998, 74, 231-238.	1.0	20
906	Molecular events in avian neoplasia: Regulators of cell death in development of Bâ€cell lymphomas in the chicken bursa of Fabricius. Avian Pathology, 1998, 27, S16-S20.	0.8	4
907	The complexity of p53 modulation: emerging patterns from divergent signals. Genes and Development, 1998, 12, 2973-2983.	2.7	1,154

#	Article	IF	CITATIONS
908	pRB plays an essential role in cell cycle arrest induced by DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11945-11950.	3.3	224
909	Chapter 10 Cell regeneration. Principles of Medical Biology, 1998, , 267-293.	0.1	O
910	The G1-phase Growth-arresting Action of Interleukin-1 Is Independent of p53 and p21/WAF1 Function. Journal of Biological Chemistry, 1998, 273, 30517-30523.	1.6	17
911	An Important Role for the Retinoblastoma Protein in Staurosporine-induced G1 Arrest in Murine Embryonic Fibroblasts. Journal of Biological Chemistry, 1998, 273, 3803-3807.	1.6	18
912	Cooperation of a Single Lysine Mutation and a C-terminal Domain in the Cytoplasmic Sequestration of the p53 Protein. Journal of Biological Chemistry, 1998, 273, 19817-19821.	1.6	48
913	The p53 Network. Journal of Biological Chemistry, 1998, 273, 1-4.	1.6	649
914	E1A signaling to p53 involves the p19 <sup>ARF</sup> tumor suppressor. Genes and Development, 1998, 12, 2434-2442.	2.7	548
915	Recent Discoveries in Cancer Genetics of Exocrine Pancreatic Neoplasia. Digestion, 1998, 59, 493-501.	1.2	51
916	Identification of a Human Homologue of the Schizosaccharomyces pombe rad 17+ Checkpoint Gene. Journal of Biological Chemistry, 1998, 273, 18340-18346.	1.6	64
917	Cleavage of CDK Inhibitor p21Cip1/Waf1 by Caspases Is an Early Event during DNA Damage-induced Apoptosis. Journal of Biological Chemistry, 1998, 273, 19207-19212.	1.6	174
918	Stabilization of p53 by Adenovirus E1A Occurs through Its Amino-terminal Region by Modification of the Ubiquitin-Proteasome Pathway. Journal of Biological Chemistry, 1998, 273, 20036-20045.	1.6	32
919	Hepatocyte injury in tyrosinemia type $1$ is induced by fumarylacetoacetate and is inhibited by caspase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9552-9557.	3.3	67
920	Chapter 8 Mechanisms of radiation-induced carcinogenesis: The thyroid model. Advances in Molecular and Cellular Endocrinology, 1998, , 169-196.	0.1	2
921	Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells. British Journal of Cancer, 1998, 77, 1378-1385.	2.9	52
922	Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. British Journal of Cancer, 1998, 77, 277-286.	2.9	82
923	Specific Mismatch Recognition in Heteroduplex Intermediates by p53 Suggests a Role in Fidelity Control of Homologous Recombination. Molecular and Cellular Biology, 1998, 18, 5332-5342.	1.1	128
924	p53-An Acrobat in Tumorigenesis. Critical Reviews in Oral Biology and Medicine, 1998, 9, 23-37.	4.4	63
925	Ischemic Neuronal Apoptosis: A View Based on Free Radical-Induced DNA Damage and Repair. Neuroscientist, 1998, 4, 88-95.	2.6	5

#	Article	IF	CITATIONS
926	Functional activation of p53 via phosphorylation following DNA damage by UV but not  radiation. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 2834-2837.	3.3	206
927	Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 8823-8828.	3.3	158
928	Expression of p53 Protein in Pterygium. European Journal of Ophthalmology, 1998, 8, 157-161.	0.7	25
929	Rubratoxin B induces apoptosis in p53-null cells. Mycotoxins, 1998, 1998, 35-37.	0.2	12
930	Differences in p53 and Bcl-2 expression in relation to cell proliferation during the development of human embryos. Journal of Clinical Pathology, 1998, 51, 131-137.	2.1	25
931	The Human ARF Cell Cycle Regulatory Gene Promoter Is a CpG Island Which Can Be Silenced by DNA Methylation and Down-Regulated by Wild-Type p53. Molecular and Cellular Biology, 1998, 18, 6457-6473.	1.1	323
932	No Requirement for V(D)J Recombination in p53-Deficient Thymic Lymphoma. Molecular and Cellular Biology, 1998, 18, 3495-3501.	1.1	78
933	Regulation of Mdm2-Directed Degradation by the C Terminus of p53. Molecular and Cellular Biology, 1998, 18, 5690-5698.	1.1	174
934	Characterization of the p53-Dependent Postmitotic Checkpoint following Spindle Disruption. Molecular and Cellular Biology, 1998, 18, 1055-1064.	1.1	466
935	Analysis of histological therapeutic effect, apoptosis rate and p53 status after combined treatment with radiation, hyperthermia and 5-fluorouracil suppositories for advanced rectal cancers. British Journal of Cancer, 1998, 77, 159-166.	2.9	22
936	Higher Sensitivity in Induction of Apoptosis in Fibroblast Cell Lines Derived from LEC Strain Rats to UV-Irradiation Journal of Veterinary Medical Science, 1998, 60, 207-212.	0.3	5
937	Molecular analysis of H2O2-induced senescent-like growth arrest in normal human fibroblasts: p53 and Rb control G1 arrest but not cell replication. Biochemical Journal, 1998, 332, 43-50.	1.7	400
938	Zonal Location of Compensatory Hepatocyte Proliferation Following Chemically Induced Hepatotoxicity in Rats and Humans. Toxicologic Pathology, 1998, 26, 621-627.	0.9	38
939	Telomere loss in cells treated with cisplatin. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 4219-4223.	3.3	141
940	Role of P53 Mutations in the Radiosensitivity Status of Tumor Cells. Tumori, 1998, 84, 517-520.	0.6	16
941	Alveolar macrophage apoptosis and TNF- $\hat{l}_{\pm}$ , but not p53, expression correlate with murine response to bleomycin. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1998, 275, L1208-L1218.	1.3	35
942	Inhibition of p53 Transactivation Function by the Human T-Cell Lymphotropic Virus Type 1 Tax Protein. Journal of Virology, 1998, 72, 1165-1170.	1.5	175
943	Role of p53 in Hematopoietic Recovery After Cytotoxic Treatment. Blood, 1998, 91, 2998-3006.	0.6	54

#	Article	IF	Citations
944	CBFÎ <sup>2</sup> -SMMHC, Expressed in M4eo Acute Myeloid Leukemia, Reduces p53 Induction and Slows Apoptosis in Hematopoietic Cells Exposed to DNA-Damaging Agents. Blood, 1998, 92, 4344-4352.	0.6	42
945	Human T-Cell Lymphotropic/Leukemia Virus Type 1 Tax Abrogates p53-Induced Cell Cycle Arrest and Apoptosis through Its CREB/ATF Functional Domain. Journal of Virology, 1998, 72, 8852-8860.	1.5	168
946	Expression of p21(waf1/cip1) Protein in Transitional Cell Bladder Tumours and Its Prognostic Value. European Urology, 1998, 34, 237-243.	0.9	44
947	Cell cycle control, checkpoint mechanisms, and genotoxic stress Environmental Health Perspectives, 1999, 107, 5-24.	2.8	206
948	Infrequent p53 gene alterations in ulcerative colitis. Brazilian Journal of Medical and Biological Research, 1999, 32, 1083-1088.	0.7	4
949	Delayed Cell Death, Giant Cell Formation and Chromosome Instability Induced by X-irradiation in Human Embryo Cells. Journal of Radiation Research, 1999, 40, 311-322.	0.8	34
950	Micronuclei formation and aneuploidy induced by <i>Vpr</i> , an accessory gene of human immunodeficiency virus type 1. FASEB Journal, 1999, 13, 621-637.	0.2	43
951	p53 induction as a genotoxic test for twenty-five chemicals undergoing in vivo carcinogenicity testing Environmental Health Perspectives, 1999, 107, 805-812.	2.8	70
952	Significance of p53 and Bcl-2 Protein Expression in Human Breast Ductal Carcinoma. Cancer Control, 1999, 6, 181-187.	0.7	7
953	Role of nitric oxide in cancer biology. Free Radical Research, 1999, 31, 671-679.	1.5	28
954	Proliferative and Apoptotic Responses in Cancers With Special Reference To Oral Cancers. Critical Reviews in Oral Biology and Medicine, 1999, 10, 58-78.	4.4	17
955	Thapsigargin has similar effect on p53 protein response to benzo[a]pyrene–DNA adducts as TPA in mouse skin. Carcinogenesis, 1999, 20, 1755-1760.	1.3	29
956	Radiation down-regulates replication origin activity throughout the S phase in mammalian cells. Nucleic Acids Research, 1999, 27, 803-809.	6.5	52
957	The level of DNA modification by (+)-syn-(11S,12R,13S,14R)- and ( $\hat{a}\in$ ")-anti-(11R,12S,13S,14R)-dihydrodiol epoxides of dibenzo[a,l]pyrene determined the effect on the proteins p53 and p21WAF1 in the human mammary carcinoma cell line MCF-7. Carcinogenesis, 1999, 20, 859-865.	1.3	38
958	Phosphoinositide 3-OH Kinase (PI3K) and PKB/Akt Delay the Onset of p53-mediated, Transcriptionally Dependent Apoptosis. Journal of Biological Chemistry, 1999, 274, 24263-24269.	1.6	128
959	Involvement of p53 in X-ray induced intrachromosomal recombination in mice. Carcinogenesis, 1999, 20, 2229-2236.	1.3	31
960	A Cyclin D-Cdk4 Activity Required for G2 Phase Cell Cycle Progression Is Inhibited in Ultraviolet Radiation-induced G2 Phase Delay. Journal of Biological Chemistry, 1999, 274, 13961-13969.	1.6	62
961	Genetic Disorders Associated with Cancer Predisposition and Genomic Instability. Progress in Molecular Biology and Translational Science, 1999, 63, 189-221.	1.9	65

#	Article	IF	CITATIONS
962	Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine $12/15$ -lipoxygenase gene expression: Evidence that 15-lipoxygenase is a mutator gene. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 4378-4383.	3.3	46
963	Benzo[a]pyrene Activates the Human p53 Gene through Induction of Nuclear Factor κB Activity. Journal of Biological Chemistry, 1999, 274, 35240-35246.	1.6	82
964	Mechanisms of G2 Arrest in Response to Overexpression of p53. Molecular Biology of the Cell, 1999, 10, 3607-3622.	0.9	169
965	Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after Â-irradiation. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 1002-1007.	3.3	246
966	Drug-induced Apoptosis and p53, BCL-2 and BAX Expression in Breast Cancer Tissues In Vivo and in Fibroblast Cells In Vitro. Japanese Journal of Clinical Oncology, 1999, 29, 323-331.	0.6	30
967	Role for p300 in Stabilization of p53 in the Response to DNA Damage. Journal of Biological Chemistry, 1999, 274, 1883-1886.	1.6	84
968	Ataxia Telangiectasia-mutated Gene Product Inhibits DNA Damage-induced Apoptosis via Ceramide Synthase. Journal of Biological Chemistry, 1999, 274, 17908-17917.	1.6	105
969	Ultraviolet-Irradiated Spermatozoa Activate Oocytes but Arrest Preimplantation Development After Fertilization and Nuclear Transplantation in Cattle1. Biology of Reproduction, 1999, 61, 1513-1520.	1.2	27
970	Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 10764-10769.	3.3	261
971	The Ability of p53 to Activate Downstream Genes p21 and MDM2, and Cell Cycle Arrest following DNA Damage Is Delayed and Attenuated in scid Cells Deficient in the DNA-dependent Protein Kinase. Journal of Biological Chemistry, 1999, 274, 13111-13117.	1.6	49
972	O 6 -Methylguanine-DNA methyltransferase activity, p53 gene status and BCNU resistance in mouse astrocytes. Carcinogenesis, 1999, 20, 2361-2365.	1.3	12
973	IFN-gamma Induction of p21WAF1 Is Required for Cell Cycle Inhibition and Suppression of Apoptosis. Journal of Interferon and Cytokine Research, 1999, 19, 1351-1361.	0.5	51
974	Regulation of p53 expression by thymidylate synthase. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3769-3774.	3.3	110
975	p34Cdc2 Kinase Activity Is Excluded from the Nucleus during the Radiation-induced G2 Arrest in HeLa Cells. Journal of Biological Chemistry, 1999, 274, 34779-34784.	1.6	18
976	Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 13777-13782.	3.3	518
977	Molecular Evolution of the Thermosensitive PAb1620 Epitope of Human p53 by DNA Shuffling. Journal of Biological Chemistry, 1999, 274, 28042-28049.	1.6	24
978	Current Concepts in Cell Toxicity. Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al ], 1999, 00, Unit 2.1.	1.1	0
979	p53 and Human Cancer: The First Ten Thousand Mutations. Advances in Cancer Research, 1999, 77, 81-137.	1.9	805

#	Article	IF	Citations
980	A 40-kDa NF1-like protein, not YY1, binds to the rat p53 promoter for transactivation in various rat organs. Biochemistry and Cell Biology, 1999, 77, 209-214.	0.9	8
981	High Affinity Insertion/Deletion Lesion Binding by p53. Journal of Biological Chemistry, 1999, 274, 3904-3909.	1.6	31
982	Chromosomal aberrations in PARP-/- mice: Genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 13191-13196.	3.3	108
983	Recruitment of ATM Protein to Double Strand DNA Irradiated with Ionizing Radiation. Journal of Biological Chemistry, 1999, 274, 25571-25575.	1.6	104
984	How does radiation kill cells?. Current Opinion in Chemical Biology, 1999, 3, 77-83.	2.8	283
985	The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma. International Journal of Radiation Oncology Biology Physics, 1999, 43, 607-616.	0.4	67
986	Association of increased radiocurability of murine carcinomas with low constitutive expression of p21WAF1/CIP1 protein. International Journal of Radiation Oncology Biology Physics, 1999, 44, 413-419.	0.4	13
987	Relationship between p21/waf-1/cip-1 and apoptosis in cervical cancer during radiation therapy. International Journal of Radiation Oncology Biology Physics, 1999, 44, 297-303.	0.4	24
988	Correlation between $\hat{I}^3$ -ray-induced G2 arrest and radioresistance in two human cancer cells. International Journal of Radiation Oncology Biology Physics, 1999, 44, 905-909.	0.4	31
989	Paclitaxel sensitivity correlates with P53 status and DNA fragmentation, but not G2/M accumulation. International Journal of Radiation Oncology Biology Physics, 1999, 44, 1119-1124.	0.4	29
990	Repair of DNA double-strand breaks and radiosensitivity to killing in an isogenic group of P53 mutant cell lines. International Journal of Radiation Oncology Biology Physics, 1999, 45, 743-751.	0.4	30
991	A point mutation of human p53, which was not detected as a mutation by a yeast functional assay, led to apoptosis but not p21Waf1/Cip1/Sdi1 expression in response to ionizing radiation in a human osteosarcoma cell line, Saos-2. International Journal of Radiation Oncology Biology Physics, 1999, 45, 975-980.	0.4	17
992	Role of p53 in the ability of 1,2-diaminocyclohexane-diacetato-dichloro-Pt(IV) to circumvent cisplatin resistance. Journal of Inorganic Biochemistry, 1999, 77, 65-70.	1.5	28
993	p53 protein expression in conjunctival squamous cell carcinomas of domestic animals. Veterinary Ophthalmology, 1999, 2, 227-231.	0.6	46
994	Thymidine Dinucleotide Mimics the Effect of Solar Simulated Irradiation on p53 and p53-Regulated Proteins. Journal of Investigative Dermatology, 1999, 112, 25-31.	0.3	53
995	Immunohistochemical and mutational analysis of p53 tumor suppressor gene in gestational trophoblastic disease: correlation with mdm2, proliferation index, and clinicopathologic parameters. International Journal of Gynecological Cancer, 1999, 9, 123-130.	1.2	30
996	p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature, 1999, 399, 814-817.	13.7	551
997	Cisplatin-resistant HeLa Cells Are Resistant to Apoptosis via p53-dependent and -independent Pathways. Japanese Journal of Cancer Research, 1999, 90, 1373-1379.	1.7	41

#	Article	IF	CITATIONS
998	Relationship between Expression of p21WAF1/CIP1 and Radio resistance in Human Gliomas. Japanese Journal of Cancer Research, 1999, 90, 638-646.	1.7	27
999	Fools rush in. Nature, 1999, 401, 535-536.	13.7	67
1000	Absence of cancer–associated changes in human fibroblasts immortalized with telomerase. Nature Genetics, 1999, 21, 115-118.	9.4	753
1001	Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway. Gene Therapy, 1999, 6, 764-770.	2.3	42
1002	Chk1 complements the G2/M checkpoint defect and radiosensitivity of ataxia-telangiectasia cells. Oncogene, 1999, 18, 249-256.	2.6	38
1003	Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene, 1999, 18, 477-485.	2.6	411
1004	Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene, 1999, 18, 551-557.	2.6	80
1005	Inhibition of RNA polymerase II as a trigger for the p53 response. Oncogene, 1999, 18, 583-592.	2.6	262
1006	C-myc overexpression and p53 loss cooperate to promote genomic instability. Oncogene, 1999, 18, 1177-1184.	2.6	128
1007	Expression of Bcl-2 protein is decreased in colorectal adenocarcinomas with microsatellite instability. Oncogene, 1999, 18, 1245-1249.	2.6	47
1008	Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells. Oncogene, 1999, 18, 1277-1283.	2.6	30
1009	The translation initiation factor, hu-Sui1 may be a target of hepatitis B X antigen in hepatocarcinogenesis. Oncogene, 1999, 18, 1677-1687.	2.6	67
1010	DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene, 1999, 18, 1723-1732.	2.6	141
1011	p53 inhibits entry into mitosis when DNA synthesis is blocked. Oncogene, 1999, 18, 283-295.	2.6	74
1012	Accentuated apoptosis in normally developing p53 knockout mouse embryos following genotoxic stress. Oncogene, 1999, 18, 2901-2907.	2.6	41
1013	p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene, 1999, 18, 1921-1934.	2.6	118
1014	cDNA expression array reveals heterogeneous gene expression profiles in three glioblastoma cell lines. Oncogene, 1999, 18, 2711-2717.	2.6	54
1015	p53-Dependent growth arrest and altered p53-immunoreactivity following metabolic labelling with 32P ortho-phosphate in human fibroblasts. Oncogene, 1999, 18, 3788-3792.	2.6	43

#	Article	IF	CITATIONS
1016	p53 compound heterozygosity in a severely affected child with Li-Fraumeni Syndrome. Oncogene, 1999, 18, 3970-3978.	2.6	33
1017	The p53 tumor suppressor protein reduces point mutation frequency of a shuttle vector modified by the chemical mutagens (±)7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene, aflatoxin B1 and meta-chloroperoxybenzoic acid. Oncogene, 1999, 18, 4672-4680.	2.6	7
1018	Function for p300 and not CBP in the apoptotic response to DNA damage. Oncogene, 1999, 18, 5714-5717.	2.6	54
1019	p53-dependent apoptosis or growth arrest induced by different forms of radiation in U2OS cells: p21WAF1/CIP1 repression in UV induced apoptosis. Oncogene, 1999, 18, 5403-5412.	2.6	70
1020	Role of two upstream open reading frames in the translational control of oncogene mdm2. Oncogene, 1999, 18, 5631-5637.	2.6	100
1021	Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. Oncogene, 1999, 18, 7706-7717.	2.6	166
1022	Human mammary epithelial cells exhibit a differential p53-mediated response following exposure to ionizing radiation or UV light. Oncogene, 1999, 18, 5795-5805.	2.6	35
1023	The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association. Oncogene, 1999, 18, 6037-6049.	2.6	98
1024	p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene, 1999, 18, 7656-7665.	2.6	174
1025	Regulation of p53 in response to DNA damage. Oncogene, 1999, 18, 7644-7655.	2.6	873
1026	A translation repressor element resides in the 3′ untranslated region of human p53 mRNA. Oncogene, 1999, 18, 6419-6424.	2.6	36
1027	Regulation of BRCA1 by protein degradation. Oncogene, 1999, 18, 6460-6468.	2.6	63
1028	Dephosphorylation of p53 at Ser20 after cellular exposure to low levels of non-ionizing radiation. Oncogene, 1999, 18, 6305-6312.	2.6	41
1029	Ectopic expression of human p53 inhibits entry into S phase and induces apoptosis in the Drosophila eye imaginal disc. Oncogene, 1999, 18, 6767-6775.	2.6	50
1030	Identification of a novel mouse p53 target gene DDA3. Oncogene, 1999, 18, 7765-7774.	2.6	45
1031	Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene, 1999, 18, 7621-7636.	2.6	572
1032	p53 status of newly established acute myeloid leukaemia cell lines. British Journal of Cancer, 1999, 79, 407-415.	2.9	25
1033	Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53. British Journal of Cancer, 1999, 79, 1111-1120.	2.9	18

#	Article	IF	CITATIONS
1034	Radiation-induced G1 arrest is not defective in fibroblasts from Li-Fraumeni families without TP53 mutations. British Journal of Cancer, 1999, 79, 1657-1664.	2.9	14
1035	Growth dysregulation and p53 accumulation in human primary colorectal cancer. British Journal of Cancer, 1999, 80, 1062-1068.	2.9	9
1036	Inhibition of proliferation and induction of apoptosis in soft tissue sarcoma cells by interferon- $\hat{l}_{\pm}$ and retinoids. British Journal of Cancer, 1999, 80, 1350-1358.	2.9	38
1037	Expression of high p53 levels in colorectal cancer: a favourable prognostic factor. British Journal of Cancer, 1999, 81, 122-126.	2.9	33
1038	Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. British Journal of Cancer, 1999, 81, 1294-1303.	2.9	26
1039	Assessment of the Prognostic Relevance of Serum Anti-p53 Antibodies in Epithelial Ovarian Cancer. Gynecologic Oncology, 1999, 72, 76-81.	0.6	45
1040	Tumor Suppressor Genes in Rodent Lung Carcinogenesis—Mutation ofp53Does Not Appear to be an Early Lesion in Lung Tumor Pathogenesis. Toxicology and Applied Pharmacology, 1999, 156, 70-77.	1.3	10
1041	Induction of the Cell Cycle Regulatory Gene p21 (Waf1, Cip1) Following Methylmercury Exposure in Vitro and in Vivo. Toxicology and Applied Pharmacology, 1999, 157, 203-212.	1.3	38
1042	Immunohistochemical detection of induced expression of wild-type p53 tumor suppressor protein in the livers of rats treated with diethylnitrosamine., 1999, 31, 75-78.		12
1043	The biological response of MCF7 breast cancer cells to proteosome inhibition or gamma-radiation is unrelated to the level of p53 induction. Apoptosis: an International Journal on Programmed Cell Death, 1999, 4, 99-107.	2.2	2
1044	The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. , 1999, 4, $115-143$ .		78
1045	Title is missing!. Molecular and Cellular Biochemistry, 1999, 191, 187-199.	1.4	34
1046	Function of poly(ADP-ribose) polymerase in response to DNA damage: Gene-disruption study in mice. Molecular and Cellular Biochemistry, 1999, 193, 149-152.	1.4	88
1047	A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO Journal, 1999, 18, 1660-1672.	3.5	622
1048	The tumor suppressor p53 can reduce stable transfection in the presence of irradiation. Journal of Biomedical Science, 1999, 6, 285-292.	2.6	6
1050	p53 and the CNS. Molecular Neurobiology, 1999, 19, 61-77.	1.9	22
1051	Radiation induced chromosome aberrations and clonogenic survival in human lymphoblastoid cell lines with different p53 status. Strahlentherapie Und Onkologie, 1999, 175, 289-292.	1.0	18
1052	Recombination and its roles in DNA repair, cellular immortalization and cancer. Age, 1999, 22, 71-88.	3.0	7

#	Article	IF	CITATIONS
1053	Enhancement of UV-induced cytotoxicity by the adeno-associated virus replication proteins. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1999, 1444, 371-383.	2.4	13
1054	p53 mutations in tumors derived from irradiated human thyroid epithelial cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1999, 425, 231-238.	0.4	16
1055	Characterization of p53 in Chinese hamster cell lines CHO-K1, CHO-WBL, and CHL: implications for genotoxicity testing. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1999, 426, 51-62.	0.4	96
1056	Cell division transforms mutagenic lesions into deletion-recombinagenic lesions in yeast cells.  Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1999, 429, 13-26.	0.4	52
1057	A comparison of gamma and neutron irradiation on Raji cells: effects on DNA damage, repair, cell cycle distribution and lethality1The first two authors contributed equally to this work.1. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1999, 429, 169-179.	0.4	16
1058	Accumulation of a tumor suppressor p53 protein in rat muscle during a space flight. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1999, 430, 271-274.	0.4	27
1059	Permanent cell cycle arrest in asynchronously proliferating normal human fibroblasts treated with doxorubicin or etoposide but not camptothecin. Biochemical Pharmacology, 1999, 58, 675-685.	2.0	45
1060	Comparison of the efficacy of 7-hydroxystaurosporine (UCN-01) and other staurosporine analogs to abrogate cisplatin-induced cell cycle arrest in human breast cancer cell lines. Biochemical Pharmacology, 1999, 58, 1713-1721.	2.0	35
1061	Apoptosis and expression of p53 response proteins and cyclin D1 after cortical impact in rat brain. Brain Research, 1999, 818, 23-33.	1.1	129
1062	Effects of three epoxidesî—,ethylene oxide, propylene oxide and epichlorohydrinî—,on cell cycle progression and cell death in human diploid fibroblasts. Chemico-Biological Interactions, 1999, 117, 219-239.	1.7	24
1063	Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leukemia Research, 1999, 23, 115-126.	0.4	115
1064	p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leukemia Research, 1999, 23, 871-880.	0.4	33
1065	Caffeine inhibits the checkpoint kinase ATM. Current Biology, 1999, 9, 1135-1138.	1.8	278
1066	Prognostic significance of Ki-67 (MIB1), PCNA and p53 in cancer of the oropharynx and oral cavity. Oral Oncology, 1999, 35, 583-589.	0.8	<b>7</b> 5
1067	p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1999, 428, 23-32.	0.4	141
1068	p53 immunohistochemistry of ulcerative colitisâ€associated with dysplasia and carcinoma. Pathology International, 1999, 49, 858-868.	0.6	44
1069	Immunohistochemical Detection of p53 and c-myc Proteins in Canine Mammary Tumours. Journal of Comparative Pathology, 1999, 120, 169-175.	0.1	17
1070	Hypoxia and Reoxygenation: a Pressure for Mutant p53 Cell Selection and Tumour Progression. Bulletin of Mathematical Biology, 1999, 61, 759-778.	0.9	14

#	Article	IF	Citations
1071	The p53 pathway and apoptosis., 1999, 181, 231-239.		187
1072	Effect of heterozygous loss ofp53 on benzo[a]pyrene-induced mutations and tumors in DNA repair-deficientXPA mice. Environmental and Molecular Mutagenesis, 1999, 34, 124-130.	0.9	37
1073	Cleavage of poly(ADP-ribose) transferase during p53-independent apoptosis in rat liver after treatent withN-nitrosomorpholine and cyproterone acetate., 1999, 24, 263-275.		13
1074	Breast cancer: Genetic predisposition and exposure to radiation., 1999, 26, 143-149.		13
1075	p53 Protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer, 1999, 85, 1293-1299.	2.0	57
1076	Cumulative prognostic value ofp53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. International Journal of Cancer, 1999, 84, 573-579.	2.3	66
1077	p53 expression and regulation by NMDA receptors in the developing rat brain. Journal of Neuroscience Research, 1999, 56, 427-440.	1.3	20
1078	p53 and Bax: Putative death factors in taste cell turnover. , 1999, 413, 168-180.		38
1079	Insights into cancer from transgenic mouse models. , 1999, 187, 43-60.		113
1080	p21WAF1 expression and endocrine response in breast cancer. , 1999, 188, 126-132.		23
1081	Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer., 1999, 39, 8-15.		95
1082	Molecular alchemy of the tumor suppressor protein p53: Metals and cell growth control. Journal of Trace Elements in Experimental Medicine, 1999, 12, 337-346.	0.8	3
1083	Molecular and anatomic considerations in the pathogenesis of breast cancer. Radiation Oncology Investigations, 1999, 7, 1-12.	1.3	11
1084	Telomeric length in individuals and cell lines with altered p53 status. Radiation Oncology Investigations, 1999, 7, 13-21.	1.3	14
1085	Tumor suppressor genes and breast cancer. Radiation Oncology Investigations, 1999, 7, 55-65.	1.3	28
1086	Heterogeneity of in vitro radiosensitivity in human bladder cancer cells. Radiation Oncology Investigations, 1999, 7, 66-76.	1.3	12
1087	Differential Regulation of E2F Transcription Factors by p53 Tumor Suppressor Protein. DNA and Cell Biology, 1999, 18, 911-922.	0.9	12
1088	Cellular responses to radiation and risk of breast cancer. European Journal of Cancer, 1999, 35, 540-548.	1.3	21

#	Article	IF	CITATIONS
1089	Control of the cell cycle and apoptosis. European Journal of Cancer, 1999, 35, 531-539.	1.3	224
1090	p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation. European Journal of Cancer, 1999, 35, 1202-1207.	1.3	33
1091	Control of the cell cycle and apoptosis. European Journal of Cancer, 1999, 35, 1886-1894.	1.3	215
1092	Bromocriptine-induced apoptosis in pituitary adenoma cells: relationship to p53 and bcl-2 expression. Journal of Clinical Neuroscience, 1999, 6, 326-331.	0.8	22
1093	Nucleotide variation in the p53 tumor-suppressor gene of voles from Chernobyl, Ukraine. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 1999, 439, 25-36.	0.9	20
1094	Cellular response to DNA damage. Link between p53 and DNA-PK. Comptes Rendus De L'Académie Des Sciences SÁ©rie 3, Sciences De La Vie, 1999, 322, 113-120.	0.8	7
1095	Requirement for p53 in ionizing-radiation-inhibition of double-strand-break rejoining by human lymphoblasts. Mutation Research DNA Repair, 1999, 434, 119-132.	3.8	18
1096	DNA structure checkpoint pathways in Schizosaccharomyces pombe. Biochimie, 1999, 81, 173-181.	1.3	90
1097	Wild-type p53 protein potentiates phototoxicity of 2-BA-2-DMHA in HT29 cells expressing endogenous mutant p53. Cancer Letters, 1999, 138, 189-195.	3.2	31
1098	Decreased expression of Bax is correlated with poor prognosis in oral and oropharyngeal carcinoma. Cancer Letters, 1999, 140, 81-91.	3.2	41
1099	Status epilepticus induces p53 sequence-specific DNA binding in mature rat brain. Molecular Brain Research, 1999, 63, 248-253.	2.5	38
1100	Activation of p53 and its target genes p21WAF1/Cip1 and PAG608/Wig-1 in ischemic preconditioning. Molecular Brain Research, 1999, 70, 304-313.	2.5	88
1101	Ribozyme-mediated specific gene replacement of the $\hat{l}\pm 1$ -antitrypsin gene in human hepatoma cells. Journal of Hepatology, 1999, 31, 53-60.	1.8	35
1102	Tumour suppressor protein p53 released by nuclease digestion increases at the onset of rat liver regeneration. Journal of Hepatology, 1999, 31, 306-314.	1.8	5
1103	Melatonin increases p53 and p21WAFl expression in MCF-7 human breast cancer cells in vitro. Life Sciences, 1999, 65, 415-420.	2.0	165
1104	Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery. FEBS Letters, 1999, 450, 197-204.	1.3	126
1105	Ap4A induces apoptosis in human cultured cells. FEBS Letters, 1999, 456, 175-180.	1.3	41
1106	Immunohistochemical detection of p53 protein accumulation in head and neck cancer: Correlation with p53 gene alterations. Human Pathology, 1999, 30, 1221-1225.	1.1	90

#	Article	IF	Citations
1107	A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochemical Pharmacology, 1999, 57, 727-741.	2.0	1,870
1108	HPV16-E7 Expression Causes Fluorodeoxyuridine-mediated Radiosensitization in SW620 Human Colon Cancer Cells. Neoplasia, 1999, 1, 177-182.	2.3	4
1109	Effects of clotrimazole on the growth, morphological characteristics, and cisplatin sensitivity of human glioblastoma cells in vitro. Journal of Neurosurgery, 1999, 90, 918-927.	0.9	31
1110	Methyl methanesulfonate and hydrogen peroxide differentially regulate p53 accumulation in hepatoblastoma cells. Toxicology Letters, 1999, 106, 201-208.	0.4	19
1111	Regulation of the p53 Tumor Suppressor Protein. Journal of Biological Chemistry, 1999, 274, 36031-36034.	1.6	499
1112	GADD45 induction of a G2/M cell cycle checkpoint. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3706-3711.	3.3	583
1113	Expression of p53 Protein and Ki-67 Antigen in Gingival Hyperplasia Induced by Nifedipine and Phenytoin. Journal of Periodontology, 1999, 70, 581-586.	1.7	43
1114	An Inhibitor of Nuclear Export Activates the p53 Response and Induces the Localization of HDM2 and p53 to U1A-Positive Nuclear Bodies Associated with the PODs. Experimental Cell Research, 1999, 248, 457-472.	1.2	129
1115	Fas Antigen Modulates Ultraviolet B-Induced Apoptosis of SVHK Cells: Sequential Activation of Caspases 8, 3, and 1 in the Apoptotic Process. Experimental Cell Research, 1999, 249, 291-298.	1.2	67
1116	p53-Independent Apoptosis and p53-Dependent Block of DNA Rereplication Following Mitotic Spindle Inhibition in Human Cells. Experimental Cell Research, 1999, 250, 339-350.	1.2	94
1117	Roles of p53 and Caspases in the Induction of Cell Cycle Arrest and Apoptosis by HIV-1 vpr. Experimental Cell Research, 1999, 251, 156-165.	1,2	71
1118	Nuclear Import of p53 during Xenopus laevis Early Development in Relation to DNA Replication and DNA Repair. Experimental Cell Research, 1999, 251, 46-56.	1.2	15
1119	Epithelial Cells of Different Organs Exhibit Distinct Patterns of p53-Dependent and p53-Independent Apoptosis Following DNA Insult. Experimental Cell Research, 1999, 252, 123-133.	1.2	19
1120	Postinjury Magnesium Treatment Attenuates Traumatic Brain Injury-Induced Cortical Induction of p53 mRNA in Rats. Experimental Neurology, 1999, 159, 584-593.	2.0	34
1121	Cellular characterisation of p53 mutants with a single missense mutation in the β-strand 326–333 and correlation of their cellular activities with in vitro properties. Journal of Molecular Biology, 1999, 288, 891-897.	2.0	16
1122	Abnormal Accumulation of G2/M-Phase Cells from LEC Strain Rats after X-Irradiation at S Phase Journal of Veterinary Medical Science, 1999, 61, 975-978.	0.3	2
1123	Lack of p53-Mediated G1 Arrest in Response to an Environmental Carcinogen. Oncology, 1999, 57, 258-264.	0.9	26
1124	Ultraviolet Radiation-Induced p53 Responses in the Epidermis are Differentiation-Dependent. Journal of Cutaneous Medicine and Surgery, 1999, 3, 280-283.	0.6	9

#	Article	IF	CITATIONS
1125	INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes and Development, 1999, 13, 2670-2677.	2.7	409
1126	p53-Oriented cancer therapies: Current progress. Annals of Oncology, 1999, 10, 139-150.	0.6	44
1127	p53-Mediated Regulation of Proliferating Cell Nuclear Antigen Expression in Cells Exposed to Ionizing Radiation. Molecular and Cellular Biology, 1999, 19, 12-20.	1.1	92
1128	The G <sub>2</sub> Checkpoint Is Maintained by Redundant Pathways. Molecular and Cellular Biology, 1999, 19, 5872-5881.	1.1	101
1129	Thymidylate Synthase Protein and p53 mRNA Form an In Vivo Ribonucleoprotein Complex. Molecular and Cellular Biology, 1999, 19, 1582-1594.	1.1	88
1130	The c- <i>fos</i> Proto-Oncogene Is a Target for Transactivation by the p53 Tumor Suppressor. Molecular and Cellular Biology, 1999, 19, 2594-2600.	1.1	58
1131	Prognostic Relevance of a Histological Grading System Using MIB-1 for Adult Soft-Tissue Sarcoma. Oncology, 2000, 58, 66-74.	0.9	55
1132	Protooncogenes as mediators of apoptosis. International Review of Cytology, 2000, 197, 137-202.	6.2	28
1133	p53 protein oxidation in cultured cells in response to pyrrolidine dithiocarbamate: a novel method for relating the amount of p53 oxidation in vivo to the regulation of p53-responsive genes. Biochemical Journal, 2000, 351, 87.	1.7	46
1134	Nitric Oxide–Induced Increase in p21 Sdi1/Cip1/Waf1 Expression During the Cell Cycle in Aortic Adventitial Fibroblasts. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 27-34.	1.1	29
1135	Vascular smooth muscle cell apoptosis in aneurysmal, occlusive, and normal human aortas. Journal of Vascular Surgery, 2000, 31, 567-576.	0.6	99
1136	Chapter 1: Developmental, Cellular, and Molecular Basis of Human Breast Cancer. Journal of the National Cancer Institute Monographs, 2000, 2000, 17-37.	0.9	198
1137	Relationship of Dibenzo[a, l]pyrene-DNA Binding to the Induction of p53, p21WAFland Cell Cycle Arrest in Human Cells in Culture. Polycyclic Aromatic Compounds, 2000, 16, 119-129.	1.4	4
1138	â€~Stealth Properties' Contribute to the Potent Action of Polycyclic Aromatic Hydrocarbon Carcinogens. Polycyclic Aromatic Compounds, 2000, 16, 89-98.	1.4	4
1139	Bax and Bcl-2 protein expression following radiation therapy versus radiation plus thermoradiotherapy in stage IIIB cervical carcinoma., 2000, 88, 132-138.		47
1140	Expression of apoptosis-regulatory genes in epithelial cells in pulmonary fibrosis in mice., 2000, 190, 221-229.		73
1141	p53 Website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis., 2000, 15, 105-113.		231
1142	BTG gene expression in the p53-dependent and -independent cellular response to DNA damage. , 2000, 27, 57-64.		81

#	Article	IF	CITATIONS
1143	The carcinogen 2-acetylaminofluorene inhibits activation and nuclear accumulation of cyclin-dependent kinase 2 in growth-induced rat liver. Molecular Carcinogenesis, 2000, 27, 190-199.	1.3	9
1144	Expression of p27 and p53 in cervical squamous cell carcinoma patients treated with radiotherapy alone. Cancer, 2000, 88, 2766-2773.	2.0	38
1145	Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 andbcl-2 proteins in clear cell renal carcinomas. Cancer, 2000, 89, 1065-1075.	2.0	11
1146	The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer, 2000, 89, 2006-2017.	2.0	28
1147	Chromium(VI) Induces p53-Dependent Apoptosis in Diploid Human Lung and Mouse Dermal Fibroblasts. Molecular Carcinogenesis, 2000, 28, 111-118.	1.3	85
1148	Requirement of wild-type p53 protein for maintenance of chromosomal integrity. Molecular Carcinogenesis, 2000, 28, 203-214.	1.3	45
1149	Modulation of transcriptional activity of p53 by ultraviolet radiation: Linkage between p53 pathway and DNA repair through damage recognition. Molecular Carcinogenesis, 2000, 28, 215-224.	1.3	16
1150	Downregulation of p53 by sustained JNK activation during apoptosis. Molecular Carcinogenesis, 2000, 29, 179-188.	1.3	21
1151	Identification of genes highly expressed in G2-arrested Chinese hamster ovary cells by differential display analysis. Journal of Clinical Laboratory Analysis, 2000, 14, 314-319.	0.9	14
1152	Low Doses of UVB or UVA Induce Chromosomal Aberrations in Cultured Human Skin Cells. Journal of Investigative Dermatology, 2000, 115, 435-440.	0.3	50
1153	Activation of an ataxia telangiectasia mutation-dependent intra-S-phase checkpoint by anti-tumour drugs in HL-60 and human lymphoblastoid cells. British Journal of Haematology, 2000, 110, 819-825.	1.2	11
1154	Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases. Histopathology, 2000, 37, 427-436.	1.6	65
1155	Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. International Journal of Radiation Oncology Biology Physics, 2000, 48, 1041-1050.	0.4	44
1156	Oral administration of an estrogen metabolite-induced potentiation of radiation antitumor effects in presence of wild-type p53 in non–small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2000, 48, 1127-1137.	0.4	29
1157	Gene Therapy for Head and Neck Cancer. Laryngoscope, 2000, 110, 708-726.	1.1	37
1158	Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as Prognostic Factors of Recurrence in T1 and T2 Laryngeal Carcinoma. Laryngoscope, 2000, 110, 1012-1017.	1.1	50
1159	Human homologue of S. pombe Rad9 interacts with BCL-2/BCL-xL and promotes apoptosis. Nature Cell Biology, 2000, 2, 1-6.	4.6	159
1160	A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nature Genetics, 2000, 26, 37-43.	9.4	207

#	Article	IF	CITATIONS
1161	Cell cycle progression and apoptosis after irradiation in an acidic environment. Cell Death and Differentiation, 2000, 7, 729-738.	5.0	39
1162	Antisense ATM gene therapy: a strategy to increase the radiosensitivity of human tumors. Gene Therapy, 2000, 7, 852-858.	2.3	37
1163	Induction of IW32 erythroleukemia cell differentiation by p53 is dependent on protein tyrosine phosphatase. Leukemia, 2000, 14, 1292-1300.	3.3	9
1164	A unique, short sequence determines p53 gene basal and UV-inducible expression in normal human cells. Oncogene, 2000, 19, 21-31.	2.6	32
1165	The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene, 2000, 19, 1206-1214.	2.6	63
1166	Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene, 2000, 19, 1245-1256.	2.6	381
1167	The loss of mdm2 induces p53 mediated apoptosis. Oncogene, 2000, 19, 1691-1697.	2.6	116
1168	Absence of p53-dependent induction of the metastatic suppressor KAI1 gene after DNA damage. Oncogene, 2000, 19, 2461-2464.	2.6	24
1169	DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling. Oncogene, 2000, 19, 3021-3031.	2.6	114
1170	Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene, 2000, 19, 3078-3085.	2.6	61
1171	Substrate specificity of the p53-associated 3′-5′ exonuclease. Oncogene, 2000, 19, 3321-3329.	2.6	30
1172	The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents. Oncogene, 2000, 19, 3498-3507.	2.6	26
1173	p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53. Oncogene, 2000, 19, 3395-3403.	2.6	30
1174	Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. Oncogene, 2000, 19, 3829-3839.	2.6	62
1175	A possible role for centrosome overduplication in radiation-induced cell death. Oncogene, 2000, 19, 5281-5290.	2.6	88
1176	IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects. Oncogene, 2000, 19, 5303-5313.	2.6	112
1177	Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant. Oncogene, 2000, 19, 5329-5337.	2.6	12
1178	Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants. Oncogene, 2000, 19, 5788-5800.	2.6	89

#	Article	IF	CITATIONS
1179	Levamisole induced apoptosis in cultured vascular endothelial cells. British Journal of Pharmacology, 2000, 131, 1577-1583.	2.7	32
1180	A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature, 2000, 404, 42-49.	13.7	815
1181	p53 sends nucleotides to repair DNA. Nature, 2000, 404, 24-25.	13.7	112
1182	The many substrates and functions of ATM. Nature Reviews Molecular Cell Biology, 2000, 1, 179-186.	16.1	691
1183	Trans-regulated Silencing and Reactivation of TP53 Tumor Suppressor Gene in Malignant Transformation and Its Reversion. Japanese Journal of Cancer Research, 2000, 91, 1111-1118.	1.7	3
1184	Induction of Apoptosis and Cell Cycle Arrest in Mouse Colon 26 Cells by Benastatin A. Japanese Journal of Cancer Research, 2000, 91, 1161-1168.	1.7	11
1185	Oxidative stress and cell cycle checkpoint function 11 Both Drs. Paules and Kaufmann received their doctoral degrees in Experimental Pathology from the University of North Carolina at Chapel Hill School of Medicine (in 1984 and 1979, respectively) Free Radical Biology and Medicine, 2000, 28, 1387-1404.	1.3	468
1186	The nitroxide tempol induces oxidative stress, p21WAF1/CIP1, and cell death in HL60 cells. Free Radical Biology and Medicine, 2000, 29, 633-641.	1.3	47
1187	p53 and breast cancer. Breast, 2000, 9, 239-246.	0.9	28
1188	The Role of p53 in Megakaryocyte Differentiation and the Megakaryocytic Leukemias of Down Syndrome. Cancer Genetics and Cytogenetics, 2000, $116$ , $1$ -5.	1.0	36
1189	Benzo(a)pyrene activates L1Md retrotransposon and inhibits DNA repair in vascular smooth muscle cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2000, 454, 35-44.	0.4	32
1190	Radiation-induced genomic instability: a paradigm-breaking phenomenon and its relevance to environmentally induced cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2000, 454, 89-109.	0.4	110
1191	Studies on the mechanism of the inhibition of human leukaemia cell growth by dietary isothiocyanates and their cysteine adducts in vitro. Biochemical Pharmacology, 2000, 60, 221-231.	2.0	145
1192	DNA fragmentation pattern induced in thymocytes by sulphur mustard. Chemico-Biological Interactions, 2000, 125, 1-15.	1.7	16
1193	Cytotoxic effects of topotecan combined with various active G2/M-phase anticancer drugs in human tumor-derived cell lines. Investigational New Drugs, 2000, 18, 139-148.	1.2	36
1194	Growth arrest and cell death in the breast tumor cell in response to ionizing radiation and chemotherapeutic agents which induce DNA damage. Breast Cancer Research and Treatment, 2000, 62, 223-235.	1.1	71
1195	Expression of apoptosis-related genes in human oocytes and embryos. Journal of Assisted Reproduction and Genetics, 2000, 17, 521-533.	1.2	37
1196	PR-000350, a novel hypoxic radiosensitizer, enhances tumor cell killing by promoting apoptosis preferentially in the S-phase fraction., 2000, 5, 69-77.		8

#	Article	IF	CITATIONS
1197	Biological and molecular characterization of an ECV-304-derived cell line resistant to p53-mediated apoptosis. , 2000, 5, 277-290.		14
1198	Senescence and immortalization of human cells. Biogerontology, 2000, 1, 103-121.	2.0	40
1199	p21 (WAF1/CIP1) Protein Expression Is Associated with Prolonged Survival but Not with p53 Expression in Epithelial Ovarian Carcinoma. Gynecologic Oncology, 2000, 77, 237-242.	0.6	51
1200	Apoptosis and the liver. Seminars in Cancer Biology, 2000, 10, 173-184.	4.3	137
1201	A Comparison of Apoptosis and Necrosis Induced by Hepatotoxins in HepG2 Cells. Toxicology and Applied Pharmacology, 2000, 164, 280-290.	1.3	46
1202	Effects of Arsenic, Cadmium, Chromium, and Lead on Gene Expression Regulated by a Battery of 13 Different Promoters in Recombinant HepG2 Cells. Toxicology and Applied Pharmacology, 2000, 168, 79-90.	1.3	146
1203	Ketoconazole Induces GO/G1 Arrest in Human Colorectal and Hepatocellular Carcinoma Cell Lines. Toxicology and Applied Pharmacology, 2000, 169, 132-141.	1.3	36
1204	The Role of the p53 Tumor Suppressor in the Response of Human Cells to Photofrin-mediated Photodynamic Therapy. Photochemistry and Photobiology, 2000, 71, 201-210.	1.3	39
1205	p53-dependent G2 arrest associated with a decrease in cyclins A2 and B1 levels in a human carcinoma cell line. British Journal of Cancer, 2000, 82, 642-650.	2.9	47
1206	Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis. British Journal of Cancer, 2000, 82, 1827-1834.	2.9	31
1207	Suppression of manganese superoxide dismutase augments sensitivity to radiation, hyperthermia and doxorubicin in colon cancer cell lines by inducing apoptosis. British Journal of Cancer, 2000, 83, 928-934.	2.9	55
1208	Combined RAF1 protein expression and p53 mutational status provides a strong predictor of cellular radiosensitivity. British Journal of Cancer, 2000, 83, 1084-1095.	2.9	20
1209	Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status. British Journal of Cancer, 2000, 83, 1380-1386.	2.9	70
1210	Inhibition of S-phase progression by adeno-associated virus Rep78 protein is mediated by hypophosphorylated pRb. EMBO Journal, 2000, 19, 4351-4361.	3.5	82
1211	Influence of Topoisomerase II Inhibitors and Ionizing Radiation on Growth Arrest and Cell Death Pathways in the Breast Tumor Cell. Cell Biochemistry and Biophysics, 2000, 33, 19-31.	0.9	12
1212	p53 Modulation of DNA Topoisomerase Ill $\hat{\textbf{l}}$ Gene Expression. Cell Biochemistry and Biophysics, 2000, 33, 209-216.	0.9	2
1213	p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. Journal of Biomedical Science, 2000, 7, 64-70.	2.6	70
1214	Activity of crude extract of Rubus crataegifolius roots as a potent apoptosis inducer and DNA topoisomerase I inhibitor. Archives of Pharmacal Research, 2000, 23, 338-343.	2.7	8

#	Article	IF	CITATIONS
1215	Expression of the p53 Tumor Suppressor Gene Is Up-Regulated by Depletion of Intracellular Zinc in HepG2 Cells. Journal of Nutrition, 2000, 130, 1688-1694.	1.3	31
1216	Mechanisms and implications of the ageâ€associated decrease in DNA repair capacity. FASEB Journal, 2000, 14, 1325-1334.	0.2	186
1217	The Role of the Sympathetic Nervous System in Radiation-induced Apoptosis in Jejunal Crypt Cells of Spontaneously Hypertensive Rats. Journal of Radiation Research, 2000, 41, 55-65.	0.8	16
1218	The role of hydroxyl radical as a messenger in Cr(VI)-induced p53 activation. American Journal of Physiology - Cell Physiology, 2000, 279, C868-C875.	2.1	114
1219	Diverse chemical carcinogens fail to induce G 1 arrest in MCF-7 cells. Carcinogenesis, 2000, 21, 1611-1618.	1.3	24
1220	Altered Expression of the Cell Cycle Regulatory Molecules pRb, p53 and MDM2 Exert a Synergetic Effect on Tumor Growth and Chromosomal Instability in Non-small Cell Lung Carcinomas (NSCLCs). Molecular Medicine, 2000, 6, 208-237.	1.9	38
1221	p53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis. Carcinogenesis, 2000, 21, 1441-1451.	1.3	13
1222	Multicolour FISH detection of radioactive iodine-induced 17cen–p53 chromosomal breakage in buccal cells from therapeutically exposed patients. Carcinogenesis, 2000, 21, 1581-1586.	1.3	6
1223	Diverse chemical carcinogens fail to induce G1 arrest in MCF-7 cells. Carcinogenesis, 2000, 21, 1611-1618.	1.3	52
1224	Multiple C-Terminal Lysine Residues Target p53 for Ubiquitin-Proteasome-Mediated Degradation. Molecular and Cellular Biology, 2000, 20, 8458-8467.	1.1	337
1225	Effect of Extracellular Signal-regulated Kinase on p53 Accumulation in Response to Cisplatin. Journal of Biological Chemistry, 2000, 275, 35778-35785.	1.6	267
1226	Regulation of the Rapamycin and FKBP-Target 1/Mammalian Target of Rapamycin and Cap-dependent Initiation of Translation by the c-Abl Protein-tyrosine Kinase. Journal of Biological Chemistry, 2000, 275, 10779-10787.	1.6	55
1227	Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3266-3271.	3.3	98
1228	The catalytic subunit of DNA-dependent protein kinase selectively regulates p53-dependent apoptosis but not cell-cycle arrest. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 1584-1588.	3.3	148
1229	Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 5357-5362.	3.3	368
1230	Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis-sensitive tumor cell lines. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 13009-13014.	3.3	170
1231	Anaplastic Changes Associated with p53 Gene Mutation in Differentiated Thyroid Carcinoma After Insufficient Radioactive Iodine (1311) Therapy. Thyroid, 2000, 10, 975-979.	2.4	30
1232	p53 expression, p53 and Ha- ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis. Carcinogenesis, 2000, 21, 1441-1451.	1.3	46

#	Article	IF	CITATIONS
1233	Evaluation of P53 Protein Overexpression, Ki67 Proliferative Activity and Mitotic Index as Markers of Tumour Recurrence in Superficial Transitional Cell Carcinoma of the Bladder. European Urology, 2000, 38, 287-296.	0.9	56
1234	Increase in wild-type p53 stability and transactivational activity by the chemopreventive agent apigenin in keratinocytes. Carcinogenesis, 2000, 21, 633-639.	1.3	102
1235	Nitric Oxide–Dependent Activation of P53 Suppresses Bleomycin-Induced Apoptosis in the Lung. Journal of Experimental Medicine, 2000, 192, 857-870.	4.2	69
1236	p53 Regulation of G 2 Checkpoint Is Retinoblastoma Protein Dependent. Molecular and Cellular Biology, 2000, 20, 4210-4223.	1.1	149
1237	Prolonged Cell Cycle Arrest in Irradiated Human Diploid Skin Fibroblasts: The Role of Nutrient Deprivation. Radiation Research, 2000, 153, 131-143.	0.7	16
1238	Multicolour FISH detection of radioactive iodine-induced 17cen–p53 chromosomal breakage in buccal cells from therapeutically exposed patients. Carcinogenesis, 2000, 21, 1581-1586.	1.3	18
1239	Pneumoconiosis-related Lung Cancers. American Journal of Respiratory and Critical Care Medicine, 2000, 162, 295-300.	2.5	48
1240	Polycyclic Aromatic Hydrocarbon Carcinogens Increase Ubiquitination of p21 Protein after the Stabilization of p53 and the Expression of p21. American Journal of Respiratory Cell and Molecular Biology, 2000, 22, 747-754.	1.4	34
1241	Wild-type p53â€"dependent etoposide-induced apoptosis mediated by caspase-3 activation in human glioma cells. Journal of Neurosurgery, 2000, 93, 289-297.	0.9	26
1242	Excision of $\hat{l}^2$ -L- and $\hat{l}^2$ -D-Nucleotide Analogs From DNA by p53 Protein. Nucleosides, Nucleotides and Nucleic Acids, 2000, 19, 435-446.	0.4	8
1243	Generation of oscillations by the p53-Mdm2 feedback loop: A theoretical and experimental study. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 11250-11255.	3.3	532
1244	The p53 Tumour Suppressor Protein. Biotechnology and Genetic Engineering Reviews, 2000, 17, 179-212.	2.4	10
1245	Lack of Effect of TP53 Status on Fluorodeoxyuridine-Mediated Radiosensitization. Radiation Research, 2000, 154, 140-144.	0.7	4
1246	Damage-mediated Phosphorylation of Human p53 Threonine 18 through a Cascade Mediated by a Casein 1-like Kinase. Journal of Biological Chemistry, 2000, 275, 9278-9283.	1.6	257
1247	p53 Mutants Have Selective Dominant-Negative Effects on Apoptosis but Not Growth Arrest in Human Cancer Cell Lines. Molecular and Cellular Biology, 2000, 20, 770-778.	1.1	67
1248	The p53 Tumor Suppressor Stimulates the Catalytic Activity of Human Topoisomerase IIα by Enhancing the Rate of ATP Hydrolysis. Journal of Biological Chemistry, 2000, 275, 18503-18510.	1.6	14
1249	A Novel AP-1 Element in the CD95 Ligand Promoter Is Required for Induction of Apoptosis in Hepatocellular Carcinoma Cells upon Treatment with Anticancer Drugs. Molecular and Cellular Biology, 2000, 20, 7826-7837.	1.1	125
1250	Dose-Dependent Biphasic Accumulation of TP53 Protein in Normal Human Embryo Cells after X Irradiation. Radiation Research, 2000, 153, 305-311.	0.7	19

#	Article	IF	CITATIONS
1251	Cancer Risk and the ATM Gene: a Continuing Debate. Journal of the National Cancer Institute, 2000, 92, 795-802.	3.0	173
1252	Influence of a Highly Purified Senna Extract on Colonic Epithelium. Digestion, 2000, 61, 113-120.	1.2	33
1253	Computerized Video Time-Lapse Microscopy Studies of Ionizing Radiation-Induced Rapid-Interphase and Mitosis-Related Apoptosis in Lymphoid Cells. Radiation Research, 2000, 153, 36-48.	0.7	64
1254	Effects of Ionizing Radiation in Targeted and Nontargeted Cells. Archives of Biochemistry and Biophysics, 2000, 376, 14-25.	1.4	104
1255	Induction of Apoptosis and Mitosis Inhibition by Degraded DNA Lipotransfection Mimicking Genotoxic Drug Effects. Biochemical and Biophysical Research Communications, 2000, 270, 406-414.	1.0	11
1256	p21CIP1 Is Dispensable for the G2 Arrest Caused by Genistein in Human Melanoma Cells. Experimental Cell Research, 2000, 258, 101-108.	1.2	56
1257	p53 Checkpoint-Defective Cells Are Sensitive to X Rays, but Not Hypoxia. Experimental Cell Research, 2000, 258, 82-91.	1.2	22
1258	Analysis of JNK, Mdm2 and p14ARF contribution to the regulation of mutant p53 stability. Journal of Molecular Biology, 2000, 295, 1009-1021.	2.0	35
1259	Nutrition, Oxidative Damage, Telomere Shortening, and Cellular Senescence: Individual or Connected Agents of Aging?. Molecular Genetics and Metabolism, 2000, 71, 32-42.	0.5	108
1260	Multiple Signaling Pathways Involving ATM. Cold Spring Harbor Symposia on Quantitative Biology, 2000, 65, 521-526.	2.0	48
1261	Bcl-2 and p53 Protein Expression, Apoptosis, and p53 Mutation in Human Epithelial Ovarian Cancers. American Journal of Pathology, 2000, 156, 409-417.	1.9	152
1262	Alterations of Cell Cycle Regulators in Localized Synovial Sarcoma. American Journal of Pathology, 2000, 156, 977-983.	1.9	84
1263	p53 splice acceptor site mutation and increased HsRAD51 protein expression in Bloom's syndrome GM1492 fibroblasts. Gene, 2000, 246, 247-254.	1.0	18
1264	MDM2 â€" master regulator of the p53 tumor suppressor protein. Gene, 2000, 242, 15-29.	1.0	578
1265	Influence of pentoxifylline, A-802710, propentofylline and A-802715 (Hoechst) on the expression of cell cycle blocks and S-phase content after irradiation damage. Biochimica Et Biophysica Acta - Molecular Cell Research, 2000, 1499, 1-10.	1.9	11
1266	Mechanisms underlying hypoxia-induced neuronal apoptosis. Progress in Neurobiology, 2000, 62, 215-249.	2.8	264
1267	Nitrotyrosine in esophageal squamous cell carcinoma and relevance to p53 expression. Cancer Letters, 2000, 153, 121-127.	3.2	26
1268	Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer Letters, 2000, 153, 219-226.	3.2	43

#	Article	IF	CITATIONS
1269	Apoptosis and cell proliferation in esophageal sqamous cell carcinoma treated by chemotherapy. Cancer Letters, 2000, 158, 211-216.	3.2	5
1270	Co-expression of p53 and bcl-2 may correlate to the presence of Epstein–Barr virus genome and the expression of proliferating cell nuclear antigen in nasopharyngeal carcinoma. Cancer Letters, 2000, 160, 199-208.	3.2	31
1271	p53 protein detection by the Western blotting technique in normal and neoplastic specimens of human endometrium. Cancer Letters, 2000, 148, 197-205.	3.2	15
1272	p53-dependent radioresistance in ovarian carcinoma cell lines. Cancer Letters, 2000, 150, 191-199.	3.2	33
1273	Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treatment Reviews, 2000, 26, 29-52.	3.4	81
1274	Turning p53 on or off: either way may treat cancer. Drug Resistance Updates, 2000, 3, 77-79.	6.5	6
1275	Karyotypic abnormalities associated with haemopoietic lineage switching are not linked with mutations to p53. International Journal of Biochemistry and Cell Biology, 2000, 32, 509-517.	1.2	1
1276	DNA damage and repair: consequences on dose-responses. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2000, 464, 35-40.	0.9	88
1277	Lack of p53 protein expression in preneoplastic rat hepatocytes in vitro after exposure to N-acetoxy-acetylaminofluorene, X-rays or a proteasome inhibitor. European Journal of Cancer, 2000, 36, 106-112.	1.3	10
1278	p53-regulated GML gene expression in non-small cell lung cancer. European Journal of Cancer, 2000, 36, 489-495.	1.3	14
1279	Phenotypic changes in mouse leukemia L1210 cells with alterations in the effector-binding subunit of ribonucleotide reductase. Advances in Enzyme Regulation, 2000, 40, 3-15.	2.9	2
1280	Apoptosis in bladder carcinomas detected with monoclonal antibody to single-stranded DNA: relation to cell cycle regulators and survival. Urology, 2000, 56, 516-520.	0.5	19
1281	The Mammalian UV Response. Cell, 2000, 103, 897-908.	13.5	280
1282	p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nature Cell Biology, 2000, 2, 709-717.	4.6	335
1283	Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells. Oncogene, 2000, 19, 5010-5019.	2.6	26
1284	Dial 9-1-1 for p53: Mechanisms of p53 Activation by Cellular Stress. Neoplasia, 2000, 2, 208-225.	2.3	188
1285	Human Keratinocytes That Express hTERT and Also Bypass a p16 INK4a -Enforced Mechanism That Limits Life Span Become Immortal yet Retain Normal Growth and Differentiation Characteristics. Molecular and Cellular Biology, 2000, 20, 1436-1447.	1.1	943
1286	MECHANISMS OF CELL-CYCLE CHECKPOINTS: AT THE CROSSROADS OF CARCINOGENESIS AND DRUG DISCOVERY*. Drug Metabolism Reviews, 2000, 32, 283-305.	1.5	48

#	Article	IF	CITATIONS
1287	Quiescence in S-phase and G 1 arrest induced by irradiation and/or hyperthermia in six human tumour cell lines of different p53 status. International Journal of Radiation Biology, 2000, 76, 717-725.	1.0	27
1288	p53 Mutation and Mitotic Infidelity. Cancer Investigation, 2000, 18, 148-155.	0.6	47
1289	Identification of a Sequence Element from p53 That Signals for Mdm2-Targeted Degradation. Molecular and Cellular Biology, 2000, 20, 1243-1253.	1.1	56
1290	Signal Transduction and Cellular Radiation Responses. Radiation Research, 2000, 153, 245-257.	0.7	305
1291	Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. British Journal of Cancer, 2000, 82, 913-923.	2.9	68
1292	Alterations in exon 4 of the p53 gene in gastric carcinoma. Gastroenterology, 2000, 118, 1039-1044.	0.6	57
1293	Variation in sensitizing effect of caffeine in human tumour cell lines after $\hat{l}^3$ -irradiation. Radiotherapy and Oncology, 2000, 54, 261-271.	0.3	33
1294	Induction of Telomerase Activity by Irradiation in Human Lymphoblasts. Radiation Research, 2001, 155, 693-697.	0.7	47
1295	FAMILIAL NEUROGENIC TUMOR SYNDROMES. Hematology/Oncology Clinics of North America, 2001, 15, 1073-1084.	0.9	7
1296	Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis. Gastroenterology, 2001, 120, 874-888.	0.6	41
1297	Accumulation of oxidative DNA damage, 8-oxo-2′-deoxyguanosine, and change of repair systems during in vitro cellular aging of cultured human skin fibroblasts. Mutation Research DNA Repair, 2001, 487, 19-30.	3.8	51
1298	Melatonin reduces X-ray irradiation-induced oxidative damages in cultured human skin fibroblasts. Journal of Dermatological Science, 2001, 26, 194-200.	1.0	50
1299	Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiotherapy and Oncology, 2001, 61, 169-175.	0.3	59
1300	The role of nucleotide excision repair and loss of p53 in mutagenesis and carcinogenesis. Toxicology Letters, 2001, 120, 209-219.	0.4	24
1301	Phenobarbitone – induced liver response in wild type and in p53 deficient mice. Toxicology Letters, 2001, 122, 131-140.	0.4	4
1302	Induction of apoptosis by Phenothiazine derivatives in V79 cells. Toxicology Letters, 2001, 125, 19-28.	0.4	19
1303	Current Concepts in Cell Death. Current Protocols in Cell Biology, 2001, 11, Unit 18.1.	2.3	3
1304	Rb Dephosphorylation and Suppression of E2F Activity in Human Breast Tumor Cells Exposed to a Pharmacological Concentration of Estradiol. Archives of Biochemistry and Biophysics, 2001, 388, 243-252.	1.4	4

#	Article	IF	Citations
1305	Dissociation of DNA Binding and in Vitro Transcriptional Activities Dependent on the C Terminus of p53 Proteins. Biochemical and Biophysical Research Communications, 2001, 280, 204-211.	1.0	6
1306	Camptothecin and Zeocin Can Increase p53 Levels during All Cell Cycle Stages. Biochemical and Biophysical Research Communications, 2001, 289, 998-1009.	1.0	17
1307	Signaling by Environmental Polycyclic Aromatic Hydrocarbons in Human Lymphocytes. Clinical Immunology, 2001, 98, 2-10.	1.4	193
1308	Characterization of Adriamycin-Induced G2 Arrest and Its Abrogation by Caffeine in FL-Amnion Cells with or without p53. Experimental Cell Research, 2001, 262, 37-48.	1.2	15
1309	Involvement of the MAP Kinase Pathways in Induction of GADD45 Following UV Radiation. Experimental Cell Research, 2001, 269, 64-72.	1.2	63
1310	Cigarette Smoke Activates Caspase-3 to Induce Apoptosis of Human Umbilical Venous Endothelial Cells. Molecular Genetics and Metabolism, 2001, 72, 82-88.	0.5	65
1311	Down-Regulation of Telomerase Activity in Malignant Lymphomas by Radiation and Chemotherapeutic Agents. American Journal of Pathology, 2001, 159, 711-719.	1.9	47
1312	p53 Involvement in the Control of Murine Hair Follicle Regression. American Journal of Pathology, 2001, 158, 1913-1919.	1.9	73
1313	Lack of ultraviolet-light inducibility of the medakafish (Oryzias latipes) tumor suppressor gene p53. Gene, 2001, 264, 197-203.	1.0	52
1314	Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction. Cancer Letters, 2001, 164, 177-188.	3.2	40
1315	Tamoxifen mutagenesis and carcinogenesis in livers of lambda/lacl transgenic rats: selective influence of phenobarbital promotion. Cancer Letters, 2001, 162, 117-122.	3.2	11
1316	Plasma hyaluronidase (Hyal-1) promotes tumor cell cycling. Cancer Letters, 2001, 163, 95-101.	3.2	46
1317	Nuclear BAG-1 localization and the risk of recurrence after radiation therapy in laryngeal carcinomas. Cancer Letters, 2001, 165, 103-110.	3.2	26
1318	Significance of contracted cholecystitis lesions as high risk for gallbladder carcinogenesis. Cancer Letters, 2001, 169, 7-14.	3.2	30
1319	Bax and Bcl-XL expression are not related to prognosis in patients with advanced esophageal squamous cell carcinoma. Cancer Letters, 2001, 174, 91-97.	3.2	13
1320	Genotoxic and non-genotoxic pathways of p53 induction. Cancer Letters, 2001, 174, 1-15.	3.2	144
1321	p53 is dispensable for apoptosis but controls neurogenesis of mouse dentate gyrus cells following <sup>3</sup> -irradiation. Molecular Brain Research, 2001, 93, 81-89.	2.5	29
1322	Overexpressed poly(ADP-ribose) polymerase delays the release of rat cells from p53-mediated G1 checkpoint. Journal of Cellular Biochemistry, 2001, 80, 85-103.	1.2	53

#	Article	IF	CITATIONS
1323	Molecular neurotoxicological models of Parkinsonism: focus on genetic manipulation of mice. Parkinsonism and Related Disorders, 2001, 8, 85-90.	1.1	12
1324	Is G1 arrest in plant seeds induced by a p53-related pathway?. Trends in Plant Science, 2001, 6, 248-251.	4.3	20
1325	Subcellular localisation of cyclin B, Cdc2 and p21WAF1/CIP1 in breast cancer. European Journal of Cancer, 2001, 37, 2405-2412.	1.3	106
1326	A DNA Damage–Induced p53 Serine 392 Kinase Complex Contains CK2, hSpt16, and SSRP1. Molecular Cell, 2001, 7, 283-292.	4.5	271
1327	From p63 to p53 across p73. FEBS Letters, 2001, 490, 163-170.	1.3	79
1328	Blocking CHK1 Expression Induces Apoptosis and Abrogates the G2 Checkpoint Mechanism. Neoplasia, 2001, 3, 411-419.	2.3	43
1329	p53, un gen supresor tumoral. Gaceta Medica De Bilbao, 2001, 98, 21-27.	0.0	2
1330	THE ROLE OF IMAGING STUDIES AND MOLECULAR MARKERS FOR SELECTING CANDIDATES FOR RADICAL PROSTATECTOMY. Urologic Clinics of North America, 2001, 28, 459-472.	0.8	30
1331	HTLV-I Tax Related Dysfunction of Cell Cycle Regulators and Oncogenesis of Adult T Cell Leukemia. Leukemia and Lymphoma, 2001, 40, 267-278.	0.6	21
1332	Oligonucleotide Enhanced Cytotoxicity of Idarubicin for Lymphoma Cells. Leukemia and Lymphoma, 2001, 42, 417-427.	0.6	7
1333	The Molecular Genetics of Therapeutic Resistance in Malignant Astrocytomas. Molecular Diagnosis and Therapy, 2001, 1, 93-99.	3.3	10
1334	Current advances in the inhibition of the auto-regulatory interaction between the p53 tumour suppressor protein and MDM2 protein. Expert Opinion on Therapeutic Patents, 2001, 11, 1825-1835.	2.4	4
1335	p53 Signaling and Cell Cycle Checkpoints. Chemical Research in Toxicology, 2001, 14, 243-263.	1.7	185
1336	DNA damage and cell cycle checkpoints in hyperoxic lung injury: braking to facilitate repair. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 281, L291-L305.	1.3	110
1337	Zinc status affects <i>p53</i> , <i>gadd45</i> , and c- <i>fos</i> expression and caspase-3 activity in human bronchial epithelial cells. American Journal of Physiology - Cell Physiology, 2001, 281, C751-C757.	2.1	64
1338	p53 protein and the response of human skin to UV. Comprehensive Series in Photosciences, 2001, , 407-418.	0.3	0
1339	Appearance of Bax Protein After Preoperative Chemoradiotherapy is a Prognostic Factor in Maxillary Cancer. Acta Oto-Laryngologica, 2001, 121, 967-972.	0.3	3
1340	Immortalization of primary rodent cells by SV40. Perspectives in Medical Virology, 2001, 5, 7-41.	0.1	0

#	Article	IF	Citations
1341	The induction and suppression of apoptosis by viruses. Perspectives in Medical Virology, 2001, 5, 351-411.	0.1	0
1342	Poly(ADP-ribose) polymerase and aging. Advances in Cell Aging and Gerontology, 2001, 4, 113-133.	0.1	0
1343	DNA instability, telomere dynamics, and cell transformation. Advances in Cell Aging and Gerontology, 2001, 4, 135-151.	0.1	0
1344	Inducible photoprotection in skin: Evidence for a eukaryotic SOS response. Advances in Cell Aging and Gerontology, 2001, 4, 227-253.	0.1	1
1346	Betulinic acid reduces ultraviolet-C-induced DNA breakage in congenital melanocytic naeval cells: evidence for a potential role as a chemopreventive agent. Melanoma Research, 2001, 11, 99-104.	0.6	39
1347	Conversion of Normal To Malignant Phenotype: Telomere Shortening, Telomerase Activation, and Genomic Instability During Immortalization of Human Oral Keratinocytes. Critical Reviews in Oral Biology and Medicine, 2001, 12, 38-54.	4.4	31
1348	Carcinogenesis: Mutations and Mutagens. Tumor Biology, 2001, 22, 191-202.	0.8	19
1349	Association of p53 Gene Mutation and Telomerase Activity in Resectable Non-Small Cell Lung Cancer. Chest, 2001, 120, 589-594.	0.4	19
1350	p27kip1 Expression Is Associated With Tumor Response to Preoperative Chemoradiotherapy in Rectal Cancer. Annals of Surgical Oncology, 2001, 8, 311-318.	0.7	60
1351	Expression of P53 during lens epithelial cell apoptosis induced by ultraviolet. Journal of Tongji Medical University, 2001, 21, 263-264.	0.1	3
1352	p53 and Ki-67 as predictive markers for radiosensitivity in squamous cell carcinoma of the oral cavity? an immunohistochemical and clinicopathologic study. International Journal of Radiation Oncology Biology Physics, 2001, 49, 147-154.	0.4	33
1353	Genistein, a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal cancer cell lines in vitro: Possible involvement of inhibition of survival signal transduction pathways. International Journal of Radiation Oncology Biology Physics, 2001, 50, 195-201.	0.4	86
1354	Inhibition of normal human lung fibroblast growth by beryllium. Toxicology, 2001, 160, 119-127.	2.0	21
1355	A molecular rationale for the how, when and why of colorectal cancer screening. Alimentary Pharmacology and Therapeutics, 2001, 15, 451-462.	1.9	20
1356	Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus. Alimentary Pharmacology and Therapeutics, 2001, 15, 1087-1100.	1.9	52
1357	In vitro induction of apoptosis for nasal angiocentric natural killer cell lymphoma-derived cell line, NK-YS, by etoposide and cyclosporine A. British Journal of Haematology, 2001, 113, 1009-1014.	1.2	32
1358	p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours. Cell Proliferation, 2001, 34, 1-14.	2.4	26
1359	Role of DNA-dependent protein kinase in neuronal survival. Journal of Neurochemistry, 2001, 78, 141-154.	2.1	52

#	Article	IF	CITATIONS
1360	Oxidative stress mediates neuronal DNA damage and apoptosis in response to cytosine arabinoside. Journal of Neurochemistry, 2001, 78, 265-275.	2.1	100
1361	Acute response of human skin to solar radiation: regulation and function of the p53 protein. Journal of Photochemistry and Photobiology B: Biology, 2001, 63, 78-83.	1.7	50
1362	Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chemistry and Biology, 2001, 8, 1151-1160.	6.2	81
1363	Cutaneous carcinomas and preinvasive neoplastic lesions. Role of MMP-2 and MMP-9 metalloproteinases in neoplastic invasion and their relationship with proliferative activity and p53 expression. Journal of Cutaneous Pathology, 2001, 28, 120-126.	0.7	29
1364	Ultraviolet-B Irradiation Alters the Cell Cycle Machinery in Murine Epidermis In Vivo. Journal of Investigative Dermatology, 2001, 117, 1171-1178.	0.3	36
1365	Diagnostic and prognostic tumor markers in the gastrointestinal tract. Journal of Surgical Oncology, 2001, 20, 147-166.	1.4	13
1366	Exposure-disease continuum for 2-chloro-2?-deoxyadenosine, a prototype ocular teratogen. 1. Dose-response analysis. Teratology, 2001, 64, 154-169.	1.8	16
1367	Transcriptional activation of stress genes and cytotoxicity in human liver carcinoma cells (HepG2) exposed to 2,4,6-trinitrotoluene, 2,4-dinitrotoluene, and 2,6-dinitrotoluene. Environmental Toxicology, 2001, 16, 209-216.	2.1	41
1368	Apoptosis induction by sennoside laxatives in man; escape from a protective mechanism during chronic sennoside use?. Journal of Pathology, 2001, 194, 493-499.	2.1	27
1369	Bcl-2 expression in pancreas development and pancreatic cancer progression. Journal of Pathology, 2001, 194, 444-450.	2.1	55
1370	Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma. Cancer, 2001, 92, 386-394.	2.0	13
1371	Quantitative p21WAF-1/p53 immunohistochemical analysis defines groups of primary invasive breast carcinomas with different prognostic indicators. International Journal of Cancer, 2001, 95, 128-134.	2.3	29
1372	Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than withP53 gene mutation. International Journal of Cancer, 2001, 95, 232-239.	2.3	28
1373	Characterization of a nuclear factor that binds to AP1-like element in the rat p53 promoter during liver regeneration. Journal of Cellular Biochemistry, 2001, 80, 124-132.	1.2	5
1374	Loss of G2/M arrest correlates with radiosensitization in two human sarcoma cell lines with mutant p53. International Journal of Cancer, 2001, 96, 110-117.	2.3	39
1375	Early molecular changes in irradiated aortic endothelium. Journal of Cellular Physiology, 2001, 188, 8-23.	2.0	35
1376	Decreasedin vitro interaction between p53 and nuclear stress proteins in thep53-deficient mouse. Electrophoresis, 2001, 22, 2092-2097.	1.3	3
1377	Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. Journal of Clinical Investigation, 2001, 108, 1411-1415.	3.9	175

#	Article	IF	CITATIONS
1378	Cooperating Oncogenic Events in Murine Mammary Tumorigenesis: Assessment of ErbB2, Mutant p53, and Mouse Mammary Tumor Virus. Experimental and Molecular Pathology, 2001, 70, 183-193.	0.9	12
1379	Hydrocarbon Carcinogens Evade Cellular Defense Mechanism of G1 Arrest in Nontransformed and Malignant Lung Cell Lines. Toxicology and Applied Pharmacology, 2001, 173, 105-113.	1.3	22
1380	Expression of p185 and p53 in benign and malignant colorectal lesions. The Histochemical Journal, $2001, 33, 51-57$ .	0.6	10
1381	Title is missing!. Molecular and Cellular Biochemistry, 2001, 222, 49-59.	1.4	52
1382	The p53 tumor suppressor: critical regulator of life & death in cancer. , 2001, 6, 7-15.		65
1383	The role of p53 in human cancer. , 2001, 51, 231-243.		45
1384	Overcoming of radioresistance in human gliomas by p21WAF1/CIP1 antisense oligonucleotide. Journal of Neuro-Oncology, 2001, 51, 111-119.	1.4	22
1385	In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53. Transgenic Research, 2001, 10, 471-478.	1.3	12
1386	Cell cycle regulators (p21, p53, pRb) in oligodendrocytic tumors: a study by novel tumor microarray technique. Journal of Neuro-Oncology, 2001, 55, 29-37.	1.4	27
1387	Translational regulation as a novel mechanism for the development of cellular drug resistance. Cancer and Metastasis Reviews, 2001, 20, 33-41.	2.7	16
1388	Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status. British Journal of Cancer, 2001, 85, 1764-1770.	2.9	16
1389	Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO Journal, 2001, 20, 4163-4172.	3.5	81
1390	High linear energy transfer carbon radiation effectively kills cultured glioma cells with either mutant or wild-type p53. International Journal of Radiation Oncology Biology Physics, 2001, 50, 803-808.	0.4	78
1391	Role of MMP-2 in Alveolar Epithelial Cell Repair after Bleomycin Administration in Rabbits. Laboratory Investigation, 2001, 81, 1309-1318.	1.7	54
1392	A Prospective Study of p53 Expression and Its Correlation With Clinical Response of Radiotherapy in Nasopharyngeal Carcinoma. Laryngoscope, 2001, 111, 131-136.	1.1	13
1393	The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nature Cell Biology, 2001, 3, E277-E286.	4.6	337
1394	Early stages of p53-induced apoptosis are reversible. Cell Death and Differentiation, 2001, 8, 182-191.	5.0	130
1395	Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation. Leukemia, 2001, 15, 567-574.	3.3	60

#	Article	IF	CITATIONS
1396	Transactivation-deficient p73 $\hat{l}$ ± (p73 $\hat{l}$ "exon2) inhibits apoptosis and competes with p53. Oncogene, 2001, 20, 514-522.	2.6	117
1397	p53-dependent radiation-induced crypt intestinal epithelial cells apoptosis is mediated in part through TNF-TNFR1 system. Oncogene, 2001, 20, 812-818.	2.6	27
1398	p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin. Oncogene, 2001, 20, 1212-1219.	2.6	18
1399	The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene, 2001, 20, 1267-1275.	2.6	71
1400	Regulation of the G2/M transition by p53. Oncogene, 2001, 20, 1803-1815.	2.6	1,366
1401	Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene, 2001, 20, 4601-4612.	2.6	132
1402	Activation of p53 transcriptional activity requires ATM's kinase domain and multiple N-terminal serine residues of p53. Oncogene, 2001, 20, 5100-5110.	2.6	92
1403	Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene, 2001, 20, 7453-7463.	2.6	156
1404	p53 enhances the fidelity of DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase. Oncogene, 2001, 20, 7635-7644.	2.6	30
1405	p53 binds to cisplatin-damaged DNA. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2001, 1517, 392-397.	2.4	31
1406	Modulation of X-ray-induced damage recognition and repair in ageing human peripheral blood mononuclear cells by an interleukin-6-type cytokine. Mechanisms of Ageing and Development, 2001, 121, 5-19.	2.2	5
1407	p53 and redox state in etoposide-induced acute myeloblastic leukemia cell death. Leukemia Research, 2001, 25, 1099-1105.	0.4	6
1408	Radiation induced apoptosis in ataxia telangiectasia homozygote, heterozygote and normal cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001, 476, 13-20.	0.4	13
1409	Evaluation of the genotoxicity of the phytoestrogen, coumestrol, in AHH-1 TK+/â^' human lymphoblastoid cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001, 474, 129-137.	0.4	20
1410	Cancer predisposition in mutant mice defective in multiple genetic pathways: uncovering important genetic interactions. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001, 477, 51-58.	0.4	30
1411	Effects of arsenite on p53, p21 and cyclin D expression in normal human fibroblasts — a possible mechanism for arsenite's comutagenicity. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001, 478, 159-168.	0.4	118
1412	Ubiquitin proteasome pathway: implications and advances in cancer therapy. Surgical Oncology, 2001, 10, 43-52.	0.8	40
1413	Effect of 2'-O-methyl antisense ORNs on expression of thymidylate synthase in human colon cancer RKO cells. Nucleic Acids Research, 2001, 29, 415-422.	6.5	17

#	Article	IF	Citations
1414	DNA Repair-Deficient Xpa and Xpa/p53 +/- Knock-Out Mice: Nature of the Models. Toxicologic Pathology, 2001, 29, 109-116.	0.9	47
1415	Stoichiometric Phosphorylation of Human p53 at Ser315Stimulates p53-dependent Transcription. Journal of Biological Chemistry, 2001, 276, 4699-4708.	1.6	84
1416	The Ataxia telangiectasia Gene Product Is Required for Oxidative Stress-induced G1 and G2Checkpoint Function in Human Fibroblasts. Journal of Biological Chemistry, 2001, 276, 21951-21959.	1.6	107
1417	Activation of a p53-independent, Sphingolipid-mediated Cytolytic Pathway in p53-negative Mouse Fibroblast Cells Treated with N-Methyl-N-nitro-N-nitrosoguanidine. Journal of Biological Chemistry, 2001, 276, 27129-27135.	1.6	27
1418	Identification of a Mouse Thiamine Transporter Gene as a Direct Transcriptional Target for p53. Journal of Biological Chemistry, 2001, 276, 37186-37193.	1.6	53
1419	Molecular Events in Radiation Transformation. Radiation Research, 2001, 155, 215-221.	0.7	4
1420	Osmotic Shock Induces G1 Arrest through p53 Phosphorylation at Ser33 by Activated p38MAPK without Phosphorylation at Ser15 and Ser20. Journal of Biological Chemistry, 2001, 276, 39115-39122.	1.6	111
1421	Aberrations of the p53 tumor suppressor gene in various tumors in dogs. American Journal of Veterinary Research, 2001, 62, 433-439.	0.3	64
1422	Induction of p53 Expression in Skin by Radiotherapy and UV Radiation: a Randomized Study. Journal of the National Cancer Institute, 2001, 93, 128-133.	3.0	42
1423	Spatial Distribution of Selected Genetic Loci in Nuclei of Human Leukemia Cells after Irradiation. Radiation Research, 2001, 155, 311-319.	0.7	28
1424	Permanent Growth Arrest in Irradiated Human Fibroblasts. Radiation Research, 2001, 155, 554-563.	0.7	7
1425	The Generation and Characterization of a Radiation-Resistant Model System to Study Radioresistance in Human Breast Cancer Cells. Radiation Research, 2001, 156, 739-750.	0.7	39
1426	Direct influence of the p53 tumor suppressor on mitochondrial biogenesis and function. FASEB Journal, 2001, 15, 635-644.	0.2	61
1427	Activation of a nuclear sphingomyelinase in radiation induced apoptosis. FASEB Journal, 2001, 15, 123-133.	0.2	44
1428	Detection of Genetic Changes in Anal Intraepithelial Neoplasia (AIN) of HIV-Positive and HIV-Negative Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 256-262.	0.9	30
1429	Identification of Genes That Mediate Sensitivity to Cisplatin. Molecular Pharmacology, 2001, 60, 1153-1160.	1.0	119
1430	ATM: Genome stability, neuronal development, and cancer cross paths. Advances in Cancer Research, 2001, 83, 209-254.	1.9	258
1431	Differential p53 protein expression in breast cancer fine needle aspirates: the potential for in vivo monitoring. British Journal of Cancer, 2001, 85, 1102-1105.	2.9	8

#	Article	IF	CITATIONS
1432	p53 Protein Overexpression in Low Grade Dysplasia (LGD) in Barrett's Esophagus: Immunohistochemical Marker Predictive of Progression. American Journal of Gastroenterology, 2001, 96, 1355-1362.	0.2	186
1433	AMF1 (GPS2) Modulates p53 Transactivation. Molecular and Cellular Biology, 2001, 21, 5913-5924.	1.1	49
1434	Requirement for HDM2 Activity in the Rapid Degradation of p53 in Neuroblastoma. Journal of Biological Chemistry, 2001, 276, 18497-18506.	1.6	23
1435	The G2 DNA Damage Checkpoint Delays Expression of Genes Encoding Mitotic Regulators. Journal of Biological Chemistry, 2001, 276, 37166-37177.	1.6	62
1436	NF-Y Mediates the Transcriptional Inhibition of thecyclin B1, cyclin B2, and cdc25CPromoters upon Induced G2 Arrest. Journal of Biological Chemistry, 2001, 276, 5570-5576.	1.6	153
1437	Negative Cell Cycle Regulation and DNA Damage-inducible Phosphorylation of the BRCT Protein 53BP1. Journal of Biological Chemistry, 2001, 276, 2708-2718.	1.6	83
1438	Opposing Regulation of Choline Deficiency-induced Apoptosis by p53 and Nuclear Factor $\hat{l}^{\text{B}}$ B. Journal of Biological Chemistry, 2001, 276, 41197-41204.	1.6	40
1439	Analysis of the Binding of p53 to DNAs Containing Mismatched and Bulged Bases. Journal of Biological Chemistry, 2001, 276, 8778-8784.	1.6	50
1440	Modeling multi-component protein–DNA complexes: the role of bending and dimerization in the complex of p53 dimers with DNA. Protein Engineering, Design and Selection, 2001, 14, 233-243.	1.0	18
1441	Feedback Regulation between Orphan Nuclear Receptor TR2 and Human Papilloma Virus Type 16. Journal of Biological Chemistry, 2001, 276, 27316-27321.	1.6	7
1442	G2-Phase Delays after Irradiation and/or Heat Treatment as Assessed by Two-Parameter Flow Cytometry. Radiation Research, 2001, 155, 50-56.	0.7	15
1443	Radiation-Induced Senescence-like Growth Arrest Requires TP53 Function but not Telomere Shortening. Radiation Research, 2001, 155, 248-253.	0.7	152
1444	p130/E2F4 Binds to and Represses the cdc2 Promoter in Response to p53. Journal of Biological Chemistry, 2001, 276, 1998-2006.	1.6	90
1445	p53 Down-Regulates CHK1 through p21 and the Retinoblastoma Protein. Molecular and Cellular Biology, 2001, 21, 1066-1076.	1.1	162
1446	AP-1 Repressor Protein JDP-2: Inhibition of UV-Mediated Apoptosis through p53 Down-Regulation. Molecular and Cellular Biology, 2001, 21, 3012-3024.	1.1	62
1447	Is p53 Haploinsufficient for Tumor Suppression? Implications for the p53 +/- Mouse Model in Carcinogenicity Testing. Toxicologic Pathology, 2001, 29, 147-154.	0.9	79
1448	c-Myc Is Necessary for DNA Damage-Induced Apoptosis in the G 2 Phase of the Cell Cycle. Molecular and Cellular Biology, 2001, 21, 4929-4937.	1.1	84
1449	Immunoexpression of Ultraviolet Photoproducts and p53 Mutation Analysis in Atypical Fibroxanthoma and Superficial Malignant Fibrous Histiocytoma. Modern Pathology, 2001, 14, 581-588.	2.9	66

#	Article	IF	CITATIONS
1450	p53 Gene Mutation and Protein Accumulation during Neoplastic Progression in Barrett's Esophagus. Modern Pathology, 2001, 14, 397-403.	2.9	92
1451	NOVEL TARGETS IN THE CELL CYCLE AND CELL CYCLE CHECKPOINTS. , 2002, , 13-cp2.		5
1452	Cancer Gene Therapy with the p53 Tumor Suppressor Gene. , 2002, , 299-313.		1
1453	Phosphodiester Oligonucleotides Inhibit Mitosis and Trigger Apoptosis by a Non-Antisense, p53-Mediated Mechanism. Oligonucleotides, 2002, 12, 21-31.	4.4	8
1454	Restoration of Transforming Growth Factor-Î <sup>2</sup> Signaling Enhances Radiosensitivity by Altering the Bcl-2/Bax Ratio in the p53 Mutant Pancreatic Cancer Cell Line MIA PaCa-2. Journal of Biological Chemistry, 2002, 277, 2234-2246.	1.6	55
1455	Integrins regulate the apoptotic response to DNA damage through modulation of p53. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3627-3632.	3.3	90
1456	p53 Serine 392 Phosphorylation Increases after UV through Induction of the Assembly of the CK2·hSPT16·SSRP1 Complex. Journal of Biological Chemistry, 2002, 277, 50206-50213.	1.6	109
1457	Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 9825-9829.	3.3	117
1458	DNA damageâ€inducible phosphorylation of p53 at Ser20 is required for p53 stabilization. Korean Journal of Biological Sciences, 2002, 6, 263-269.	0.1	0
1459	Human Immunodeficiency Virus Type 1 Nef Binds to Tumor Suppressor p53 and Protects Cells against p53-Mediated Apoptosis. Journal of Virology, 2002, 76, 2692-2702.	1.5	113
1460	Abrogation of the radiation-induced G2 checkpoint by the staurosporine derivative UCN-01 is associated with radiosensitisation in a subset of colorectal tumour cell lines. British Journal of Cancer, 2002, 87, 352-358.	2.9	29
1461	Differential Activation of p53 by the Various Adducts of Mitomycin C. Journal of Biological Chemistry, 2002, 277, 40513-40519.	1.6	50
1462	Transcriptional Activation of the MUC2 Gene by p53. Journal of Biological Chemistry, 2002, 277, 48270-48275.	1.6	50
1463	p53 protein and p21 mRNA levels and caspase-3 activity are altered by zinc status in aortic endothelial cells. American Journal of Physiology - Cell Physiology, 2002, 283, C631-C638.	2.1	26
1464	The combination of ionizing radiation and expression of a wild type p53 gene via recombinant adenovirus induced a prominent tumour suppressing effect in human oral squamous cell carcinoma. British Journal of Radiology, 2002, 75, 657-662.	1.0	11
1465	The significance of immunohistochemistry in the diagnosis and therapy of neoplasms. Expert Opinion on Biological Therapy, 2002, 2, 371-393.	1.4	14
1466	Alpha-Particle-Induced Increases in the Radioresistance of Normal Human Bystander Cells. Radiation Research, 2002, 157, 3-7.	0.7	120
1467	Large-scale gene expression analysis in molecular target discovery. Leukemia, 2002, 16, 473-477.	3.3	44

#	Article	IF	CITATIONS
1468	Importance of TP53 and RB in the Repair of Potentially Lethal Damage and Induction of Color Junctions after Exposure to Ionizing Radiation. Radiation Research, 2002, 158, 707-714.	0.7	19
1469	Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 1235-1240.	3.3	44
1470	The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA. Carcinogenesis, 2002, 23, 1025-1032.	1.3	103
1471	Interactions between p53, hMSH2-hMSH6 and HMG I(Y) on Holliday junctions and bulged bases. Nucleic Acids Research, 2002, 30, 2427-2434.	6.5	39
1472	Formation of 8-hydroxydeoxyguanosine and cell-cycle arrest in the rat liver via generation of oxidative stress by phenobarbital: association with expression profiles of p21WAF1/Cip1, cyclin D1 and Ogg1. Carcinogenesis, 2002, 23, 341-349.	1.3	94
1473	Normal p53 Function in Primary Cells Deficient for Siah Genes. Molecular and Cellular Biology, 2002, 22, 8155-8164.	1.1	33
1474	The Epstein-Barr Virus Immediate-Early Protein BZLF1 Regulates p53 Function through Multiple Mechanisms. Journal of Virology, 2002, 76, 12503-12512.	1.5	100
1475	7-Hydroxystaurosporine (UCN-01) Preferentially Sensitizes Cells with a Disrupted TP53 to Gamma Radiation in Lung Cancer Cell Lines. Radiation Research, 2002, 158, 84-93.	0.7	19
1476	E2F1 Induces Phosphorylation of p53 That Is Coincident with p53 Accumulation and Apoptosis. Molecular and Cellular Biology, 2002, 22, 5308-5318.	1.1	99
1477	Novel Function of the Cyclin A Binding Site of E2F in Regulating p53-Induced Apoptosis in Response to DNA Damage. Molecular and Cellular Biology, 2002, 22, 78-93.	1.1	98
1478	X Radiation Causes a Persistent Induction of Reactive Oxygen Species and a Delayed Reinduction of TP53 in Normal Human Diploid Fibroblasts. Radiation Research, 2002, 158, 210-219.	0.7	54
1479	High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis, 2002, 23, 949-958.	1.3	46
1480	Mutations in the p53 Gene in Acute Myeloid Leukemia Patients Correlate with Poor Prognosis. Hematology, 2002, 7, 13-19.	0.7	22
1481	Genetic alterations in ovarian cancer cells that might account for sensitivity to chemotherapy in patients. International Review of Cytology, 2002, 219, 157-198.	6.2	8
1482	p53 immunohistochemical expression: messages in cervical carcinogenesis. Pathology, 2002, 34, 326-331.	0.3	10
1483	Detection of the Anti-P53 Antibodies in Dogs with Tumors Journal of Veterinary Medical Science, 2002, 64, 973-979.	0.3	9
1484	Chapter 3 Interactions between the cell cycle and the myogenic program. Advances in Developmental Biology and Biochemistry, 2002, 11, 53-74.	0.3	2
1485	Altered expression of rb and p53 in uveal melanomas following plaque radiotherapy11The author has no proprietary interest in this study American Journal of Ophthalmology, 2002, 133, 242-248.	1.7	20

#	Article	IF	CITATIONS
1486	Historical and Current Highlights in Radiation Biology: Has Anything Important Been Learned by Irradiating Cells?. Radiation Research, 2002, 158, 251-291.	0.7	71
1487	Molecular Markers in Prostate Cancer: The Role in Preoperative Staging. Clinical Prostate Cancer, 2002, 1, 42-50.	2.1	22
1488	Caffeine Induces TP53-Independent G1-Phase Arrest and Apoptosis in Human Lung Tumor Cells in a Dose-Dependent Manner. Radiation Research, 2002, 157, 166-174.	0.7	40
1489	Two Molecularly Distinct G 2 /M Checkpoints Are Induced by Ionizing Irradiation. Molecular and Cellular Biology, 2002, 22, 1049-1059.	1.1	449
1490	Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guérin therapy. Urology, 2002, 59, 409-413.	0.5	45
1491	A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy. Cell, 2002, 109, 335-346.	13.5	966
1492	Convergence of the Fanconi Anemia and Ataxia Telangiectasia Signaling Pathways. Cell, 2002, 109, 459-472.	13.5	421
1493	Molecular aspects of photodynamic therapy: low energy pre-sensitization of hypericin-loaded human endometrial carcinoma cells enhances photo-tolerance, alters gene expression and affects the cell cycle. FEBS Letters, 2002, 512, 287-290.	1.3	12
1494	Falkor, a novel cell growth regulator isolated by a functional genetic screen. Oncogene, 2002, 21, 6713-6721.	2.6	19
1495	In vivo expression of p53 and Bcl-2 and their role in programmed cell death in premalignant and malignant lung lesions. Lung Cancer, 2002, 35, 155-163.	0.9	10
1496	c-Myc Can Induce DNA Damage, Increase Reactive Oxygen Species, and Mitigate p53 Function. Molecular Cell, 2002, 9, 1031-1044.	4.5	809
1497	Thymidylate synthase as a translational regulator of cellular gene expression. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2002, 1587, 174-182.	1.8	101
1498	A role for p53 in the frequency and mechanism of mutation. Mutation Research - Reviews in Mutation Research, 2002, 511, 45-62.	2.4	73
1499	Cell kinetic changes in human squamous cell carcinomas during radiotherapy studied using the in vivo administration of two halogenated pyrimidines. European Journal of Cancer, 2002, 38, 1100-1106.	1.3	9
1500	The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene. Gene, 2002, 282, 207-214.	1.0	57
1501	The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors. Cancer Letters, 2002, 184, 223-230.	3.2	64
1502	Inhibitory effect of glycolic acid on ultraviolet B-induced c-fos expression, AP-1 activation and p53–p21 response in a human keratinocyte cell line. Cancer Letters, 2002, 186, 125-135.	3.2	30
1503	Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma. Gastroenterology Clinics of North America, 2002, 31, 461-479.	1.0	26

#	Article	IF	CITATIONS
1504	Differential Cytotoxicity and Gene Expression in Human Liver Carcinoma (HepG2) Cells Exposed to Arsenic Trioxide, and Monosodium Acid Methanearsonate (MSMA). International Journal of Molecular Sciences, 2002, 3, 1117-1132.	1.8	38
1505	Gene induction studies and toxicity of chemical mixtures Environmental Health Perspectives, 2002, 110, 947-956.	2.8	39
1506	Tumor Suppressor p53 Mediates Apoptotic Cell Death Triggered by Cyclosporin A. Journal of Biological Chemistry, 2002, 277, 14102-14108.	1.6	44
1507	Mercury Induces Cytotoxicity and Transcriptionally Activates Stress Genes in Human Liver Carcinoma (HepG2) Cells. International Journal of Molecular Sciences, 2002, 3, 965-984.	1.8	37
1508	Molecular biology and genetics of breast cancer development: A clinical perspective. Seminars in Radiation Oncology, 2002, 12, 285-295.	1.0	30
1509	Human urinary bladder epithelial cells lacking wild-type p53 function are deficient in the repair of 4-aminobiphenyl–DNA adducts in genomic DNA. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2002, 499, 103-117.	0.4	6
1510	Low dose, low-LET ionizing radiation-induced radioadaptation and associated early responses in unirradiated cells. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2002, 503, 1-9.	0.4	157
1511	Efficient repair of bulky anti-BPDE DNA adducts from non-transcribed DNA strand requires functional p53 but not p21waf1/cip1 and pRb. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2002, 505, 13-25.	0.4	26
1512	Augmentation of apoptosis by the combination of bleomycin with trifluoperazine in the presence of mutant p53. Journal of Experimental Therapeutics and Oncology, 2002, 2, 19-26.	0.5	16
1513	A working model for the time sequence of genetic changes in breast tumorigenesis 11No competing interests declared Journal of the American College of Surgeons, 2002, 194, 202-216.	0.2	20
1514	The DNA repair protein ku is involved in gp130-mediated signal transduction events in PBMC from young but not from elderly subjects. Experimental Gerontology, 2002, 37, 321-328.	1.2	7
1515	Radiation sensitivity depends on OGG1 activity status in human leukemia cell lines. Free Radical Biology and Medicine, 2002, 32, 212-220.	1.3	40
1516	Protease inhibitor-induced stabilization of p21waf1/cip1 and cell-cycle arrest in chemical carcinogen-exposed mammary and lung cells. Molecular Carcinogenesis, 2002, 33, 1-8.	1.3	11
1517	P53: An ubiquitous target of anticancer drugs. International Journal of Cancer, 2002, 98, 161-166.	2.3	136
1518	Nuclear factor-?B, induced in human carcinoma cell line A2780 by the new anthracycline men 10755, is devoid of transcriptional activity. International Journal of Cancer, 2002, 102, 476-482.	2.3	7
1519	Increased expression of T-fimbrin gene after DNA damage in CHO cells and inactivation of T-fimbrin by CpG methylation in human colorectal cancer cells. International Journal of Cancer, 2002, 97, 211-216.	2.3	13
1520	Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis. Cancer, 2002, 95, 624-633.	2.0	51
1521	Effects of hyperthermia on p53 protein expression and activity. Journal of Cellular Physiology, 2002, 190, 365-374.	2.0	28

#	Article	IF	CITATIONS
1522	Does p53 affect organismal aging?. Journal of Cellular Physiology, 2002, 192, 23-33.	2.0	145
1523	Catalytic inhibitors of topoisomerase II are DNA-damaging agents: induction of chromosomal damage by merbarone and ICRF-187. Environmental and Molecular Mutagenesis, 2002, 39, 348-356.	0.9	58
1524	Transcriptional regulation of the glial cell-specific JC virus by p53. Archives of Pharmacal Research, 2002, 25, 208-213.	2.7	2
1525	Determination of glutathione-S-transferase traces in preparations of p53 C-terminal domain (aa320–393). Bioelectrochemistry, 2002, 55, 115-118.	2.4	19
1526	Possible attenuation of the G2 DNA damage cell cycle checkpoint in HeLa cells by extremely low frequency (ELF) electromagnetic fields. Cancer Cell International, 2002, 2, 3.	1.8	19
1527	Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. International Journal of Radiation Oncology Biology Physics, 2002, 54, 910-920.	0.4	77
1528	Establishment of a novel clonal murine bone marrow stromal cell line for assessment of p53 responses to genotoxic stress. Toxicology, 2002, 179, 257-266.	2.0	8
1529	Hsp 27 is better associated with the expression of inducible thermotolerance in human pancreatic tumor cell lines than hsp 70, p53 or p21/waf1/cip1. Journal of Thermal Biology, 2002, 27, 47-54.	1.1	2
1530	Blue Light Inhibits the Growth of B16 Melanoma Cells. Japanese Journal of Cancer Research, 2002, 93, 551-558.	1.7	46
1531	Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene, 2002, 21, 974-979.	2.6	105
1532	MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts. Oncogene, 2002, 21, 867-877.	2.6	36
1533	Activation of ATM and phosphorylation of p53 by heat shock. Oncogene, 2002, 21, 1090-1096.	2.6	54
1534	P16INK4A is implicated in both the immediate and adaptative response of human keratinocytes to UVB irradiation. Oncogene, 2002, 21, 2652-2661.	2.6	33
1535	The p53 network in lung carcinogenesis. Oncogene, 2002, 21, 6898-6907.	2.6	130
1536	ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth. Oncogene, 2002, 21, 7488-7496.	2.6	168
1537	GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity. Oncogene, 2002, 21, 8696-8704.	2.6	184
1538	A Lack of Association Between p53 Mutations and Recurrent Nasopharyngeal Carcinomas Refractory to Radiotherapy. Laryngoscope, 2002, 112, 2015-2019.	1.1	15
1539	Molecular Analysis of Surgical Margins in Head and Neck Squamous Cell Carcinoma Patients. Laryngoscope, 2002, 112, 2129-2140.	1.1	104

#	ARTICLE	IF	CITATIONS
1540	Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. International Journal of Radiation Oncology Biology Physics, 2002, 52, 294-303.	0.4	119
1541	The effects of pentoxifylline on the survival of human glioma cells with continuous and intermittent stereotactic radiosurgery irradiation. International Journal of Radiation Oncology Biology Physics, 2002, 54, 542-550.	0.4	20
1542	Antitumor Effects of Miconazole on Human Colon Carcinoma Xenografts in Nude Mice through Induction of Apoptosis and GO/G1 Cell Cycle Arrest. Toxicology and Applied Pharmacology, 2002, 180, 22-35.	1.3	32
1543	Diol- and Triol-Type Ginseng Saponins Potentiate the Apoptosis of NIH3T3 Cells Exposed to Methyl Methanesulfonate. Toxicology and Applied Pharmacology, 2002, 181, 192-202.	1.3	17
1544	The mechanisms of endogenous control of hepatocyte proliferation are different in mice of two inbred strains (BALB/c and AKR). Doklady Biological Sciences, 2002, 383, 161-163.	0.2	3
1545	All-trans-retinoic acid-mediated modulation of p53 during neural differentiation in murine embryonic stem cells. Cell Biology and Toxicology, 2002, 18, 243-257.	2.4	23
1546	Partial purification and characterization of an 80-kDa transcription factor binding to bHLH motif in the rat p53 promoter. Molecular Biology Reports, 2002, 29, 337-345.	1.0	0
1547	Apoptosis of Cortical Neurons in Ischemic Insult. Neurophysiology, 2002, 34, 436-450.	0.2	0
1548	Expression of p53 Protein and Tumor Angiogenesis as Prognostic Factors in Nasopharyngeal Carcinoma Patients. Pathology Research and Practice, 2002, 198, 97-102.	1.0	16
1549	Inhibition of p21-mediated ROS accumulation can rescue p21-induced senescence. EMBO Journal, 2002, 21, 2180-2188.	3.5	303
1550	Comparison of p53 Mutational Status with mRNA and Protein Expression in a Panel of 24 Human Breast Carcinoma Cell Lines. Breast Cancer Research and Treatment, 2003, 79, 37-46.	1.1	46
1551	Loss of Heterozygosity and DNA Aneuploidy in Colorectal Adenocarcinoma. Annals of Surgical Oncology, 2003, 10, 1086-1094.	0.7	46
1552	Chemosensitization and Radiosensitization of Human Cancer by Antisense Anti-MDM2 Oligonucleotides. Annals of the New York Academy of Sciences, 2003, 1002, 217-235.	1.8	54
1553	Plasmid vaccine encoding HN gene from newcastle disease virus has marked antitumoral effect in vitro. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2003, 15, 161-166.	0.7	1
1554	BRCA1 and p53: compensatory roles in DNA repair. Journal of Molecular Medicine, 2003, 81, 700-707.	1.7	41
1555	Radiation induces p53 -dependent cell apoptosis in bladder cancer cells with wild-type- p53 but not in p53 -mutated bladder cancer cells. Urological Research, 2003, 31, 387-396.	1.5	40
1556	Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line. Journal of Cancer Research and Clinical Oncology, 2003, 129, 175-182.	1.2	27
1557	Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. Journal of Cancer Research and Clinical Oncology, 2003, 129, 709-718.	1.2	29

#	Article	IF	CITATIONS
1558	The p53–Mdm2 module and the ubiquitin system. Seminars in Cancer Biology, 2003, 13, 49-58.	4.3	665
1559	Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: Results of a ten-year prospective study. Journal of Thoracic and Cardiovascular Surgery, 2003, 125, 1121-1131.	0.4	53
1560	Multiple subphases of DNA repair and poly(ADP-ribose) synthesis in Chinese hamster ovary (CHO-K1) cells. European Journal of Cell Biology, 2003, 82, 201-207.	1.6	8
1561	Caffeine and human DNA metabolism: the magic and the mystery. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2003, 532, 85-102.	0.4	81
1562	Iron-induced oxidative damage and apoptosis in cerebellar granule cells: attenuation by tetramethylpyrazine and ferulic acid. European Journal of Pharmacology, 2003, 467, 41-47.	1.7	111
1563	Tissue-specific regulation of checkpoint kinase 2 expression by p53. Experimental and Molecular Pathology, 2003, 75, 131-136.	0.9	8
1564	Identification of transcriptome profiles for the DNA-damaging agents bleomycin and hydrogen peroxide in L5178Y mouse lymphoma cells. Environmental and Molecular Mutagenesis, 2003, 42, 19-25.	0.9	24
1565	Expression of Ku86 confers favorable outcome of tonsillar carcinoma treated with radiotherapy. Head and Neck, 2003, 25, 313-321.	0.9	24
1566	P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head and Neck, 2003, 25, 654-661.	0.9	144
1567	TP53 and gastric carcinoma: A review. Human Mutation, 2003, 21, 258-270.	1.1	216
1568	TP53 mutations in workers exposed to occupational carcinogens. Human Mutation, 2003, 21, 240-251.	1.1	26
1569	Direct interaction with and activation of p53 by SMAR1 retards cell-cycle progression at G2/M phase and delays tumor growth in mice. International Journal of Cancer, 2003, 103, 606-615.	2.3	77
1570	Involvement of p53 in specific anti-neuroectodermal tumor activity of aloe-emodin. International Journal of Cancer, 2003, 106, 836-847.	2.3	70
1571	G1 tetraploidy checkpoint and the suppression of tumorigenesis. Journal of Cellular Biochemistry, 2003, 88, 673-683.	1.2	205
1572	Caffeine induces G2/M arrest and apoptosis via a novel p53-dependent pathway in NB4 promyelocytic leukemia cells. Journal of Cellular Physiology, 2003, 196, 276-283.	2.0	53
1573	Association of JNK1 with p21waf1 and p53: Modulation of JNK1 activity. Molecular Carcinogenesis, 2003, 36, 38-44.	1.3	19
1574	Inhibition of DNA repair by Pentoxifylline and related methylxanthine derivatives. Toxicology, 2003, 193, 153-160.	2.0	43
1575	Animal Models of Melanoma: An HGF/SF Transgenic Mouse Model May Facilitate Experimental Access to UV Initiating Events. Pigment Cell & Melanoma Research, 2003, 16, 16-25.	4.0	76

#	Article	IF	CITATIONS
1576	Cutaneous Photobiology. The Melanocyte vs. the Sun: Who Will Win the Final Round?. Pigment Cell & Melanoma Research, 2003, 16, 434-447.	4.0	149
1577	Simultaneous acceleration of the cell cycle and suppression of apoptosis by splice variant delta-6 of the candidate tumour suppressor LUCA-15/RBM5. Genes To Cells, 2003, 8, 109-119.	0.5	42
1578	p53 expression in normal paraffin-embedded tissue using different antibodies and antigen retrieval buffer systems. Histopathology, 2003, 42, 83-87.	1.6	18
1579	Molecular Mechanisms of Chemotherapy-Induced Hair Loss. Journal of Investigative Dermatology Symposium Proceedings, 2003, 8, 72-75.	0.8	75
1580	Ultraviolet Irradiation Induces Apoptosis in Human Immature, But Not in Skin Mast Cells. Journal of Investigative Dermatology, 2003, 121, 837-844.	0.3	30
1581	The p53 tumour suppressor gene. British Journal of Surgery, 2003, 85, 1460-1467.	0.1	162
1582	Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms. Prostate, 2003, 54, 194-205.	1.2	86
1583	Delayed expression of apoptosis in human lymphoma cells undergoing low-dose taxol-induced mitotic stress. British Journal of Cancer, 2003, 88, 1649-1658.	2.9	23
1584	Adenovirus-mediated PTEN treatment combined with caffeine produces a synergistic therapeutic effect in colorectal cancer cells. Cancer Gene Therapy, 2003, 10, 803-813.	2.2	30
1585	Adenovirus-mediated transfer of the PTEN gene inhibits human colorectal cancer growth in vitro and in vivo. Gene Therapy, 2003, 10, 1961-1969.	2.3	55
1586	The radioresistance biological function of the SCF/kit signaling pathway is mediated by the zinc-finger transcription factor Slug. Oncogene, 2003, 22, 4205-4211.	2.6	83
1587	P53 and radiation responses. Oncogene, 2003, 22, 5774-5783.	2.6	444
1588	Gadd45a contributes to p53 stabilization in response to DNA damage. Oncogene, 2003, 22, 8536-8540.	2.6	83
1589	Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 2003, 22, 7265-7279.	2.6	2,838
1590	Cellular and molecular mechanisms responsible for progression of Barrett's metaplasia to esophageal carcinoma. Hematology/Oncology Clinics of North America, 2003, 17, 453-470.	0.9	2
1591	p53-associated 3′→5′ exonuclease activity in nuclear and cytoplasmic compartments of cells. Oncogene, 2003, 22, 233-245.	2.6	39
1592	Apoptosis or growth arrest: modulation of the cellular response to p53 by proliferative signals. Oncogene, 2003, 22, 555-571.	2.6	33
1593	Adenoviral-mediated transfer of p53 or retinoblastoma protein blocks cell proliferation and induces apoptosis in culture-activated hepatic stellate cells. Journal of Hepatology, 2003, 38, 169-178.	1.8	28

#	Article	IF	CITATIONS
1594	Blockage of transcription as a trigger for p53 accumulation by 2-acetylaminofluorene DNA-adducts. Life Sciences, 2003, 73, 1759-1771.	2.0	6
1595	Enhancement of lung carcinogenesis by nonylphenol and genistein in a F344 rat multiorgan carcinogenesis model. Cancer Letters, 2003, 192, 25-36.	3.2	33
1596	High susceptibility of p53 knockout mice to esophageal and urinary bladder carcinogenesis induced by N, N-dibutylnitrosamine. Cancer Letters, 2003, 194, 45-54.	3.2	14
1597	Gene expression profile of human cells irradiated in G1 and G2 phases of cell cycle. Cancer Letters, 2003, 195, 221-233.	3.2	47
1598	Pifithrin- $\hat{l}_{\pm}$ supresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neuroscience, 2003, 120, 191-205.	1.1	149
1599	Radiation sensitivity and mutation position of p53. International Congress Series, 2003, 1258, 239-243.	0.2	2
1600	Accumulation of alanine mutant p53 at Ser15, Thr18, and Ser20 after X-irradiation. International Congress Series, 2003, 1258, 251-254.	0.2	0
1601	Ara-C induces apoptosis in monkey fibroblast cells. Toxicology in Vitro, 2003, 17, 367-373.	1.1	17
1602	Overexpression of HSP70 is induced by ionizing radiation in C3H 10T1/2 cells and protects from DNA damage. Toxicology in Vitro, 2003, 17, 561-566.	1,1	76
1603	Overexpression of the human inducible nitric oxide synthase gene enhances radiation-induced apoptosis in colorectal cancer cells via a caspase-dependent mechanism. Nitric Oxide - Biology and Chemistry, 2003, 8, 119-126.	1.2	57
1604	3-Deazauridine triggers dose-dependent apoptosis in myeloid leukemia cells and enhances retinoic acid-induced granulocytic differentiation of HL-60 cells. International Journal of Biochemistry and Cell Biology, 2003, 35, 1482-1494.	1,2	11
1605	Genotoxic effect of raw betel-nut extract in relation to endogenous glutathione levels and its mechanism of action in mammalian cells. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2003, 538, 1-12.	0.9	44
1606	Hypersensitivity of DNA polymerase $\hat{l}^2$ null mouse fibroblasts reflects accumulation of cytotoxic repair intermediates from site-specific alkyl DNA lesions. DNA Repair, 2003, 2, 27-48.	1.3	88
1607	p53 and regulation of DNA damage recognition during nucleotide excision repair. DNA Repair, 2003, 2, 947-954.	1.3	150
1608	Cytoplasmic p21 WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Research, 2003, 5, R242-9.	2.2	85
1609	Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10794-10799.	3.3	1,031
1610	Docetaxel in non-small cell lung cancer: a review. Expert Opinion on Pharmacotherapy, 2003, 4, 553-565.	0.9	49
1611	Caffeine Could Not Efficiently Sensitize Homologous Recombination Repair-Deficient Cells to Ionizing Radiation-Induced Killing. Radiation Research, 2003, 159, 420-425.	0.7	46

#	Article	IF	Citations
1612	COP9 Signalosome Subunit 3 Is Essential for Maintenance of Cell Proliferation in the Mouse Embryonic Epiblast. Molecular and Cellular Biology, 2003, 23, 6798-6808.	1.1	107
1613	Caffeine-Induced Radiosensitization is Independent of Nonhomologous End Joining of DNA Double-Strand Breaks. Radiation Research, 2003, 159, 426-432.	0.7	43
1614	Sequential Alteration of Apoptosis, p53 Expression, and Cell Proliferation in the Rat Pancreas Treated with 4-Hydroxyaminoquinoline 1-Oxide. Toxicologic Pathology, 2003, 31, 625-631.	0.9	5
1615	mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation. Molecular and Cellular Biology, 2003, 23, 462-472.	1.1	230
1616	Invited Review: Effect of oxygen deprivation on cell cycle activity: a profile of delay and arrest. Journal of Applied Physiology, 2003, 94, 2068-2083.	1.2	52
1617	Influence of Induced Reactive Oxygen Species in p53-Mediated Cell Fate Decisions. Molecular and Cellular Biology, 2003, 23, 8576-8585.	1.1	296
1618	Neocarzinostatin Induces an Effective p53-Dependent Response in Human Papillomavirus-Positive Cervical Cancer Cells. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 671-680.	1.3	22
1619	Arrest of mammalian fibroblasts in G1 in response to actin inhibition is dependent on retinoblastoma pocket proteins but not on p53. Journal of Cell Biology, 2003, 161, 67-77.	2.3	56
1620	Hypoxia induces p53 through a pathway distinct from most DNA-damaging and stress-inducing agents. Carcinogenesis, 2003, 24, 1177-1182.	1.3	22
1621	Influence of Environmental pH on G2-Phase Arrest Caused by Ionizing Radiation. Radiation Research, 2003, 159, 86-93.	0.7	37
1622	A Role for the Phosphorylation of hRad9 in Checkpoint Signaling. Journal of Biological Chemistry, 2003, 278, 26620-26628.	1.6	85
1623	Nuclear Factor-Y Binding to the Topoisomerase Ilα Promoter Is Inhibited by Both the p53 Tumor Suppressor and Anticancer Drugs. Molecular Pharmacology, 2003, 63, 359-367.	1.0	17
1624	Supramolecular Complex Formation between Rad6 and Proteins of the p53 Pathway during DNA Damage-Induced Response. Molecular and Cellular Biology, 2003, 23, 2463-2475.	1.1	45
1625	Proline Oxidase Induces Apoptosis in Tumor Cells, and Its Expression Is Frequently Absent or Reduced in Renal Carcinomas. Journal of Biological Chemistry, 2003, 278, 9784-9789.	1.6	89
1626	Base Excision Repair Intermediates Induce p53-independent Cytotoxic and Genotoxic Responses. Journal of Biological Chemistry, 2003, 278, 39951-39959.	1.6	162
1627	Intra-G1 arrest in response to UV irradiation in fission yeast. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10758-10763.	3.3	25
1628	A Defect in the p53 Response Pathway Induced by de Novo Purine Synthesis Inhibition. Journal of Biological Chemistry, 2003, 278, 48861-48871.	1.6	40
1629	Sticky Anaphase Aberrations after G2-Phase Arrest of Gamma-Irradiated Human Skin Fibroblasts: TP53 Independence of Formation and TP53 Dependence of Consequences. Radiation Research, 2003, 159, 57-71.	0.7	3

#	ARTICLE	IF	CITATIONS
1630	Diabetic LDL Triggers Apoptosis in Vascular Endothelial Cells. Diabetes, 2003, 52, 1240-1247.	0.3	57
1631	Hyperproliferation and p53 Status of Lens Epithelial Cells Derived from αB-crystallin Knockout Mice. Journal of Biological Chemistry, 2003, 278, 36876-36886.	1.6	37
1632	Analysing p53 tumour suppressor functions in mice. Expert Opinion on Therapeutic Targets, 2003, 7, 89-99.	1.5	9
1633	Cell-Cycle Gene Expression in Lovastatin-Induced Medulloblastoma Apoptosis. Canadian Journal of Neurological Sciences, 2003, 30, 349-357.	0.3	13
1634	Angiogenesis, p53, and bcl-2 Expression as Prognostic Indicators in Endometrial Cancer. International Journal of Gynecological Pathology, 2003, 22, 254-260.	0.9	26
1635	Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood, 2003, 102, 1842-1848.	0.6	81
1636	Fanconi anemia type C and p53 cooperate in apoptosis and tumorigenesis. Blood, 2003, 102, 4146-4152.	0.6	67
1637	The interface between the cell cycle and programmed cell death in higher plants: from division unto death. Advances in Botanical Research, 2003, 40, 143-181.	0.5	4
1638	Inhibition of Replication Induces Non-Apoptotic Cell Death in Fibroblast Cell Lines Derived from LEC Rats Journal of Veterinary Medical Science, 2003, 65, 249-254.	0.3	1
1639	Association Between p53 Protein Expression and Chemosensitivity in Pretreatment Biopsy Specimens of Oral Squamous Cell Carcinoma. Oral Medicine & Pathology, 2004, 9, 149-154.	0.3	5
1641	Effect of Ionizing Irradiation on Human Esophageal Cancer Cell Lines by cDNA Microarray Gene Expression Analysis. Journal of Nippon Medical School, 2004, 71, 172-180.	0.3	37
1642	Differential response of p53 target genes to p73 overexpression in SH-SY5Y neuroblastoma cell line. Journal of Cell Science, 2004, 117, 293-301.	1.2	32
1643	Accumulation of the Cell Cycle Regulators TP53 and CDKN1A (p21) in Human Fibroblasts after Exposure to Low- and High-LET Radiation. Radiation Research, 2004, 161, 675-684.	0.7	47
1644	Comparison of Endogenous TP53 Genomic Status with Clonogenicity and Different Modes of Cell Death after X Irradiation. Radiation Research, 2004, 161, 39-47.	0.7	6
1645	Histopathological and Molecular Changes During Apoptosis Produced by 7H-Dibenzo[c,g]-Carbazole in Mouse Liver. Toxicologic Pathology, 2004, 32, 202-211.	0.9	15
1646	p53 and stress in the ER. Genes and Development, 2004, 18, 241-244.	2.7	21
1647	Enhancers and Suppressors of Testicular Cancer Susceptibility in Single- and Double-Mutant Mice. Genetics, 2004, 166, 925-933.	1.2	17
1648	p53 Elevation in Relation to Levels and Cytotoxicity of Mono- and Bifunctional Melphalan-DNA Adducts. Molecular Pharmacology, 2004, 66, 1301-1309.	1.0	20

#	Article	IF	CITATIONS
1649	The effects of single doses of $\hat{A}$ radiation on the wound healing behaviour of human Tenon's capsule fibroblasts. British Journal of Ophthalmology, 2004, 88, 169-173.	2.1	12
1650	Patterns of Chromosomal Alterations in Breast Ductal Carcinoma In situ. Clinical Cancer Research, 2004, 10, 5160-5167.	3.2	115
1651	p53 Activation in Chronic Radiation-Treated Breast Cancer Cells. Cancer Research, 2004, 64, 221-228.	0.4	30
1652	Accumulation of 8-Hydroxy-2'- Deoxyguanosine Adducts in HBx Recombinant HepG2 Cells and HBx Transgenic Mice. Digestion, 2004, 70, 117-126.	1.2	2
1653	Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial cells. FASEB Journal, 2004, 18, 146-148.	0.2	138
1654	Repression of GO/G1 Traverse in Human Fibroblasts Exposed to Low Levels of Ionizing Radiation. Journal of Biological Chemistry, 2004, 279, 43667-43674.	1.6	2
1655	Comprehensive Proteomic Analysis of Interphase and Mitotic 14-3-3-binding Proteins. Journal of Biological Chemistry, 2004, 279, 32046-32054.	1.6	195
1656	DNA-dependent Protein Kinase and Checkpoint Kinase 2 Synergistically Activate a Latent Population of p53 upon DNA Damage. Journal of Biological Chemistry, 2004, 279, 15269-15273.	1.6	34
1657	Differential Cell Killing by Lymphomagenic Murine Leukemia Viruses Occurs Independently of p53 Activation and Mitochondrial Damage. Journal of Virology, 2004, 78, 5088-5096.	1.5	9
1658	PTEN Gene Targeting Reveals a Radiation-Induced Size Checkpoint in Human Cancer Cells. Cancer Research, 2004, 64, 6906-6914.	0.4	86
1659	Ser392 Phosphorylation Regulates the Oncogenic Function of Mutant p53. Cancer Research, 2004, 64, 4749-4754.	0.4	76
1660	MDM4 (MDMX) Overexpression Enhances Stabilization of Stress-induced p53 and Promotes Apoptosis. Journal of Biological Chemistry, 2004, 279, 8169-8180.	1.6	35
1661	Double Strand Break Repair by Homologous Recombination Is Regulated by Cell Cycle-independent Signaling via ATM in Human Glioma Cells. Journal of Biological Chemistry, 2004, 279, 15402-15410.	1.6	107
1662	Induction of CDK inhibitor p21 gene as a new therapeutic strategy against pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 286, L727-L733.	1.3	34
1663	Invasion of Normal Human Fibroblasts Induced by v-FosIs Independent of Proliferation, Immortalization, and theTumor Suppressors p16 INK4a andp53. Molecular and Cellular Biology, 2004, 24, 1540-1559.	1.1	33
1664	The Involvement of p53 in Paraquat-Induced Apoptosis in Human Lung Epithelial-Like Cells. International Journal of Toxicology, 2004, 23, 33-40.	0.6	21
1665	High-Content Screening with siRNA Optimizes a Cell Biological Approach to Drug Discovery: Defining the Role of P53 Activation in the Cellular Response to Anticancer Drugs. Journal of Biomolecular Screening, 2004, 9, 557-568.	2.6	62
1666	Genetic link between p53 and genes required for formation of the zonula adherens junction. Cancer Science, 2004, 95, 436-441.	1.7	10

#	Article	IF	Citations
1667	Nucleocytoplasmic shuttling of signal transducers. Nature Reviews Molecular Cell Biology, 2004, 5, 209-219.	16.1	240
1668	Caffeine inhibits homology-directed repair of I-Scel-induced DNA double-strand breaks. Oncogene, 2004, 23, 824-834.	2.6	45
1669	A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells. Oncogene, 2004, 23, 1712-1723.	2.6	13
1670	ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest. Oncogene, 2004, 23, 3284-3295.	2.6	84
1671	Nuclear accumulation of p53 following inhibition of transcription is not due to diminished levels of MDM2. Oncogene, 2004, 23, 5505-5512.	2.6	40
1672	p14ARF is a component of the p53 response following ionizing irradiation of normal human fibroblasts. Oncogene, 2004, 23, 6040-6046.	2.6	41
1673	p53-dependent transcription can exhibit both on/off and graded response after genotoxic stress. Oncogene, 2004, 23, 6175-6185.	2.6	33
1674	HPMA copolymers containing doxorubicin bound by a proteolytically or hydrolytically cleavable bond: comparison of biological properties in vitro. Journal of Controlled Release, 2004, 99, 301-314.	4.8	48
1675	Genealogy, expression, and molecular mechanisms in apoptosis. , 2004, 101, 1-15.		53
1676	The treatment of skin carcinoma, induced by UV B radiation, using $1$ -oxo- $5\hat{l}^2$ , $6\hat{l}^2$ -epoxy-witha- $2$ -enolide, isolated from the roots of Withania somnifera, in a rat model. Phytomedicine, 2004, $11$ , 452-460.	2.3	31
1677	Influence of p53 and caspase 3 activity on cell death and senescence in response to methotrexate in the breast tumor cell. Biochemical Pharmacology, 2004, 68, 1699-1708.	2.0	50
1678	Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. Cancer Detection and Prevention, 2004, 28, 114-118.	2.1	42
1679	Gene expression profiling of p53-sensitive and -resistant tumor cells using DNA microarray. Apoptosis: an International Journal on Programmed Cell Death, 2004, 9, 171-179.	2.2	4
1680	Gamma irradiation-induced apoptosis in murine pre-B cells prevents the condensation of fibrillar chromatin in early S phase. Apoptosis: an International Journal on Programmed Cell Death, 2004, 9, 765-776.	2.2	27
1681	Is low-dose hyper-radiosensitivity a measure of G2-phase cell radiosensitivity?. Cancer and Metastasis Reviews, 2004, 23, 197-207.	2.7	58
1682	Implications of apoptosis regulators in tumorigenesis. Cancer and Metastasis Reviews, 2004, 23, 367-387.	2.7	51
1683	NF-κB prevents cells from undergoing Cr(VI)-induced apoptosis. Molecular and Cellular Biochemistry, 2004, 255, 129-137.	1.4	11
1684	p53: Twenty five years understanding the mechanism of genome protection. Journal of Physiology and Biochemistry, 2004, 60, 287-307.	1.3	103

#	Article	IF	CITATIONS
1685	Molecular targets for potentiation of radiation-induced cell killing. Breast Cancer, 2004, 11, 121-128.	1.3	1
1686	P53-independent thermosensitization by mitomycin c in human non–small-cell lung cancer cells. International Journal of Radiation Oncology Biology Physics, 2004, 59, 852-860.	0.4	15
1687	Role of cell cycle in mediating sensitivity to radiotherapy. International Journal of Radiation Oncology Biology Physics, 2004, 59, 928-942.	0.4	870
1688	Foetal rat lung epithelial (FRLE) cells: alterations in cellular homeostasis and gene expression in response to etoposide, hydrogen peroxide and sodium butyrate. Toxicology, 2004, 195, 209-220.	2.0	3
1689	Response of human cord blood cells to styrene exposure: evaluation of its effects on apoptosis and gene expression by genomic technology. Toxicology, 2004, 200, 145-157.	2.0	27
1690	Computational studies and peptidomimetic design for the human p53-MDM2 complex. Proteins: Structure, Function and Bioinformatics, 2004, 58, 222-234.	1.5	78
1691	Hypoglycemia induced changes in cell death and cell proliferation in the organogenesis stage embryonic mouse heart. Birth Defects Research Part A: Clinical and Molecular Teratology, 2004, 70, 121-131.	1.6	6
1692	Lipomatous hemangiopericytoma of the head and neck: immunohistochemical and dna ploidy analyses. Head and Neck, 2004, 26, 544-549.	0.9	13
1693	Comparison of gene expression changes induced in mouse and human cells treated with direct-acting mutagens. Environmental and Molecular Mutagenesis, 2004, 44, 401-419.	0.9	44
1694	Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer, 2004, 100, 1936-1942.	2.0	74
1695	p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer, 2004, 100, 1859-1867.	2.0	60
1696	The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast. Cancer, 2004, 100, 2317-2327.	2.0	95
1697	p53, p16 and cyclin D1: Molecular determinants of radiotherapy treatment response in oral carcinoma. International Journal of Cancer, 2004, 109, 710-716.	2.3	38
1698	Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Critical Reviews in Oncology/Hematology, 2004, 52, 103-116.	2.0	122
1699	Evidence that Unrejoined DNA Double-Strand Breaks are not Predominantly Responsible for Chromosomal Radiosensitivity of AT Fibroblasts. Radiation Research, 2004, 162, 554-565.	0.7	14
1700	Differential Response to Radiation of TP53-Inactivated Cells by Overexpression of Dominant-Negative Mutant TP53 or HPVE6. Radiation Research, 2004, 161, 504-510.	0.7	9
1701	Dose and Dose-Rate Effects of Low-Dose Ionizing Radiation on Activation of Trp53 in Immortalized Murine Cells. Radiation Research, 2004, 162, 296-307.	0.7	38
1702	Crystal Structure of a Superstable Mutant of Human p53 Core Domain. Journal of Biological Chemistry, 2004, 279, 1291-1296.	1.6	147

#	Article	IF	CITATIONS
1703	The Tumor Suppressor Gene TP53: Implications for Cancer Management and Therapy. Critical Reviews in Clinical Laboratory Sciences, 2004, 41, 551-583.	2.7	31
1704	Autofluorescence (safe) bronchoscopy and p21/ki-67 immunostaining related to carcinogenesis. Photodiagnosis and Photodynamic Therapy, 2004, 1, 13-22.	1.3	1
1705	Expression Patterns of Cyclins D1, E and Cyclin-Dependent Kinase Inhibitors p21(Waf1/Cip1) and p27(Kip1) in Urothelial Carcinoma: Correlation with Other Cell-Cycle-Related Proteins (Rb, p53, Ki-67 and PCNA) and Clinicopathological Features. Urologia Internationalis, 2004, 73, 65-73.	0.6	20
1706	Alteration of autoantibodies against p53 in Taiwanese lung cancer patients undergoing chemotherapy. Clinica Chimica Acta, 2004, 349, 87-96.	0.5	5
1707	Association of Ubc9, an E2 ligase for SUMO conjugation, with p53 is regulated by phosphorylation of p53. FEBS Letters, 2004, 573, 15-18.	1.3	41
1708	Stabilization of alanine substituted p53 protein at Ser15, Thr18, and Ser20 in response to ionizing radiation. Biochemical and Biophysical Research Communications, 2004, 323, 906-911.	1.0	9
1709	Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock. Experimental Cell Research, 2004, 295, 525-538.	1.2	119
1710	Physalis peruviana extract induces apoptosis in human Hep G2 cells through CD95/CD95L system and the mitochondrial signaling transduction pathway. Cancer Letters, 2004, 215, 199-208.	3.2	70
1711	Principles of Tumor Suppression. Cell, 2004, 116, 235-246.	13.5	850
1712	Free Radicals, Oxidative Stress, and Cancer. CRC Series in Modern Nutrition Science, 2004, , .	0.0	0
1713	High Sensitivity of Fibroblast Cell Lines Derived from LEC Rats to Heat Treatment. Journal of Veterinary Medical Science, 2004, 66, 1177-1182.	0.3	1
1714	Germline p53 Mutation Presenting as Synchronous Tumors. Journal of Pediatric Hematology/Oncology, 2005, 27, 441-443.	0.3	15
1715	Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood, 2005, 106, 318-327.	0.6	118
1716	Flavin-containing oxidases regulate progression from G1 to S phase of the cell cycle in normal human diploid fibroblasts. Radiation Physics and Chemistry, 2005, 72, 315-321.	1.4	3
1718	Chapters 6 and 7. Annals of the ICRP, 2005, 35, 93-140.	3.0	3
1719	Quantitative high-throughput measurement of gene expression with sub-zeptomole sensitivity by capillary electrophoresis. Analytical Biochemistry, 2005, 345, 284-295.	1.1	1
1720	Apoptosis in Human Skin: Role in Pathogenesis of Various Diseases and Relevance for Therapy. Annals of the New York Academy of Sciences, 2005, 1051, 52-63.	1.8	29
1721	Detection of centrosome amplification as a surrogate marker of dysfunction in the p53 pathway -p53 gene mutation or MDM2 overexpression. Veterinary and Comparative Oncology, 2005, 3, 203-210.	0.8	4

#	Article	IF	CITATIONS
1722	Increased peripheral blood Tâ€cell apoptosis and decreased Bclâ€2 in chronic obstructive pulmonary disease. Immunology and Cell Biology, 2005, 83, 160-166.	1.0	18
1723	Molecular aetiology and pathogenesis of basal cell carcinoma. British Journal of Dermatology, 2005, 152, 1108-1124.	1.4	115
1724	Differential effects of 5-aminolaevulinic acid photodynamic therapy and psoralen + ultraviolet A therapy on p53 phosphorylation in normal human skin in vivo. British Journal of Dermatology, 2005, 153, 1001-1010.	1.4	26
1725	p12CDK2-AP1 mediates DNA damage responses induced by cisplatin. Oncogene, 2005, 24, 407-418.	2.6	16
1726	Fen1 is induced p53 dependently and involved in the recovery from UV-light-induced replication inhibition. Oncogene, 2005, 24, 8304-8313.	2.6	34
1727	Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature, 2005, 434, 907-913.	13.7	1,870
1728	Dehydroepiandrosterone inhibits the proliferation of human umbilical vein endothelial cells by enhancing the expression of p53 and p21, restricting the phosphorylation of retinoblastoma protein, and is androgen- and estrogen-receptor independent. FEBS Journal, 2005, 272, 1343-1353.	2.2	46
1729	Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyosarcoma. Cancer Genetics and Cytogenetics, 2005, 161, 1-19.	1.0	70
1730	Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell, 2005, 7, 469-483.	7.7	2,137
1731	Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detection and Prevention, 2005, 29, 241-248.	2.1	45
1732	EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochemical Pharmacology, 2005, 70, 1568-1578.	2.0	153
1733	Gadd45a, a p53- and BRCA1-regulated stress protein, in cellular response to DNA damage. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 569, 133-143.	0.4	180
1734	Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 577, 195-202.	0.4	100
1735	Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells. International Journal of Cancer, 2005, 115, 55-64.	2.3	30
1736	Reduced p53 in peripheral blood mononuclear cells from patients with rheumatoid arthritis is associated with loss of radiation-induced apoptosis. Arthritis and Rheumatism, 2005, 52, 1047-1057.	6.7	43
1737	Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR. Molecular Carcinogenesis, 2005, 44, 174-182.	1.3	40
1738	Apoptosis in UV-C light irradiated p53 wild-type, apaf-1 and p53 knockout mouse embryonic fibroblasts: Interplay of receptor and mitochondrial pathway. Apoptosis: an International Journal on Programmed Cell Death, 2005, 10, 1295-1304.	2.2	15
1739	Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancer. International Journal of Colorectal Disease, 2005, 20, 94-102.	1.0	10

#	Article	IF	CITATIONS
1740	Increased expression of p53 and p21 (Waf1/Cip1) in the lesional skin of bleomycin-induced scleroderma. Archives of Dermatological Research, 2005, 296, 509-513.	1.1	11
1741	Growth in Epithelial Cell Proliferation and Apoptosis Correlates Specifically to the Inflammation Activity of Inflammatory Bowel Diseases: Ulcerative Colitis Shows Specific p53- and EGFR Expression Alterations. Diseases of the Colon and Rectum, 2005, 48, 775-786.	0.7	46
1742	Pseudolaric acid B induces apoptosis through p53 and bax/ Bcl-2 pathways in human melanoma a375-s2 cells. Archives of Pharmacal Research, 2005, 28, 68-72.	2.7	36
1743	In vitro anti— irradiation effects of a polypeptide from Chlamys farreri. Chinese Journal of Clinical Oncology, 2005, 2, 473-479.	0.0	0
1744	p53 and cell-cycle-regulated protein expression in small intestinal cells after fast-neutron irradiation in mice. Molecular and Cellular Biochemistry, 2005, 270, 21-28.	1.4	17
1745	Apoptosis and proliferation: correlation with p53 in astrocytic tumours. Journal of Neuro-Oncology, 2005, 73, 93-100.	1.4	17
1746	Brief Report: Towards a dietary prevention of hereditary breast cancer. Cancer Causes and Control, 2005, 16, 125-138.	0.8	37
1747	Responses of genes involved in cell cycle control to diverse DNA damaging chemicals in human lung adenocarcinoma A549 cells. Cancer Cell International, 2005, 5, 28.	1.8	14
1748	Effect of Light Irradiation and Sex Hormones on Jurkat T Cells: 17β-Estradiol but Not Testosterone Enhances UVA-Induced Cytotoxicity in Jurkat Lymphocytes. International Journal of Environmental Research and Public Health, 2005, 2, 156-163.	1.2	2
1749	Effect of <i>Helicobacter pylori </i> infection on <i>p53 </i> expression of gastric mucosa and adenocarcinoma with microsatellite instability. World Journal of Gastroenterology, 2005, 11, 4363.	1.4	28
1750	Serum anti-p53 antibodies do not occur in patients with heart failure due to idiopathic dilated and ischemic cardiomyopathies. European Journal of Heart Failure, 2005, 7, 1095-1098.	2.9	0
1751	Methylator-induced, Mismatch Repair-dependent G2 Arrest Is Activated through Chk1 and Chk2. Molecular Biology of the Cell, 2005, 16, 1513-1526.	0.9	77
1752	How adeno-associated virus Rep78 protein arrests cells completely in S phase. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13634-13639.	3.3	76
1753	Less Efficient G2-M Checkpoint Is Associated with an Increased Risk of Lung Cancer in African Americans. Cancer Research, 2005, 65, 9566-9573.	0.4	37
1754	Human Immunodeficiency Virus Type 1 Inhibits DNA Damage-Triggered Apoptosis by a Nef-Independent Mechanism. Journal of Virology, 2005, 79, 5489-5498.	1.5	66
1755	The effect of α-phenyl-N-t-butylnitrone on ionizing radiation-induced apoptosis in U937 cells. Free Radical Research, 2005, 39, 1325-1333.	1.5	13
1756	Isolation and Characterization of Highly Radioresistant Malignant Hamster Fibroblasts that Survive Acute $\hat{I}^3$ Irradiation with 20 Gy. Radiation Research, 2005, 164, 745-754.	0.7	5
1758	tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 407-412.	3.3	559

#	Article	IF	Citations
1759	The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. British Journal of Cancer, 2005, 92, 284-289.	2.9	35
1760	The 8-kDa Dynein Light Chain Binds to p53-binding Protein 1 and Mediates DNA Damage-induced p53 Nuclear Accumulation. Journal of Biological Chemistry, 2005, 280, 8172-8179.	1.6	99
1761	p130/p107/p105Rb-dependent transcriptional repression during DNA-damage-induced cell-cycle exit at G2. Journal of Cell Science, 2005, 118, 1821-1832.	1.2	85
1762	An evaluation of the ability of pifithrin- $\hat{l}\pm$ and - $\hat{l}^2$ to inhibit p53 function in two wild-type p53 human tumor cell lines. Molecular Cancer Therapeutics, 2005, 4, 1369-1377.	1.9	58
1763	Caffeine Inhibits Human Immunodeficiency Virus Type 1 Transduction of Nondividing Cells. Journal of Virology, 2005, 79, 2058-2065.	1.5	35
1764	The p53-Mdm2 association in epithelial cells in idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. Journal of Clinical Pathology, 2005, 58, 583-589.	1.0	39
1765	Telomerase expression is sufficient for chromosomal integrity in cells lacking p53 dependent G1 checkpoint function. Journal of Carcinogenesis, 2005, 4, 18.	2.5	16
1766	Induction of p53 by Urokinase in Lung Epithelial Cells. Journal of Biological Chemistry, 2005, 280, 28133-28141.	1.6	21
1767	Cancer development induced by graded expression of Snail in mice. Human Molecular Genetics, 2005, 14, 3449-3461.	1.4	67
1768	Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Molecular Cancer Therapeutics, 2005, 4, 901-909.	1.9	52
1769	High-Dose Estrogen and Clinical Selective Estrogen Receptor Modulators Induce Growth Arrest, p21, and p53 in Primate Ovarian Surface Epithelial Cells. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3688-3695.	1.8	40
1770	Role of p53/p21Waf1/Cip1 in the regulation of polyamine analogue-induced growth inhibition and cell death in human breast cancer cells. Cancer Biology and Therapy, 2005, 4, 1006-1013.	1.5	17
1771	p53 in cancer: A paradigm for modern management of cancer. Journal of the Royal College of Surgeons of Edinburgh, 2005, 3, 197-205.	0.8	46
1772	The two edges of the ATM sword: Co-operation between repair and checkpoint functions. Radiotherapy and Oncology, 2005, 76, 112-118.	0.3	72
1773	Grape Seed Proanthocyanidins Induce Apoptosis through p53, Bax, and Caspase 3 Pathways. Neoplasia, 2005, 7, 24-36.	2.3	80
1774	Studies on radiation-induced apoptosis in G0human lymphocytes. International Journal of Radiation Biology, 2005, 81, 587-599.	1.0	29
1775	Oncogenes as Novel Targets for Cancer Therapy (Part IV). Molecular Diagnosis and Therapy, 2005, 5, 397-407.	3.3	13
1776	In the Quest for Stable Rescuing Mutants of p53:  Computational Mutagenesis of Flexible Loop L1. Biochemistry, 2005, 44, 1423-1432.	1.2	23

#	Article	IF	Citations
1777	Modulation of p53 Binding to Holliday Junctions and 3-Cytosine Bulges by Phosphorylation Eventsâ€. Biochemistry, 2005, 44, 2536-2544.	1.2	18
1778	Pyrimidine and Purine Analogues, Effects on Cell Cycle Regulation and the Role of Cell Cycle Inhibitors to Enhance Their Cytotoxicity. Nucleosides, Nucleotides and Nucleic Acids, 2005, 24, 1997-2022.	0.4	24
1779	Growth arrest and non-apoptotic programmed cell death associated with the up-regulation of c-myc mRNA expression in T-47D breast tumor cells following exposure to Epipremnum pinnatum (L.) Engl. hexane extract. Journal of Ethnopharmacology, 2005, 96, 375-383.	2.0	21
1780	Long-term 17î±-ethinyl estradiol treatment decreases cyclin E and cdk2 expression, reduces cdk2 kinase activity and inhibits S phase entry in regenerating rat liver. Journal of Hepatology, 2005, 43, 478-484.	1.8	11
1781	SW480, a p53 Double-mutant Cell Line Retains Proficiency for Some p53 Functions. Journal of Molecular Biology, 2005, 352, 44-57.	2.0	77
1782	Apigenin induced apoptosis through p53-dependent pathway in human cervical carcinoma cells. Life Sciences, 2005, 76, 1367-1379.	2.0	137
1783	Regulation of ionizing radiation-induced apoptosis by a manganese porphyrin complex. Biochemical and Biophysical Research Communications, 2005, 334, 298-305.	1.0	32
1784	Differential Rates of Apoptosis in Bronchoalveolar Lavage and Blood of Lung Transplant Patients. Journal of Heart and Lung Transplantation, 2005, 24, 1305-1314.	0.3	14
1785	Regulation of p53 Translation and Induction after DNA Damage by Ribosomal Protein L26 and Nucleolin. Cell, 2005, 123, 49-63.	13.5	594
1786	Influence of double-strand-break repair pathways on radiosensitivity throughout the cell cycle in CHO cells. DNA Repair, 2005, 4, 782-792.	1.3	94
1787	The association between p53 expression, stage and histological features in endometrial cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2005, 123, 111-116.	0.5	16
1788	Genetic mutual relationship between PTEN and p53 in gastric cancer. Cancer Letters, 2005, 227, 33-38.	3.2	26
1789	Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 123-129.	0.8	2
1790	Novel trends in follicular development, atresia and corpus luteum regression: a role for apoptosis. Reproductive BioMedicine Online, 2005, 11, 93-103.	1.1	56
1791	Gene Expression Profiles of Normal Human Fibroblasts after Exposure to Ionizing Radiation: A Comparative Study of Low and High Doses. Radiation Research, 2005, 164, 17-26.	0.7	184
1792	Intracellular Trafficking of Plasmids during Transfection Is Mediated by Microtubules. Molecular Therapy, 2006, 13, 422-428.	3.7	156
1793	The Delayed Manifestation of T-Cell Receptor (TCR) Variants in X-Irradiated Mice Depends on Trp 53 Status. Radiation Research, 2006, 166, 55-60.	0.7	13
1794	ATM Engages Autodegradation of the E3 Ubiquitin Ligase COP1 After DNA Damage. Science, 2006, 313, 1122-1126.	6.0	131

#	Article	IF	CITATIONS
1795	Ovariectomy exacerbates oxidative stress and cardiopathyinduced by adriamycin. Gynecological Endocrinology, 2006, 22, 74-79.	0.7	27
1796	Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?. Diagnostic Pathology, 2006, 1, 41.	0.9	16
1797	Comparison of the Human and Worm p53 Structures Suggests a Way for Enhancing Stabilityâ€. Biochemistry, 2006, 45, 3925-3933.	1.2	21
1798	Correlation between proliferating cell nuclear antigen and p53 protein expression and 5-year survival rate in nasopharyngeal carcinoma. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2006, 27, 101-105.	0.6	12
1799	Identification of cytoplasmic p53 protein in corneal epithelium of vertebrates. Experimental Eye Research, 2006, 82, 674-681.	1.2	6
1800	Antimutagenic effect of polysaccharide ginsan extracted from Panax ginseng. Food and Chemical Toxicology, 2006, 44, 517-521.	1.8	33
1801	Array CGH analysis reveals chromosomal aberrations in mouse lung adenocarcinomas induced by the human lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Biochemical and Biophysical Research Communications, 2006, 341, 856-863.	1.0	25
1802	CYP1A1 in polycyclic aromatic hydrocarbon-induced B lymphocyte growth suppression. Biochemical and Biophysical Research Communications, 2006, 342, 227-235.	1.0	22
1803	Transient stability of the helical pattern of region F19–L22 of the N-terminal domain of p53: A molecular dynamics simulation study. Biochemical and Biophysical Research Communications, 2006, 343, 110-116.	1.0	15
1804	Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines. Cancer Letters, 2006, 236, 302-308.	3.2	27
1805	Use of autoantibodies in breast cancer screening and diagnosis. Expert Review of Anticancer Therapy, 2006, 6, 1215-1223.	1.1	29
1806	Clastogenicity of the fungicide afugan in cultured human lymphocytes. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2006, 604, 53-59.	0.9	58
1807	Arsenic in the aetiology of cancer. Mutation Research - Reviews in Mutation Research, 2006, 612, 215-246.	2.4	282
1808	Predictive value of p53 and PCNA expression for occult neck metastases in patients with clinically node-negative oral tongue cancer. Otolaryngology - Head and Neck Surgery, 2006, 135, 858-864.	1.1	15
1809	Neuregulin $1-\hat{l}$ 'eta Cytoprotective Role in AML 12 Mouse Hepatocytes Exposed to Pentachlorophenol. International Journal of Environmental Research and Public Health, 2006, 3, 11-22.	1.2	16
1810	Stop or die!. Nature Reviews Cancer, 2006, 6, S20-S20.	12.8	0
1812	p53-Mediated Apoptosis, Neuroglobin Overexpression, and Globin Deposits in a Patient With Hereditary Ferritinopathy. Journal of Neuropathology and Experimental Neurology, 2006, 65, 716-721.	0.9	20
1813	A multiscale mathematical model of cancer, and its use in analyzing irradiation therapies. Theoretical Biology and Medical Modelling, 2006, 3, 7.	2.1	162

#	Article	IF	CITATIONS
1814	Inhibition of homologous recombination repair with Pentoxifylline targets G2 cells generated by radiotherapy and induces major enhancements of the toxicity of cisplatin and melphalan given after irradiation. , 2006, $1,12.$		15
1815	p53 mutation in metastatic melanomas and primary melanomas from sunâ€exposed and sunâ€protected sites. Journal of the European Academy of Dermatology and Venereology, 1995, 4, 48-53.	1.3	0
1816	Infrared radiation induces the p53 signaling pathway: role in infrared prevention of ultraviolet B toxicity. Experimental Dermatology, 2006, 15, 130-137.	1.4	59
1817	The p53 Tumor Suppressor Gene: From Molecular Biology to Clinical Investigation. Annals of the New York Academy of Sciences, 2000, 910, 121-139.	1.8	260
1818	Relationship between skin response to ultraviolet exposure and skin color type. Pigment Cell & Melanoma Research, 2006, 19, 606-614.	4.0	129
1819	Radiation-induced cutaneous carcinoma of the head and neck: is there an early role for p53 mutations?. Clinical and Experimental Dermatology, 2006, 31, 793-798.	0.6	13
1820	Phylogenetic analysis of the p53 family. Biophysics (Russian Federation), 2006, 51, 571-580.	0.2	0
1821	Expression of DNA damage response proteins and complete remission after radiotherapy of stage IB–IIA of cervical cancer. British Journal of Cancer, 2006, 94, 1683-1689.	2.9	17
1822	Inactivation of the p53 pathway in retinoblastoma. Nature, 2006, 444, 61-66.	13.7	550
1823	Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo. Cell Death and Differentiation, 2006, 13, 973-983.	5.0	33
1824	The complexity of p53 stabilization and activation. Cell Death and Differentiation, 2006, 13, 941-950.	5.0	589
1825	The p53–Bcl-2 connection. Cell Death and Differentiation, 2006, 13, 1256-1259.	5.0	294
1826	The identification of an internal ribosomal entry site in the 5′-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage. Oncogene, 2006, 25, 4613-4619.	2.6	114
1827	Oxidative stress induces a prolonged but reversible arrest in p53-null cancer cells, involving a Chk1-dependent G2 checkpoint. Oncogene, 2006, 25, 6037-6047.	2.6	37
1828	Molecular predictors of response and outcome in ovarian cancer. Critical Reviews in Oncology/Hematology, 2006, 60, 19-37.	2.0	36
1829	Synthesis and biological evaluation of $1$ -(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 2293-2298.	1.0	31
1830	Cell Cycle Features of Primate Embryonic Stem Cells. Stem Cells, 2006, 24, 547-556.	1.4	165
1831	Hypericin-induced Photocytotoxicity is Connected with G2/M Arrest in HT-29 and S-Phase Arrest in U937 Cells. Photochemistry and Photobiology, 2006, 82, 1285.	1.3	24

#	Article	IF	CITATIONS
1832	Control of the G <sub>2</sub> /M Transition. Molecular Biotechnology, 2006, 32, 227-248.	1.3	238
1833	DNA damage, p14ARF, Nucleophosmin (NPM/B23), and cancer. Journal of Molecular Histology, 2006, 37, 239-251.	1.0	66
1834	P53 regulation of leukemia cells with the blockage of MDM2 by antisense oligonucleotides. Journal of Huazhong University of Science and Technology [Medical Sciences], 2006, 26, 414-416.	1.0	0
1835	The inhibitory action of long-chain fatty acids on the DNA binding activity of p53. Lipids, 2006, 41, 521-527.	0.7	6
1836	Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases. Current Colorectal Cancer Reports, 2006, 2, 85-93.	1.0	2
1837	Evaluation of thep53 tumor suppressor gene mutation in normal rat salivary gland tissue after radioiodine application: An experimental study. Advances in Therapy, 2006, 23, 456-468.	1.3	8
1838	Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer. Surgery, 2006, 140, 149-160.	1.0	30
1839	Antiproliferative and newly attributed apoptotic activities from an invasive marine alga: Caulerpa racemosa var. cylindracea. Journal of Experimental Marine Biology and Ecology, 2006, 339, 111-119.	0.7	55
1840	Bystander effect: Biological endpoints and microarray analysis. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2006, 597, 98-112.	0.4	86
1841	p53—A Natural Cancer Killer: Structural Insights and Therapeutic Concepts. Angewandte Chemie - International Edition, 2006, 45, 6440-6460.	7.2	98
1842	Regulation of the p53 transcriptional activity. Journal of Cellular Biochemistry, 2006, 97, 448-458.	1.2	86
1843	The p53 tumor suppressor participates in multiple cell cycle checkpoints. Journal of Cellular Physiology, 2006, 209, 13-20.	2.0	273
1844	Radiation-induced gene expression profile of human cells deficient in 8-hydroxy-2′-deoxyguanine glycosylase. International Journal of Cancer, 2006, 118, 633-642.	2.3	21
1846	Sucralfate Protects Intestinal Epithelial Cells from Radiation-Induced Apoptosis in Rats. Journal of Radiation Research, 2006, 47, 1-8.	0.8	34
1847	c-Fos is required for excision repair of UV-light induced DNA lesions by triggering the re-synthesis of XPF. Nucleic Acids Research, 2006, 34, 6530-6539.	6.5	46
1848	Novel P53 mutations detected by FAMA in colorectal cancers. Annals of Oncology, 2006, 17, vii78-vii83.	0.6	8
1849	Translational regulation of p53 as a potential tumor therapy target. Future Oncology, 2006, 2, 145-153.	1.1	3
1850	The prognostic value of proliferating cell nuclear antigen (PCNA) and p53 protein expression in patients with advanced nasopharyngeal carcinoma. Acta Oto-Laryngologica, 2006, 126, 769-774.	0.3	12

#	Article	IF	CITATIONS
1851	Grape seed extract induces anoikis and caspase-mediated apoptosis in human prostate carcinoma LNCaP cells: possible role of ataxia telangiectasia mutated–p53 activation. Molecular Cancer Therapeutics, 2006, 5, 1265-1274.	1.9	68
1852	Transgenic extracellular superoxide dismutase protects postnatal alveolar epithelial proliferation and development during hyperoxia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2006, 290, L32-L40.	1.3	60
1853	Chemoresistance in solid tumours. Annals of Oncology, 2006, 17, x315-x324.	0.6	150
1854	DNA Polymerase $\hat{l}$ , the Product of the Xeroderma Pigmentosum Variant Gene and a Target of p53, Modulates the DNA Damage Checkpoint and p53 Activation. Molecular and Cellular Biology, 2006, 26, 1398-1413.	1.1	94
1855	Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage. Molecular Cancer Therapeutics, 2006, 5, 885-892.	1.9	34
1856	Mouse Double Minute 2 Associates with Chromatin in the Presence of p53 and Is Released to Facilitate Activation of Transcription. Cancer Research, 2006, 66, 3463-3470.	0.4	32
1857	The clinical significance of autoantibodies in gastrointestinal malignancies: an overview. Expert Opinion on Biological Therapy, 2007, 7, 493-507.	1.4	14
1858	Hydrogen sulfideâ€induces DNA damage and changes in apoptotic gene expression in human lung fibroblast cells. FASEB Journal, 2007, 21, 247-255.	0.2	129
1859	A role for DNA-mediated charge transport in regulating p53: Oxidation of the DNA-bound protein from a distance. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18907-18912.	3.3	45
1860	Methylation-Acetylation Interplay Activates p53 in Response to DNA Damage. Molecular and Cellular Biology, 2007, 27, 6756-6769.	1.1	168
1861	Abrogation of the Transactivation Activity of p53 by BCCIP Down-regulation. Journal of Biological Chemistry, 2007, 282, 1570-1576.	1.6	35
1862	Human tumor cells segregate into radiosensitivity groups that associate with ATM and TP53 status. Acta Oncol $\tilde{A}^3$ gica, 2007, 46, 628-638.	0.8	31
1863	Identification of Primary Transcriptional Regulation of Cell Cycle-Regulated Genes upon DNA Damage. Cell Cycle, 2007, 6, 972-981.	1.3	23
1864	Ursolic acid regulates high glucose-induced apoptosis. Free Radical Research, 2007, 41, 638-644.	1.5	19
1865	The Role of p53 in Nitric Oxide–Induced Cardiomyocyte Cell Death. DNA and Cell Biology, 2007, 26, 465-475.	0.9	3
1866	Silencing of HPV 18 Oncoproteins With RNA Interference Causes Growth Inhibition of Cervical Cancer Cells. Reproductive Sciences, 2007, 14, 20-28.	1.1	37
1867	Ataxia Telangiectasia-Mutated and p53 Are Potential Mediators of Chloroquine-Induced Resistance to Mammary Carcinogenesis. Cancer Research, 2007, 67, 12026-12033.	0.4	55
1868	Regulation of Ionizing Radiation-induced Apoptosis by Mitochondrial NADP+-dependent Isocitrate Dehydrogenase. Journal of Biological Chemistry, 2007, 282, 13385-13394.	1.6	79

#	Article	IF	CITATIONS
1869	Structural Basis for p53 Binding-induced DNA Bending. Journal of Biological Chemistry, 2007, 282, 691-699.	1.6	30
1870	Regulation of p53 Expression in Response to 5-Fluorouracil in Human Cancer RKO Cells. Clinical Cancer Research, 2007, 13, 4245-4251.	3.2	40
1871	Restoration of Wildâ€Type p53 Function in Human Tumors: Strategies for Efficient Cancer Therapy. Advances in Cancer Research, 2007, 97, 321-338.	1.9	29
1872	Human Glioblastoma U87MG Cells Transduced with a Dominant Negative p53 (TP53) Adenovirus Construct Undergo Radiation-Induced Mitotic Catastrophe. Radiation Research, 2007, 168, 183-192.	0.7	16
1873	Ataxia Telangiectasia-Mutated–Dependent DNA Damage Checkpoint Functions Regulate Gene Expression in Human Fibroblasts. Molecular Cancer Research, 2007, 5, 813-822.	1.5	14
1874	Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA. Molecular and Cellular Biology, 2007, 27, 662-677.	1.1	147
1875	Effects of mRg2, a Mixture of Ginsenosides Containing 60% Rg2, on the Ultraviolet B–Induced DNA Repair Synthesis and Apoptosis in NIH3T3 Cells. International Journal of Toxicology, 2007, 26, 151-158.	0.6	24
1876	Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets. Annals of Oncology, 2007, 18, 709-715.	0.6	21
1877	p53-Dependent change in replication timing of the human genome. Biochemical and Biophysical Research Communications, 2007, 364, 289-293.	1.0	11
1878	Central Role of p53 in the Suntan Response and Pathologic Hyperpigmentation. Cell, 2007, 128, 853-864.	13.5	552
1879	p53 translational control: A new facet of p53 regulation and its implication for tumorigenesis and cancer therapeutics. Gene, 2007, 395, 1-7.	1.0	76
1880	N-t-Butyl hydroxylamine regulates ionizing radiation-induced apoptosis in U937 cells. Biochimie, 2007, 89, 1509-1516.	1.3	5
1881	The enigmatic effects of caffeine in cell cycle and cancer. Cancer Letters, 2007, 247, 26-39.	3.2	151
1882	Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide. Journal of the American Chemical Society, 2007, 129, 2456-2457.	6.6	498
1883	A Fluid Salt-bridging Cluster and the Stabilization of p53. Journal of Molecular Biology, 2007, 373, 1334-1347.	2.0	19
1884	DNA damage-induced signalling in ataxia-telangiectasia and related syndromes. Radiotherapy and Oncology, 2007, 83, 231-237.	0.3	39
1885	Cap-independent regulation of gene expression in apoptosis. Molecular BioSystems, 2007, 3, 825.	2.9	63
1886	Regulation of the cellular DNA double-strand break response. Biochemistry and Cell Biology, 2007, 85, 663-674.	0.9	82

#	Article	IF	CITATIONS
1887	Mechanisms of action of the carcinogenic heterocyclic amine PhIP. Toxicology Letters, 2007, 168, 269-277.	0.4	35
1888	Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Molecular Cancer, 2007, 6, 16.	7.9	46
1889	Acute ammonia neurotoxicity in vivo involves increase in cytoplasmic protein P53 without alterations in other markers of apoptosis. Journal of Neuroscience Research, 2007, 85, 2491-2499.	1.3	25
1890	A review of ground-based heavy ion radiobiology relevant to space radiation risk assessment: Cataracts and CNS effects. Advances in Space Research, 2007, 40, 1307-1319.	1.2	15
1891	Synthesis and in-vitro biological activity of macrocyclic urea Chk1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6499-6504.	1.0	11
1892	Expression of the regulatory cell cycle proteins p21, p27, p14, p16, p53, mdm2, and cyclin E in bone marrow biopsies with acute myeloid leukemia. Correlation with patients' survival. Pathology Research and Practice, 2007, 203, 199-207.	1.0	27
1893	Base excision repair of ionizing radiation-induced DNA damage in G1 and G2 cell cycle phases. Cancer Cell International, 2007, 7, 15.	1.8	47
1894	The p53 knowledgebase: an integrated information resource for p53 research. Oncogene, 2007, 26, 1517-1521.	2.6	40
1895	Versatile functions of p53 protein in multicellular organisms. Biochemistry (Moscow), 2007, 72, 1399-1421.	0.7	62
1896	The association of the TP53 polymorphisms Pro72Arg and C( $\hat{a}$ °594)CC with diabetic polyneuropathy in Russian Muscovites with type 1 diabetes mellitus. Molecular Biology, 2007, 41, 901-905.	0.4	9
1897	Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase â€~Synoviolin'. EMBO Journal, 2007, 26, 113-122.	3 <b>.</b> 5	313
1898	Stra13 is induced by genotoxic stress and regulates ionizingâ€radiationâ€induced apoptosis. EMBO Reports, 2007, 8, 401-407.	2.0	41
1899	The Contribution of Calpains in the Downâ€regulation of Mdm2 and p53 Proteolysis in Reconstructed Human Epidermis in Response to Solar Irradiation <sup>¶</sup> . Photochemistry and Photobiology, 2005, 81, 975-983.	1.3	0
1900	Overexpression of inducible nitric oxide synthase and accumulation of 8â€OHdG in nasopharyngeal carcinoma. Histopathology, 2008, 52, 213-223.	1.6	17
1901	Immunohistochemical evaluation of p53 expression with different antibodies in malignant canine tumours with or without p53 gene mutation. Veterinary and Comparative Oncology, 2007, 5, 108-118.	0.8	12
1902	Infrequent p53 mutations in patients with areca quid chewingâ€essociated oral squamous cell carcinomas in Taiwan. Journal of Oral Pathology and Medicine, 1999, 28, 221-225.	1.4	16
1903	Combining arrayâ€based approaches for the identification of candidate tumor suppressor loci in mature lymphoid neoplasms. Apmis, 2007, 115, 1107-1134.	0.9	17
1904	p53 Promoter-based Reporter Gene in vitro Assays for Quick Assessment of Agents with Genotoxic Potential. Acta Biochimica Et Biophysica Sinica, 2007, 39, 181-186.	0.9	3

#	Article	IF	CITATIONS
1905	Increased expression of p53 enhances transcription-coupled repair and global genomic repair of a UVC-damaged reporter gene in human cells. DNA Repair, 2007, 6, 588-601.	1.3	12
1906	p53 and the pathogenesis of skin cancer. Toxicology and Applied Pharmacology, 2007, 224, 241-248.	1.3	155
1907	The environmental carcinogen 3-nitrobenzanthrone and its main metabolite 3-aminobenzanthrone enhance formation of reactive oxygen intermediates in human A549 lung epithelial cells. Toxicology and Applied Pharmacology, 2007, 221, 222-234.	1.3	42
1908	Analysis of DNA double-strand break repair pathways in mice. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2007, 614, 95-108.	0.4	60
1909	Apoptotic markers in the mitochondria, cytosol, and nuclei of brain cells during ammonia toxicity. Neurochemical Journal, 2007, 1, 78-85.	0.2	3
1910	8-Hydroxydeoxyguanosine induces senescence-like changes in KG-1, human acute myelocytic leukemia cell line. Biotechnology and Bioprocess Engineering, 2007, 12, 114-120.	1.4	0
1911	Synergistic interaction between tetrandrine and chemotherapeutic agents and influence of tetrandrine on chemotherapeutic agent-associated genes in human gastric cancer cell lines. Cancer Chemotherapy and Pharmacology, 2007, 60, 703-711.	1.1	34
1912	Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases. Current Oncology Reports, 2007, 9, 193-201.	1.8	17
1913	Head and Neck Squamous Cell Cancer: Biology (II) and Translational Methods. Indian Journal of Otolaryngology, 2007, 59, 245-251.	0.1	0
1914	Pre-irradiation with low-dose 12C6+ beam significantly enhances the efficacy of AdCMV-p53 gene therapy in human non-small lung cancer. Science in China Series G: Physics, Mechanics and Astronomy, 2007, 50, 221-230.	0.2	4
1915	Clinical biomarkers and imaging for radiotherapy-induced cell death. Cancer and Metastasis Reviews, 2008, 27, 471-480.	2.7	76
1916	Protein–DNA array-based identification of transcription factor activities differentially regulated in skeletal muscle of normal and dystrophin-deficient mdx mice. Molecular and Cellular Biochemistry, 2008, 312, 17-24.	1.4	29
1917	The effect of p53 gene expression on the inhibition of cell proliferation by paclitaxel. Cancer Chemotherapy and Pharmacology, 2008, 62, 379-385.	1.1	7
1918	A new triterpenoid from Panax ginseng exhibits cytotoxicity through p53 and the caspase signaling pathway in the HepG2 cell line. Archives of Pharmacal Research, 2008, 31, 323-329.	2.7	26
1919	Epigallocatechin gallate, a constituent of green tea, regulates high glucose-induced apoptosis. Archives of Pharmacal Research, 2008, 31, 34-40.	2.7	5
1920	Caspase-2 activation in neural stem cells undergoing oxidative stress-induced apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2008, 13, 354-363.	2.2	52
1921	Vesicular stomatitis virus matrix protein gene enhances the antitumor effects of radiation via induction of apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2008, 13, 1205-1214.	2.2	14
1922	Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients. Journal of Surgical Oncology, 2008, 98, 349-357.	0.8	56

#	Article	IF	Citations
1923	Signaling of DNA damage is not sufficient to induce p53 response: (Re)Activation of wt p53 protein strongly depends on cellular context. Journal of Cellular Biochemistry, 2008, 103, 1607-1620.	1.2	8
1924	In vitro evaluation of the clastogenicity of fumagillin. Environmental and Molecular Mutagenesis, 2008, 49, 594-601.	0.9	28
1925	Structural features of DNA interaction with caffeine and theophylline. Journal of Molecular Structure, 2008, 875, 392-399.	1.8	51
1926	G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells. Human Cell, 2008, 21, 28-37.	1.2	21
1927	Structural insight into the TFIIE–TFIIH interaction: TFIIE and p53 share the binding region on TFIIH. EMBO Journal, 2008, 27, 1161-1171.	3.5	51
1928	Detection of the p53 response in zebrafish embryos using new monoclonal antibodies. Oncogene, 2008, 27, 629-640.	2.6	65
1929	p21WAF1/CIP1 induction by 5-azacytosine nucleosides requires DNA damage. Oncogene, 2008, 27, 3615-3623.	2.6	84
1930	Cancer-associated antigens and antigen arrays in serological diagnostics of malignant tumors. Biochemistry (Moscow), 2008, 73, 562-572.	0.7	12
1931	Superficial, Nodular, and Morpheiform Basal-Cell Carcinomas Exhibit Distinct Gene Expression Profiles. Journal of Investigative Dermatology, 2008, 128, 1797-1805.	0.3	48
1932	The Melanocortin 1 Receptor and the UV Response of Human Melanocytes—A Shift in Paradigm <sup>â€</sup> . Photochemistry and Photobiology, 2008, 84, 501-508.	1.3	101
1933	Expression of p53, bcl-2, and bax as predictors of response to radiotherapy in esophageal cancer. Ecological Management and Restoration, 0, 13, 185-190.	0.2	4
1934	Protein phosphatase 4 regulates apoptosis, proliferation and mutation rate of human cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 1490-1502.	1.9	24
1935	Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells. Biochemical Pharmacology, 2008, 75, 2020-2033.	2.0	119
1936	The role of oncogenes, tumour suppressor genes and growth factors in oral squamous cell carcinoma: a case of apoptosis versus proliferation. Oral Diseases, 1995, 1, 172-188.	1.5	50
1937	Apoptosisâ€associated proteins in oral hairy leukoplakia. Oral Diseases, 1996, 2, 279-284.	1.5	18
1938	Taming the PI3K team to hold inflammation and cancer at bay. , 2008, 118, 192-205.		61
1939	Verminoside- and verbascoside-induced genotoxicity on human lymphocytes: Involvement of PARP-1 and p53 proteins. Toxicology Letters, 2008, 178, 71-76.	0.4	34
1940	Utility of Biomarkers in Prediction of Response to Ablative Therapy in Barrett's Esophagus. Gastroenterology, 2008, 135, 370-379.	0.6	76

#	Article	IF	Citations
1941	In GFP with high risk HPV-18E6 fusion protein expressed 293T and MCF-7 cells, the endogenous wild-type p53 could be transiently phosphorylated at multiple sites. Journal of Experimental and Clinical Cancer Research, 2008, 27, 35.	3.5	2
1942	Modulation of apoptosis of eckol against ionizing radiation in mice. Biochemical and Biophysical Research Communications, 2008, 372, 792-797.	1.0	20
1943	Management of the NO Neck in Oral Squamous Cell Carcinoma. Oral and Maxillofacial Surgery Clinics of North America, 2008, 20, 477-497.	0.4	52
1944	A quantitative overview of radiosensitivity of human tumor cells across histological type and TP53 status. International Journal of Radiation Biology, 2008, 84, 253-264.	1.0	57
1945	A limited role for p53 in modulating the immediate phenotype of Apc loss in the intestine. BMC Cancer, 2008, 8, 162.	1.1	26
1946	Regulation of normal cell cycle progression by flavin-containing oxidases. Oncogene, 2008, 27, 20-31.	2.6	58
1947	Functional Genomics and a New Era in Radiation Biology and Oncology. BioScience, 2008, 58, 491-500.	2.2	17
1948	p53 status-dependent sensitization of human tumour cells to hyperthermia by plant flavonol. International Journal of Hyperthermia, 2008, 24, 415-424.	1.1	1
1949	Epithelial cell fate following lung injury. Expert Review of Respiratory Medicine, 2008, 2, 573-582.	1.0	7
1950	UVB-Induced Murine Bone Marrow Derived Macrophages and Apoptosis. Immunological Investigations, 2008, 37, 293-313.	1.0	5
1951	Effect of neutron capture therapy on the cell cycle of human squamous cell carcinoma cells. International Journal of Radiation Biology, 2008, 84, 191-199.	1.0	20
1952	Relative Biological Effectiveness of 6 MeV Neutrons with Respect to Cell Inactivation and Disturbances of the G1Phase. Radiation Research, 2008, 169, 207-213.	0.7	4
1953	G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. British Journal of Cancer, 2008, 98, 523-528.	2.9	302
1954	p53-Induced DNA Bending: The Interplay between p53â^'DNA and p53â^'p53 Interactions. Journal of Physical Chemistry B, 2008, 112, 6716-6724.	1.2	29
1955	Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells. Biological Chemistry, 2008, 389, 57-67.	1.2	3
1956	Interaction of Heterogeneous Nuclear Ribonucleoprotein C1/C2 with a Novel <i>cis</i> Flement within p53 mRNA as a Response to Cytostatic Drug Treatment. Molecular Pharmacology, 2008, 73, 1558-1567.	1.0	52
1957	Aurora Kinase A Inhibition Leads to p73-Dependent Apoptosis in p53-Deficient Cancer Cells. Cancer Research, 2008, 68, 8998-9004.	0.4	110
1958	Low-Dose Local Kidney Irradiation Inhibits Progression of Experimental Crescentic Nephritis by Promoting Apoptosis. American Journal of Nephrology, 2008, 28, 555-568.	1.4	11

#	Article	IF	CITATIONS
1959	ATR signaling can drive cells into senescence in the absence of DNA breaks. Genes and Development, 2008, 22, 297-302.	2.7	149
1960	Loss of p53 synthesis in zebrafish tumors with ribosomal protein gene mutations. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10408-10413.	3.3	124
1961	Gain of Oncogenic Function of p53 Mutants Induces Invasive Phenotypes in Human Breast Cancer Cells by Silencing <i>CCN5/WISP-2</i> . Cancer Research, 2008, 68, 4580-4587.	0.4	54
1962	Posttranscriptional Regulation of p53 and its Targets by RNABinding Proteins. Current Molecular Medicine, 2008, 8, 845-849.	0.6	40
1963	The inherent instability of mutant p53 is alleviated by <i>Mdm2</i> or <i>p16<sup>INK4a</sup></i> loss. Genes and Development, 2008, 22, 1337-1344.	2.7	317
1964	Notch activates cell cycle reentry and progression in quiescent cardiomyocytes. Journal of Cell Biology, 2008, 183, 129-141.	2.3	164
1965	<i>p53</i> Loss Synergizes with Estrogen and Papillomaviral Oncogenes to Induce Cervical and Breast Cancers. Cancer Research, 2008, 68, 2622-2631.	0.4	51
1966	Growth arrest in human T-cells is controlled by the non-coding RNA growth-arrest-specific transcript 5 ( <i>GAS5</i> ). Journal of Cell Science, 2008, 121, 939-946.	1.2	213
1967	DNA Damage Responses: Mechanisms and Roles in Human Disease. Molecular Cancer Research, 2008, 6, 517-524.	1.5	171
1968	Karyotypic Instability and Centrosome Aberrations in the Progeny of Finite Life-Span Human Mammary Epithelial Cells Exposed to Sparsely or Densely Ionizing Radiation. Radiation Research, 2008, 170, 23-32.	0.7	28
1969	Involvement of Epithelial Cell Apoptosis in Interstitial Lung Diseases. Internal Medicine, 2008, 47, 345-353.	0.3	39
1970	Evaluation of the immunoexpression of COX-1, COX-2 and p53 in Crohn's disease. Arquivos De Gastroenterologia, 2008, 45, 295-300.	0.3	22
1972	Deficiency of Clusterin Inhibits Neointimal Hyperplasia After Vascular Injury. Journal of Atherosclerosis and Thrombosis, 2009, 16, 772-781.	0.9	12
1973	High expression of the circadian gene mPer2 diminishes the radiosensitivity of NIH 3T3 cells. Brazilian Journal of Medical and Biological Research, 2009, 42, 882-891.	0.7	5
1974	<i>&gt;p53</i> Gene Expression and 2-Methoxyestradiol Treatment Differentially Induce Nuclear Factor Kappa B Activation in Human Lung Cancer Cells with Different p53 Phenotypes. DNA and Cell Biology, 2009, 28, 615-623.	0.9	6
1975	Stress response of a p53 homologue in the radioresistant Sf9 insect cells. International Journal of Radiation Biology, 2009, 85, 238-249.	1.0	13
1976	DNA Damage Triggers p21 <sup>WAF1</sup> -dependent Emi1 Down-Regulation That Maintains G2 Arrest. Molecular Biology of the Cell, 2009, 20, 1891-1902.	0.9	66
1977	lonizing Radiation Induces ATM-independent Degradation of p21Cip1 in Transformed Cells. Journal of Biological Chemistry, 2009, 284, 15061-15070.	1.6	27

#	ARTICLE	IF	CITATIONS
1978	p53 regulates mtDNA copy number and mitocheckpoint pathway. Journal of Carcinogenesis, 2009, 8, 8.	2.5	119
1979	Transient Dephosphorylation of p53 Serine 376 as an Early Response to Ionizing Radiation. Radiation Research, 2009, 171, 725-734.	0.7	2
1980	Recent Advances in Validating MDM2 as a Cancer Target. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 882-903.	0.9	42
1981	Cooperativity Dominates the Genomic Organization of p53-Response Elements: A Mechanistic View. PLoS Computational Biology, 2009, 5, e1000448.	1.5	19
1982	HDAC Inhibitor, Valproic Acid, Induces p53-Dependent Radiosensitization of Colon Cancer Cells. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 689-699.	0.7	73
1983	Targeting the Cell Cycle to Kill Cancer Cells. , 2009, , 429-453.		2
1984	Posttranslational Modification of p53: Cooperative Integrators of Function. Cold Spring Harbor Perspectives in Biology, 2009, 1, a000950-a000950.	2.3	372
1985	Caffeine Markedly Enhanced Radiation-Induced Bystander Effects. Plasma Science and Technology, 2009, 11, 250-254.	0.7	2
1986	Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Research, 2009, 37, 78-95.	6.5	50
1987	Etoposide Induces TRP53-Dependent Apoptosis and TRP53-Independent Cell Cycle Arrest in Trophoblasts of the Developing Mouse Placenta1. Biology of Reproduction, 2009, 80, 813-822.	1.2	7
1988	Transcriptional Regulation of Estrogen Receptor-α by p53 in Human Breast Cancer Cells. Cancer Research, 2009, 69, 3405-3414.	0.4	90
1989	High Incidence of Protein-Truncating <i>TP53</i> Mutations in BRCA1-Related Breast Cancer. Cancer Research, 2009, 69, 3625-3633.	0.4	142
1990	6-Mercaptopurine (6-MP) induces cell cycle arrest and apoptosis of neural progenitor cells in the developing fetal rat brain. Neurotoxicology and Teratology, 2009, 31, 104-109.	1.2	30
1991	Methoxychlor inhibits growth of antral follicles by altering cell cycle regulators. Toxicology and Applied Pharmacology, 2009, 240, 1-7.	1.3	21
1992	Molecular fingerprinting of radiation resistant tumors: Can we apprehend and rehabilitate the suspects?. BMC Cancer, 2009, 9, 225.	1.1	18
1993	Selective induction of apoptosis of NB <sub>4</sub> cells from G <sub>2</sub> +M phase by sodium arsenite at lower doses. European Journal of Haematology, 1998, 61, 27-35.	1.1	35
1994	p53â€mediated regulation of cell cycle progression: Pronounced impact of cellular microenvironment. Journal of Cellular Physiology, 2009, 219, 459-469.	2.0	3
1995	Preferred drifting along the DNA major groove and cooperative anchoring of the p53 core domain: mechanisms and scenarios. Journal of Molecular Recognition, 2010, 23, 232-240.	1.1	5

#	Article	IF	CITATIONS
1996	Resveratrol addiction: To die or not to die. Molecular Nutrition and Food Research, 2009, 53, 115-128.	1.5	270
1997	Association study between P53 and P73 gene polymorphisms and the sporadic late-onset form of Alzheimer's disease. Journal of Neural Transmission, 2009, 116, 1179-1184.	1.4	15
1998	Oncogenes do not Fully Override Cell-intrinsic Traits: Pronounced Impact of the Cellular Programme. Cancer Microenvironment, 2009, 2, 215-225.	3.1	0
1999	Studies of interaction of tumor suppressor p53 with apo-MT using surface plasmon resonance. Analytical and Bioanalytical Chemistry, 2009, 395, 2569-2575.	1.9	18
2000	Mechanisms of radiation-induced gene responses. Stem Cells, 2009, 15, 15-25.	1.4	3
2001	Oxidative stress, signal transduction, and intercellular communication in radiation carcinogenesis. Stem Cells, 1997, 15, 59-67.	1.4	14
2002	Sulfur dioxide and benzo(a)pyrene modulates CYP1A and tumorâ€related gene expression in rat liver. Environmental Toxicology, 2010, 25, 169-179.	2.1	7
2003	Nuclear accumulation and activation of p53 in embryonic stem cells after DNA damage. BMC Cell Biology, 2009, 10, 46.	3.0	91
2004	Role of p53 mutation in the effect of boron neutron capture therapy on oral squamous cell carcinoma. Radiation Oncology, 2009, 4, 63.	1.2	23
2005	The first 30 years of p53: growing ever more complex. Nature Reviews Cancer, 2009, 9, 749-758.	12.8	1,684
2007	Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene, 2009, 28, 4295-4305.	2.6	134
2008	Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. British Journal of Cancer, 2009, 101, 816-821.	2.9	144
2009	DNA mismatch repair (MMR)â€dependent 5â€fluorouracil cytotoxicity and the potential for new therapeutic targets. British Journal of Pharmacology, 2009, 158, 679-692.	2.7	66
2010	Antiproliferative effect of ferrocifen drug candidates on malignant pleural mesothelioma cell lines. Inorganica Chimica Acta, 2009, 362, 4037-4042.	1.2	22
2011	Synthesis, characterization and deepening in the comprehension of the biological action mechanisms of a new nickel complex with antiproliferative activity. Journal of Inorganic Biochemistry, 2009, 103, 666-677.	1.5	95
2012	5-Benzylidene-hydantoins: Synthesis and antiproliferative activity on A549 lung cancer cell line. European Journal of Medicinal Chemistry, 2009, 44, 3471-3479.	2.6	38
2013	Regulatory changes of apoptotic factors in the bovine corpus luteum after induced luteolysis. Molecular Reproduction and Development, 2009, 76, 220-230.	1.0	38
2014	The Role of Mutation and Epimutation in the Development of Human Disease. Molecular Pathology Library, 2009, , 41-54.	0.1	2

#	Article	IF	CITATIONS
2015	Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer. Advanced Drug Delivery Reviews, 2009, 61, 572-588.	6.6	31
2016	Neurotoxic effect of Caulerpa racemosa var. cylindracea by neurite inhibition on the neuroblastoma cell line. Russian Journal of Marine Biology, 2009, 35, 342-350.	0.2	8
2017	Apoptosis gene profiling reveals spatio-temporal regulated expression of the p53/Mdm2 pathway during lens development. Experimental Eye Research, 2009, 88, 1137-1151.	1.2	25
2018	Effects of sulfur dioxide derivatives on expression of oncogenes and tumor suppressor genes in human bronchial epithelial cells. Food and Chemical Toxicology, 2009, 47, 734-744.	1.8	31
2019	Conformational detection of p53's oligomeric state by FlAsH Fluorescence. Biochemical and Biophysical Research Communications, 2009, 384, 66-70.	1.0	12
2020	Ammonia-induced activation of p53 in cultured astrocytes: Role in cell swelling and glutamate uptake. Neurochemistry International, 2009, 55, 98-105.	1.9	45
2021	Apoptotic Chromatin Changes., 2009,, 293-364.		4
2022	MDM2-A, a common <i>Mdm2</i> splice variant, causes perinatal lethality, reduced longevity and enhanced senescence. DMM Disease Models and Mechanisms, 2009, 2, 47-55.	1.2	15
2023	Statistically significant association of the single nucleotide polymorphism (SNP) rs13181 (ERCC2) with predisposition to Squamous Cell Carcinomas of the Head and Neck (SCCHN) and Breast cancer in the north Indian population. Journal of Experimental and Clinical Cancer Research, 2009, 28, 104.	3.5	26
2024	The cell cycle and acute kidney injury. Kidney International, 2009, 76, 604-613.	2.6	177
2025	p53: Balancing tumour suppression and implications for the clinic. European Journal of Cancer, 2009, 45, 217-234.	1.3	6
2026	Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood, 2009, 113, 4281-4288.	0.6	31
2028	Zinc deficiency and neurodevelopment: The case of neurons. BioFactors, 2010, 36, 117-124.	2.6	82
2029	Regulation of tumor suppressor p53 at the RNA level. Journal of Molecular Medicine, 2010, 88, 645-652.	1.7	61
2030	Effects of ginsenoside Rg2 on the ultraviolet B-induced DNA damage responses in HaCaT cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2010, 382, 89-101.	1.4	20
2031	The role of TP53 and p21 gene polymorphisms in breast cancer biology in a well specified and characterized German cohort. Journal of Cancer Research and Clinical Oncology, 2010, 136, 1369-1375.	1.2	16
2032	Increased expression of p27 is associated with the cisplatin resistance in gastric cancer cell line YCC-3. Archives of Pharmacal Research, 2010, 33, 1127-1132.	2.7	15
2033	Toenail selenium status and DNA repair capacity among female BRCA1 mutation carriers. Cancer Causes and Control, 2010, 21, 679-687.	0.8	23

#	Article	IF	CITATIONS
2034	Immunohistochemical Characterization of a Squamous Cell Carcinoma in a Harbour Porpoise (Phocoena phocoena) from German Waters. Journal of Comparative Pathology, 2010, 143, 179-184.	0.1	10
2035	Influence of TEGDMA on the mammalian cell cycle in comparison with chemotherapeutic agents. Dental Materials, 2010, 26, 232-241.	1.6	35
2036	Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Letters, 2010, 584, 3675-3681.	1.3	207
2037	The DNA damage response—Repair or despair?. Environmental and Molecular Mutagenesis, 2010, 51, 879-889.	0.9	34
2038	Elevated lung cancer risk is associated with deficiencies in cell cycle checkpoints: genotype and phenotype analyses from a caseâ€control study. International Journal of Cancer, 2010, 126, 2199-2210.	2.3	24
2039	Signaling pathways implicated in PGF2α effects on Fgf2+/+ and Fgf2â^'/â^' osteoblasts. Journal of Cellular Physiology, 2010, 224, 465-474.	2.0	28
2040	17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells. Leukemia Research, 2010, 34, 1493-1500.	0.4	7
2041	Discovery and Characterization of 2-Anilino-4- (Thiazol-5-yl)Pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents. Chemistry and Biology, 2010, 17, 1111-1121.	6.2	92
2042	Toxic effects of lactational exposure to 2,3,7,8â€tetrachlorodibenzoâ€∢i>pà€dioxin (TCDD) on development of male reproductive system: Involvement of antioxidants, oxidants, and p53 protein. Environmental Toxicology, 2010, 25, 1-8.	2.1	38
2043	Pediatric Neuro-Oncology. Blue Books of Neurology, 2010, , 150-200.	0.1	O
2044	Immunohistochemical study of $\hat{l}^2$ -catenin and functionally related molecular markers in tongue squamous cell carcinoma and its correlation with cellular proliferation. Oncology Letters, 2010, 1, 437-443.	0.8	9
2045	Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. Journal of Cell Biology, 2010, 188, 369-381.	2.3	401
2046	Enhanced Gadd45 expression and delayed G2/M progression are p53-dependent in zinc-supplemented human bronchial epithelial cells. Experimental Biology and Medicine, 2010, 235, 932-940.	1.1	11
2047	Inactivation of the Quinone Oxidoreductases NQO1 and NQO2 Strongly Elevates the Incidence and Multiplicity of Chemically Induced Skin Tumors. Cancer Research, 2010, 70, 1006-1014.	0.4	44
2048	Inhibition of Human T-Cell Proliferation by Mammalian Target of Rapamycin (mTOR) Antagonists Requires Noncoding RNA Growth-Arrest-Specific Transcript 5 (GAS5). Molecular Pharmacology, 2010, 78, 19-28.	1.0	121
2049	Viral-based gene delivery and regulated gene expression for targeted cancer therapy. Expert Opinion on Drug Delivery, 2010, 7, 19-35.	2.4	24
2050	p53 Research: The Past Thirty Years and the Next Thirty Years. Cold Spring Harbor Perspectives in Biology, 2010, 2, a000893-a000893.	2.3	358
2051	Three prime exonuclease I (TREX1) is Fos/AP-1 regulated by genotoxic stress and protects against ultraviolet light and benzo(a)pyrene-induced DNA damage. Nucleic Acids Research, 2010, 38, 6418-6432.	6.5	52

#	Article	IF	CITATIONS
2052	<i>N</i> -acetylcysteine protects alveolar epithelial cells from hydrogen peroxide–induced apoptosis through scavenging reactive oxygen species and suppressing c-Jun N-terminal <i>kinase</i> . Experimental Lung Research, 2010, 36, 352-361.	0.5	20
2053	A Six-Week Course of Bacillus Calmette-Guérin Prophylaxis Is Insufficient to Prevent Tumor Recurrence in Nonmuscle Invasive Bladder Cancer with Strong-Positive Expression of p53. Oncology, 2010, 79, 440-446.	0.9	11
2054	Expression of luteal estrogen receptor, interleukin-1, and apoptosis-associated genes after PGF2 $\hat{l}$ ± administration in rabbits at different stages of pseudopregnancy. Domestic Animal Endocrinology, 2010, 39, 116-130.	0.8	34
2055	Facilitation of DNA damage-induced apoptosis by endoplasmic reticulum protein mitsugumin23. Biochemical and Biophysical Research Communications, 2010, 392, 196-200.	1.0	10
2056	Induction of oxidative stress and apoptosis by silver nanoparticles in the liver of adult zebrafish. Aquatic Toxicology, 2010, 100, 151-159.	1.9	423
2057	Induction of apoptosis and cell cycle arrest in L-1210 murine lymphoblastic leukaemia cells by (2 <i>E</i> )-3-(2-naphthyl)-1-(3′-methoxy-4′-hydroxy-phenyl)-2-propen-1-one. Journal of Pharmacy and Pharmacology, 2010, 62, 1128-1136.	1.2	22
2058	Stepping up melanocytes to the challenge of UV exposure. Pigment Cell and Melanoma Research, 2010, 23, 171-186.	1.5	108
2059	Nuclear transcription factors in mammalian mitochondria. Genome Biology, 2010, 11, 215.	13.9	83
2060	Expression of oncogenes and tumor suppressor genes in lungs of rats exposed to sulfur dioxide and benzo(a)pyrene. Inhalation Toxicology, 2010, 22, 322-329.	0.8	11
2061	Expression of mutant p53 and of the multidrug resistant proteins P-glycoprotein and glutathione S-transferase-pi correlated in colorectal adenocarcinoma. Scandinavian Journal of Gastroenterology, 2010, 45, 925-934.	0.6	9
2062	DNA-Dependent Protein Kinase and Ataxia Telangiectasia Mutated (ATM) Promote Cell Survival in Response to NK314, a Topoisomerase IIα Inhibitor. Molecular Pharmacology, 2011, 80, 321-327.	1.0	17
2063	Prognostic biomarkers in ovarian cancer. Cancer Biomarkers, 2011, 8, 231-251.	0.8	34
2064	Caffeine-suppressed ATM pathway leads to decreased p53 phosphorylation and increased programmed cell death in gamma-irradiated leukaemic molt-4 cells. Journal of Applied Biomedicine, 2011, 9, 49-56.	0.6	10
2065	USP1 Deubiquitinates ID Proteins to Preserve a Mesenchymal Stem Cell Program in Osteosarcoma. Cell, 2011, 146, 918-930.	13.5	212
2066	miR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway. Biomedicine and Pharmacotherapy, 2011, 65, 436-442.	2.5	40
2067	Targeting apoptotic and autophagic pathways for cancer therapeutics. Cancer Letters, 2011, 300, 105-114.	3.2	149
2068	Induction of ROS, p53, p21 in DEHP- and MEHP-exposed LNCaP cells-protection by selenium compounds. Food and Chemical Toxicology, 2011, 49, 1565-1571.	1.8	51
2069	Di-Mercapto Succinic Acid (DMSA) and vitamin C chelating potency in lead intoxication, regarding oxidative stress and apoptotic related proteins in rabbits. Journal of Genetic Engineering and Biotechnology, 2011, 9, 121-131.	1.5	3

#	Article	IF	CITATIONS
2070	Cancer stem cell overexpression of nicotinamide N-methyltransferase enhances cellular radiation resistance. Radiotherapy and Oncology, 2011, 99, 373-378.	0.3	55
2071	Tumor Suppressors and Cell-Cycle Proteins in Lung Cancer. Pathology Research International, 2011, 2011, 1-12.	1.4	35
2072	Association between AgNORs and Immunohistochemical Expression of ER, PR, HER2/neu, and p53 in Breast Carcinoma. Pathology Research International, 2011, 2011, 1-6.	1.4	8
2073	Proteasomal Degradation of p53 by Human Papillomavirus E6 Oncoprotein Relies on the Structural Integrity of p53 Core Domain. PLoS ONE, 2011, 6, e25981.	1.1	38
2074	Analysis of the Mutagenic and Apoptotic Effects of Tritiated Water on Spleen T Lymphocytes of Wild Mice and p53-Deficient Mice. Fusion Science and Technology, 2011, 60, 1193-1196.	0.6	1
2075	Involvement of hGLD-2 in cytoplasmic polyadenylation of human p53 mRNA. Apmis, 2011, 119, 769-775.	0.9	10
2076	An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity. EMBO Journal, 2011, 30, 2167-2176.	3.5	95
2077	The ATM kinase signaling induced by the low-energy $\hat{l}^2$ -particles emitted by 33P is essential for the suppression of chromosome aberrations and is greater than that induced by the energetic $\hat{l}^2$ -particles emitted by 32P. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2011, 708, 28-36.	0.4	8
2078	Epstein-Barr virus Latent Membrane Protein LMP1 reduces p53 protein levels independent of the PI3K-Akt pathway. BMC Research Notes, 2011, 4, 551.	0.6	13
2079	Ret finger protein 2 enhances ionizing radiation-induced apoptosis via degradation of AKT and MDM2. European Journal of Cell Biology, 2011, 90, 420-431.	1.6	55
2080	Sublethal radiation injury uncovers a functional transition during erythroid maturation. Experimental Hematology, 2011, 39, 434-445.	0.2	42
2081	Evaluation of apoptotic effect of cyclic imide derivatives on murine B16F10 melanoma cells. Bioorganic and Medicinal Chemistry, 2011, 19, 6285-6291.	1.4	22
2082	Selective proapoptotic activity of polyphenols from red wine on teratocarcinoma cell, a model of cancer stem-like cell. Investigational New Drugs, 2011, 29, 239-247.	1.2	28
2083	Estrogen receptor beta decreases survival of p53-defective cancer cells after DNA damage by impairing G2/M checkpoint signaling. Breast Cancer Research and Treatment, 2011, 127, 417-427.	1.1	42
2084	Elevated transcription of the p53 gene in early S-phase leads to a rapid DNA-damage response during S-phase of the cell cycle. Apoptosis: an International Journal on Programmed Cell Death, 2011, 16, 950-958.	2.2	25
2085	In vitro anti-mesothelioma activity of cisplatin–gemcitabine combinations: evidence for sequence-dependent effects. Cancer Chemotherapy and Pharmacology, 2011, 67, 265-273.	1.1	19
2086	A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemotherapy and Pharmacology, 2011, 67, 1225-1237.	1.1	58
2087	Imunoexpression of Ki-67 and p53 in Rectal Cancer Tissue After Treatment with Neoadjuvant Chemoradiation. Journal of Gastrointestinal Cancer, 2011, 42, 34-39.	0.6	4

#	ARTICLE	IF	CITATIONS
2088	Prognostic Significance of p53 Protein Expression in Early Gastric Cancer. Pathology and Oncology Research, 2011, 17, 349-355.	0.9	24
2089	Induction of epstein-barr virus (EBV) lytic cycle in vitro causes lipid peroxidation, protein oxidation and DNA damage in lymphoblastoid B cell lines. Lipids in Health and Disease, 2011, 10, 111.	1.2	9
2090	Influence of cell cycle on responses of MCF-7 cells to benzo[a]pyrene. BMC Genomics, 2011, 12, 333.	1.2	58
2091	Magnesium deficiency suppresses cell cycle progression mediated by increase in transcriptional activity of p21Cip1 and p27Kip1 in renal epithelial NRK-52E cells. Journal of Cellular Biochemistry, 2011, 112, 3563-3572.	1.2	12
2092	A partially degraded product of phytate suppresses the proliferation of HCT116 colorectal cancer cells. Food Chemistry, 2011, 125, 1219-1225.	4.2	7
2093	MLN8054, A Small Molecule Inhibitor of Aurora Kinase A, Sensitizes Androgen-Resistant Prostate Cancer to Radiation. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1189-1197.	0.4	33
2094	Cholesterol Secosterol Aldehydes Induce Amyloidogenesis and Dysfunction of Wild-Type Tumor Protein p53. Chemistry and Biology, 2011, 18, 920-927.	6.2	38
2095	Modulation of biological processes in the nucleus by delivery of DNA oligonucleotides conjugated with gold nanoparticles. Biomaterials, 2011, 32, 2593-2604.	5.7	34
2096	Multiple Stress Signals Activate Mutant p53 <i>In Vivo</i> . Cancer Research, 2011, 71, 7168-7175.	0.4	104
2097	Cooperative Role of the RNA-Binding Proteins Hzf and HuR in p53 Activation. Molecular and Cellular Biology, 2011, 31, 1997-2009.	1.1	36
2098	ADP-Ribosylarginine Hydrolase Regulates Cell Proliferation and Tumorigenesis. Cancer Research, 2011, 71, 5327-5335.	0.4	45
2099	p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome. Genes and Cancer, 2011, 2, 404-419.	0.6	125
2100	Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9–mediated EMT. Neuro-Oncology, 2011, 13, 1059-1073.	0.6	51
2101	Biliverdin reductase A in the prevention of cellular senescence against oxidative stress. Experimental and Molecular Medicine, 2011, 43, 15.	3.2	34
2102	A Limited Role of p53 on the Ability of a Hexane Fraction of American Ginseng to Suppress Mouse Colitis. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-11.	3.0	8
2103	Genes and Cancer. , 2012, , 561-596.e6.		O
2104	HPV 5 and 8 E6 Abrogate ATR Activity Resulting in Increased Persistence of UVB Induced DNA Damage. PLoS Pathogens, 2012, 8, e1002807.	2.1	123
2105	Terpinen-4-ol Induces Apoptosis in Human Nonsmall Cell Lung Cancer In Vitro and In Vivo. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-13.	0.5	49

#	Article	IF	CITATIONS
2106	Quantitative Proteomics Profiling of Murine Mammary Gland Cells Unravels Impact of Annexin-1 on DNA Damage Response, Cell Adhesion, and Migration. Molecular and Cellular Proteomics, 2012, $11$ , $381-393$ .	2.5	43
2107	Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death and Differentiation, 2012, 19, 768-778.	5.0	157
2108	Defective DNA Mismatch Repair-dependent c-Abl-p73-GADD45 $\hat{l}\pm$ Expression Confers Cancer Chemoresistance. , 2012, , 191-210.		0
2109	Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors. Cancers, 2012, 4, 989-1035.	1.7	29
2110	Redox modulation of the DNA damage response. Biochemical Pharmacology, 2012, 84, 1292-1306.	2.0	86
2111	Attractor Landscape Analysis Reveals Feedback Loops in the p53 Network That Control the Cellular Response to DNA Damage. Science Signaling, 2012, 5, ra83.	1.6	146
2112	From tumor prevention to therapy: Empowering p53 to fight back. Drug Resistance Updates, 2012, 15, 258-267.	6.5	22
2113	The Asian-American E6 Variant Protein of Human Papillomavirus 16 Alone Is Sufficient To Promote Immortalization, Transformation, and Migration of Primary Human Foreskin Keratinocytes. Journal of Virology, 2012, 86, 12384-12396.	1.5	44
2114	3D-QSAR study of Chk1 kinase inhibitors based on docking. Journal of Molecular Modeling, 2012, 18, 3669-3694.	0.8	13
2115	Long-term Smoking Mediated Down-regulation of Smad3 Induces Resistance to Carboplatin in Non-Small Cell Lung Cancer. Neoplasia, 2012, 14, 644-IN23.	2.3	19
2116	Ribosomal protein S3 interacts with TRADD to induce apoptosis through caspase dependent JNK activation. Biochemical and Biophysical Research Communications, 2012, 421, 474-478.	1.0	37
2117	Molecular dynamics studies on Mdm2 complexes: An analysis of the inhibitor influence. Biochemical and Biophysical Research Communications, 2012, 424, 341-347.	1.0	20
2118	Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Proliferation, 2012, 45, 487-498.	2.4	1,120
2119	Prognostic Value of Cell-Cycle Regulation Biomarkers in Bladder Cancer. Seminars in Oncology, 2012, 39, 524-533.	0.8	61
2120	Wound Modulation After Filtration Surgery. Survey of Ophthalmology, 2012, 57, 530-550.	1.7	124
2121	Molecular Dynamic Simulation Insights into the Normal State and Restoration of p53 Function. International Journal of Molecular Sciences, 2012, 13, 9709-9740.	1.8	25
2122	IPH-926 lobular breast cancer cells harbor a p53 mutant with temperature-sensitive functional activity and allow for profiling of p53-responsive genes. Laboratory Investigation, 2012, 92, 1635-1647.	1.7	26
2123	The Molecular Toxicology of Mitomycin C. Advances in Molecular Toxicology, 2012, 6, 243-299.	0.4	11

#	Article	IF	Citations
2124	Genotoxic Agents Promote the Nuclear Accumulation of Annexin A2: Role of Annexin A2 in Mitigating DNA Damage. PLoS ONE, 2012, 7, e50591.	1.1	40
2125	Apoptosis as a Therapeutic Target in Cancer and Cancer Stem Cells: Novel Strategies and Futures Perspectives., 0,,.		2
2126	Benzo(a)pyrene induces p73 mRNA expression and necrosis in human lung adenocarcinoma H1299 cells. Environmental Toxicology, 2012, 27, 202-210.	2.1	15
2127	Contrasting DNA damage checkpoint responses in epithelium of the human seminal vesicle and prostate. Prostate, 2012, 72, 1060-1070.	1.2	4
2128	Concepts in MDM2 Signaling: Allosteric Regulation and Feedback Loops. Genes and Cancer, 2012, 3, 291-297.	0.6	17
2129	Molecular analysis of <i>Ceruloplasmin</i> in a South African cohort presenting with oesophageal cancer. International Journal of Cancer, 2012, 131, 623-632.	2.3	11
2130	Crosstalk between the DNA damage response pathway and microRNAs. Cellular and Molecular Life Sciences, 2012, 69, 2895-2906.	2.4	26
2131	Chromosome instability and deregulated proliferation: an unavoidable duo. Cellular and Molecular Life Sciences, 2012, 69, 2009-2024.	2.4	36
2132	CCN5/WISP-2: A micromanager of breast cancer progression. Journal of Cell Communication and Signaling, 2012, 6, 63-71.	1.8	40
2133	The chemoadjuvant potential of grape seed procyanidins on p53â€related cell death in oral cancer cells. Journal of Oral Pathology and Medicine, 2012, 41, 322-331.	1.4	25
2134	Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2012, 1823, 593-604.	1.9	52
2135	Taxane resistance in breast cancer: A closed HER2 circuit?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 197-206.	3.3	22
2136	Cell response induced by internalized bacterial magnetic nanoparticles under an external static magnetic field. Biomaterials, 2012, 33, 5650-5657.	5.7	17
2137	A prognostic signature of defective p53â€dependent G1 checkpoint function in melanoma cell lines. Pigment Cell and Melanoma Research, 2012, 25, 514-526.	1.5	19
2138	Identification of FDAâ€approved Drugs that Computationally Bind to MDM2. Chemical Biology and Drug Design, 2012, 80, 631-637.	1.5	25
2139	Differential response of nucleus pulposus intervertebral disc cells to high salt, sorbitol, and urea. Journal of Cellular Physiology, 2012, 227, 1179-1187.	2.0	40
2140	Novel cell lines established from pediatric brain tumors. Journal of Neuro-Oncology, 2012, 107, 269-280.	1.4	38
2141	Time course changes of anti- and pro-apoptotic proteins in apigenin-induced genotoxicity. Chinese Medicine, 2013, 8, 9.	1.6	12

#	Article	IF	CITATIONS
2142	Diosmin abrogates chemically induced hepatocarcinogenesis via alleviation of oxidative stress, hyperproliferative and inflammatory markers in murine model. Toxicology Letters, 2013, 220, 205-218.	0.4	41
2143	In Vivo Activation of the p53 Tumor Suppressor Pathway by an Engineered Cyclotide. Journal of the American Chemical Society, 2013, 135, 11623-11633.	6.6	208
2144	Bidentate Ligands on Osmium(VI) Nitrido Complexes Control Intracellular Targeting and Cell Death Pathways. Journal of the American Chemical Society, 2013, 135, 14060-14063.	6.6	88
2145	Biomarkers and Targeted Therapeutics in Colorectal Cancer. Surgical Oncology Clinics of North America, 2013, 22, 841-855.	0.6	3
2146	A Study of Cancer Heterogeneity: From Genetic Instability to Epigenetic Diversity in Colorectal Cancer. , 2013, , 363-388.		3
2147	Saikosaponin-d increases the radiosensitivity of smmc-7721 hepatocellular carcinoma cells by adjusting the $g0/g1$ and $g2/m$ checkpoints of the cell cycle. BMC Complementary and Alternative Medicine, 2013, 13, 263.	3.7	33
2148	Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC). Experimental Hematology and Oncology, 2013, 2, 15.	2.0	29
2149	Remifentanil preconditioning alleviating brain damage of cerebral ischemia reperfusion rats by regulating the JNK signal pathway and TNF-α/TNFR1 signal pathway. Molecular Biology Reports, 2013, 40, 6997-7006.	1.0	28
2150	Biological evidence for a causal role of HPV16 in a small fraction of laryngeal squamous cell carcinoma. British Journal of Cancer, 2013, 109, 172-183.	2.9	95
2151	DNA damage response in peritumoral regions of oesophageal cancer microenvironment. Carcinogenesis, 2013, 34, 139-145.	1.3	18
2152	Autophagy, Apoptosis, Mitoptosis and Necrosis: Interdependence Between Those Pathways and Effects on Cancer. Archivum Immunologiae Et Therapiae Experimentalis, 2013, 61, 43-58.	1.0	233
2153	A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Research and Treatment, 2013, 137, 483-492.	1.1	96
2154	The TP53 signaling network in mammals and worms. Briefings in Functional Genomics, 2013, 12, 129-141.	1.3	11
2155	Homologous recombination mediates cellular resistance and fraction size sensitivity to radiation therapy. Radiotherapy and Oncology, 2013, 108, 155-161.	0.3	28
2156	HPV 5 and 8 E6 expression reduces ATM protein levels and attenuates LINE-1 retrotransposition. Virology, 2013, 443, 69-79.	1.1	35
2157	Feline mammary carcinoma stem cells are tumorigenic, radioresistant, chemoresistant and defective in activation of the ATM/p53 DNA damage pathway. Veterinary Journal, 2013, 196, 414-423.	0.6	22
2158	Preorbital Carcinoma in Two Kirk's Dik-diks (Madoqua kirkii). Journal of Comparative Pathology, 2013, 148, 414-418.	0.1	3
2159	Dynamic Readers for 5-(Hydroxy)Methylcytosine and Its Oxidized Derivatives. Cell, 2013, 152, 1146-1159.	13.5	888

#	Article	IF	CITATIONS
2160	The mutant p53 mouse as a pre-clinical model. Oncogene, 2013, 32, 4325-4330.	2.6	48
2161	Biological clues to potent DNA-damaging activities in food and flavoring. Food and Chemical Toxicology, 2013, 55, 557-567.	1.8	16
2162	Boron neutron capture therapy as a novel modality of radiotherapy for oral cancer: Principle and antitumor effect. Oral Science International, 2013, 10, 9-14.	0.3	15
2163	Inquiry into chemotherapyâ€induced p53 activation in cancer cells as a model for teaching signal transduction. Biochemistry and Molecular Biology Education, 2013, 41, 419-432.	0.5	8
2164	Polyplex Exposure Inhibits Cell Cycle, Increases Inflammatory Response, and Can Cause Protein Expression without Cell Division. Molecular Pharmaceutics, 2013, 10, 1306-1317.	2.3	27
2165	Modulation of Benzo[a]pyrene-Induced Toxic Effects in Japanese Medaka ( <i>Oryzias latipes</i> ) by 2,2′,4,4′-Tetrabromodiphenyl Ether. Environmental Science & Environment	4.6	26
2166	DNA synthesis inhibition in response to benzo[a]pyrene dihydrodiol epoxide is associated with attenuation of p34cdc2: Role of p53. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2013, 755, 61-67.	0.9	6
2167	Cardiac mitochondrial proteomic expression in inbred rat strains divergent in survival time after hemorrhage. Physiological Genomics, 2013, 45, 243-255.	1.0	3
2168	Stochastic and Deterministic Models of Cellular p53 Regulation. Frontiers in Oncology, 2013, 3, 64.	1.3	30
2169	Caffeine suppresses homologous recombination through interference with RAD51-mediated joint molecule formation. Nucleic Acids Research, 2013, 41, 6475-6489.	6.5	24
2170	Inclusion Complex of Zerumbone with Hydroxypropyl- $<$ b> $<$ i> $ ^2<$  i> $<$  b>-Cyclodextrin Induces Apoptosis in Liver Hepatocellular HepG2 Cells via Caspase 8/BID Cleavage Switch and Modulating Bcl2/Bax Ratio. Evidence-based Complementary and Alternative Medicine, 2013, 2013, 1-16.	0.5	19
2171	Increases in apoptosis, caspase activity and expression of p53 and bax, and the transition between two types of mitochondrion-rich cells, in the gills of the climbing perch, Anabas testudineus, during a progressive acclimation from freshwater to seawater. Frontiers in Physiology, 2013, 4, 135.	1.3	74
2172	Annexin A2: The Importance of Being Redox Sensitive. International Journal of Molecular Sciences, 2013, 14, 3568-3594.	1.8	36
2173	The purinergic P2Y14 receptor axis is a molecular determinant for organism survival under in utero radiation toxicity. Cell Death and Disease, 2013, 4, e703-e703.	2.7	6
2174	Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy. Cell Death and Disease, 2013, 4, e791-e791.	2.7	48
2175	In vitro radiosensitization by pentoxifylline does not depend on p53 status. International Journal of Radiation Biology, 2013, 89, 462-470.	1.0	1
2176	Gene expression signatures but not cell cycle checkpoint functions distinguish AT carriers from normal individuals. Physiological Genomics, 2013, 45, 907-916.	1.0	1
2177	In Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition. PLoS ONE, 2013, 8, e62564.	1.1	27

#	Article	IF	CITATIONS
2178	p53 and Cell Cycle Dependent Transcription of kinesin family member 23 (KIF23) Is Controlled Via a CHR Promoter Element Bound by DREAM and MMB Complexes. PLoS ONE, 2013, 8, e63187.	1.1	39
2179	Inhibition of Nutlin-Resistant HDM2 Mutants by Stapled Peptides. PLoS ONE, 2013, 8, e81068.	1.1	27
2180	Tousled-Like Kinase-Dependent Phosphorylation of Rad9 Plays a Role in Cell Cycle Progression and G2/M Checkpoint Exit. PLoS ONE, 2013, 8, e85859.	1.1	28
2181	CoCl2, a Mimic of Hypoxia, Induces Formation of Polyploid Giant Cells with Stem Characteristics in Colon Cancer. PLoS ONE, 2014, 9, e99143.	1.1	101
2182	Cell Cycle Checkpoints., 2014,, 753-777.		0
2183	Cell Cycle Checkpoints. , 2014, , 779-815.		0
2184	Doxorubicin and 5-fluorouracil induced accumulation and transcriptional activity of p53 are independent of the phosphorylation at serine 15 in MCF-7 breast cancer cells. Cancer Biology and Therapy, 2014, 15, 1000-1012.	1.5	12
2185	A Low-dose Arsenic-induced p53 Protein-mediated Metabolic Mechanism of Radiotherapy Protection. Journal of Biological Chemistry, 2014, 289, 5340-5347.	1.6	18
2186	Garlic-derived compound S-allylmercaptocysteine inhibits cell growth and induces apoptosis via the JNK and p38 pathways in human colorectal carcinoma cells. Oncology Letters, 2014, 8, 2591-2596.	0.8	25
2187	The Influence of TRP53 in the Dose Response of Radiation-Induced Apoptosis, DNA Repair and Genomic Stability in Murine Haematopoietic Cells. Dose-Response, 2014, 12, dose-response.1.	0.7	7
2188	Parkin Sensitizes toward Apoptosis Induced by Mitochondrial Depolarization through Promoting Degradation of Mcl-1. Cell Reports, 2014, 9, 1538-1553.	2.9	126
2189	<scp>IRES</scp> mediated translational regulation of p53 isoforms. Wiley Interdisciplinary Reviews RNA, 2014, 5, 131-139.	3.2	33
2190	Molecular features of neural stem cells enable their enrichment using pharmacological inhibitors of survivalâ€promoting kinases. Journal of Neurochemistry, 2014, 128, 376-390.	2.1	9
2191	p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis in Response to Oxidative Damage., 2014,, 195-209.		0
2192	Parallel Profiling of the Transcriptome, Cistrome, and Epigenome in the Cellular Response to Ionizing Radiation. Science Signaling, 2014, 7, rs3.	1.6	51
2193	A study on the extracts of Cuscuta reflexa Roxb. in treatment of cyclophosphamide induced alopecia. DARU, Journal of Pharmaceutical Sciences, 2014, 22, 7.	0.9	10
2194	Assessment of the genotoxic effects of organophosphorus insecticides phorate and trichlorfon in human lymphocytes. Environmental Toxicology, 2014, 29, 577-587.	2.1	27
2195	Reversal of the DNA-Binding-Induced Loop L1 Conformational Switch in an Engineered Human p53 Protein. Journal of Molecular Biology, 2014, 426, 936-944.	2.0	36

#	Article	IF	CITATIONS
2196	p53 Tumor Suppressor Protein Stability and Transcriptional Activity Are Targeted by Kaposi's Sarcoma-Associated Herpesvirus-Encoded Viral Interferon Regulatory Factor 3. Molecular and Cellular Biology, 2014, 34, 386-399.	1.1	29
2197	GPER functions as a tumor suppressor in triple-negative breast cancer cells. Journal of Cancer Research and Clinical Oncology, 2014, 140, 713-723.	1.2	56
2198	Anthracyclines as radiosensitizers: a $Cu(II)$ complex of a simpler analogue modifies DNA in Chinese Hamster V79 cells under low-dose $\hat{I}^3$ radiation. Journal of Radioanalytical and Nuclear Chemistry, 2014, 299, 1665-1670.	0.7	7
2199	Iron Metabolism Regulates p53 Signaling through Direct Heme-p53 Interaction and Modulation of p53 Localization, Stability, and Function. Cell Reports, 2014, 7, 180-193.	2.9	170
2200	Acute exposure to thimerosal induces antiproliferative properties, apoptosis, and autophagy activation in human Chang conjunctival cells. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 275-284.	1.0	5
2201	Role of p53 in the entrainment of mammalian circadian behavior rhythms. Genes To Cells, 2014, 19, 441-448.	0.5	11
2202	<i>TP53</i> Promoter Methylation in Primary Glioblastoma: Relationship with <i>TP53</i> Protein Expression and Mutation Status. DNA and Cell Biology, 2014, 33, 217-226.	0.9	23
2203	Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression. Journal of Biological Chemistry, 2014, 289, 20543-20558.	1.6	47
2204	Apoptotic effect of synthetic 2′,4′,5′-trimethoxychalcones in human K562 and Jurkat leukemia cells. Medicinal Chemistry Research, 2014, 23, 4301-4319.	1.1	9
2205	G2-block after irradiation of cells with different p53 status. Strahlentherapie Und Onkologie, 2014, 190, 1075-1079.	1.0	6
2206	The role of neuropathology in the management of progressive glioblastoma. Journal of Neuro-Oncology, 2014, 118, 461-478.	1.4	10
2207	CELLFOODâ,,¢ induces apoptosis in human mesothelioma and colorectal cancer cells by modulating p53, c-myc and pAkt signaling pathways. Journal of Experimental and Clinical Cancer Research, 2014, 33, 24.	3.5	16
2208	TRIM24 Is a p53-Induced E3-Ubiquitin Ligase That Undergoes ATM-Mediated Phosphorylation and Autodegradation during DNA Damage. Molecular and Cellular Biology, 2014, 34, 2695-2709.	1.1	74
2209	Cloning and characterization of an apoptosis-related DNA fragmentation factor (DFF) from oyster, Crassostrea hongkongensis. Fish and Shellfish Immunology, 2014, 38, 119-126.	1.6	8
2210	Low-dose radiation exposure induces a HIF-1-mediated adaptive and protective metabolic response. Cell Death and Differentiation, 2014, 21, 836-844.	5.0	75
2211	The $\hat{I}^2$ -catenin E3 ubiquitin ligase SIAH-1 is regulated by CSN5/JAB1 in CRC cells. Cellular Signalling, 2014, 26, 2051-2059.	1.7	21
2212	Ataxia-telangiectasia: future prospects. The Application of Clinical Genetics, 2014, 7, 159.	1.4	42
2213	Differential S-phase progression after irradiation of p53 functional versus non-functional tumour cells. Radiology and Oncology, 2014, 48, 354-360.	0.6	1

#	Article	IF	Citations
2214	Silver nanoparticles induce p53-mediated apoptosis in human bronchial epithelial (BEAS-2B) cells. Journal of Toxicological Sciences, 2014, 39, 401-412.	0.7	26
2215	Radiation-induced signaling pathways that promote cancer cell survival (Review). International Journal of Oncology, 2014, 45, 1813-1819.	1.4	149
2216	Histone deacetylase inhibitors cause TP53-dependent induction of p21/Waf1 in tumor cells with TP53 mutations. Cell and Tissue Biology, 2015, 9, 191-197.	0.2	1
2217	Stress-mediated Sin3B activation leads to negative regulation of subset of p53 target genes. Bioscience Reports, 2015, 35, .	1.1	3
2218	Imatinib inhibits inactivation of the ATM/ATR signaling pathway and recovery from adriamycin/doxorubicinâ€induced DNA damage checkpoint arrest. Cell Biology International, 2015, 39, 923-932.	1.4	19
2219	Endogenous Retinoic Acid Required to Maintain the Epidermis Following Ultraviolet Light Exposure in SKHâ€1 Hairless Mice. Photochemistry and Photobiology, 2015, 91, 901-908.	1.3	10
2220	The glucosinolate metabolite 1â€methoxyâ€3â€indolylmethyl alcohol induces a gene expression profile in mouse liver similar to the expression signature caused by known genotoxic hepatocarcinogens. Molecular Nutrition and Food Research, 2015, 59, 685-697.	1.5	12
2221	Nanoparticleâ€Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma. Advanced Healthcare Materials, 2015, 4, 2719-2726.	3.9	69
2222	Effects of homocysteine on mesenchymal cell proliferation and differentiation during chondrogenesis on limb development. Journal of Applied Toxicology, 2015, 35, 1390-1397.	1.4	8
2223	CAPE Analogs Induce Growth Arrest and Apoptosis in Breast Cancer Cells. Molecules, 2015, 20, 12576-12589.	1.7	24
2224	Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM. Oncotarget, 2015, 6, 33755-33768.	0.8	42
2225	Ultraviolet Radiation-Induced Cytogenetic Damage in White, Hispanic and Black Skin Melanocytes: A Risk for Cutaneous Melanoma. Cancers, 2015, 7, 1586-1604.	1.7	4
2226	Triple-negative breast cancer: new perspectives for targeted therapies. OncoTargets and Therapy, 2015, 8, 177.	1.0	109
2227	Numerical simulation of ultradian oscillations in p53–Mdm2-network under stress conditions. Mathematical Models and Computer Simulations, 2015, 7, 281-293.	0.1	4
2228	RNA sequencing supports distinct reactive oxygen species-mediated pathways of apoptosis by high and low size mass fractions of Bay leaf (Lauris nobilis) in HT-29 cells. Food and Function, 2015, 6, 2507-2524.	2.1	8
2229	Enhanced antigen detection in immunohistochemical staining using a †digitized' chimeric antibody. Protein Engineering, Design and Selection, 2015, 29, gzv054.	1.0	0
2230	Sphingolipids in the DNA damage response. Advances in Biological Regulation, 2015, 58, 38-52.	1.4	44
2231	Suppression of <i>CHK1</i> by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. Cancer Discovery, 2015, 5, 550-563.	7.7	24

#	Article	IF	CITATIONS
2232	Acute Dosing and p53-Deficiency Promote Cellular Sensitivity to DNA Methylating Agents. Toxicological Sciences, 2015, 144, 357-365.	1.4	9
2233	The role of DNA damage responses in p53 biology. Archives of Toxicology, 2015, 89, 501-517.	1.9	138
2234	Acetylation of HDAC1 and degradation of SIRT1 form a positive feedback loop to regulate p53 acetylation during heat-shock stress. Cell Death and Disease, 2015, 6, e1747-e1747.	2.7	40
2235	The different radiation response and radiation-induced bystander effects in colorectal carcinoma cells differing in p53 status. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 778, 61-70.	0.4	28
2236	Opportunities and challenges of radiotherapy for treating cancer. Nature Reviews Clinical Oncology, 2015, 12, 527-540.	12.5	452
2237	p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2015, 14, 1117-1129.	1.9	32
2238	Adiposity is associated with p53 gene mutations in breast cancer. Breast Cancer Research and Treatment, 2015, 153, 635-645.	1.1	4
2239	Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. BMC Cancer, 2015, 15, 422.	1.1	16
2240	New distinct compartments in the G $<$ sub $>$ 2 $<$ /sub $>$ phase of the cell cycle defined by the levels of $^{\hat{1}3}$ H2AX Cell Cycle, 2015, 14, 3261-3269.	1.3	7
2241	Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes. Clinical and Experimental Metastasis, 2015, 32, 755-767.	1.7	9
2242	Metabolic responses induced by DNA damage and poly (ADP-ribose) polymerase (PARP) inhibition in MCF-7 cells. Metabolomics, 2015, 11, 1779-1791.	1.4	20
2243	Immunomodulatory effect of diethylcarbamazine citrate plus filarial excretory–secretory product on rat hepatocarcinogenesis. International Immunopharmacology, 2015, 24, 173-181.	1.7	7
2244	A novel function of HER2/Neu in the activation of G2/M checkpoint in response to $\hat{l}^3$ -irradiation. Oncogene, 2015, 34, 2215-2226.	2.6	31
2245	The prognostic significance of p53 expression in gastric cancer: a meta-analysis. Journal of Cancer Research and Clinical Oncology, 2015, 141, 735-748.	1.2	17
2246	DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene, 2015, 34, 2815-2822.	2.6	81
2247	Cytotoxic and genotoxic effects of dioxacarb by human peripheral blood lymphocytes CAs and Allium test. Cytotechnology, 2015, 67, 1023-1030.	0.7	5
2248	p53 signaling is involved in leptin-induced growth of hepatic and breast cancer cells. Korean Journal of Physiology and Pharmacology, 2016, 20, 487.	0.6	14
2249	Inhibition of histone deacetylases induces formation of multipolar spindles and subsequent p53-dependent apoptosis in nasopharyngeal carcinoma cells. Oncotarget, 2016, 7, 44171-44184.	0.8	9

#	ARTICLE	IF	CITATIONS
2250	Analysis of Residual DSBs in Ataxia-Telangiectasia Lymphoblast Cells Initiating Apoptosis. BioMed Research International, 2016, 2016, 1-12.	0.9	6
2251	Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer. Oncotarget, 2016, 7, 60807-60822.	0.8	23
2252	Agmatine Ameliorates High Glucose-Induced Neuronal Cell Senescence by Regulating the p21 and p53 Signaling. Experimental Neurobiology, 2016, 25, 24-32.	0.7	21
2253	Higher Initial DNA Damage and Persistent Cell Cycle Arrest after Carbon Ion Irradiation Compared to X-irradiation in Prostate and Colon Cancer Cells. Frontiers in Oncology, 2016, 6, 87.	1.3	28
2254	Cap-Independent Translational Control of Carcinogenesis. Frontiers in Oncology, 2016, 6, 128.	1.3	54
2255	Roles of RNA-Binding Proteins in DNA Damage Response. International Journal of Molecular Sciences, 2016, 17, 310.	1.8	93
2256	The liverâ€specific microRNAâ€122*, the complementary strand of microRNAâ€122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry. Hepatology, 2016, 64, 1623-1636.	3.6	48
2257	Targeting irradiationâ€induced mitogenâ€activated protein kinase activation in vitro and in an ex vivo model for human head and neck cancer. Head and Neck, 2016, 38, E2049-61.	0.9	16
2258	Prognostic significance of p53 expression in patients with esophageal cancer: a meta-analysis. BMC Cancer, 2016, 16, 373.	1.1	26
2259	Human pregnane X receptor compromises the function of p53 and promotes malignant transformation. Cell Death Discovery, 2016, 2, 16023.	2.0	24
2260	Validation of the antiproliferative effects of Euphorbia tirucalli extracts in breast cancer cell lines. Molecular Biology, 2016, 50, 98-110.	0.4	23
2261	Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant <i>KRAS</i> Lung Cancer. Clinical Cancer Research, 2016, 22, 5851-5863.	3.2	67
2262	Mitochondrial Copy Number as a Biomarker for Autism?. Pediatrics, 2016, 137, e20160049.	1.0	3
2263	MDM2 oligomers: antagonizers of the guardian of the genome. Oncogene, 2016, 35, 6157-6165.	2.6	15
2264	Condensin II mutation causes T-cell lymphoma through tissue-specific genome instability. Genes and Development, 2016, 30, 2173-2186.	2.7	41
2265	Gastric/GE Junction Cancer., 2016,, 906-933.e5.		3
2266	The Role of p53/p21/p16 in DNA-Damage Signaling and DNA Repair. , 2016, , 243-256.		15
2267	Functional characterization of p53 pathway components in the ancient metazoan Trichoplax adhaerens. Scientific Reports, 2016, 6, 33972.	1.6	12

#	Article	IF	Citations
2268	DNA Repair and Its Influence on Points of Departure for Alkylating Agent Genotoxicity., 2016,, 67-82.		3
2269	Basic Knowledge of Glioblastoma Radiobiology. Current Clinical Pathology, 2016, , 139-153.	0.0	0
2270	Prunus mume Sieb. et Zucc. fruit ameliorates alcoholic liver injury in mice by inhibiting apoptosis and inflammation through oxidative stress. Journal of Functional Foods, 2016, 25, 135-148.	1.6	20
2271	Protective effects of Rg2 against UVB-induced DNA damage in HaCaT cells is dependent on p53 expression. Animal Cells and Systems, 2016, 20, 152-156.	0.8	2
2272	p53 expression but not p16INK4A correlates with human papillomavirus-associated esophageal squamous cell carcinoma in Kazakh population. Infectious Agents and Cancer, 2016, 11, 19.	1.2	16
2273	Centrosomes are multifunctional regulators of genome stability. Chromosome Research, 2016, 24, 5-17.	1.0	27
2274	A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 193-200.	1.1	66
2275	Quantitative Measurement of Histone Tail Acetylation Reveals Stage-Specific Regulation and Response to Environmental Changes during <i>Drosophila</i> Development. Biochemistry, 2016, 55, 1663-1672.	1.2	9
2276	Effect of apigenin-7-glucoside, genkwanin and naringenin on tyrosinase activity and melanin synthesis in B16F10 melanoma cells. Life Sciences, 2016, 144, 80-85.	2.0	100
2277	Melatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesis. Cancer Letters, 2016, 370, 145-152.	3.2	47
2278	An Observed Effect of p53 Status on the Bystander Response to Radiation-Induced Cellular Photon Emission. Radiation Research, 2017, 187, 169.	0.7	22
2279	Large-Scale Analysis of CRISPR/Cas9 Cell-Cycle Knockouts Reveals the Diversity of p53-Dependent Responses to Cell-Cycle Defects. Developmental Cell, 2017, 40, 405-420.e2.	3.1	175
2280	Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 69-92.	3.3	65
2281	Polyalthia longifolia Methanolic Leaf Extracts (PLME) induce apoptosis, cell cycle arrest and mitochondrial potential depolarization by possibly modulating the redox status in hela cells. Biomedicine and Pharmacotherapy, 2017, 89, 499-514.	2.5	19
2282	Measuring Fluorescence Anisotropy as One of Very Useful Analytical Methods to Obtain Detailed Information of the Complex Binding Interaction. Bulletin of the Korean Chemical Society, 2017, 38, 406-409.	1.0	0
2283	Transcriptional and post-transcriptional regulation of the ionizing radiation response by ATM and p53. Scientific Reports, 2017, 7, 43598.	1.6	31
2284	Molecular Alterations in Pancreatic Cancer. , 2017, , 11-23.		0
2286	Clear cell renal cell carcinoma: a comparative study of histological and chromosomal characteristics between primary tumors and their corresponding metastases. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 107-115.	1.4	13

#	Article	IF	CITATIONS
2287	Hepatitis C Virus Indirectly Disrupts DNA Damage-Induced p53 Responses by Activating Protein Kinase R. MBio, 2017, $8$ , .	1.8	22
2288	The expanding role of the Ehmt2/G9a complex in neurodevelopment. Neurogenesis (Austin, Tex ), 2017, 4, e1316888.	1.5	18
2289	Clinical effects of p53 overexpression in squamous cell carcinoma of the sinonasal tract. Medicine (United States), 2017, 96, e6424.	0.4	9
2290	The Evolution of Tumor Formation in Humans and Mice with Inherited Mutations in the p53 Gene. Current Topics in Microbiology and Immunology, 2017, 407, 205-221.	0.7	4
2291	DNA double-strand breaks in human induced pluripotent stem cell reprogramming and long-term in vitro culturing. Stem Cell Research and Therapy, 2017, 8, 73.	2.4	31
2292	Census and evaluation of p53 target genes. Oncogene, 2017, 36, 3943-3956.	2.6	685
2293	DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression. Nature Communications, 2017, 8, 14728.	5.8	284
2294	Exponential rolling circle amplification and its sensing application for highly sensitive DNA detection of tumor suppressor gene. Sensors and Actuators B: Chemical, 2017, 243, 1240-1247.	4.0	27
2295	Florfenicol-induced Mitochondrial Dysfunction Suppresses Cell Proliferation and Autophagy in Fibroblasts. Scientific Reports, 2017, 7, 13554.	1.6	25
2296	Therapeutics targeting Bcl-2 in hematological malignancies. Biochemical Journal, 2017, 474, 3643-3657.	1.7	64
2297	Tia1 dependent regulation of mRNA subcellular location and translation controls p53 expression in B cells. Nature Communications, 2017, 8, 530.	5.8	48
2298	Putting p53 in Context. Cell, 2017, 170, 1062-1078.	13.5	1,355
2299	Phototoxicity in a laryngeal cancer cell line enhanced by a targeting amphiphilic chlorin photosensitizer. Photodiagnosis and Photodynamic Therapy, 2017, 19, 355-362.	1.3	2
2300	Meta-analysis of clinical significance of p53 protein expression in patients with osteosarcoma. Future Oncology, 2017, 13, 1883-1891.	1.1	13
2301	Defining key concepts of intestinal and epithelial cancer biology through the use of mouse models. Carcinogenesis, 2017, 38, 953-965.	1.3	5
2302	DNA damage and the bystander response in tumor and normal cells exposed to X-rays. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2017, 821, 20-27.	0.9	11
2303	Luteolysis in Ruminants: Past Concepts, New Insights, and Persisting Challenges., 2017, , 159-182.		8
2304	Factors affecting the <i>in vitro </i> micronucleus assay for evaluation of nanomaterials. Mutagenesis, 2017, 32, 151-159.	1.0	31

#	Article	IF	CITATIONS
2305	Biochemical alterations in the oocyte in support of early embryonic development. Cellular and Molecular Life Sciences, 2017, 74, 469-485.	2.4	16
2306	Telomere biology in aging and cancer: early history and perspectives. Genes and Genetic Systems, 2017, 92, 107-118.	0.2	17
2307	Grape seed proanthocyanidins induce mitochondrial pathway‑mediated apoptosis in human colorectal carcinoma cells. Oncology Letters, 2017, 14, 5853-5860.	0.8	7
2308	Regulation of the DNA Damage Response by Autophagy. , 2017, , 213-236.		O
2309	Targeting IRES-Mediated p53 Synthesis for Cancer Diagnosis and Therapeutics. International Journal of Molecular Sciences, 2017, 18, 93.	1.8	21
2310	Current Approaches to Diagnosis and Treatment of Ductal Carcinoma In Situ and Future Directions. Progress in Molecular Biology and Translational Science, 2017, 151, 33-80.	0.9	6
2311	Opposite Effects of SET7/9 on Apoptosis of Human Acute Myeloid Leukemia Cells and Lung Cancer Cells. Journal of Cancer, 2017, 8, 2069-2078.	1.2	16
2312	Pathway of 3-MCPD-induced apoptosis in human embryonic kidney cells. Journal of Toxicological Sciences, 2017, 42, 43-52.	0.7	14
2313	The prolactinâ€release inhibitor paeoniflorin suppresses proliferation and induces apoptosis in prolactinoma cells via the mitochondriaâ€dependent pathway. Journal of Cellular Biochemistry, 2018, 119, 5704-5714.	1.2	10
2314	Glutaredoxin-1 Silencing Induces Cell Senescence via p53/p21/p16 Signaling Axis. Journal of Proteome Research, 2018, 17, 1091-1100.	1.8	54
2315	The secondary Fusarium metabolite aurofusarin induces oxidative stress, cytotoxicity and genotoxicity in human colon cells. Toxicology Letters, 2018, 284, 170-183.	0.4	26
2316	Evidence for a radiation-responsive â€~p53 gateway' contributing significantly to the radioresistance of lepidopteran insect cells. Scientific Reports, 2018, 8, 2.	1.6	187
2317	Transcriptional levels of the cancerâ€related genes <i>p53</i> , <i>TAp63/73,</i> and <i>â^†Np63/73</i> in the blue mussel ( <i>Mytilus edulis</i> ) after lead exposure. Invertebrate Biology, 2018, 137, 60-65.	0.3	5
2318	Recurring mutations in <i>RPL15</i> are linked to hydrops fetalis and treatment independence in Diamond-Blackfan anemia. Haematologica, 2018, 103, 949-958.	1.7	22
2319	Differences between the tolerance of camel oocytes and cumulus cells to acute and chronic hyperthermia. Journal of Thermal Biology, 2018, 74, 47-54.	1.1	25
2320	Genes and Cancer. , 2018, , 493-527.e6.		O
2321	Deconstructing networks of p53-mediated tumor suppression in vivo. Cell Death and Differentiation, 2018, 25, 93-103.	5.0	167
2322	Saikosaponin D inhibits proliferation of human osteosarcoma cells via the p53 signaling pathway. Experimental and Therapeutic Medicine, 2019, 17, 488-494.	0.8	13

#	Article	IF	CITATIONS
2323	Identification and preclinical evaluation of the small molecule, NSC745887, for treating glioblastomas via suppressing DcR3-associated signaling pathways. Oncotarget, 2018, 9, 11922-11937.	0.8	5
2324	Blebbistatin modulates prostatic cell growth and contrapctility through myosin II signaling. Clinical Science, 2018, 132, 2189-2205.	1.8	9
2325	Anti-cancer effects of 3,5-dimethylaminophenol in A549 lung cancer cells. PLoS ONE, 2018, 13, e0205249.	1.1	4
2326	Identification of Kinases and Interactors of p53 Using Kinase-Catalyzed Cross-Linking and Immunoprecipitation. Journal of the American Chemical Society, 2018, 140, 16299-16310.	6.6	12
2327	Influence of TP53 gene somatic mutations in Helicobacter pylori infected gastric tumor. Meta Gene, 2018, 17, 108-114.	0.3	2
2328	Estrogen receptor positive breast tumors resist chemotherapy by the overexpression of P53 in Cancer Stem Cells. Journal of the Egyptian National Cancer Institute, 2018, 30, 45-48.	0.6	9
2329	Mechanistic considerations in chemotherapeutic activity of caffeine. Biomedicine and Pharmacotherapy, 2018, 105, 312-319.	2.5	29
2330	Total Skin Electron Irradiation and Sequential Malignancies in Mycosis Fungoides Patients: Longitudinal Study. Clinical Oncology, 2018, 30, 618-624.	0.6	2
2331	Double Strand Break DNA Repair occurs via Non-Homologous End-Joining in Mouse MII Oocytes. Scientific Reports, 2018, 8, 9685.	1.6	25
2332	Measuring cell cycle-dependent DNA damage responses and p53 regulation on a cell-by-cell basis from image analysis. Cell Cycle, 2018, 17, 1358-1371.	1.3	18
2333	Testosterone regulates myosin II isoforms expression and functional activity in the rat prostate. Prostate, 2018, 78, 1283-1298.	1.2	4
2334	p53 Is Active in Human Amniotic Fluid Stem Cells. Stem Cells and Development, 2018, 27, 1507-1517.	1.1	6
2335	Fibronectin Promotes the Malignancy of Glioma Stem-Like Cells Via Modulation of Cell Adhesion, Differentiation, Proliferation and Chemoresistance. Frontiers in Molecular Neuroscience, 2018, 11, 130.	1.4	61
2336	Interstitial lung disease is associated with an increased risk of lung cancer in systemic sclerosis: Longitudinal data from the Canadian Scleroderma Research Group. Journal of Scleroderma and Related Disorders, 2018, 3, 221-227.	1.0	8
2337	The Guardian of the Genome Revisited: p53 Downregulates Genes Required for Telomere Maintenance, DNA Repair, and Centromere Structure. Cancers, 2018, 10, 135.	1.7	93
2338	Investigations into the therapeutic potential of Asphodeline liburnica roots: In vitro and in silico biochemical and toxicological perspectives. Food and Chemical Toxicology, 2018, 120, 172-182.	1.8	13
2339	A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 97.	3 <b>.</b> 5	45
2340	Gallic Acid as a Putative Antioxidant in Usage Against Liver Disease. , 2018, , 317-322.		2

#	Article	IF	CITATIONS
2341	Cell-Cycle Regulation., 2018,, 257-269.		3
2342	Angiogenesis in human brain tumors: screening of drug response through a patient-specific cell platform for personalized therapy. Scientific Reports, 2018, 8, 8748.	1.6	29
2343	Apoptosis as a Mechanism of Developmental Neurotoxicity., 2018,, 91-112.		1
2344	Cold atmospheric plasma treatment inhibits growth in colorectal cancer cells. Biological Chemistry, 2018, 400, 111-122.	1.2	32
2345	In vitro behavior and UV response of melanocytes derived from carriers of CDKN 2A mutations and MC 1R variants. Pigment Cell and Melanoma Research, 2019, 32, 259-268.	1.5	3
2346	Targeting Therapies for the p53 Protein in Cancer Treatments. Annual Review of Cancer Biology, 2019, 3, 21-34.	2.3	65
2347	The Molecular Physiology of Ageing: New Targets for Regenerative Medicine., 2019,, 15-29.		0
2348	Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells. Cancer Cell International, 2019, 19, 195.	1.8	13
2349	Ecophysiology, genotoxicity, histopathology, and gene responses of naphthalene injected Colossoma macropomum (Cuvier, 1818) exposed to hypoxia. Genetics and Molecular Biology, 2019, 42, 411-424.	0.6	5
2350	Role of the Molecular Chaperones Hsp70 and Hsp90 in the DNA Damage Response. Heat Shock Proteins, 2019, , 345-358.	0.2	3
2351	Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition. Journal of Cancer, 2019, 10, 3860-3870.	1.2	26
2352	Flavopereirine Suppresses the Growth of Colorectal Cancer Cells through P53 Signaling Dependence. Cancers, 2019, 11, 1034.	1.7	12
2353	Rag1 immunodeficiencyâ€induced early aging and senescence in zebrafish are dependent on chronic inflammation and oxidative stress. Aging Cell, 2019, 18, e13020.	3.0	23
2354	Roles of p53 Family Structure and Function in Non-Canonical Response Element Binding and Activation. International Journal of Molecular Sciences, 2019, 20, 3681.	1.8	18
2355	Inflammatory signaling in genomically instable cancers. Cell Cycle, 2019, 18, 1830-1848.	1.3	21
2356	Signal Transduction in Radiation Oncology. , 2019, , 1-17.		0
2357	Label propagation defines signaling networks associated with recurrently mutated cancer genes. Scientific Reports, 2019, 9, 9401.	1.6	1
2358	Notch pathway: a bistable inducer of biological noise?. Cell Communication and Signaling, 2019, 17, 133.	2.7	10

#	Article	IF	CITATIONS
2359	In Silico Design of MDM2â€Targeting Peptides from a Naturally Occurring Constrained Peptide. ChemMedChem, 2019, 14, 1710-1716.	1.6	1
2360	p53 nuclear accumulation as an early indicator of lethal prostate cancer. British Journal of Cancer, 2019, 121, 578-583.	2.9	10
2361	Antiproliferative and pro‑apoptotic effects of Cyclocarya� paliurus polysaccharide and X‑ray irradiation combination on SW480 colorectal cancer cells. Molecular Medicine Reports, 2019, 20, 3535-3542.	1.1	3
2362	Hereditary Endometrial and Ovarian Cancers. , 2019, , 45-55.		0
2363	Transcriptomic profiling reveals p53 as a key regulator of doxorubicin-induced cardiotoxicity. Cell Death Discovery, 2019, 5, 102.	2.0	44
2364	Fipronil induces apoptosis and cell cycle arrest in porcine oocytes during in vitro maturation. Apoptosis: an International Journal on Programmed Cell Death, 2019, 24, 718-729.	2.2	11
2365	A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1. Cancer Discovery, 2019, 9, 962-979.	7.7	58
2366	Integrated Regulation of HuR by Translation Repression and Protein Degradation Determines Pulsatile Expression of p53 Under DNA Damage. IScience, 2019, 15, 342-359.	1.9	34
2367	Recombinant Aflatoxin-Degrading F420H2-Dependent Reductase from Mycobacterium smegmatis Protects Mammalian Cells from Aflatoxin Toxicity. Toxins, 2019, 11, 259.	1.5	23
2368	The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair. Scientific Reports, 2019, 9, 6539.	1.6	42
2369	Molecular Diagnostics in Colorectal Cancer. , 2019, , 143-155.		2
2370	The p53 mRNA: an integral part of the cellular stress response. Nucleic Acids Research, 2019, 47, 3257-3271.	6.5	57
2371	Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer. Theranostics, 2019, 9, 761-777.	4.6	42
2372	Stress-activated miR-204 governs senescent phenotypes of chondrocytes to promote osteoarthritis development. Science Translational Medicine, 2019, $11$ , .	5.8	96
2373	Deciphering the Pharmacological Mechanism of the Herb Radix Ophiopogonis in the Treatment of Nasopharyngeal Carcinoma by Integrating iTRAQ-Coupled 2-D LC-MS/MS Analysis and Network Investigation. Frontiers in Pharmacology, 2019, 10, 253.	1.6	11
2374	Activation of p53-Mediated Apoptosis Pathway in HSC3 Cancer Cell Irradiated by Atmospheric DBD Oxygen Plasma. IEEE Transactions on Plasma Science, 2019, 47, 1093-1099.	0.6	14
2375	Genomic and GeneChip expression profiling reveals the inhibitory effects of Amorphophalli Rhizoma in TNBC cells. Journal of Ethnopharmacology, 2019, 235, 206-218.	2.0	15
2376	Chromatin control in double strand break repair. Advances in Protein Chemistry and Structural Biology, 2019, 115, 69-94.	1.0	4

#	Article	IF	Citations
2377	Radiationâ€activated prosurvival signaling pathways in cancer cells. Precision Radiation Oncology, 2019, 3, 111-120.	0.4	7
2378	Oligomeric proanthocyanidins (OPCs) from grape seed extract suppress the activity of ABC transporters in overcoming chemoresistance in colorectal cancer cells. Carcinogenesis, 2019, 40, 412-421.	1.3	24
2379	Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment. Biomedicine and Pharmacotherapy, 2019, 109, 484-492.	2.5	108
2380	Advances in renewable plant-derived protein source: The structure, physicochemical properties affected by ultrasonication. Ultrasonics Sonochemistry, 2019, 53, 83-98.	3.8	101
2381	Methods to Screen Compounds Against Mutant p53 Misfolding and Aggregation for Cancer Therapeutics. Methods in Molecular Biology, 2019, 1873, 265-277.	0.4	2
2382	Identification of a novel cell cycleâ€related gene signature predicting survival in patients with gastric cancer. Journal of Cellular Physiology, 2019, 234, 6350-6360.	2.0	68
2383	Effects of Ferroportin-Mediated Iron Depletion in Cells Representative of Different Histological Subtypes of Prostate Cancer. Antioxidants and Redox Signaling, 2019, 30, 1043-1061.	2.5	36
2384	Environmental Arsenic Exposure and Human Health Risk. Advances in Water Security, 2020, , 103-129.	0.8	16
2385	DNA Damage Response Pathways and Cancer. , 2020, , 154-164.e4.		7
2386	Nobiletin and related polymethoxylated flavones bind to and inhibit the nuclear export factor Exportin-1 in NK leukemia cell line KHYG-1. Biochemical and Biophysical Research Communications, 2020, 521, 457-462.	1.0	4
2387	Hepatic oxidative stress, up-regulation of pro-inflammatory cytokines, apoptotic and oncogenic markers following 2-methoxyethanol administrations in rats. Biochemistry and Biophysics Reports, 2020, 24, 100806.	0.7	11
2388	Quantitative analysis of PAH compounds in DWH crude oil and their effects on Caenorhabditis elegans germ cell apoptosis, associated with CYP450s upregulation. Science of the Total Environment, 2020, 745, 140639.	3.9	7
2389	ECRG2, a novel transcriptional target of p53, modulates cancer cell sensitivity to DNA damage. Cell Death and Disease, 2020, 11, 543.	2.7	5
2390	2-[(4-Hydroxybenzyl) Amino] Phenol (HBAP) Restores the Mutated p53 to the Level Similar to That of Wild-Type p53 Protein and Inhibits Breast Cancer Growth in vivo to by Inducing Tumor Cells Apoptosis. Frontiers in Cell and Developmental Biology, 2020, 8, 574799.	1.8	3
2391	P53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer's disease. Acta Neuropathologica Communications, 2020, 8, 132.	2.4	78
2392	Melatonin as a Radio-Sensitizer in Cancer. Biomedicines, 2020, 8, 247.	1.4	14
2393	The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines. Cells, 2020, 9, 1775.	1.8	38
2394	Comprehensive approaches on chemical composition and biological properties of <i>Daphne pontica</i> L. extracts. Plant Biosystems, 2022, 156, 116-129.	0.8	2

#	Article	IF	CITATIONS
2395	p53 drives a transcriptional program that elicits a non-cell-autonomous response and alters cell state in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23663-23673.	3.3	26
2396	In vivo exposure to codeine induces reproductive toxicity: role of HER2 and p53/Bcl-2 signaling pathway. Heliyon, 2020, 6, e05589.	1.4	24
2397	Trisenox Disrupts MDM2-DAXX-HAUSP Complex and Induces Apoptosis in a Mouse Model of Acute Leukemia. Journal of Cancer, 2020, 11, 4373-4383.	1.2	2
2398	Acute exposure of 532 nm laser differentially regulates skin tissue transcription factors. PLoS ONE, 2020, 15, e0230175.	1.1	1
2399	Common cancer mutations R175H and R273H drive the p53 DNA-binding domain towards aggregation-prone conformations. Physical Chemistry Chemical Physics, 2020, 22, 9225-9232.	1.3	21
2400	Dominantly Inherited Hereditary Nonpolyposis Colorectal Cancer Not Caused by MMR Genes. Journal of Clinical Medicine, 2020, 9, 1954.	1.0	15
2401	Upregulation of fibronectin following loss of p53 function is a poor prognostic factor in ovarian carcinoma with a unique immunophenotype. Cell Communication and Signaling, 2020, 18, 103.	2.7	11
2402	Modulation of DNA Damage Response by Sphingolipid Signaling: An Interplay that Shapes Cell Fate. International Journal of Molecular Sciences, 2020, 21, 4481.	1.8	11
2403	The GTPase KRAS suppresses the p53 tumor suppressor by activating the NRF2-regulated antioxidant defense system in cancer cells. Journal of Biological Chemistry, 2020, 295, 3055-3063.	1.6	17
2404	An in vitro investigation into the protective and genotoxic effects of myricetin bulk and nano forms in lymphocytes of MGUS patients and healthy individuals. Toxicology Letters, 2020, 327, 33-40.	0.4	7
2405	Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation. Oncogene, 2020, 39, 4344-4357.	2.6	22
2406	Context is key: Understanding the regulation, functional control, and activities of the p53 tumour suppressor. Cell Biochemistry and Function, 2021, 39, 235-247.	1.4	16
2407	DNA-Damage-Induced Alternative Splicing of p53. Cancers, 2021, 13, 251.	1.7	10
2408	Effects of redox interference on the pancreatic mitochondria and the abnormal blood glucose. Free Radical Research, 2021, 55, 119-130.	1.5	2
2409	p53, A Victim of the Prion Fashion. Cancers, 2021, 13, 269.	1.7	8
2410	Screening of FDA-Approved Drug Library Identifies Adefovir Dipivoxil as Highly Potent Inhibitor of T Cell Proliferation. Frontiers in Immunology, 2020, 11, 616570.	2.2	5
2411	Conditioned Media of Choroid Plexus Epithelium Cells Attenuates High Pi-Induced Calcification of MOVAS Cells by Inhibiting ROS-Mediated Signal Pathways. Frontiers in Physiology, 2021, 12, 607739.	1.3	0
2412	Isoforms of the p53 Family and Gastric Cancer: A Ménage à Trois for an Unfinished Affair. Cancers, 2021, 13, 916.	1.7	33

#	Article	IF	CITATIONS
2413	Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study. Gastric Cancer, 2021, 24, 844-857.	2.7	14
2414	Regulation of p53 by E3s. Cancers, 2021, 13, 745.	1.7	17
2415	Sustained CHK2 activity, but not ATM activity, is critical to maintain a G1 arrest after DNA damage in untransformed cells. BMC Biology, 2021, 19, 35.	1.7	7
2416	Spectroscopic Investigations and DFT Studies of Synthesized 4- Acetamidophenyl 3,4,5-Trimethoxybenzoate and 4-acetyl phenyl 3,4,5-trimethoxybenzoate a Novel Conjugate of Gallic Acid. Letters in Organic Chemistry, 2021, 18, 134-142.	0.2	0
2417	Combined Inactivation of Pocket Proteins and APC/CCdh1 by Cdk4/6 Controls Recovery from DNA Damage in G1 Phase. Cells, 2021, 10, 550.	1.8	0
2418	Healthâ€promoting bioactivity and in vivo genotoxicity evaluation of a hemiepiphyte fig, <i>Ficus dubia</i> . Food Science and Nutrition, 2021, 9, 2269-2279.	1.5	10
2419	Double Insurance for OC: miRNA-Mediated Platinum Resistance and Immune Escape. Frontiers in Immunology, 2021, 12, 641937.	2.2	5
2420	Heterogeneities in Cell Cycle Checkpoint Activation Following Doxorubicin Treatment Reveal Targetable Vulnerabilities in TP53 Mutated Ultra High-Risk Neuroblastoma Cell Lines. International Journal of Molecular Sciences, 2021, 22, 3664.	1.8	4
2421	Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an 18F-Labeled Analogue of the MDM2 Inhibitor SP-141. Pharmaceuticals, 2021, 14, 358.	1.7	2
2422	The Role of the Meiotic Component in Reproduction of B-RAF-Mutated Melanoma: A Review and "Brainstorming―Session. , 0, , .		2
2423	Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells—Relevance for Understanding (Germ Cell) Tumorigenesis. International Journal of Molecular Sciences, 2021, 22, 5377.	1.8	10
2424	Role of Dietary Antioxidants in p53-Mediated Cancer Chemoprevention and Tumor Suppression. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-18.	1.9	26
2425	Molecular and Clinical Characterization of Patients With Metastatic Castration Resistant Prostate Cancer Achieving Deep Responses to Bipolar Androgen Therapy. Clinical Genitourinary Cancer, 2022, 20, 97-101.	0.9	14
2426	Facile Formation of PAMAM Dendrimer Nanoclusters for Enhanced Gene Delivery and Cancer Gene Therapy. ACS Applied Bio Materials, 2021, 4, 7168-7175.	2.3	14
2427	Live cell, image-based high-throughput screen to quantitate p53 stabilization and viability in human papillomavirus positive cancer cells. Virology, 2021, 560, 96-109.	1.1	3
2428	De-dimerization of PTB is catalyzed by PDI and is involved in the regulation of p53 translation. Nucleic Acids Research, 2021, 49, 9342-9352.	6.5	4
2429	p53 mRNA Metabolism Links with the DNA Damage Response. Genes, 2021, 12, 1446.	1.0	13
2430	Protective effects of <i>Camellia sinensis</i> fruit and fruit peels against oxidative DNA damage. Journal of Applied Biological Chemistry, 2021, 64, 237-244.	0.2	O

#	Article	IF	CITATIONS
2431	From the Evasion of Degradation to Ubiquitin-Dependent Protein Stabilization. Cells, 2021, 10, 2374.	1.8	14
2432	Ganglioside GD2: a novel therapeutic target in tripleâ€negative breast cancer. Annals of the New York Academy of Sciences, 2022, 1508, 35-53.	1.8	15
2433	Tau Oligomers Neurotoxicity. Life, 2021, 11, 28.	1.1	42
2435	Flow cytometric analysis of p53 oncoprotein expression in cutaneous melanoma. British Journal of Surgery, 1997, 84, 803-807.	0.1	10
2436	Molecular mechanisms of human carcinogenesis. , 2006, , 321-349.		24
2437	Apoptosis in Hematopoiesis and Leukemogenesis. Blood Cell Biochemistry, 1996, , 151-201.	0.3	4
2438	The First Twenty-Five Years of p53 Research. , 2007, , 1-25.		6
2439	20 Years of DNA Damage Signaling to p53., 2007,, 53-71.		1
2440	Gatekeepers of the Guardian: p53 Regulation by Post-Translational Modification, MDM2 and MDMX. , 2007, , 73-113.		5
2441	Role of the p53 Family in Stabilizing the Genome and Preventing Polyploidization. Advances in Experimental Medicine and Biology, 2010, 676, 73-91.	0.8	22
2442	Regulation of Gene Expression by the Ubiquitin–Proteasome System and Implications for Neurological Disease. , 2011, , 281-315.		1
2443	Ubiquitin Family Members in the Regulation of the Tumor Suppressor p53. Sub-Cellular Biochemistry, 2010, 54, 116-135.	1.0	4
2444	Induction of p53 Protein as a Marker for Ionizing Radiation Exposure In Vivo., 1999,, 583-589.		1
2445	Molecular Genetics of Pancreatic Carcinoma. , 1998, , 3-20.		3
2446	Potential Regulators of Physiological Cell Death in the Corpus Luteum., 1997,, 161-181.		6
2447	The role of p53 in malignancy. Cancer Treatment and Research, 1996, 84, 113-137.	0.2	2
2448	Apoptosis and Cancer Chemotherapy. Cancer Treatment and Research, 1996, 87, 345-356.	0.2	20
2449	Atrazine potentiation of arsenic trioxide-induced cytotoxicity and gene expression in human liver carcinoma cells (HepG2)., 2001,, 49-59.		2

#	Article	IF	CITATIONS
2450	Biochemical and Molecular Mechanisms of Cisplatin Resistance. Cancer Treatment and Research, 2002, 112, 263-284.	0.2	48
2451	Regulation of cell cycle progression following DNA damage. , 1995, 1, 149-162.		11
2452	The PITSLRE protein kinase family. , 1995, 1, 329-338.		23
2453	Genotoxin-Induced Apoptosis: Implications for Carcinogenesis. , 1994, , 331-340.		4
2454	P53: A Determinant of the Cell Cycle Response to DNA Damage. Advances in Experimental Medicine and Biology, 1993, 339, 291-296.	0.8	16
2455	Mechanisms of resistance to alkylating agents. Cancer Treatment and Research, 1994, 73, 249-262.	0.2	9
2456	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Cyclooxygenases, and the Cell Cycle. Advances in Experimental Medicine and Biology, 1999, 470, 119-126.	0.8	14
2457	Complexity, Retinoid-Responsive Gene Networks, and Bladder Carcinogenesis. Advances in Experimental Medicine and Biology, 1999, 462, 449-467.	0.8	13
2458	Stress-responsive signal transduction: emerging concepts and biological significance., 1998,, 85-117.		2
2459	Osteosarcoma. Cancer Treatment and Research, 1997, 92, 215-251.	0.2	14
2460	DNA damage checkpoints: Implications for cancer therapy. , 1996, 2, 165-173.		46
2461	Cellular responses to antimetabolite anticancer agents: cytostasis versus cytotoxicity. , 1996, 2, 175-185.		9
2462	Mechanisms of Cisplatin Resistance and Its Reversal In Human Tumors. , 1995, , 225-264.		6
2463	Regulation of Apoptosis by the Transforming Gene Products of Adenovirus. , 1994, , 47-62.		7
2464	In Vitro Survival of Human Neoplastic Germ Cells. Advances in Experimental Medicine and Biology, 1998, 444, 59-66.	0.8	5
2465	The Human DNA-Activated Protein Kinase, DNA-PK: Substrate Specificity. , 1995, , 395-406.		8
2466	Transformation and Tumorigenesis Mediated by the Adenovirus E1A and E1B Oncogenes. Infectious Agents and Pathogenesis, 1995, , 195-225.	0.1	13
2467	Simian Virus 40 Large T Antigen Induces Chromosome Damage that Precedes and Coincides with Complete Neoplastic Transformation. Infectious Agents and Pathogenesis, 1995, , 15-26.	0.1	3

#	Article	IF	Citations
2468	Transformation by Polyomaviruses. Infectious Agents and Pathogenesis, 1995, , 27-50.	0.1	5
2469	Analyzing Cell Cycle Checkpoints in Response to Ionizing Radiation in Mammalian Cells. Methods in Molecular Biology, 2014, 1170, 313-320.	0.4	17
2470	The Role of Genomic Instability in the Development of Human Cancer. , 2002, , 115-142.		9
2471	Does Apoptosis Contribute to Tumor Cell Sensitivity to Anticancer Agents?., 1999, , 1-19.		4
2472	Thymineless Death., 1999,, 423-435.		2
2473	Targeted Senolytic Strategies Based on the Senescent Surfaceome. Healthy Ageing and Longevity, 2020, , 103-130.	0.2	3
2474	Genetic instability and tumor cell variation. , 1998, , 179-234.		1
2475	UV activation of mammalian stress protiens. , 1996, , 255-271.		17
2476	Signaling events controlling the molecular response to genotoxic stress. , 1996, 77, 273-288.		46
2477	Mammalian DNA repair responses and genomic instability. , 1996, 77, 289-305.		12
2478	The p53 Tumor Suppressor Gene: Structure, Function and Mechanism of Action. Results and Problems in Cell Differentiation, 1999, 23, 145-172.	0.2	9
2479	Radiation-Induced Cell Death and its Implications in Human Disease. Results and Problems in Cell Differentiation, 1998, 24, 213-232.	0.2	3
2480	p53. , 2010, , 345-357.		1
2481	Established and Novel Cdk/Cyclin Complexes Regulating the Cell Cycle and Development. Results and Problems in Cell Differentiation, 2011, 53, 365-389.	0.2	63
2482	Genomic Instability and Its Role in Neoplasia. Current Topics in Microbiology and Immunology, 1997, 221, 37-46.	0.7	43
2483	Apoptosis: molecular regulation of cell death. , 1996, , 19-44.		3
2484	Mutation and Expression of TP53 in Malignant Melanomas. Recent Results in Cancer Research, 1995, 139, 137-154.	1.8	38
2485	Fiber-Induced Hydroxyl Radical Formation and DNA Damage. , 1994, , 23-37.		2

#	ARTICLE	IF	CITATIONS
2486	Biologische Grundlagen der Strahlentherapie. , 1996, , 109-160.		3
2487	Cancer-Prone Hereditary Diseases Associated with Abnormalities of DNA Repair. Recent Results in Cancer Research, 1994, 136, 322-331.	1.8	4
2488	Wild-Type versus Mutant p53. Molecular Biology Intelligence Unit, 1995, , 19-54.	0.2	2
2489	Ceramide, a Mediator of Cytosine Arabinoside Induced Apoptosis. Molecular Biology Intelligence Unit, 1997, , 77-90.	0.2	1
2490	Chemical induced alterations in p53 signaling. Exs, 2009, 99, 181-208.	1.4	4
2492	The biology of radioresistance: similarities, differences and interactions with drug resistance. , 1994, , 325-345.		2
2493	Colonic Carcinoma: A Common Tumor with Multiple Genomic Abnormalities. , 1994, , 47-91.		3
2494	DNA Damage Response Pathways and Cancer. , 2008, , 139-152.		3
2495	Arsenite Genotoxicity May Be Mediated by Interference with DNA Damage-inducible Signaling. , 1999, , 233-241.		5
2496	Mechanisms of liver tumor promotion. , 1995, , 199-226.		13
2497	Gastric/GE Junction Cancer., 2012,, 903-933.		4
2498	Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases Journal of Biological Chemistry, 1994, 269, 9253-9260.	1.6	135
2499	G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently Journal of Biological Chemistry, 1993, 268, 8298-8308.	1.6	135
2500	The p53 tumor suppressor protein, a modulator of cell proliferation Journal of Biological Chemistry, 1992, 267, 15259-15262.	1.6	147
2503	Regulation of p73 by c-Abl through the p38 MAP kinase pathway. , 0, .		1
2504	MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts. , 0, .		1
2505	Alerting the immune system to DNA damage: micronuclei as mediators. Essays in Biochemistry, 2020, 64, 753-764.	2.1	19
2506	Expression of p53, bcl-2, and bax as predictors of response to radiotherapy in esophageal cancer. Ecological Management and Restoration, 2000, 13, 185-190.	0.2	8

#	Article	IF	CITATIONS
2507	DNA-Binding Activity of Wild-Type p53 Protein is Mediated by the Central Part of the Molecule and Controlled by Its C Terminus. Cancer Detection and Prevention, 1998, 22, 1-13.	2.1	14
2508	Immunohistochemical Prediction of Radiation Response and Local Control in Radiation Therapy for Cervical Cancer. Cancer Detection and Prevention, 1998, 22, 120-128.	2.1	13
2509	Association of p53, K-ras and Proliferating Cell Nuclear Antigen with Rat Lung Lesions Following Exposure to Simulated Nuclear Fuel Particles. Cancer Detection and Prevention, 1999, 23, 194-203.	2.1	4
2510	Differential requirement for p19ARF in the p53-dependent arrest induced by DNA damage, microtubule disruption, and ribonucleotide depletion. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 3266-71.	3.3	49
2511	Thermodynamic stability of wild-type and mutant p53 core domain. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 14338-14342.	3.3	369
2512	A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 14775-14780.	3.3	90
2513	Stabilization and activation of p53 are regulated independently by different phosphorylation events. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 2284-2289.	3.3	63
2514	A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity. Journal of Experimental Medicine, 1999, 190, 1375-1382.	4.2	564
2515	Mutation in the bimD gene of Aspergillus nidulans confers a conditional mitotic block and sensitivity to DNA damaging agents Genetics, 1993, 134, 1085-1096.	1.2	52
2516	Characterization of G1 checkpoint control in the yeast Saccharomyces cerevisiae following exposure to DNA-damaging agents Genetics, 1994, 138, 271-281.	1.2	144
2517	Modeling and measurement of signaling outcomes affecting decision making in noisy intracellular networks using machine learning methods. Integrative Biology (United Kingdom), 2020, 12, 122-138.	0.6	6
2518	Comparative Analysis of Histologic Homologues of Endometrial and Ovarian Carcinoma. American Journal of Surgical Pathology, 1998, 22, 319-326.	2.1	51
2519	The Treatment of Anaplastic Oligodendrogliomas and Mixed Gliomas. Neurosurgery, 1993, 32, 365???371.	0.6	7
2520	Prognostic Implications of p53 Overexpression in Supratentorial Astrocytic Tumors. Neurosurgery, 1994, 35, 831???838.	0.6	5
2521	Tumor Necrosis Factor-?? Induces p53-dependent Apoptosis in Rat Glioma Cells. Neurosurgery, 1995, 37, 758???763.	0.6	6
2522	DNA Damage Responses and Chemosensitivity in the EÂ-myc Mouse Lymphoma Model. Cold Spring Harbor Symposia on Quantitative Biology, 2000, 65, 499-510.	2.0	26
2523	The expression of retinoblastoma protein in epidermis is induced by ultraviolet B exposure. British Journal of Dermatology, 1996, 135, 406-411.	1.4	5
2524	Coexpression of p21Waf1/Cip1and p53 in sun-exposed normal epidermis, but not in neoplastic epidermis. British Journal of Dermatology, 1996, 135, 717-720.	1.4	14

#	ARTICLE	IF	CITATIONS
2525	Cell renewal, cell differentiation and programmed cell death (apoptosis) in pilomatrixoma. British Journal of Dermatology, 1997, 137, 714-720.	1.4	11
2526	Flow cytometric BrdUrd-pulse-chase study of X-ray-induced alterations in cell cycle progression. Cell Proliferation, 1996, 29, 43-57.	2.4	11
2527	IMMUNOHISTOCHEMICAL ANALYSIS OF p53 AND PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) IN BLADDER CANCER: POSITIVE IMMUNOSTAINING AND RADIOSENSITIVITY. International Journal of Urology, 1995, 2, 302-308.	0.5	18
2528	Human cytomegalovirus elevates levels of the cellular protein p53 in infected fibroblasts. Journal of Virology, 1994, 68, 8028-8034.	1.5	105
2529	An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with Cys/His sequence motifs. Journal of Virology, 1994, 68, 2521-2528.	1.5	487
2530	Inhibition of p53 DNA binding by human papillomavirus E6 proteins. Journal of Virology, 1994, 68, 4262-4273.	1.5	199
2531	The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. Journal of Virology, 1994, 68, 5698-5705.	1.5	186
2532	Cooperation of simian virus 40 large and small T antigens in metabolic stabilization of tumor suppressor p53 during cellular transformation. Journal of Virology, 1995, 69, 6115-6121.	1.5	45
2533	Adeno-associated virus vectors transduce primary cells much less efficiently than immortalized cells. Journal of Virology, 1995, 69, 1473-1479.	1.5	144
2534	Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. Journal of Virology, 1996, 70, 8653-8659.	1.5	233
2535	Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development?. Journal of Virology, 1996, 70, 2095-2100.	1.5	26
2536	BK virus large T antigen: interactions with the retinoblastoma family of tumor suppressor proteins and effects on cellular growth control. Journal of Virology, 1996, 70, 2378-2386.	1.5	110
2537	Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells. Journal of Virology, 1997, 71, 8149-8156.	1.5	30
2538	Assembly of complete, functionally active herpes simplex virus DNA replication compartments and recruitment of associated viral and cellular proteins in transient cotransfection assays. Journal of Virology, 1997, 71, 3146-3160.	1.5	60
2539	Perturbation of the p53 response by human papillomavirus type 16 E7. Journal of Virology, 1997, 71, 3710-3718.	1.5	47
2540	Simian virus 40 T antigen can regulate p53-mediated transcription independent of binding p53. Journal of Virology, 1997, 71, 5620-5623.	1.5	23
2541	Human cytomegalovirus IE2 86-kilodalton protein binds p53 but does not abrogate G1 checkpoint function. Journal of Virology, 1997, 71, 5861-5870.	1.5	78
2542	Adenovirus Type 12-Induced Fragility of the Human <i>RNU2</i> Locus Requires p53 Function. Journal of Virology, 1998, 72, 4183-4191.	1.5	19

#	Article	IF	CITATIONS
2543	p53 Protein Is a Suppressor of Papillomavirus DNA Amplificational Replication. Journal of Virology, 1998, 72, 6822-6831.	1.5	39
2544	Simian Virus 40 Large T Antigen J Domain and Rb-Binding Motif Are Sufficient To Block Apoptosis Induced by Growth Factor Withdrawal in a Neural Stem Cell Line. Journal of Virology, 1999, 73, 6791-6799.	1.5	30
2545	The E7 Oncoprotein of Human Papillomavirus Type 16 Stabilizes p53 through a Mechanism Independent of p19 <sup>ARF</sup> . Journal of Virology, 1999, 73, 7590-7598.	1.5	60
2546	Identification of a Minimal Transforming Domain of p53: Negative Dominance through Abrogation of Sequence-Specific DNA Binding. Molecular and Cellular Biology, 1992, 12, 5581-5592.	1.1	192
2547	The Ionizing Radiation-Induced Replication Protein A Phosphorylation Response Differs between Ataxia Telangiectasia and Normal Human Cells. Molecular and Cellular Biology, 1993, 13, 7222-7231.	1.1	88
2548	Complementation by Wild-Type p53 of Interleukin-6 Effects on M1 Cells: Induction of Cell Cycle Exit and Cooperativity with c- <i>myc</i> Suppression. Molecular and Cellular Biology, 1993, 13, 7942-7952.	1.1	50
2549	p53-mediated cell death: relationship to cell cycle control. Molecular and Cellular Biology, 1993, 13, 1415-1423.	1.1	126
2550	Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. Molecular and Cellular Biology, 1993, 13, 1456-1463.	1.1	72
2551	Mapping of the p53 and mdm-2 Interaction Domains. Molecular and Cellular Biology, 1993, 13, 4107-4114.	1.1	340
2552	Induction of Cellular p53 Activity by DNA-Damaging Agents and Growth Arrest. Molecular and Cellular Biology, 1993, 13, 4242-4250.	1.1	143
2553	Transactivation of the Human p53 Tumor Suppressor Gene by c-Myc/Max Contributes to Elevated Mutant p53 Expression in Some Tumors. Molecular and Cellular Biology, 1994, 14, 7805-7815.	1.1	40
2554	Endogenous p53 Protein Generated from Wild-Type Alternatively Spliced p53 RNA in Mouse Epidermal Cells. Molecular and Cellular Biology, 1994, 14, 1698-1708.	1.1	36
2555	DNA Strand Breaks: the DNA Template Alterations That Trigger p53-Dependent DNA Damage Response Pathways. Molecular and Cellular Biology, 1994, 14, 1815-1823.	1.1	268
2556	Radiation Effects on DNA Synthesis in a Defined Chromosomal Replicon. Molecular and Cellular Biology, 1994, 14, 1901-1908.	1.1	28
2557	Induction Versus Progression of Brain Tumor Development: Differential Functions for the pRB- and p53-Targeting Domains of Simian Virus 40 T Antigen. Molecular and Cellular Biology, 1994, 14, 2686-2698.	1.1	47
2558	Hypoxia Induces Accumulation of p53 Protein, but Activation of a G <sub>1</sub> -Phase Checkpoint by Low-Oxygen Conditions Is Independent of p53 Status. Molecular and Cellular Biology, 1994, 14, 6264-6277.	1.1	210
2559	The tumor suppressor p53 can reduce stable transfection in the presence of irradiation. , 1999, 6, 285.		1
2560	Cellular Radiosensitivity, Radioresistant DNA Synthesis, and Defect in Radioinduction of p <a href="mailto:sup">sup</a> > 53/sup> in Fibroblasts From Atherosclerosis Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 947-953.	1.1	11

#	Article	IF	CITATIONS
2561	p53 expression during normal tissue regeneration in response to acute cutaneous injury in swine Journal of Clinical Investigation, 1994, 93, 2206-2214.	3.9	66
2562	Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells Journal of Clinical Investigation, 1995, 95, 973-979.	3.9	111
2563	Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma Journal of Clinical Investigation, 1995, 95, 1606-1611.	3.9	182
2564	p53-dependent ceramide response to genotoxic stress Journal of Clinical Investigation, 1998, 102, 329-339.	3.9	148
2565	Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death Journal of Clinical Investigation, 1995, 96, 1874-1886.	3.9	65
2566	Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53 Journal of Clinical Investigation, 1997, 99, 403-413.	3.9	653
2567	Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure Journal of Clinical Investigation, 1998, 101, 777-782.	3.9	248
2568	Reducing radiation-induced gastrointestinal toxicity â€" the role of the PHD/HIF axis. Journal of Clinical Investigation, 2016, 126, 3708-3715.	3.9	44
2569	Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. Journal of Clinical Investigation, 2000, 105, 533-539.	3.9	90
2570	Measurement of Spontaneous and Therapeutic Agent-Induced Apoptosis With BCL-2 Protein Expression in Acute Myeloid Leukemia. Blood, 1997, 89, 243-255.	0.6	5
2571	Thrombopoietin Upregulates the Promoter Conformation of p53 in a Proliferation-Independent Manner Coincident With a Decreased Expression of Bax: Potential Mechanisms for Survival Enhancing Effects. Blood, 1997, 90, 4394-4402.	0.6	1
2572	The Fanconi Anemia Polypeptide, FAC, Binds to the Cyclin-Dependent Kinase, cdc2. Blood, 1997, 90, 1047-1054.	0.6	2
2573	CBFÎ <sup>2</sup> -SMMHC, Expressed in M4eo Acute Myeloid Leukemia, Reduces p53 Induction and Slows Apoptosis in Hematopoietic Cells Exposed to DNA-Damaging Agents. Blood, 1998, 92, 4344-4352.	0.6	6
2574	Modulation of Cell Signal Transduction by Tea and Ginger. Oxidative Stress and Disease, 2008, , .	0.3	1
2575	CD44-dependent lymphoma cell dissemination: a cell surface CD44 variant, rather than standard CD44, supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes. Journal of Cell Science, 2001, 114, 3463-3477.	1.2	40
2576	Relation between expression pattern of p53 and survivin in cutaneous basal cell carcinomas. Medical Science Monitor, 2011, 17, BR74-BR80.	0.5	15
2577	Feedbacks, Bifurcations, and Cell Fate Decision-Making in the p53 System. PLoS Computational Biology, 2016, 12, e1004787.	1.5	46
2578	Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic Agents. PLoS ONE, 2010, 5, e12996.	1.1	77

#	ARTICLE	IF	Citations
2579	Endogenous Human MDM2-C Is Highly Expressed in Human Cancers and Functions as a p53-Independent Growth Activator. PLoS ONE, 2013, 8, e77643.	1.1	23
2580	Structure of a Stapled Peptide Antagonist Bound to Nutlin-Resistant Mdm2. PLoS ONE, 2014, 9, e104914.	1.1	33
2581	Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair. PLoS ONE, 2016, 11, e0146968.	1.1	21
2582	A Temperature Sensitive Variant of p53 Drives p53-Dependent MicroRNA Expression without Evidence of Widespread Post-Transcriptional Gene Silencing. PLoS ONE, 2016, 11, e0148529.	1.1	9
2583	Role of RUNX Family Transcription Factors in DNA Damage Response. Molecules and Cells, 2020, 43, 99-106.	1.0	24
2584	The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer. Endocrine-Related Cancer, 2018, 25, R663-R685.	1.6	57
2585	P53-Dependent UVB Responsiveness of Human Keratinocytes Can Be Altered by Cultivation on Cell Cycle-arrested Dermal Fibroblasts. Photochemistry and Photobiology, 2000, 71, 321.	1.3	8
2586	The Contribution of Calpains in the Down-regulation of Mdm2 and p53 Proteolysis in Reconstructed Human Epidermis in Response to Solar Irradiation¶. Photochemistry and Photobiology, 2005, 81, 975.	1.3	7
2587	From yeast to humans: Understanding the biology of DNA Damage Response (DDR) kinases. Genetics and Molecular Biology, 2020, 43, e20190071.	0.6	13
2588	P53 and Rb tumor suppressor gene alterations in gastric cancer. Revista Do Hospital Das Clinicas, 2004, 59, 172-180.	0.5	15
2589	Epidermal growth factor receptor activity is elevated in glioma cancer stem cells and is required to maintain chemotherapy and radiation resistance. Oncotarget, 2017, 8, 72494-72512.	0.8	27
2590	Potential therapeutic targets of <i>TP53</i> gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. Oncotarget, 2018, 9, 16234-16247.	0.8	24
2591	Inhibition of RAC1 GTPase sensitizes pancreatic cancer cells to $\hat{I}^3$ -irradiation. Oncotarget, 2014, 5, 10251-10270.	0.8	34
2592	The induction of the p53 tumor suppressor protein bridges the apoptotic and autophagic signaling pathways to regulate cell death in prostate cancer cells. Oncotarget, 2014, 5, 10678-10691.	0.8	36
2593	Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors. Oncotarget, 2015, 6, 32339-32352.	0.8	10
2594	Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides. Oncotarget, 2016, 7, 32232-32246.	0.8	15
2595	P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy. Oncotarget, 2013, 4, 705-714.	0.8	96
2596	Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis. Translational Cancer Research, 2016, 5, 707-724.	0.4	44

#	Article	IF	Citations
2597	Cell Survival Signaling in Neuroblastoma. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 563-575.	0.9	29
2598	The Calotropis Gigantea Methanolic Extract Induces Apoptosis in Human Breast Carcinoma Cells. Iranian Journal of Medical Sciences, 2019, 44, 483-492.	0.3	4
2599	Loss of Heterozygosity at 1p, 7q, 17p, and 22q in Meningiomas. Journal of Korean Neurosurgical Society, 2010, 48, 14.	0.5	6
2600	Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India. World Journal of Gastroenterology, 2009, 15, 1381.	1.4	22
2601	Co-mutation of p53, <i>K-ras </i> genes and accumulation of p53 protein and its correlation to clinicopathological features in rectal cancer. World Journal of Gastroenterology, 2004, 10, 3688.	1.4	23
2602	Mutations of p53 gene exons 4-8 in human esophageal cancer. World Journal of Gastroenterology, 2005, 11, 2998.	1.4	10
2603	Magnifying chromoendoscopy combined with immunohistochemical staining for early diagnosis of gastric cancer. World Journal of Gastroenterology, 2013, 19, 404.	1.4	7
2604	Apoptosis and its relationship with cell proliferation, p53, Waf1p21, bcl-2 and c-myc in esophageal carcinogenesis studied with a high-risk population in northern China. World Journal of Gastroenterology, 1998, 4, 287.	1.4	31
2605	<i> Helicobacter pylori (i) infection generated gastric cancer through p53-Rb tumor-suppressor system mutation and telomerase reactivation. World Journal of Gastroenterology, 2003, 9, 54.</i>	1.4	51
2606	Mechanism and its regulation of tumor-induced angiogenesis. World Journal of Gastroenterology, 2003, 9, 1144.	1.4	243
2607	Protective and inhibitory effects of acteoside from Abeliophyllum distichum Nakai against oxidative DNA damage. Molecular Medicine Reports, 2020, 22, 2076-2084.	1.1	12
2608	The relationship between cisplatin - induced apoptosis and p53 , bcl - 2 and bax expression in human lung cancer cells. Korean Journal of Internal Medicine, 1999, 14, 42-52.	0.7	30
2609	Prognostic Significance of Immunohistochemical Expression of p53 and Retinoblastoma Gene Protein (pRB) in Curatively Resected Gastric Cancer. Korean Journal of Internal Medicine, 2005, 20, 1.	0.7	6
2610	Reduced P53 staining in actinic keratosis is associated with squamous cell carcinoma: A preliminary study. Indian Journal of Dermatology, 2013, 58, 325.	0.1	15
2611	Oral verrucous hyperplasia versus oral verrucous carcinoma: A clinicopathologic dilemma revisited using p53 as immunohistochemical marker. Journal of Oral and Maxillofacial Pathology, 2016, 20, 362.	0.3	12
2612	Activity of p53 in human amniotic fluid stem cells increases their potentiality as a candidate for stem cell therapy. Brain Circulation, 2019, 5, 134.	0.7	2
2613	Chemoprevention of rat liver toxicity and carcinogenesis by Spirulina. International Journal of Biological Sciences, 2009, 5, 377-387.	2.6	88
2614	Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance. ELife, 2020, 9, .	2.8	36

#	Article	IF	CITATIONS
2615	Expression of p53, p63, podoplanin and Ki-67 in recurring versus non-recurring oral leukoplakia. Scientific Reports, 2021, 11, 20781.	1.6	4
2616	Pharmacology, Toxicology, and Metabolism of Sennoside A, A Medicinal Plant-Derived Natural Compound. Frontiers in Pharmacology, 2021, 12, 714586.	1.6	18
2617	Pharmacological Gene Therapy for Experimental Brain Tumors. , 2000, , 303-314.		0
2618	Relationship between p53, p21 and Apoptosis in Colorectal Cancer Japanese Journal of Gastroenterological Surgery, 2000, 33, 1751-1757.	0.0	0
2619	Pulmonary Malignancies: Pathophysiology and Treatment., 2001,, 406-432.		0
2620	Cancer Cell Properties., 2001,, 1161-1170.		O
2621	Inactivation of Negative Growth Regulators During Neoplastic Transformation., 2002,, 81-111.		2
2623	p53 and Its Targets. , 2002, , 77-96.		0
2624	Pankreaskarzinom., 2002,, 187-206.		0
2626	Molecular basis for development of gastric cancer -in vivo and in vitro studies. Keio Journal of Medicine, 2002, 51, 57-62.	0.5	O
2627	Zellbiologische Grundlagen. , 2002, , 3-30.		0
2628	Epithelial cell cycling predicts p53 responsiveness to $\hat{i}^3$ -irradiation during post-natal mammary gland development. Development (Cambridge), 2002, 129, 2997-3008.	1.2	17
2630	Zellzyklus und Apoptose., 2003,, 130-184.		2
2632	Apoptosis and Cancer. , 2003, , 177-199.		O
2633	Preoperative Staging of Prostate Cancer: The Role of Molecular Markers. , 2003, , 91-100.		0
2634	Signal Transduction and Apoptosis Pathways as Therapeutic Targets. Progress in Molecular and Subcellular Biology, 2004, 36, 307-323.	0.9	0
2635	Effects of Ionising Radiation in the Low-Dose Range â€" Radiobiological Basis. , 2004, , 37-81.		0
2636	Light-Induced Dermal Toxicity. , 2004, , 1105-1177.		1

#	Article	IF	CITATIONS
2639	Substanzklassen und Wirkmechanismen. , 2006, , 1437-1454.		1
2640	TP53 Mutation and Li-Fraumeni Syndrome. , 2007, , 251-261.		1
2642	Expressão do p53 no carcinoma epidermóide do lábio. Revista Do Colegio Brasileiro De Cirurgioes, 2007, 34, 92-97.	0.3	0
2643	<i>Drosophila</i> Telomere Elongation. Novartis Foundation Symposium, 1997, 211, 53-75.	1.2	10
2645	TGFÎ <sup>2</sup> : Roles in DNA Damage Responses. , 2008, , 321-333.		0
2646	Molecular Genetics of Lung and Pleural Neoplasms. , 2008, , 47-157.		2
2647	Roles of Mutation and Epimutation in the Development of Lung Disease. Molecular Pathology Library, 2008, , 53-61.	0.1	0
2648	Radiation Induced DNA Damage Checkpoints. , 2008, , 267-284.		0
2650	Mouse Models of DNA Double Strand Break Repair Deficiency and Cancer., 2009,, 285-305.		0
2651	TP53 Mutation and Li-Fraumeni Syndrome. , 2009, , 247-257.		0
2652	TP53 Mutation and Li-Fraumeni Syndrome. , 2009, , 85-96.		0
2653	Cell Cycle Regulation and DNA Damage. , 2009, , 81-107.		0
2654	Molecular Basis of Human Malignancy. , 2009, , 41-55.		1
2655	Short Introduction to the Cell Cycle. , 2010, , 3-14.		1
2657	The p53 Master Regulator and Rules of Engagement with Target Sequences. , 2010, , 2205-2216.		0
2658	Radiobiologic Principles. , 2010, , 3-30.		0
2659	Human Papillomaviruses., 2010,, 207-252.		0
2661	Apoptosis In Vivo. , 2011, , 625-640.		1

#	Article	IF	CITATIONS
2663	Tumor Markers. , 2012, , 617-667.		1
2664	CARF Regulates Cellular Senescence and Apoptosis through p53-Dependent and -Independent Pathways. , 2013, , 137-157.		O
2665	DNA Damage Response Pathways and Cancer. , 2014, , 142-153.e3.		2
2666	Cancer of the Stomach and Gastroesophageal Junction. , 2014, , 1240-1270.e7.		1
2667	Colonic cancer. , 2014, , 49-68.		0
2668	Cell Loss in Irradiated Tumours. Medical Radiology, 1993, , 129-145.	0.0	0
2669	The Relationship between Thermosensitivity of the Cell and Cancer-Related Genes Thermal Medicine(Japanese Journal of Hyperthermic Oncology), 1993, 9, 250-266.	0.4	0
2670	Tumour suppressor genes and molecular chaperones. , 1993, , 113-117.		0
2671	The Impact of Molecular Genetics on Cancer Research. , 1993, , 3-13.		0
2672	Ataxia-Telangiectasia: Defective in a P53-Dependent Signal Transduction Pathway. , 1993, , 163-173.		O
2673	Biochemical Defects in Ataxia-Telangiectasia. , 1993, , 235-255.		4
2674	Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiation in vitro. , 1994, , 265-288.		1
2675	Apoptosis and Cancer Therapy. , 1994, , 71-85.		3
2676	Molecular Controls of Cell Cycle Progression Following DNA Damage: Roles of P53 and Ataxia-Telangiectasia Gene Products. , 1994, , 117-135.		0
2677	Wenn ein Gen fehlt — Die Rolle der Tumorsuppressorgene bei der Krebsentstehung. Heidelberger Jahrbucher, 1994, , 99-120.	0.2	0
2678	The Two Amino Terminal Transforming Functions of the SV40 Large T-Antigen are Required to Overcome P53 Mediated Growth Arrest. , 1994, , 311-317.		0
2679	The Antibody Response Against P53 in Cancer Patients. , 1994, , 1-7.		0
2681	Loss of p53 Protein During Radiation Transformation of Primary Human Mammary Epithelial Cells. Molecular and Cellular Biology, 1994, 14, 2468-2478.	1.1	26

#	Article	IF	CITATIONS
2682	The Novel Primary Response Gene <i>MyD118</i> and the Proto-Oncogenes <i>myb</i> , <i>myc</i> , and <i>bcl-2</i> Modulate Transforming Growth Factor $\hat{I}^21$ -induced Apoptosis of Myeloid Leukemia Cells. Molecular and Cellular Biology, 1994, 14, 2352-2360.	1.1	68
2683	Apoptosis in Erythroid Progenitors Deprived of Erythropoietin Occurs during the G <sub>1</sub> and S Phases of the Cell Cycle without Growth Arrest or Stabilization of Wild-Type p53. Molecular and Cellular Biology, 1994, 14, 4183-4192.	1.1	27
2684	Lessons from developmental biology. Cancer Biology and Medicine, 1995, , 85-97.	0.1	0
2685	Life, death and genomic change in perturbed cell cycles. , 1995, , 75-81.		3
2686	Hyperthermic sensitivity of cancer cells Thermal Medicine(Japanese Journal of Hyperthermic) Tj ETQq0 0 0 rgBT	/Oyerlock :	10 <sub>0</sub> Tf 50 582
2687	Modulation of Apoptosis by Oncogenes. , 1995, , 103-122.		0
2688	Genetic Alterations in Colon Cancer. , 1995, , 139-189.		0
2689	Oncogenes in Renal Cell Carcinoma. , 1995, , 26-32.		1
2690	Biophysical and Biochemical Properties of the p53 Protein. Molecular Biology Intelligence Unit, 1995, , 55-72.	0.2	0
2691	Lymphocyte Death, p53, and the Problem of the "Undead―Cell. Current Topics in Microbiology and Immunology, 1995, 200, 123-135.	0.7	3
2692	The role of the p53 protein in the apoptotic response., 1995,, 41-44.		1
2693	Insights from transgenic mice regarding the role of bcl-2 in normal and neoplastic lymphoid cells. , 1995, , 53-59.		0
2694	Regulation and Modulation of the Function of p53. Molecular Biology Intelligence Unit, 1995, , 73-112.	0.2	0
2695	P53-Mediated Apoptosis. , 1996, , 83-101.		1
2696	Alterations in Cell Cycle Control During Tumor Progression: Effects on Apoptosis and the Response to Therapeutic Agents. Current Topics in Microbiology and Immunology, 1996, 213 ( Pt 2), 197-213.	0.7	3
2697	The Molecular Basis of Ovarian Cell Death. , 1996, , 37-50.		2
2698	Prognostic significance of p53 expression and growth fraction in surgically resected non-small cell lung cancer The Journal of the Japanese Association for Chest Surgery, 1996, 10, 23-30.	0.0	0
2699	ç°èfžå"期è³;節ã®ç•°å¸ã«é–¢ä¸Žã™ã,∢p 53, p21WAF1, Proliferating cell nuclear antigenã•ã,‰ãӻãŸå§è,癌	Ēã®ç™ºç"Ÿ O:O	¦ãƒ»é€²å±∙.N

#	Article	IF	CITATIONS
2700	The Use of Isolated Hepatocytes from Rats with Enzyme-altered Foci: Studies of p53 Expression. ATLA Alternatives To Laboratory Animals, 1996, 24, 393-397.	0.7	3
2701	Cell Cycle Control of Genetic Stability. , 1997, , 33-52.		0
2702	Neoplastic Progression in Barrett's Esophagus. , 1997, , 195-214.		0
2703	Radiation-Induced Responses in Mammalian Cells. , 1997, , 185-219.		4
2704	Medical Background: Human DNA Damage Recognition and Processing Disorders. Molecular Biology Intelligence Unit, 1997, , 1-30.	0.2	0
2706	p53-Dependent Signaling in Response to DNA Damage or Arrest of DNA Synthesis and its Role in Cell Cycle Control. , 1997, , 69-81.		0
2707	Relationship between apoptosis and p53 protein expression in squamous cell carcinoma of the esophagus. Annals of Cancer Research and Therapy, 1997, 5, 91-94.	0.1	0
2708	UVB Irradiation, Mismatch Repair and Cutaneous Melanoma. , 1997, , 727-737.		0
2710	Analysis of cell cycle check point and apoptosis induction in Ataxia Telangiectasia. Juntendoì,, Igaku, 1998, 44, 167-179.	0.1	0
2711	The p53 Tumor Suppressor Gene in Lung Cancer: From Molecular to Serological Diagnosis. , 1998, , 221-230.		0
2712	The molecular genetics of colonic cancer. Cancer Treatment and Research, 1998, 98, 351-382.	0.2	1
2713	Poly(ADP-Ribose) Polymerase in Response to DNA Damage. , 1998, , 487-515.		1
2714	The role of p53 in apoptosis., 1998,, 5-35.		2
2715	Experimental and Clinical Gene Therapies for Brain Tumors. , 1998, , 191-203.		3
2716	Mammalian Cell-Cycle Responses to DNA-Damaging Agents. , 1998, , 465-486.		1
2717	Transcriptional Responses to Damage Created by Ionizing Radiation. , 1998, , 223-262.		0
2718	Promoters for Expression of Gene Products within Neurons and Glia. , 1998, , 121-146.		0
2719	Potential Applications of Cell Cycle Manipulation to Clinical Response. Cancer Treatment and Research, 1998, 93, 169-190.	0.2	2

#	Article	IF	CITATIONS
2720	Function of the p53 Gene Family. , 1999, , 53-68.		0
2721	Analysis of bcl-2, p53 Expression and Apoptosis During Colorectal Carcinogenesis Nihon Daicho Komonbyo Gakkai Zasshi, 1999, 52, 387-393.	0.1	o
2722	Cell Cycle and Apoptosis., 1999,, 131-169.		0
2723	Pentoxifylline Inhibits the Irradiation Induced G2/M Block and Alters DNA Synthesis in P53 Mutant and Repair Deficient Cells., 1999,, 305-310.		0
2725	Genesis and Progression of Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. , 1999, , 203-212.		0
2726	Protein kinase CK2-dependent regulation of p53 function: Evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable., 1999,, 187-199.		16
2727	Activation of p53 Protein Function in Response to Cellular Irradiation. , 1999, , 591-598.		0
2728	Protein Expression and Brain Plasticity After Transient Middle Cerebral Artery Occlusion in the Rat. , 1999, , 193-202.		1
2729	Function of poly(ADP-ribose) polymerase in response to DNA damage: Gene-disruption study in mice. , 1999, , 149-152.		42
2731	Progress in the Molecular Medicine of Cancer. , 0, , 129-152.		0
2733	Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death. Oncotarget, 2015, 6, 34573-34591.	0.8	3
2735	Immunohistochemical Expression of Human Epidermal Growth Factor Receptor 2 (HER2) and p53 in Gastric Adenocarcinoma: A Pilot Study from North India. Journal of Clinical and Diagnostic Research JCDR, 2017, 11, EC43-EC45.	0.8	1
2736	A novel isolation method for cancer prognostic factors via the p53 pathway by a combination of in vitro and in silico analyses. Oncoscience, 2018, 5, 88-98.	0.9	0
2742	CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies. Cancer Research, 2022, 82, 36-45.	0.4	19
2743	MDM2 and MDMX Regulators of p53 Activity. , 2005, , 155-185.		0
2745	Apoptosis in the Development and Treatment of Laryngeal Cancer: Role of p53, Bcl-2 and Clusterin. , 2009, , 237-249.		0
2746	Overview of Senescence., 2007,, 145-157.		0
2768	Chk2/hCds1 functions as a DNA damage checkpoint in $G(1)$ by stabilizing p53. Genes and Development, 2000, 14, 278-88.	2.7	597

#	Article	IF	CITATIONS
2769	Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells. EMBO Journal, 1995, 14, 6148-56.	<b>3.</b> 5	203
2770	Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. EMBO Journal, 1995, 14, 6184-92.	3.5	34
2771	Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO Journal, 1994, 13, 1368-74.	<b>3.</b> 5	64
2772	A developmental checkpoint couples the initiation of sporulation to DNA replication in Bacillus subtilis. EMBO Journal, 1994, 13, 1566-73.	3.5	25
2773	Programmed cell death and Bcl-2 protection in the absence of a nucleus. EMBO Journal, 1994, 13, 1899-910.	3.5	133
2774	UV light-induced DNA synthesis arrest in HeLa cells is associated with changes in phosphorylation of human single-stranded DNA-binding protein. EMBO Journal, 1994, 13, 2114-23.	3.5	77
2775	A temperature-sensitive mutant of human p53. EMBO Journal, 1994, 13, 2535-44.	<b>3.</b> 5	51
2776	Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO Journal, 1994, 13, 4816-22.	<b>3.</b> 5	159
2777	Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells. EMBO Journal, 1994, 13, 4823-30.	<b>3.</b> 5	20
2778	Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein. EMBO Journal, 1994, 13, 5393-400.	3.5	19
2779	Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. EMBO Journal, 1995, 14, 1382-91.	3.5	42
2780	Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression. EMBO Journal, 1995, 14, 1392-401.	3.5	43
2781	mdm2 expression is induced by wild type p53 activity. EMBO Journal, 1993, 12, 461-8.	3.5	516
2782	Sequence-specific DNA binding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes. EMBO Journal, 1993, 12, 2799-808.	3.5	64
2783	Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO Journal, 1993, 12, 5057-64.	3.5	87
2784	Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO Journal, 1996, 15, 1615-24.	3.5	59
2785	p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO Journal, 1996, 15, 1992-2002.	3.5	117
2786	Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO Journal, 1996, 15, 827-38.	3.5	118

#	Article	IF	CITATIONS
2787	Translational regulation of human p53 gene expression. EMBO Journal, 1996, 15, 4392-401.	3.5	64
2788	Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. EMBO Journal, 1996, 15, 6178-88.	3.5	122
2791	Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochemical Journal, 2000, 352 Pt 1, 1-17.	1.7	30
2792	Transgenic models of retinoblastoma: what they tell us about its cause and treatment. Transactions of the American Ophthalmological Society, 1994, 92, 385-400; discussion 400-1.	1.4	14
2793	Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. Journal of Medical Genetics, 1999, 36, 610-4.	1.5	98
2794	Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma. American Journal of Pathology, 1997, 151, 461-70.	1.9	28
2795	The potential role of BAX and BCL-2 expression in diffuse alveolar damage. American Journal of Pathology, 1997, 151, 999-1007.	1.9	74
2796	Differentiation-dependent p53 regulation of nucleotide excision repair in keratinocytes. American Journal of Pathology, 1997, 150, 1457-64.	1.9	51
2797	Decreased DNA repair but normal apoptosis in ultraviolet-irradiated skin of p53-transgenic mice. American Journal of Pathology, 1996, 148, 1113-23.	1.9	86
2798	Molecular diagnosis of p53 mutations in gastric carcinoma by touch preparation. American Journal of Pathology, 1996, 148, 405-13.	1.9	12
2799	Association of p53 and WAF1 expression with apoptosis in diffuse alveolar damage. American Journal of Pathology, 1996, 149, 531-8.	1.9	61
2800	Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. American Journal of Pathology, 1995, 147, 545-60.	1.9	344
2801	Characterization of human aortic smooth muscle cells expressing HPV16 E6 and E7 open reading frames. American Journal of Pathology, 1995, 147, 753-62.	1.9	10
2802	Effect of vitamin A deficiency on the integrity of hepatocytes after partial hepatectomy. American Journal of Pathology, 1995, 147, 699-706.	1.9	15
2803	p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. American Journal of Pathology, 1995, 147, 884-8.	1.9	87
2804	p53 gene mutations and MDM2 amplification are uncommon in primary carcinomas of the uterine cervix. American Journal of Pathology, 1993, 143, 1398-405.	1.9	48
2805	High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. American Journal of Pathology, 1993, 143, 845-56.	1.9	76
2806	Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. American Journal of Pathology, 1994, 145, 1291-5.	1.9	87

#	ARTICLE	IF	CITATIONS
2807	The interaction of taxol and vinblastine with radiation induction of p53 and p21 WAF1/CIP1. The British Journal of Cancer Supplement, 1996, 27, S82-5.	0.1	5
2808	Nitric oxide involvement in the toxicity of hydroxyguanidine in leukaemia HL60 cells. The British Journal of Cancer Supplement, 1996, 27, S172-6.	0.1	0
2809	Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. Molecular Medicine, 1997, 3, 441-51.	1.9	67
2810	Transcription abnormalities potentiate apoptosis of normal human fibroblasts. Molecular Medicine, 1997, 3, 852-63.	1.9	29
2813	Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations. Oncogene, 1996, 12, 2267-78.	2.6	49
2814	Copper-Induced Cytotoxicity and Transcriptional Activation of Stress Genes in Human Liver Carcinoma (HepG(2)) Cells. Me, 2008, 10, 285-290.	1.0	15
2815	Unbalanced replication as a major source of genetic instability in cancer cells. American Journal of Blood Research, 2012, 2, 160-9.	0.6	7
2816	Role of p53 in Anticancer Drug Treatment- and Radiation-Induced Injury in Normal Small Intestine. Cancer Biology and Medicine, 2012, 9, 1-8.	1.4	21
2818	Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53. International Journal of Clinical and Experimental Pathology, 2014, 7, 552-64.	0.5	31
2820	Therapeutic Potential of Arsenic Trioxide (ATO) in Treatment of Hepatocellular Carcinoma: Role of Oxidative Stress in ATO-Induced Apoptosis. Annals of Clinical Pathology, 2017, 5, .	0.5	7
2821	p53-dependent activation of the mouse MCK gene promoter: identification of a novel p53-responsive sequence and evidence for cooperation between distinct p53 binding sites. Gene Expression, 1995, 5, 19-33.	0.5	6
2822	Differential upregulation of p53-responsive genes by genotoxic stress in hematopoietic cells containing wild-type and mutant p53. Gene Expression, 1999, 8, 197-206.	0.5	11
2823	P53 Immunoexpression in Laryngeal Squamous Cell Carcinoma. Current Health Sciences Journal, 2017, 43, 325-329.	0.2	0
2825	Heterogeneous genomic aberrations in esophageal squamous cell carcinoma: a review. American Journal of Translational Research (discontinued), 2020, 12, 1553-1568.	0.0	5
2826	TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing. Cancer Genomics and Proteomics, 2016, 13, 231-8.	1.0	14
2827	Cell cycle and cancer. , 2000, 2, 12-22.		3
2828	Oncogene or Tumor Suppressor: The Coordinative Role of Lysine Methyltransferase SET7/9 in Cancer Development and the Related Mechanisms. Journal of Cancer, 2022, 13, 623-640.	1.2	9
2829	Advances in the Current Understanding of How Low-Dose Radiation Affects the Cell Cycle. Cells, 2022, 11, 356.	1.8	16

#	Article	IF	Citations
2830	Protein kinase CK2-dependent regulation of p53 function: evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable. Molecular and Cellular Biochemistry, 1999, 191, 187-99.	1.4	22
2831	Function of poly(ADP-ribose) polymerase in response to DNA damage: gene-disruption study in mice. Molecular and Cellular Biochemistry, 1999, 193, 149-52.	1.4	39
2832	Atrazine potentiation of arsenic trioxide-induced cytotoxicity and gene expression in human liver carcinoma cells (HepG2). Molecular and Cellular Biochemistry, 2001, 222, 49-59.	1.4	13
2833	The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy. Cancers, 2022, 14, 1143.	1.7	23
2834	Timeâ€series transcriptomics and proteomics reveal alternative modes to decode p53 oscillations. Molecular Systems Biology, 2022, 18, e10588.	3.2	16
2835	Towards a Molecular Classification of Sinonasal Carcinomas: Clinical Implications and Opportunities. Cancers, 2022, 14, 1463.	1.7	17
2836	Stochastic Sensors for the Enantioselective Determination of Serine in Blood for the Early Diagnosis of Breast Cancer. Analytical Letters, 0, , 1-8.	1.0	1
2837	Cell Signaling Pathways That Promote Radioresistance of Cancer Cells. Diagnostics, 2022, 12, 656.	1.3	25
2838	The Role of Lysine Methyltransferase SET7/9 in Proliferation and Cell Stress Response. Life, 2022, 12, 362.	1.1	6
2840	Detailed chromosome analysis of wild-type, immortalized fibroblasts with SV40T, E6E7, combinational introduction of cyclin dependent kinase 4, cyclin D1, telomerase reverse transcriptase. In Vitro Cellular and Developmental Biology - Animal, 2021, 57, 998-1005.	0.7	6
2841	Therapeutic Targeting of Exportin-1 in Childhood Cancer. Cancers, 2021, 13, 6161.	1.7	3
2842	The First Twenty-Five Years of p53 Research. , 2007, , 1-25.		0
2843	20 Years of DNA Damage Signaling to p53., 2007,, 53-71.		0
2844	Gatekeepers of the Guardian: p53 Regulation by Post-Translational Modification, MDM2 and MDMX. , 2007, , 73-113.		0
2857	Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death. International Journal of Molecular Sciences, 2022, 23, 5005.	1.8	38
2858	Targeting Ribosome Biogenesis in Cancer: Lessons Learned and Way Forward. Cancers, 2022, 14, 2126.	1.7	31
2859	Advances in Pickering emulsions stabilized by protein particles: Toward particle fabrication, interaction and arrangement. Food Research International, 2022, 157, 111380.	2.9	47
2862	Syntaxin 18 regulates the DNA damage response and epithelial-to-mesenchymal transition to promote radiation resistance of lung cancer. Cell Death and Disease, 2022, 13, .	2.7	1

#	Article	IF	CITATIONS
2863	Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome <i>c</i> release, and caspase activation. Molecular Cancer Therapeutics, 2005, 4, 207-216.	1.9	119
2866	Irradiation-Induced Rescue of Thymocyte Differentiation and V(D)J Recombination in Mice Lacking the Catalytic Subunit of DNA-Dependent Protein Kinase. Journal of Immunology, 1999, 163, 6065-6071.	0.4	2